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ABSTRACT	
In this thesis, the chemical synthesis and biological activity of aeruginosins are described. 
Aeruginosins are a class of secondary metabolites produced by cyanobacteria. Cyanobacteria 
belong to the oldest living organisms on Earth, capable of inhabiting the most remote and 
hostile areas. 
Chapter I: Over the past years, an augmentation of harmful algal blooms (HABs) has been 
observed in waters all over the world. HABs pose a threat for animals and humans alike. In 
the past, the research focus was mainly laid on the investigation of the toxicity of 
microcystins and nodularins. Recent results showed that also chlorinated and sulfated 
aeruginosins such as 828A have to be considered as cyanotoxins. In this chapter, the 
successful synthesis of four congeners of aeruginosin 828A bearing different permutations of 
the chlorine and sulfate substituents is reported. Performed toxicity tests against the 
crustacean Thamnocephalus platyurus indicate that especially the sulfate group exerts a 
notable influence on the toxicity of the aeruginosins.  
Chapter II: In this chapter, the results of a purely synthetically driven research project are 
described. The efforts which were taken in order to elucidate strategies towards the total 
synthesis of the recently isolated aeruginosin KT608A are summarized. Two novel synthetic 
approaches were developed for the preparation of the D-diepi-Choi core structure present in 
KT608A. Substantial differences in the NMR spectral data between the synthetic material and 
the isolated natural product resulted in proposing a revised structure for aeruginosin KT608A. 
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1. Cyanobacteria – Tiny Organisms with a Toxic Punch 
Cyanobacteria are a phylum of prokaryotic organisms belonging to the domain of bacteria. 
The name cyano (Greek for blue) is derived from the colorful appearance of some 
cyanobacteria strains (Figure 1). Owing to their distinct color, cyanobacteria are also referred 
to  as  “blue-green  algae”,  albeit  this  name  can  be  deceptive  in  a  sense  that  algae are eukaryotes 
in   contrast   to   the   prokaryotic   cyanobacteria.   The   name   “blue-green   algae”   originates   from  
earlier days in which the distinction of biological fine structures of algae and cyanobacteria 
was difficult. Due to fossil findings in Australia it is estimated that the evolution of 
cyanobacteria occurred 3.5 billion years ago, making them one of the oldest organisms on 
Earth.[1,2] During these 3.5 billion years, cyanobacteria had a tremendous influence on the life 
on Earth: for instance led their ability to perform photosynthesis to O2 enrichment in the 
atmosphere 2.4 billion years ago. This change from a reductive to an oxidative atmosphere 
paved the way for aerobic terrestrial life and can therefore be considered as one of the most 
significant events in the history of life on Earth.[3] Cyanobacteria preferably grow in marine 
and fresh water. Besides aquatic cyanobacteria, also strains exist which are known to grow in 
terrestrial habitats and in soil.[4] Thereby, cyanobacteria show a remarkable adaptability to 
environmental stress. For example, strains were found enduring very low temperatures in the 
Antarctic but also others which tolerate high temperatures of up to 74 °C in hot springs, such 
as in the Yellowstone National Park (Figure 1).[5,6] Even extremely dry desert regions and 
volcanic ash can be inhabited by cyanobacteria.[7,8] 
 
Figure 1 Cyanobacteria in the Grand Prismatic hot spring at Yellowstone National Park. [9]  
GENERAL INTRODUCTION 
 3
1.1. Cyanobacterial Secondary Metabolites 
Besides ordinary metabolites including fatty acids, polysaccharides and lipopeptides, 
cyanobacteria produce various carotenoids which are responsible for the distinct 
cyanobacterial colors. A further characteristic of cyanobacteria is the production of 
structurally diverse peptide-like secondary metabolites created over nonribosomal 
biosynthetic pathways. Cyanobacteria incorporate various modified amino acids into these 
nonribosomal peptides (NRP), thereby allowing for tuning of the NRP biological function. 
Examples for NRPs include the cyclic polypeptides microcystins (MC) and cyanopeptolins. 
Because of their diversity and pharmacological functions, cyanobacterial metabolites have 
attracted attention as potential drug candidates.[10] Among the biologically active metabolites
produced by cyanobacteria, there are numerous toxic compounds. The most prevalent 
cyanotoxins are depicted in Figure 2, including microcystin-LR (A), anatoxin-a (B), 
cylindrospermopsin (C), saxitoxin (D), β-methylamino-L-alanine (E) and nodularin-R (F). 
Whereas microcystins, cylindrospermopsin and nodularins, such as compounds A, C and F 
for example, show a hepatotoxic effect by damaging the liver, anatoxin-a (B), saxitoxin (D) 
and β-methylamino-L-alanine (E) exhibit neurotoxic effects.[11]
Figure 2 A selection of the most prevalent cyanotoxins: microcystin-LR (A), anatoxin-a (B), 
cylindrospermopsin (C), saxitoxin (D), β-methylamino-L-alanine (E) and nodularin-R (F). 
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1.2. Harmful Algal Blooms (HABs) 
As described in the previous section, cyanobacteria are capable of producing potent toxins. 
These venomous metabolites produced by aquatic cyanobacteria can be a threat for animals 
and humans alike: Eutrophication of waters in combination with rising temperatures caused 
by the climate change led to an augmentation of harmful algal blooms (HABs) all over the 
world.[12,13] HABs are described by an uncontrollable growth of cyanobacteria spreading over 
large areas, thereby intoxicating the waters. In 2014, one of the largest blooms ever was 
observed in Lake Erie[14,15] (Figure 3) resulting in a cut-off of the local drinking water supply 
of half a million people. Other examples for the formation of HABs are the Baltic Sea[16] in 
summer 2015 or the Yellow Sea in China in 2013. Recently, also lakes in Switzerland and 
Germany have been affected by the occurrence of toxic cyanobacteria blooms.[17] 
That water intoxication by cyanobacteria can have dramatic consequences is illustrated by a 
tragic case in Brazil in 1996. In a clinic in Curuaru, dialysis patients were treated with 
cyanobacteria contaminated water. Caused by the cyanotoxins, 116 people showed severe 
intoxications and 52 even lost their lives.[18] All in all, an increase of intoxications triggered 
by cyanobacteria has been observed over the past years. Uptake of the cyanotoxins usually 
occurs via oral intake but other mechanisms such as skin contact or inhalation are also 
possible.[19] 
 
Figure 3 Satellite picture recorded by NASA showing the harmful algal bloom in Lake Erie in 
2014.[20] 
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2. Aeruginosins
Besides the secondary metabolites described in the previous sections, cyanobacteria produce 
another group of natural products which are linear modified NRPs, called aeruginosins. The 
first member of this new class of natural products was isolated by Murakami and co-workers 
in 1994. By screening metabolites of the cyanobacterium Microcystis aeruginosa, Murakami 
et al. were able to isolate and characterize aeruginosin 298A (1).[21] Unlike the cyclic NRPs
microcystin and cyanopeptolin, aeruginosin 298A (1) is built up in a linear fashion. Further, 
compound 1 showed the presence of a thus far unknown, unique 2-carboxy-6-
hydroxyoctahydroindole (Choi) moiety. Such a modified amino acid as presented by the Choi 
unit had not been observed in natural products until the isolation of A298A (1). As a result, 
A298 (1) was classified as a new class of secondary metabolites named aeruginosin in 
allusion to the cyanobacteria strain M. aeruginosa. Aside from the Choi motif, the group of 
Murakami described a 4-hydroxyphenyllactic acid (Hpla) and an L-leucine (L-Leu) residue on 
the N-terminus and an argininol (Argol) side chain on the C-terminus of aeruginosin 298A (1) 
(left, Figure 4). Since Murakami et al. were not able to determine all stereochemical 
information in aeruginosin 298A (1), the absolute configuration of natural product 1 remained 
unclear until Tulinsky and co-workers succeeded in recording an X-ray crystallographic 
structure of aeruginosin 1. Tulinsky and his group managed to grow single crystals of a 
ternary complex of aeruginosin 298 (1) bound to hirugen-thrombin.[22] The obtained
crystallographic data at 2.1 Å resolution indicated the presence of L-Choi, L-Argol, L-Leu and 
D-Hpla moieties in compound 1 (center, Figure 4). However, total syntheses reported
simultaneously by Bonjoch[23] and Wipf[24] revealed that the absolute configuration of the
leucine residue in A298A (1) is D and not L as reported by Tulinsky (right, Figure 4). 
Figure 4 Proposed structures of aeruginosin 298A (1) by Murakami (left, 1994), Tulinksy 
(center, 1998) and Bonjoch and Wipf (right, 2000). 
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From the structure of aeruginosin 298A (1), a general configuration for the class of 
aeruginosins can be derived (Figure 9, page 13): Aeruginosins consist of four modified or 
unmodified amino acids which are linked in a linear manner. The core unit comprises the 
proline-based Choi unit onto which a guanidine-containing residue is joined on the 
C-terminus. The N-terminus is normally enclosed by a bulky hydrophobic acid at the first
position (with respect to the Choi) and a phenyllactic acid (Pla) or Hpla derivative at the 
second position (with respect to the Choi). To date the structures of around 60 naturally 
occurring aeruginosins are known (see Table on pages 14 and 15). For a better overview over 
the structures, the different aeruginosins were divided into four groups. The affiliation to a 
particular group was executed according to the special characteristics of the respective 
aeruginosins. Group one comprises ordinary aeruginosins which do not contain any additional 
distinctive features (Figure 5, page 8). Group two consists of aeruginosins bearing a 
halogenated Hpla residue on the N-terminus (Figure 6, page 9). Group three contains 
glycosylated aeruginosins (Figure 7, page 11) and group four involves aeruginosins which 
exhibit an alteration in the L-Choi motif (Figure 8, page 12). Of course, an alternative 
classification of the different aeruginosins based on other criteria would also be possible: for 
example a classification not by structural features but by isolation source. 
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2.1. Ordinary Aeruginosins 
One year after the isolation of aeruginosin 298A (1), Murakami and co-workers reported the 
identification of aeruginosin 98B (2) in M. aeruginosa. Aeruginosin 98B (2) bears an 
agmantin (Agma) residue on the N-terminus and contains a sulfated hydroxyl group on the 
L-Choi (Figure 5).[25] In the following years, researchers from the Boehringer Mannheim 
GmbH reported on the isolation and characterization of oscillarin (3) from Oscillatoria 
agardhii.[26] Oscillarin (3) featured a novel 1-(N-amidino-'3-pyrrolino)ethyl (Adc) unit on the 
N-terminus. In 1996 and 1998, Murakami et al. disclosed three new members of the 
aeruginosin family, namely aeruginosins 102A (4), 102B (5) and 103A (6) from 
M. viridis.[27,28] These newly isolated aeruginosins were characterized by a C-terminal 1-
amidino-2-hydroxy-3-aminopiperidine (Ahap). Due to a tautomeric equilibrium arising from 
the Ahap subunit, the analysis and characterization of natural products 4, 5 and 6 turned out to 
be difficult. Nonetheless, Murakami et al. were able to elucidate the structures of aeruginosins 
4, 5 and 6. Microcin SF608 (7) was discovered in 1999 by Carmeli and his group while 
screening protease inhibitors from M. aeruginosa. Natural product 7 featured the known 
Agma residue on the C-terminus and L-Phe and L-Hpla subunits on the N-terminus.[29] In the 
same year, Murakami et al. published the isolation of aeruginosin 298B (8). The special 
feature of A298B (8) is the lack of the arginine-mimicking residue on the C-terminus.[30] Most 
recently, Sivonen and co-workers reported the isolation of a series of aeruginosins from 
Nodularia spumigena. The aeruginosins disclosed by Sivonen et al. were characterized by 
fatty acid residues on the N-terminus.[31] The C-terminal unit of these aeruginosins was either 
decorated with an argininal moiety (Argal) (present in aeruginosins NAL1 (9), NAL2 (10) 
and NAL3 (11)) or an argininol residue (Argol) (present in aeruginosins NOL1 (12), NOL2 
(13), NOL3 (14) and NOL4 (15), see Figure 5). 
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Figure 5 Structures of known ordinary aeruginosins. 
 
2.2. Aeruginosins Bearing Halogenated Hpla Residues 
Already in 1995, Murakami and co-workers described the presence of a meta chlorinated 
4-hydroxyphenyllactic acid residue (m-Cl-Hpla) in aeruginosin 98A (16).[25] Later, with 
aeruginosin 98C (17), they could isolate a brominated variant of 16 together with congeners 
featuring an O-sulfated-m-Cl-Hpla moiety (aeruginosins 89 A (33) and 89 B (34)). In 
aeruginosin 101 (18), even a dichlorinated Hpla residue (m-Cl2-Hpla) was observed (Figure 
6).[30] Further, Carmeli et al. demonstrated that halogenation of the Hpla unit in aeruginosins 
isolated from M. aeruginosa is highly likely.[32–36] With aeruginosins KY608 (19), 
KY642 (20), GE766 (21), GE686 (22), GE810 (23) and GE730 (24), they identified 
congeners of aeruginosin 98A (16) containing various permutations regarding the bromine, 
chlorine and sulfate substituents. In the case of aeruginosin DA495B (25), also a chlorinated 
variant lacking the agmantin residue on the C-terminus could be isolated, together with four 
GENERAL INTRODUCTION 
 
 
 
 9
 
additional chlorinated congeners. All of them possessed the prevalent agmantin 
pharmacophore on the C-terminus but differed in the amino acid present in the second 
position. Aeruginosins DA688 (26) and DA722 (27) featured a Leu residue whereas 
DA642A (31) and DA642B (32) contained a Phe moiety.[34] Further, with the isolation of 
aeruginosins LH650A (35), LH650B (36) and LH606 (37) from Microcystis spp.[36] and 
aeruginosins IN608 (29) and IN652 (30) from Microcystis sp.,[33] Carmeli et al. could show 
that chlorination of the Hpla unit is not restricted to the cyanobacteria strain M. aeruginosa: 
Natural products 35 and 36 contained a 1-amidino-2-methoxy-3-aminopiperidine (Amap) 
moiety on the C-terminus whereas compound 37 featured a novel 1-amidino-2-
aminopyrrolidine (Aap) residue. IN608 (29) and IN652 (30) exhibited a similar structure to 
aeruginosins DA688 (26) and DA722 (27) as well as to GE642 (28) (Figure 6). 
 
Figure 6 Structures of aeruginosins bearing a halogenated Hpla residue. 
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2.3. Glycopeptidic Aeruginosins 
A further class of aeruginosins is characterized by an additional carbohydrate substituent 
(Figure 7). In 1997, Murakami disclosed the first members of this aeruginosin group by 
isolating aeruginosins 205A (38) and 205B (39) from Oscillatoria sp.[37] Murakami et al. 
proposed a structure featuring a central 6-chloro-Choi unit (Ccoi) and a 3-hydroxyleucine 
residue onto which a xylopyranose (Xyl) moiety is added (top left, Figure 7). NMR data 
obtained from the total synthesis of the Ccoi unit by Bonjoch and co-workers revealed distinct 
deviations compared to those of isolated natural products 38 and 39. Therefore, doubts 
concerning the structure of the Ccoi moiety arose.[38] Synthetic studies towards the synthesis 
of aeruginosin 205A (38) and 205B (39) performed by Hanessian et al. strongly support a 
structure featuring a chloroleucine (Cleu) residue and a xylosylated L-Choi motif with a 
sulfate group at the xylose O4 position.[39] In 2004, Quinn and co-workers reported on the 
isolation of dysinosin B, another aeruginosin containing a glycosyl residue attached to the 
L-Choi unit.[40] In contrast to the xylose moiety present in aeruginosins 205A (38) and 
205B (39), Dysinosin B (41) consists of a glucose (Glu) residue. In 2007, the groups of 
Hemscheidt and Dittmann discovered further congeners of aeruginosin 205 with the isolation 
of aeruginoside 126A (42) and 126B (40) from Planktothrix agardhii.[41] Compound 40 had 
the same structural motifs as aeruginosins 205, but lacked the chlorine and sulfate groups. 
Aeruginoside 126A (42) differed from aeruginoside 126B (40) by the substituent on the 
C-terminus, which is an Adc residue in 126A (42) and an Agma moiety in 126B (40). In 
2014, Blom et al. published the isolation of aeruginosin 828A (43) from P. rubescens.[42] 
Natural product 43 constitutes the chlorinated and sulfated congener of aeruginoside 126A 
(42). Further glycopeptidic aeruginosin species were described by Sivonen and co-workers 
who found four aeruginosins bearing pentose (Pen) substituents on the L-Choi moiety in the 
strain N. spumigena with NAL4 (44), NOL4 (45), NOL6 (46) and NOL7 (47).[31] Most 
recently, Hrouzek and his group reported the isolation of aeruginosin 865 (48) from Nostoc 
sp.[43] A865A (48) concurs with the group of glycosylated aeruginosins by featuring a 
mannuronic acid (ManA) moiety on the L-Choi motif. In conclusion, the addition of a 
carbohydrate unit displays a common structural variation in aeruginosins.  
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Figure 7 Structures of the known glycopeptidic aeruginosins. 
 
2.4. Aeruginosins with an Altered Choi Unit 
The aeruginosins presented in the previous sections were defined by a central 2-L-carboxy-6-
hydroxyoctahydroindole (L-Choi) unit. However, variations of the Choi motif were also 
detected in a couple of isolated aeruginosins. The presence of a core unit divergent from the 
ordinary L-Choi is the characteristic feature of the aeruginosins described in this section 
(Figure 8). Dysinosins are one series of natural products matching this criterion. 
Dysinosins A (49), C (51) and D (52) are special in different respects: First, they were 
isolated from Australian sponges and not from cyanobacteria strains like other aeruginosins 
and second, they comprise an extra hydroxyl group at the Choi C5 position (5-OH-L-Choi). 
Additional to this unique 5-OH-L-Choi subunit, the dysinosins are characterized by a glyceric 
acid residue on the N-terminus which is sulfated in the case of dysinosins A (49) and 
C (50).[40,44] With chlorodysinosin A (51), a variant containing a Cleu residue could be 
isolated.[45] A further aeruginosin not constituting of the L-Choi core is aeruginosin 
EI461 (53). Carmeli et al. identified differences in the chemical shifts for the Choi unit of 
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EI461 (53) compared to the typical shifts attributed to the L-Choi. They concluded therefore 
that compound 53 must feature a different diastereoisomer of the Choi and proposed the 
presence of a D-diepi-Choi core in EI461 (53).[46] Later, the originally proposed structure of 
EI461 (53) was revised by Bonjoch and co-workers proving – through total synthesis – that 
aeruginosin EI461 (53) indeed consists of an L-diepi-Choi instead of the proposed 
D-diepi-Choi.[47] Nonetheless, the D-diepi-Choi motif was later identified in aeruginosins 
KT608A (54), KT608B (55) and KT650 (56).[48] Aeruginosin GH553 (57) possesses the same 
D-diepi-Choi core but with an additional acetyl group on the O atom at C5 position 
(O-Ac-D-diepi-Choi).[48] The last L-Choi variation is exhibited by aeruginosins DA495A (58), 
DA511 (59) and KB676 (60). These aeruginosins all contain an L-6-epi-Choi instead of the 
L-Choi unit in their structure.[34,49] Furthermore, KB676 (60) features a novel prenylated 
agmantin (pren-Agma) residue on the C-terminus. 
 
Figure 8 Known aeruginosins with a modified L-Choi unit. 
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2.5. General Structure and Biological Activity 
In the past two decades, aeruginosins gained attention because of their potential as inhibitors 
of serine proteases like thrombin and trypsin.[50] Serine proteases are important enzymes that 
control a number of physiological processes, including blood coagulation, digestion and 
immune response processes.[51] Potential applications for serine protease inhibitors, such as 
aeruginosins, therefore lie in the treatment of thrombosis or the use as potential dietary 
supplements. Serine proteases like trypsin are optimized for the cleavage of peptide bonds 
which are in proximity to positively charged amino acids like lysine and arginine.[52] The 
inhibition of such proteases is therefore related to the arginine mimicking residues on the 
C-terminus (R3) of aeruginosins. These basic residues can be recognized by the enzymes, 
hence inducing their inhibition. The most potent inhibition for thrombin and trypsin has so far 
been reported for chlorodysinosin A (50) with IC50 values of 0.0038 µg mL−1 and 
0.025 µg mL−1, respectively.[53] Other aeruginosin members like oscillarin (3)[54] or 
aeruginosin 828A (43) have also revealed potent enzyme inhibition of thrombin and trypsin. 
Recent results by Blom et al. suggest that especially chlorinated and sulfated aeruginosins 
have to be considered not only as protease inhibitors but also as potent biotoxins.[42] The 
investigation of venomous aeruginosins forms the topic of the first chapter of this thesis and 
will be discussed in more detail below. For an overview on enzyme inhibition and biological 
activity of all known aeruginosins, see the Table on pages 14–15. IC50 values are not indicated 
in the table but can be obtained from the corresponding references. Further, the source of 
isolation as well as the structural features of each aeruginosin is reported. Concerning 
structural characterization, R1 represents the residue on the N-terminus, R2 the amino acid in 
the second position and R3 the arginine mimicking moiety on the C-terminus (Figure 9).  
 
Figure 9 General structure of aeruginosins. 
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Aeruginosin Isolation Source R
1 R2 Choi R3 Biological Activity 
298A (1)[21] M. aeruginosa Hpla Leu L-Choi Argol TRP, THB, PLM, PAP, CHT 
98B (2)[25] M. aeruginosa Hpla allo-Ile O-SO3-L-Choi Agma TRP, THB, PLM, PAP, CHT 
Oscillarin (3)[26] O. agardhii Pla Phe L-Choi Adc TRP, THB 
102A (4)[27] M. viridis O-SO3-Hpla Tyr L-Choi Ahap (3S) TRP, THB, PLM 
102B (5) [27] M. viridis O-SO3-Hpla Tyr L-Choi Ahap (3R) TRP, THB, PLM 
103A (6) [28] M. viridis Hpla Tyr L-Choi O-Et-Ahap TRP, THB, PLM 
Microcin SF608 (7)[29] M. aeruginosa Hpla Phe L-Choi Agma TRP, CHT 
298B (8)[30] M. aeruginosa Hpla Leu L-Choi NH2 TRP, THB, PLM, PAP, CHT 
NAL1 (9)[31] N. spumigena C4H9 Tyr L-Choi Argal n.d. 
NAL2 (10)[31] N. spumigena C6H13 Tyr L-Choi Argal n.d. 
NAL3 (11)[31] N. spumigena C8H17 Tyr L-Choi Argal n.d. 
NOL1 (12)[31] N. spumigena CH3 Tyr L-Choi Argol n.d. 
NOL2 (13)[31] N. spumigena C4H9 Tyr L-Choi Argol n.d. 
NOL3 (14)[31] N. spumigena C6H13 Tyr L-Choi Argol n.d. 
NOL4 (15)[31] N. spumigena C8H17 Tyr L-Choi Argol n.d. 
98A (16)[25] M. aeruginosa m-Cl-Hpla allo-Ile O-SO3-L-Choi Agma TRP, THB, PLM, PAP, CHT 
98C (17)[30] M. aeruginosa m-Br-Hpla allo-Ile O-SO3-L-Choi Agma TRP, THB, PLM, CHT 
101 (18)[30] M. aeruginosa m-Cl2-Hpla allo-Ile O-SO3-L-Choi Agma TRP, THB, PLM, CHT 
KY608 (19)[32] M. sp. m-Cl-Hpla allo-Ile L-Choi Agma TRP 
KY642 (20)[32] M. sp. m-Cl2-Hpla allo-Ile L-Choi Agma TRP 
GE766 (21)[35] M. aeruginosa m-Cl/Br-Hpla allo-Ile O-SO3-L-Choi Agma TRP, THB 
GE686 (22)[35] M. aeruginosa m-Cl/Br-Hpla allo-Ile L-Choi Agma TRP, THB 
GE810 (23)[35] M. aeruginosa m-Br2-Hpla allo-Ile O-SO3-L-Choi Agma TRP, THB 
GE730 (24)[35] M. aeruginosa m-Br2-Hpla allo-Ile L-Choi Agma TRP, THB 
DA495B (25)[34] M. aeruginosa m-Cl-Hpla allo-Ile L-Choi NH2 TRP, THB 
DA688 (26)[34] M. aeruginosa m-Cl-Hpla Leu O-SO3-L-Choi Agma TRP, THB 
DA722 (27)[34] M. aeruginosa m-Cl-Hpla Leu L-Choi Agma TRP, THB 
GE642 (28)[35] M. aeruginosa m-Cl2-Hpla Leu O-SO3-L-Choi Agma TRP, THB 
IN608 (29)[33] M. sp. m-Cl2-Hpla Leu L-Choi Agma TRP 
IN652 (30)[33] M. sp. m-Br-Hpla Leu L-Choi Agma TRP 
DA642A (31)[34] M. aeruginosa m-Cl-Hpla (2S) Phe L-Choi Agma TRP, THB 
DA642B (32)[34] M. aeruginosa m-Cl-Hpla (2R) Phe L-Choi Agma TRP, THB 
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89A (33)[30] M. aeruginosa O-SO3-m-Cl-Hpla Leu L-Choi Ahap (3S) TRP, THB, PLM, PAP, CHT 
89B (34)[30] M. aeruginosa O-SO3-m-Cl-Hpla Leu L-Choi Ahap (3R) TRP, THB, PLM, PAP, CHT 
LH650A (35)[36] M. spp. m-Cl-Hpla Leu L-Choi Amap (2R) TRP, THB 
LH650B (36)[36] M. spp. m-Cl-Hpla Leu L-Choi Amap (2S) TRP, THB 
LH606 (37)[36] M. spp. m-Cl-Hpla Leu L-Choi Aap (2S) TRP, THB 
205A (38)[37] O. agardhii Pla Cleu O-Xyl-L-Choi Agma TRP, THB 
205B (39)[37] O. agardhii Pla Cleu O-Xyl-L-Choi Agma TRP, THB 
126B (40)[41] P. agardhii Pla Leu O-Xyl-L-Choi Agma n.d. 
Dysinosin B (41)[40] L. chlorea O-SO3-glyceric acid Val O-Glu-L-Choi Adc THB 
126A (42)[41] P. agardhii Pla Leu O-Xyl-L-Choi Adc TRP, THB 
828A (43)[42] P. rubescens Pla Cleu O-Xyl-L-Choi Adc TRP, THB, TOX 
NAL4 (44)[31] N. spumigena C8H17 Tyr O-Pen-L-Choi Argal n.d. 
NOL5 (45)[31] N. spumigena C6H13 Tyr O-Pen-L-Choi Argol n.d. 
NOL6 (46)[31] N. spumigena C8H17 Tyr O-Pen-L-Choi Argol n.d. 
NOL7 (47)[31] N. spumigena C10H21 Tyr O-Pen-L-Choi Argol n.d. 
865 (48)[43] Nostoc sp. Hpla Leu O-ManA-L-Choi Agma anti-inflammatory 
Dysinosin A (49)[44] Dysideidae* O-SO3-glyceric acid Leu 5-OH-L-Choi Adc THB 
Chlorodysin. A (50)[45] Dysideidae* O-SO3-glyceric acid Cleu 5-OH-L-Choi Adc THB 
Dysinosin C (51)[40] L chlorea* O-SO3-glyceric acid Val 5-OH-L-Choi Adc THB 
Dysinosin D (52)[40] L. chlorea* glyceric acid Val 5-OH-L-Choi Adc THB 
EI461 (53)[46] M. aeruginosa Hpla Leu L-diepi-Choi NH2 TRP 
KT608A (54)[48] M. aeruginosa Hpla (2S) Phe D-diepi-Choi Agma TRP 
KT608B (55)[48] M. aeruginosa Hpla (2R) Phe D-diepi-Choi Agma TRP 
KT650 (56)[48] M. aeruginosa 2-OAc-Hpla (2R) Phe D-diepi-Choi Agma TRP 
GH553 (57)[48] M. aeruginosa Hpla Tyr O-Ac-D-diepi-Choi NH2 TRP 
DA495A (58)[34] M. aeruginosa Hpla Phe L-6-epi-Choi NH2 TRP, THB 
DA511 (59)[34] M. aeruginosa Hpla Tyr L-6-epi-Choi NH2 TRP, THB 
KB676 (60)[49] M. spp. Hpla Phe L-6-epi-Choi pren-Agma TRP 
CHT = Chymotrypsin; PAP = Papain; PLM = Plasmin; TOX = toxic against T. Platyurus; TRP = Trypsin; THB = Thrombin. Aeruginosins not 
isolated from cyanobacteria are indicated by an asterisk (*). 
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2.6. Biosynthesis of the L-Choi Moiety 
Scheme 1 shows the proposed biosynthesis of the L-Choi core occurring in cyanobacteria. 
Arogenate (65) is assumed to be the key intermediate in the L-Choi (69) biosynthesis.[41] The
biosyntheses of amino acids phenylalanine and tyrosine are also supposed to involve 
arogenate intermediate 65.[55] Arogenate (65) is synthesized via the known shikimate pathway
starting from phosphoenolpyruvate (61) and erythrose 4-phosphate (62). Coupling of 
compound 61 with 62 followed by several enzymatic steps gives rise to chorismate (63). A 
Claisen rearrangement of chorismate (63) forms prephenate (64), followed by amination of 64 
by an aminotransferase to afford arogenate (65).[56] The further biosynthesis of the L-Choi
(69) is carried out by the aeruginosin specific enzymes AerC-AerF:[41] Oxidation of arogenate
(65) by the enzyme AerC leads to ketone 66. Subsequent intramolecular aza-Michael addition
of the amine on the α,β-unsaturated ketone is induced by AerE to achieve ring closure 
yielding bicyclic compound 67. Decarboxylation of 67 by enzyme AerD leads to the 
formation of intermediate 68 which is reduced by AerF to the L-Choi core structure 69 in the 
last step (Scheme 1).[41]
Scheme 1 Biosynthetic pathway of the L-Choi core structure 69 present in aeruginosins. 
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1. Introduction
In this chapter, the results of a research project founded on the observation that particular 
cyanobacteria strains had stopped the production of toxic microcystins at a certain 
evolutionary point are reported. Driven by curiosity we addressed this biological singularity 
by using chemical total synthesis combined with biological testing. 
1.1. Isolation and Bioactivity of Aeruginosin 828A 
Aeruginosin 828A (A828A) (2.1) was isolated in collaboration with the group of 
PD Dr. Judith Blom from the limnological station of the University of Zurich. The toxicity of 
six cyanobacterial Planktothrix strains collected from lakes in Switzerland was evaluated by 
Dr. Esther Kohler using HPLC-guided fractionation. All fractions were subjected to acute 
toxicity screenings against the crustacean Thamnocephalus platyurus, in order to detect 
fractions containing toxic compounds. Besides the detection of already known cyanotoxins 
like microcystins (MC), the presence of ten chlorosulfopeptides was observed. Interestingly, 
the chlorosulfopeptides were found only in four microcystin deficient cyanobacteria strains 
such as Planktothrix rubescens (Figure 10). Therefore, the venomousness of these 
cyanobacteria strains could not be derived from microcystins.  
Figure 10 Epifluorescence micrograph of Planktothrix rubescens (left); Planktothrix rubescens 
bloom in Lake Hallwil, Switzerland (right).[1]  
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More detailed investigations on these microcystin deficient strains showed that the toxicity 
assigned to these strains is attributed to aeruginosin 828A (2.1), a thus far unknown member 
of the aeruginosin family. For structural elucidation a purified sample of isolated A828A (2.1) 
was sent to Dr. Verena Grundler from the research group of Prof. Karl Gademann, who could 
assign the structure of aeruginosin 828A (2.1) to be as shown in Figure 11.[2]
Figure 11 Structure of the cyanotoxin aeruginosin 828A (2.1) isolated form P. rubescens 
1.1.1. Bioactivity of aeruginosin A828A 
With the pure, isolated A828A (2.1) several biological assays were performed. The toxicity 
towards the freshwater crustacean Thamnocephalus platyurus revealed an LC50 value of 
22.8 PM, which is comparable to already known toxic microcystins.[3] This points out the
high venomousness potential of A828A (2.1). Furthermore, the enzyme inhibition property of 
2.1 on the serine proteases trypsin and thrombin was found to be in the nanomolar range for 
both trypsin (IC50 = 112 nm) and thrombin (IC50 = 21.8 nm).[2] Recently, Fent and co-workers
also reported anti-inflammatory activity of A828A (2.1) in human hepatoma cell lines.[4]
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1.1.2. Microcystin deficient cyanobacteria 
As mentioned before, A828A (2.1) was isolated form a Planktothrix strain lacking 
microcystin (MC) production. Analysis of the genome of microcystin deficient Planktothrix 
strains revealed that mutations in the microcystin synthase (mcy) gene cluster might be 
responsible for the loss of microcystin production during evolution. Strains lacking MC 
production showed either insertions in the mcyA or mcyD genes or a deletion in the mcyHA 
gene (Figure 12).[5,6] These mutations are responsible for the inactivation of the mcy gene 
cluster, thus, the MC production is shut down. It is estimated that the loss of MC production 
of certain Planktothrix strains occurred millions of years ago.[7] However, the exact site of 
these mutations in the phylogenetic lineage could not be determined. Interestingly, a loss of 
the capability to produce MCs does not seem to have a disadvantageous effect on the total 
population of cyanobacteria. This has been shown by Ostermaier and Kurmayer via 
comparison of the total population of MC producing and MC deficient Planktothrix strains 
over a period of two years.[5] Consequently, a valid hypothesis is that the evolutionary 
disadvantage caused by the loss of MC production is counterbalanced by the production of 
other secondary metabolites, such as A828A (2.1), which are able to restore the toxic 
phenotype of the cyanobacterium. 
 
Figure 12 Microcystin synthase (mcy) gene cluster of Planktothrix (topmost). Mutations 
responsible for the inactivation of the mcy gene cluster: insertion in the mcyA gene (2 nd from 
top), insertion in the mcyD gene (3rd and 4th from top) and deletion in the mcyHA gene 
(bottom).[8] 
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1.2. Chlorinated Natural Products – Bioactivity and Biosynthesis 
Halogenated secondary metabolites are widely spread in nature and have been found in over 
4000 natural products. Among these, compounds containing a carbon-chlorine bond are most 
abundant with over 2300 isolated examples.[9] The reason why nature incorporates halogen 
and especially chlorine atoms into secondary metabolites is due to the versatile role these 
substituents can have on the function of a molecule. With the simple exchange of a hydrogen 
to a chloride atom, the whole bioactivity of a compound can be altered.[10] The remarkable 
influence of chlorinations on the bioactivity of natural products is illustrated by the following 
examples vancomycin, salinosporamide A, neomangicol A and rebeccamycin (Figure 13). 
Vancomycin was isolated from the bacterium Amycolatopsis orientalis in 1953 and is used as 
antibiotic for the treatment of multi-drug resistant bacterial infections. Harris and co-workers 
have shown that the two chlorine substituents in vancomycin are essential for its clinically 
active conformation, due to the controlling effect on the atropisomeric distribution expressed 
by the chlorine atoms.[11] Salinasporamide A was isolated from the bacteria Salinaspora 
tropica and is currently in clinical trials for multiple myeloma treatment. The mechanism of 
action of salinasporamide A rests on the potent inhibition of the proteasome 20S. The densely 
functionalized E-lactone of salinasporamide A serves as electrophile, which is attacked by the 
hydroxyl group of the Thr21 unit of proteasome 20S. The obtained hydroxyl group from the 
former lactone can then attack the chlorinated carbon atom in an intramolecular fashion to 
form a tetrahydrofuran ring. With this, the reforming of the E-lactone accompanied by the 
release of the inhibitor from the enzyme is prevented, thus leading to an irreversible, covalent 
inhibition of proteasome 20S.[12] A further example is the sesterterpene neomangicol A: 
Renner and co-workers demonstrated that only neomangicol A shows cytotoxic effects in 
vitro against HCT-116 human colon tumor cell lines whereas the dechloro congener is 
inactive.[13] A similar behavior was observed for rebeccamycin. While rebeccamycin showed 
antimicrobial activity, its derivative lacking the chlorine substituent displayed no such 
activity.[14] All these examples demonstrate the tremendous influence chlorine atoms can have 
on the bioactivity of a specific compound. 
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Figure 13 Selected chlorinated natural products with biological activities: vancomycin, 
salinosporamide A, neomangicol A and rebeccamycin. 
 
1.2.1. Chlorine effect in aeruginosins 
Studies on a chlorine dependent bioactivity for natural products of the aeruginosin family was 
described by Hanessian and co-workers. They observed a remarkably enhanced in vitro 
enzyme inhibitory activity against thrombin Factor IIA and Factor VIIA of one order of 
magnitude going from non-chlorinated dysinosin A (IC50 = 46.0 nM and 0.326 PM) to 
chlorodysinosin A (IC50 = 5.70 nM and 0.039 PM) (Figure 14).[15] The results of this 
observable  ‘chlorine  effect’  were  further  supported  by  the  synthesis  of  unnatural  chlorinated  
and non-chlorinated aeruginosin hybrids, which showed the same effect for enzyme inhibition 
as described for dysinosin A and chlorodysinosin A.[15] 
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Figure 14 Enzyme inhibitory activity against thrombin Factor IIA and Factor VIIA of 
dysinosin A and chlorodysinosin A. 
 
1.2.2.  Chlorination of unreactive carbon centers in natural products biosynthesis 
Nature provides a variety of different chlorination pathways.[10] Most common is the 
incorporation of the chlorine atom as a hypochlorite (Cl+) using heme-iron (Fe-CPO)[16,17] or 
vanadium (V-CPO)[18,19] dependent chloroperoxidases or flavin dependent chlorogenases.[20] 
The discovery of CPOs goes back to the work of Hager and co-workers in the 1960s and they 
have since been intensively studied.[16] While heme-iron CPOs find a broad application in 
nature’s   biosynthesis,   V-CPOs are especially common in the biosynthesis of halogenated 
marine natural products.[19] Furthermore, the enzymatic incorporation of chlorine atoms as a 
chloride (Cl−) using S-adenosylmethionine (SAM) has been reported recently.[21] However, 
for unreactive carbon centers like the C3 position of chloroleucine (Cleu), these chlorination 
methods are unlikely to occur, due to the poor reactivity of this center against electrophilic 
Cl+ from the CPOs and nucleophilic Cl− from the enzymatic pathway. 
 
Figure 15 Chlorination of the leucine residue in the barbamide biosynthesis, investigated by 
Hartung and co-workers.[22] 
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Therefore, it was presumed that yet another chlorination pathway might exist which indeed 
was discovered in the late 1990s by the groups of Hartung[22] and Sitachitta[23] during the 
investigation of the biosynthesis of the natural product barbamide (2.4) (Figure 15). In 2006, 
Walsh et al. were then able to fully characterize the catalytic, radical mechanism for the 
chlorination of the methyl group of the leucine residue in barbamide (2.4).[24] The chlorination 
pathway comprises the enzymes BarB1 and BarB2 which contain a ferrous ion chelated by 
the co-factor α-ketoglutarate (α-KG) in the active pocket. Oxidation accompanied by 
decarboxylation of the ketoglutarate 2.6 leads to the FeIV species 2.8. Ligand exchange of the 
obtained succinic acid by chloride yields chlorine-iron complex 2.9. Single electron transfer 
from the substrate to complex 2.9 leads to the reduction of the FeIV center to FeIII and to the 
formation of an alkyl radical. Homolytic cleavage of the Cl-Fe bond reduces the FeIII core to 
FeII and allows formation of the C-Cl bond by radical recombination. Chelation of the 
co-factor D-KG closes the catalytic cycle (Scheme 2).[24] 
 
Scheme 2 Radical chlorination mechanism for the chlorination of unreactive carbon centers, 
proposed by Walsh and co-workers.[24] 
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2. Aim of the Project 
This project builds on the results obtained by Dr. Esther Kohler, who reported on the toxicity 
of aeruginosin 828A (2.1).[2] Our goal was to investigate an efficient fully synthetic route to 
A828A (2.1), which allows for the confirmation of the elucidated structure by Dr. Verena 
Grundler on the one hand and the toxicity against the freshwater crustacean Thamnocephalus 
platyurus on the other hand. With pure synthetic A828A (2.1) in hand, contamination derived 
toxicity, which is possible in isolated compounds, can be excluded. After the elaboration of a 
synthetic strategy towards A828A (2.1) it was envisioned to synthesize and characterize other 
chlorosulfopeptides with all possible permutations with regard to the sulfate and chloride 
groups present, namely A126A (2.11), A748A (2.12) and A794A (2.13) (Figure 16). 
Biological testing of these congeners shall clarify the effect of sulfate and chlorine groups on 
the toxicity. Interestingly, congener A126A (2.11) is also a naturally occurring aeruginosin, 
isolated from a cyanobacterium capable of producing MCs,[25,26] making it especially 
interesting for the comparison with A828A (2.1). 
 
Figure 16 Naturally occurring aeruginosin 828A (2.1) and aeruginoside 126A (2.11) as well as 
derivatives aeruginosin 748A (2.12) and aeruginosin 794A (2.13) 
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3. Retrosynthetic Considerations and Synthetic Strategies 
3.1. Retrosynthetic Analysis of A828A 
Aeruginosin 828A (2.1) is built up of five different subunits, linked together through three 
peptide bonds and one glycosyl linkage (Figure 17). The core unit consists of an L-2-carboxy-
6-octahydroindole (L-Choi) residue which is attached to an 1-(N-amidino-'3-pyrrolino)ethyl 
(Adc) side chain on the C-terminus and to a chloroleucine (Cleu) amino acid on the 
N-terminus. Further, the oxygen at C6 position of the L-Choi is linked to a sulfated xylose 
(Xyl) residue. Finally, the structure of A828A is accomplished by a phenyllactic acid (Pla) 
unit at the N-terminus of the Cleu unit. For the synthesis of congeners A748A (2.12), 
A794A (2.13) and A126A (2.11) the same disconnections as for A828A (2.1) can be 
considered, leading to five similar fragments as described above: For A748A (2.12), the Xyl 
residue would be exchanged by a Xyl unit bearing no sulfate group at the oxygen at C4 
position; for A794A (2.13), the Cleu residue is replaced by a leucine (Leu) unit and for 
A126A (2.11), a Leu moiety and a non-sulfated Xyl residue would be required. Retrosynthetic 
considerations for the different building blocks will be discussed in the subsequent section. 
 
Figure 17 A828A (2.1) consists of five different subunits (Xyl, L-Choi, Adc, Cleu and Pla), 
linked together via three peptide bonds and one glycosyl linkage. 
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3.2. Retrosynthetic Analysis of the Building Blocks 
The synthetic strategies for the Adc side chain (2.14) and the Cleu moiety (2.15) have already 
been reported in the syntheses of dysinosin A and chlorodysinosin A,[27,28] respectively, and 
could be adopted for the synthesis of A828A (2.1). The Adc side chain is prepared starting 
from D-methylene-J-butyrolactone (2.16) and the Cleu residue starting from isobutyraldehyde 
(2.17). D-phenyllactic building block 2.18 can be derived from D-phenyllactic acid which is 
accessible from D-phenylalanine (2.19) according to known literature procedures.[29,30] 
Protection of the hydroxyl group of D-phenyllactic acid provides a suitable Pla building block. 
For the L-Choi center structure 2.20 various syntheses have been reported by different 
research groups. Hanessian and co-workers reported a straightforward synthesis for L-Choi 
starting from L-glutamic acid (2.21).[31] Finally, the Xyl residue 2.22 can be obtained from 
D-xylose (2.23) using orthogonal protection strategies for the hydroxyl group at C4 position 
(PG) with regard to the hydroxyl groups at positions C2 and C3 (PG1) to allow for a late stage 
introduction of the sulfate group at O4 position. Further, installation of an appropriate leaving 
group (LG) at the anomeric center of the Xyl residue is envisioned (Scheme 3). The 
preparation of the different building blocks will be described in Section 4. 
 
Scheme 3 Cartoons of the simplified building blocks (top). Retrosynthetic analysis of the 
different building blocks (bottom).  
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3.3. Different Assembly Strategies 
For the assembly of the building blocks, several different strategies can be considered and 
three selected strategies will be discussed in more detail. 
Strategy A (left, Scheme 4) includes glycosylation of the L-Choi with the Xyl residue. 
Deprotection of the amine of the L-Choi allows for peptide coupling with the Pla-Cleu-OH 
dipeptide. Liberation of the acid of the L-Choi and the hydroxyl group at C4 position of the 
Xyl residue is performed in a single step. Further, the Xyl-Pla-Cleu-L-Choi-OH tripeptide is 
coupled to the Adc building block. Sulfonation of the oxygen at C4 position of the Xyl 
residue followed by global deprotection gives access to A828A (2.1). The advantage of this 
strategy is that the challenging α-xylosylation takes place at the very beginning of the 
assembly. Furthermore, the introduction of the Pla-Cleu-OH as a dipeptide saves two 
synthetic steps. The disadvantage is the global deprotection at the end in the presence of the 
labile sulfate group. The pursuit of this strategy will be discussed in Section 5. 
Strategy B (middle, Scheme 4) comprises a more classical peptide synthesis approach via an 
assembly from the C to the N terminus.[32] Peptide coupling of the L-Choi with the Adc unit is 
followed by glycosylation with the Xyl residue. Further, deprotection of the L-Choi amine is 
followed by coupling to the Cleu residue. Deprotection of the Cleu amine followed by peptide 
coupling with the Pla-OH unit provides the glycosylated tetrapeptide. Sulfonation and 
subsequent deprotection yield A828A (2.1). The poor step economy as well as the low 
orthogonality of the protecting groups makes this route unfavorable. 
Strategy C (right, Scheme 4) starts with an early peptide coupling of the L-Choi unit with the 
Pla-Cleu-OH dipeptide, followed by glycosylation with the Xyl moiety. In this strategy a 
xylosyl donor which already bears a masked sulfate group is used for the glycosylation step. 
After saponification of the methyl ester of the L-Choi, the glycosylated Pla-Cleu-L-Choi-OH 
is coupled to the Adc side chain. Global deprotection followed by final unmasking of the 
sulfate provides A828A (2.1). The advantages of this strategy are the early introduction of the 
sulfate and the increased stability and convenience of its masked analogue. A drawback is that 
glycosylations with masked sulfates are relatively unexplored. The results following this 
strategy will be discussed in Section 8. 
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Scheme 4 Strategies A, B and C for the assembly of the building blocks of A828A (2.1). 
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4. Synthesis of the Different Building Blocks 
4.1. L-Choi-Synthesis 
The L-Choi building block was synthesized following a procedure of Hanessian and 
co-workers[31] (Scheme 5): The free amine group of L-glutamic methyl ester (2.24) was 
protected with a tert-butyloxycarbonyl (Boc) group to give 2.25. Further, α-functionalization 
was carried out with LiHMDS as base and but-3-en-1-yl trifluoromethanesulfonate as the 
electrophile to give alkylated glutamic methyl ester 2.26 in a moderate yield. Removal of the 
Boc protecting group in formic acid was followed by ring closure in refluxing toluene to give 
lactame 2.27 in an excellent yield. The obtained lactame 2.27 was either protected with a Boc 
or with a carboxybenzyl (Cbz) protecting group to give the corresponding protected lactames 
2.28 and 2.29, respectively. Reduction of both lactames was performed with LiHBEt3 to yield 
a diastereomeric mixture of cyclic hemiaminals which were subsequently acetylated using 
Ac2O to give acetyl esters 2.30 and 2.31. Intermediates 2.30 and 2.31 were the precursors for 
the aza-Prins carbocyclization and gave access to octahydroindoles 2.32 and 2.33. The 
chair-like transition state of the aza-Prins carbocyclization, followed by the favored equatorial 
attack of the bromide on the carbocation provides the formation of a single desired 
diastereomer of 6-bromo-octahydroindole compounds 2.32 and 2.33. Replacement of the 
bromide atom by an acetate group was achieved by treating the 6-bromo-octahydroindoles 
with an excess of tert-butylammonium acetate under inversion of the stereochemistry at C6 
position giving octahydroindoles 2.34 and 2.35. Finally, saponification of acetyl esters 2.34 
and 2.35 to the corresponding alcohols gave rise to the protected (2S,3aS,6R-
hydroxy,7aS)octahydroindole 2-carboxylic acid (L-Choi) core units 2.36 and 2.37 in excellent 
yields.  
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Scheme 5 Synthesis of L-Choi derivatives 2.36 and 2.37. Reagents and conditions: a) Boc2O, 
NEt3, CH2Cl2, 0 °C to r.t., 20 h, 99%; b) LiHMDS, THF, –78 °C, 45 min, then but-3-en-1-yl 
trifluoromethanesulfonate, –78 °C, 20 min, 63%; c) formic acid, r.t., 5 h, quant.; d) toluene, 
reflux, 1.5 h, quant.; e) Boc2O, Et3N, DMAP, CH2Cl2, 0 °C to r.t., 16 h, 68% for 2.28; f) 
LiHMDS, THF, –78 °C, 20 min, then benzyl chloroformate, –78 °C, 1 h, 71% for 2.29; g) 
LiHBEt3, THF, –78 °C, 1 h; h) Ac2O, Et3N, DMAP, CH2Cl2, r.t., 20 h (2.30: 44% over two steps 
from 2.28, 2.31: 72% over two steps from 2.29); i) SnBr4, CH2Cl2, –78 °C, 30 min (2.32: 87% 
from 2.30, 2.33: 84% from 2.31); j) Bu4NOAc, toluene, 45–47 °C, 3 h (2.34: 62% from 2.32, 
2.35: 53% from 2.33); k) NaOMe, MeOH, r.t., 6 h (2.36: 86% from 2.34, 2.37: 86% from 2.35). 
  
CHAPTER I: TOXICITY AND SYNTHESIS OF AERUGINOSIN CHLOROSULFOPEPTIDES 
 
 
 
36 
4.2. Synthesis of Pla-Cleu-OH Dipeptide 2.47 
Chloroleucine derivative 2.47 was synthesized according to a procedure developed towards 
the total synthesis of chlorodysinosin A[28] and aeruginosin 205A[33] (Scheme 6): 
Isobutyraldehyde (2.21) was converted into ester 2.38 in a good yield in a Horner-
Wadsworth-Emmons (HWE) reaction. Subsequently, ester 2.38 was reduced to the 
corresponding allyl alcohol 2.39 using DIBAL, followed by an enantioselective epoxidation 
of the olefin using Sharpless conditions to access epoxide 2.40.[34] Protection of the free 
primary alcohol of 2.40 with a tert-butyldimethylsilyl (TBS) group followed by epoxide 
opening by treatment with NaN3 yielded a regioisomeric mixture of azides 2.41 and 2.42.  
 
Scheme 6 Synthesis of Pla-Cleu-OH dipeptide 2.47. Reagents and conditions: a) triethyl 
phosphonoacetate, NaH, benzene, 70 °C, 1.5 h, 65%; b) DIBAL, CH2Cl2, –78 °C, 1.5 h, 75%; 
c) D(–)-diethyl tartrate, t-BuOOH, Ti(i-OPr)4, 4 Å MS, CH2Cl2, –20 °C, 14 h, 46%; d) NaN3, 
MeOEtOH/H2O (20:1), 120 °C, 24 h; e) TBSCl, Et3N, DMAP, CH2Cl2, 0 °C, 2 h, 89% over two 
steps; f) PPh3, MeCN, 50 °C, 18 h, 79%; g) tert-butylsulfinyl chloride, Et3N, CH2Cl2, 0 °C, 2 h; 
h) m-CPBA, CH2Cl2, 0 °C, 1.5 h, 84% over two steps; i) CeCl3·H2O, MeCN, 85 °C, 84 h, 54%; 
j) TfOH, anisole, CH2Cl2, r.t., 20 h; k) Pla-OH 2.51, PyBOP, 2,6-lutidine, CH2Cl2, 0 °C to r.t., 
16 h, 68% over two steps; l) CrO3, H5IO6, MeCN/H2O (99.3:0.7), 0 °C, 1 h, 90%. 
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Reduction of the azides to the corresponding amines was achieved using Staudinger 
conditions and was accompanied by the elimination of H2O and the formation of aziridine 
2.43. Protection of the aziridine with a tert-butylsulfinyl group using tert-butylsulfinyl 
chloride was followed by subsequent oxidation of the sulfoxide to the sulfone using m-CPBA 
to give access to 2.44. The key step of this building block synthesis was the regiocontrolled 
opening of aziridine 2.44 using an excess of CeCl3·H2O as the chloride donor yielding 
D-chloro-amine 2.45 as a single regioisomer.[28] The conditions for the chlorination of 
aziridine 2.44 also resulted in the cleavage of the TBS protecting group. The desired 
confirmation of D-chloro-amino alcohol 2.45 was confirmed by X-ray crystallographic 
analysis (Figure 18).  
 
Figure 18 X-ray crystallographic structure of D-chloro-amino alcohol 2.45, ellipsoids plotted at 
40% probability level. Selected bond parameters: Cl1–C7 = 1.824(3), N1–S1 = 1.619(2), S1–O1 
= 1.427(2), S1–O2 = 1.4224(19) Å; S1–N1–C5 = 124.81(16), O1–S1–O2 = 118.92(13) °. 
 
Continiung with the literature procedure[33], cleavage of the tert-butylsulfonyl group 
followed by peptide coupling of the free amine with the Pla-OH side chain 2.51 was 
investigated (for the synthesis of 2.51 see Section 4.3). The conditions described in the 
literature for this two-step sequence are as follows: Treatment of D-chloro-amino 
alcohol 2.45 with an excess of TfOH (5.0 eq.) and anisole (20.0 eq.) in CH2Cl2 gives the 
free amine as a triflate salt and coupling to the Pla-OH acid 2.51 is conducted using 
PyBOP as coupling reagent and 2,6-lutidine as base. However, these synthetic 
conditions resulted in a poor yield (< 20%). Changing the coupling reagent from PyBOP 
to DEBPT or DMTMM and the base from 2,6-lutidine to NMM did not lead to an 
improvement. In the literature procedure, lyophilization techniques were performed to 
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remove the excess TfOH from the crude product. However, with this method we were 
not able to fully remove the TfOH from the crude residue, which might be the reason for 
the low yield of the subsequent peptide coupling. Therefore, focus was set on a more 
efficient removal of the TfOH by using a basic resin or neutralization with NH3 (g). 
Unfortunately, the TfOH could not be removed using these methods but we were finally 
pleased to find a rather simple solution for this problem by leaving the excess of TfOH 
in the crude product but instead and consequently adding two more equivalents of the 
base 2,6-lutidine during the peptide coupling step. With this alteration of the literature 
procedure the yield of dipeptide 2.46 could be increased from less than 20% to 68%, an 
even higher value than the reported 60%. In order to finish the synthesis of the 
Pla-Cleu-OH side chain, the alcohol of dipeptide 2.46 was oxidized to the corresponding 
acid in an excellent yield using CrO3 and H5IO6. To summarize, Pla-Cleu-OH dipeptide 
2.47 was successfully synthesized over twelve steps with an overall yield of 4.3% 
starting from commercially available isobutyraldehyde 2.21. 
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4.3. Synthesis of Pla-Leu-OH Dipeptide 2.53 
For the syntheses of aeruginoside 126A (2.11) and the analogue aeruginosin 794A (2.13), a 
building block containing a leucine (Leu) instead of a chloroleucine residue was required. The 
synthesis of Pla-Leu-OH dipeptide 2.53 started with commercially available D-phenylalanine 
(2.23) which upon treatment with NaNO2 in aqueous 2 M sulphuric acid was converted into D-
phenyllactic acid (Pla) (2.48) with retention of the stereochemistry and in a good yield of 
77%.[29,30] Phenyllactic acid (2.48) was esterified to the corresponding methyl ester 2.49 in an 
almost quantitative yield followed by protection of the free secondary hydroxyl group with an 
acid labile MOM group to access 2.50. Saponification of the methyl ester of 2.50 yielded acid 
2.51 which was coupled with H-D-Leu-OMe using PyBOP as peptide coupling reagent and 
2,6-lutidine as base. Subsequent saponification of the leucine methyl ester 2.52 finally gave 
access to Pla-Leu-OH dipeptide 2.53 in an excellent yield (Scheme 7). 
 
Scheme 7 Synthesis of Pla-Leu-OH dipeptide 2.53. Reagents and conditions: a) NaNO2, aq. 2 M 
H2SO4, r.t., 20 h, 77%; b) HCl, MeOH, toluene, 75 °C, 4 h, 94%; c) MOMBr, DIPEA, CH 2Cl2, 
r.t., 15 h, 73%; d) LiOH, THF/H2O (5:3), r.t., 1 h, 97%; e) H-D-Leu-OMe, PyBOP, 2,6-lutidine, 
CH2Cl2, r.t., 20 h, 81%; g) LiOH, THF/H2O 5:3, r.t., 2 h, 98%. 
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4.4. Synthesis of the Adc Building Block 
4.4.1. Synthesis of Adc precursor 2.62 
The Adc subunit 2.62 was synthesized following a procedure from Hanessian and 
co-workers[27] (Scheme 8): Commercially available D-methylene-J-butyrolactone (2.17) was 
transformed to the corresponding methyl ester 2.54 by treatment with fuming sulfuric acid in 
methanol.[35] Since reclosing to the lactone was observed during flash column 
chromatography (SiO2), the primary alcohol of ester 2.54 was directly protected with a tert-
butyldiphenylsilane (TBDPS) group without further purification, to prevent lactone formation. 
Unfortunately, this sequence provided 2.55 in a poor yield of only 30% over two steps. 
Nevertheless, ester 2.55 was reduced with a 1 M DIBAL solution in toluene to give alcohol 
2.56 in an excellent yield of 90%.  
 
Scheme 8 Synthesis of the Adc subunit precursor 2.62. Reagents and conditions: a) MeOH, 
H2SO4, r.t., 16 h; b) TBDPSCl, imidazole, DMF, r.t., 15 h, 30% over two steps; c) 1 M DIBAL, 
DCM, −78 °C, 1 h, 90%; d) MsCl, TEA, allylamine, DCM, r.t., 16 h, 76%; e) Boc2O, TEA, 
CH2Cl2, r.t., 1 h, 96%; f) Grubbs' II, CH2Cl2, r.t., 16 h, 96%; g) TBAF, THF, r.t., 1 h, 77%; h) 
PPh3, DEAD, diphenylphosphoryl azide, r.t., 1 h, 72%; i) TFA, CH2Cl2, r.t., 4 h; j) Goodman's 
reagent, Et3N, CHCl3, r.t., 17 h, 78% over two steps. 
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In situ mesylation of the primary alcohol of 2.56 allowed SN2 attack of allylamine to yield 
amine 2.57 which was subsequently reacted with Boc2O to obtain the protected amine 2.58 in 
a yield  of  73%  over  two  steps.  Ring  closing  metathesis  (RCM)  using  Grubbs’  2nd generation 
catalyst converted amine 2.58 into pyrroline 2.59 in an almost quantitative yield of 96%. 
Deprotection of the primary alcohol of pyrroline 2.59 was achieved by treatment with a TBAF 
solution in THF and resulted in the formation of free alcohol 2.60 in a good yield of 77%. 
Using  Mitsunobu’s   reaction   conditions,   alcohol   2.60 was converted into the corresponding 
azide 2.61 with diphenylphosphoryl azide as azide source. Further, the Boc protecting group 
was   cleaved   under   acidic   conditions   and   the   obtained   free   amine   reacted  with   Goodman’s  
reagent giving access to Adc precursor 2.62.  
 
4.4.2. Reduction of azide 2.62 to Adc subunit 2.63 
With the Adc precursor 2.62 in hand, we focused on the reduction of the azide functionality to 
the corresponding primary amine present in the Adc subunit 2.63.   Using   Staudinger’s  
conditions for this transformation as described by Hanessian and co-workers successfully 
reduced the azide to the amine (Scheme 9). However, separation of the side product 
triphenylphosphine oxide from the desired product turned out to be problematic, because flash 
column chromatography (SiO2 or Al2O3) led to decomposition and purification by 
recrystallization was not successful. We opted then for an alternative to the Staudinger 
reduction. Since pyrroline 2.62 possesses two sensitive functions (the Boc-protected 
guanidine and the double bond of the pyrroline) prone to undergo overreduction, well-known 
methods such as reduction with lithium aluminium hydride or hydrogenation with Pd/C under 
a H2 atmosphere are unsuitable.[36] We were delighted to find a catalytic hydrogenation 
reaction   using   Lindlar’s   catalyst   which   remained   the   dihydropyrrole   untouched (Scheme 
9).[37,38] 
 
Scheme 9 Reduction of azide 2.62 to Adc subunit 2.63. Reagents and conditions: a) PPh3, H2O, 
THF, r.t., 16 h, then AcOH, 72%; b) Lindlar’s  catalyst,  H2 (1 bar), MeOH, r.t., 90 min, 96%.  
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Using these conditions, not only could the yield be increased from 72% (lit.) to 96%, but also 
the purity of Adc subunit 2.63 was enhanced as illustrated in Figure 19. The 1H NMR 
spectrum from the Adc subunit 2.63 gained via the Staudinger reduction (red) shows 
impurities of triphenylphosphine oxide (~7.75 to 8.00 ppm) and an acetate peak (singlet at 
1.91 ppm) derived from the work up with acetic acid, whereas the compound obtained by the 
catalytic hydrogenation only shows negligible impurities (blue). 
 
Figure 19 Comparison of the 1H NMR spectra obtained from the reduction of azide 2.62 to Adc 
subunit 2.63. In red: the reduction using Staudinger conditions; in blue: the reduction by 
catalytic  hydrogenation  using  Lindlar’s  catalyst.  
 
4.4.3. Unexpected oxidation of 2,5-dihydropyrrole 2.61 to pyrrole 2.64 
A main challenge towards the synthesis of aeruginosin 828A (2.1) and its congeners was the 
coordinated synthesis of the different building blocks in a sense that each building block had 
to be available at the exact stage of the synthesis when they were incorporated into the total 
synthesis. 2,5-dihydropyrrole 2.61, a late stage precursor of the Adc subunit 2.63, illustrates 
an example that this proved to be problematic at some points of the synthesis: 2,5-
dihydropyrrole 2.61 was synthesized as described in Section 4.4.1. and obtained in a scale of 
440 mg over eight steps. For the completion of Adc subunit 2.63 two additional steps were 
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required (for details see Section 4.4.1.). These final steps were performed on a 100 mg scale 
leading to 66 mg of the desired Adc subunit 2.63. Since these 66 mg of 2.63 contained minor 
impurities (for details see Section 4.4.2), additional purification of 2.63 had to be performed 
just before merging 2.63 into the building block assembly. As described in Section 4.4.2, 
purification by flash column chromatography of Adc subunit 2.63 led to decomposition 
thereof. Unfortunately, by that time the remaining 340 mg of late stage precursor 2.61 had 
almost entirely been oxidized to the corresponding pyrrole 2.64 during storage in the 
refrigerator (Scheme 10). As the reverse of the oxidation reaction – the reduction of the 
pyrrole to the 2,5-dihydropyrrole – is precarious in the presence of the azide and Boc 
functionalities, the whole synthesis of the Adc building block had to be repeated. 
Surprisingly, this type of oxidation was only observed for 2,5-dihydropyrrole 2.61 and neither 
natural product aeruginosin 828A (2.1) nor Adc subunit 2.63 showed observable traces of the 
pyrrole compound during isolation or storage. 
 
Scheme 10 Spontaneous oxidation of 2,5-dihydropyrrole 2.61 to pyrrole 2.64. 
Reagents and conditions: a) O2, 4 °C, 90 d, 80%. 
 
4.5. Synthesis of Xyl Donor 2.69 
The synthesis of xylose donor 2.69 was achieved starting form commercially available 
D-xylose (2.15) (Scheme 11). Global acetylation of all the hydroxyl groups provided fully 
acetylated xylose moiety 2.65 as a mixture of α and β anomers. Further, the acetate group at 
the anomeric position was replaced by a thiophenol group, catalyzed by BF3·Et2O, to give 
xyloside 2.66 as the single β-anomer.[39] The exclusive formation of the β-anomer can be 
explained by a neighboring group participation of the acetyl group at C2 position which 
interacts with the oxonium ion, obtained as intermediate during the glycosylation, thereby 
blocking the α-position for a possible attack by the thiophenol.[40] Removal of all acetyl 
groups was achieved by treating 2.66 with a methanolic NaOMe solution to yield 2.67. 
Subsequently, regioselective protection of the OH-group at C4 position of 2.67 with a benzoyl 
(Bz) protecting group was achieved in 81% yield using benzoyl chloride and Me2SnCl2 as 
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catalyst.[41] The 2-OH and 3-OH groups were protected with a butane diacetal (BDA) group 
using 2,3-butanedione, trimethyl orthoformate and camphorsulfonic acid.[42] Initial attempts 
of BDA protection always led to an inseparable mixture of two isomers caused by a non-
steroselective formation of the acetals within the BDA group (see bottom 1H NMR spectrum 
in Figure 21). Since the BDA group only serves as protecting group during the synthesis, it 
would in fact be possible to use a mixture of isomers for future synthetic steps. However, in 
order to avoid the challenging interpretation of analytical data due to the presence of 
diastereomeric mixtures in the successive total synthesis, we opted for an optimization of the 
reaction conditions and found the reaction time to be crucial for product formation. Increasing 
the reaction time from 20 h to 64 h led to the formation of a single diastereoisomer of xylosyl 
donor 2.69 (Scheme 11). The configuration of xylose donor 2.69 was confirmed by X-ray 
crystallographic analysis (Figure 20).  
 
Scheme 11 Synthesis of Xyl donor 2.69. Reagents and conditions: a) AcCl, pyridine, 0 °C, 24 h; 
b) BF3·Et2O, thiophenol, CH2Cl2, 0 °C to r.t., 98% over two steps; c) NaOMe, MeOH, r.t., 2 h, 
61%; d) Me2SnCl2, DIPEA, BzCl, THF/H2O (9:1), r.t., 4 h, 76%; e) 2,3-butanedione, trimethyl 
orthoformate, CSA, MeOH, 66 °C, 64 h, 69%. 
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Figure 20 X-ray crystallographic structure of xyloside 2.69, showing the relative orientation of 
the methyl and methoxy groups at C19 and C22. Ellipsoids plotted at 40% probability level.  
 
Figure 21 Selected part of the 1H NMR spectra of xyloside 2.69 (top) and the diastereomeric 
mixture of xyloside 2.69 (bottom). 
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5. Synthesis of Aeruginosin 828A and Aeruginosin 748A – 
Assembly of the Different Building Blocks 
5.1. Xylosylation 
With all the different building blocks in hand, we started to focus on the assembly thereof. 
Since the α-xylosylation appeared to be synthetically most challenging, we sought for an 
incorporation of the xylosyl moiety at an early stage of the assembly. For this, xylosyl donor 
2.69, with a thiophenol group at the anomeric carbon atom, was treated with NIS as activator 
and AgOTf as promoter to form an iodo-sulfonium species in situ,[43] allowing for an attack of 
the hydroxyl group of the respective L-choi derivative. The glycosylation with L-choi 
derivative 2.36 proceeded with a moderate yield of 42%. Fortunately, the formation of the 
desired α-anomer  was  favored  in  contrast  to  the  β-anomer by a ratio of 2:1 (according to 1H 
NMR spectra analysis) (Scheme 12).  
 
Scheme 12 Glycosylation of L-choi derivatives 2.36 and 2.37 with xylosyl donor 2.69. Reagents 
and conditions: a) NIS, AgOTf, 4 Å MS, CH2Cl2, 0 °C to r.t., 2 h, (2.70: 42% from 2.36,  α/β  
(2:1)); b) NIS, AgOTf, Et2O, 0 °C to r.t., 2 h, (2.71: 79% from 2.37,  α/β  (5:3)). 
 
Because the separation of the two anomers of 2.70 turned out to be arduous, the anomeric 
mixture was used for the next step, cleaving the Boc group from the secondary amine of the 
L-Choi unit. Various acidic conditions for this deprotection always harmed not only the Boc 
group but also the BDA protecting group of the xylosyl residue. To overcome the problem of 
the poor orthogonality of the BDA and Boc groups, there were two options: either exchange 
the BDA group of xylosyl moiety 2.69 by a more stable group or exchange the Boc group of 
L-choi derivative 2.36 by a more orthogonal group with respect to the BDA group. The latter 
strategy was chosen by preparing L-choi derivative 2.37 containing a Cbz group on the 
secondary amine. Since the glycosylation system with NIS as activator and AgOTf as 
promoter provided a favored  selectivity  for  the  desired  α-anomer, these conditions were also 
applied for the glycosylation of xylosyl donor 2.69 with L-choi derivative 2.37, to achieve a 
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comparable anomeric selectivity and yield for 2.71 as obtained before for 2.70. Fortunately, 
the two anomers of 2.71 could be separated from each other. Minor optimizations, mainly by 
changing the solvent from CH2Cl2 to Et2O, finally allowed the xylosylation to proceed with a 
good  yield  of  79%  and  an  anomeric  ratio  of  5:3  favoring  the  α-anomer (Scheme 12). 
5.2. Amine Deprotection 
To progress with the total synthesis of aeruginosin 828A and the assembly of the different 
building blocks, the Cbz protecting group had to be cleaved from the xylosylated L-choi 
derivative 2.71. As similar transformations for this deprotection had already been investigated 
for aglycon derivatives of L-Choi by other research groups,[27] we were optimistic to rapidly 
find suitable conditions for this deprotection. Unfortunately, the catalytic hydrogenation 
reaction with Pd/C described in the literature only resulted in the recovery of the starting 
material (Table 1, Entry 1). Furthermore, neither increasing the catalyst loading from 0.3 to 
3.0 equivalents (Entry 2), nor raising the H2 pressure from 1 to 10 bar (Entry 3) led to any 
conversion of the starting material. In pursue of enhancing the reactivity of the catalyst, an 
excess of acetic acid was added to the reaction mixture, which was rewarded with no success 
(Entry 4). Changing the catalytic species from Pd/C to the more active Pd(OH)2 did not lead 
to any progress either, since no conversion was observed applying low pressure (Entry 5) or 
decomposition of the starting material was witnessed at a high pressure of 15 bar (Entry 6). 
Neither did the use of additives such as acetic acid or triethylamine result in an enhancement 
of the reactivity (Entries 7 and 8). Pleasingly, 2.71 was treated with PdCl2 and Et3N dissolved 
in triethylsilane, according to a protocol of Birkofer and co-workers,[44] which led to 88% 
yield of the desired free amine (Entry 9).  
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Table 1 Conditions for the Cbz deprotection of Xyl-L-Choi-Cbz derivative 2.71.  
 
Entry Catalyst Additive H2 pressure Observation 
1 Pd/C (0.3 eq.) - 1 bar SM 
2 Pd/C (3.0 eq.) - 1 bar SM 
3 Pd/C (0.3 eq.) - 10 bara SM 
4 Pd/C (0.3 eq.) AcOH 1 bar SM 
5 Pd(OH)2 (3.0 eq.) - 1 bar SM 
6 Pd(OH)2 (3.0 eq.) - 15 bara decomposition 
7 Pd(OH)2 (3.0 eq.) AcOH 1 bar SM 
8 Pd(OH)2 (3.0 eq.) Et3N 1 bar SM 
9b PdCl2 (1.0 eq.) Et3SiH - 88% of 2.72 
All reactions were performed in MeOH at room temperature unless otherwise stated. 
Reaction vessel were repeatedly evacuated and flushed with H2. aReactions were 
performed in a low-pressure autoclave. bReaction was perfomed under neat conditions.  
 
5.2.1. Cleavage of the undesired amino silylether 2.73 by treatment with SiO2 
The reaction conditions described in Table 1, Entry 9 proved to be sensitive in a sense that 
the yields varied over a wide range. We propose that N-triethylsilyl intermediate 2.73 
(Scheme 13) was formed as by-product during the reaction. Similar by-products had been 
observed by Ohfune and co-workers[45] which had used comparable conditions for their 
deprotection. Therefore, we assume that amino silylether 2.73 interacted with the silica gel 
during purification and that the free amine was not been formed until in contact with the silica 
gel. The amount of liberated free amine is therefore dependent on the time used for 
purification, leading to the poor reproducibility of this reaction. This problem was 
circumvented by simply stirring the obtained crude residue containing amino silylether 2.73 in 
a suspension of SiO2 in MeOH for 30 min prior to purification. 
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Scheme 13 Cleavage of the undesired amino silylether 2.73. Reagents and Conditions: a) SiO2, 
MeOH, r.t., 30 min. 
 
5.3. Peptide Coupling of Xyl-L-Choi Unit 2.72 with Pla-Cleu-OH Dipeptide 2.47 
With Xyl-L-Choi amine 2.72 in hand, the investigation of the peptide coupling of this amine 
residue to the Pla-Cleu-OH dipeptide 2.47 was started (for the synthesis of dipeptide 2.47 see 
Section 4.2.). First attempts with benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) (Figure 22) as coupling reagent and NMM as base (Entry 1, 
Table 2) led to the formation of a single product. Unfortunately, the mass of the isolated 
product did not correspond to the desired tripeptide 2.74, but to product 2.75 containing a 
double bond in the Cleu residue, obtained via elimination of HCl. Similar HCl elimination 
and racemization had already been described in the literature for the synthesis of other 
aeruginosins.[28,46] The mechanism of racemization followed by elimination of HCl during 
peptide coupling will be discussed in the following Section 5.3.1. We then started to screen 
different conditions and coupling reagents for the peptide coupling: First, the base NMM was 
replaced by the slightly less basic and sterically more demanding 2,6-lutidine, to again obtain 
exclusively eliminated product 2.75 (Entry 2, Table 2). Further, the coupling reagent was 
changed from PyBOP to bromotri(pyrrolidino)phosphonium hexafluorophosphate (PyBrOP) 
(Figure 22), since PyBrOP is described in the literature as an efficient peptide coupling 
reagent for N-methylated amino esters,[47,48] which should be suitable for the L-Choi-
derivative 2.72 also containing a secondary amine. This exchange of the coupling reagent did 
not give the desired product 2.74 either, but again the eliminated product 2.75 (Entry 3, Table 
2). Next, more classical peptide coupling conditions were attempted with the well-known 
coupling reagent (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-
oxid hexafluorophosphate) (HATU) (Figure 22)  and DIPEA as base. This time, traces of the 
desired product were observed accompanied by eliminated product and starting material, 
which were the major products according to UPLC mass analysis (Entry 4, Table 2).  
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Table 2 Conditions for the peptide coupling of Xyl-L-Choi amine 2.72 with Pla-Cleu-OH 
dipeptide 2.47. 
 
Entry Coupling Reagent Base Solvent Temp. Observationa 
1 PyBOP (1.5 eq.) NMM (3.0 eq.) CH2Cl2 r.t. 80% of 2.75 
2 PyBOP (1.5 eq.) 2,6-lutidine (3.0 eq.) CH2Cl2 r.t. 2.75 
3 PyBrOP (1.5 eq.) DIPEA (3.0 eq.) CH2Cl2 r.t. 2.75 
4 HATU (1.2 eq.) DIPEA (1.2 eq.) CH2Cl2 r.t. Mainly 2.75 + SM 
5 DEPBT (1.5 eq.)b 2,6-lutidine (3.0 eq.) CH2Cl2 r.t. Mainly 2.75 + SM 
6 DEPBT (1.5 eq.)b 2,6-lutidine (1.5 eq.) CH2Cl2 r.t. Mainly 2.75 + SM 
7 DEPBT (1.5 eq.)b 2,6-lutidine (3.0 eq.) CH2Cl2 0 °C Mainly 2.75 + SM 
8 DEPBT (1.5 eq.)b DIPEA (3.0 eq.) CH2Cl2 r.t. Mainly 2.75 + SM 
9 DEPBT (1.5 eq.)b NMM (3.0 eq.) CH2Cl2 r.t. Mainly 2.75 + SM 
10 DEPBT (1.5 eq.)b 2,6-lutidine (3.0 eq.) THF r.t. Mainly 2.75 + SM 
11 DEPBT (1.5 eq.)b 2,6-lutidine (3.0 eq.) THF/CH2Cl2 r.t. Mainly 2.75 + SM 
12 DEPBT (1.5 eq.)b 2,6-lutidine (3.0 eq.) CHCl3 r.t. Mainly 2.75 + SM 
13 DEPBT (1.5 eq.)b 2,6-lutidine (3.0 eq.) DMF r.t. Mainly 2.75 + SM 
14 DEPBT (1.5 eq.)b NaHCO3 (10.0 eq.) THF 0 °C SM 
15 DEPBT (1.5 eq.)b - THF 0 °C SM 
16 DMTMM (1.5 eq.) NMM (2.0 eq.) CH2Cl2 r.t. 87% of 2.74  
The reactions were carried out under careful exclusion of water under argon. aThe screening was 
performed with small amounts, thus the yield was not always determined, but the conversion was 
monitored by UPLC. bThe DEPBT was recrystallized before usage.  
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Thereafter, the conditions described in the total synthesis of aeruginosin 205 A and B, 
containing similar Cleu and L-Choi residues, were tested.[33] The peptide coupling in the 
synthesis of aeruginosin 205 A and B was performed with (3-(diethoxyphosphoryloxy)-1,2,3-
benzotriazin-4(3H)-one (DEPBT) (Figure 22) and an excess of three equivalents of 2,6-
lutidine as base. Applying these reaction conditions to the coupling of 2.72 and 2.47 provided 
a mixture of the desired compound 2.74 as minor product and eliminated compound 2.75 as 
the major product (Entry 5, Table 2). Further, the reaction was accompanied by a long 
reaction time of over 24 h with still no full consumption of the starting materials. Since 
DEPBT as coupling reagent provided the best results so far, optimizations were carried out. 
First by reducing the excess of the base 2,6-lutidine from three equivalents to 1.5 equivalents, 
leading to no improvement (Entry 6, Table 2). Further, the reaction temperature was 
decreased from room temperature to 0 °C in order to prevent the elimination reaction, which 
was not successful either (Entry 7, Table 2). The influence of the base was investigated by 
exchanging 2-6-lutidine with DIPEA and NMM, without observing any critical effect on the 
outcome of the reaction (Entries 8 and 9, Table 2). Additionally, a screening of the solvent 
influence on the result of the reaction was carried out by using THF, THF/CH2Cl2, CHCl3 and 
DMF as solvents instead of CH2Cl2. Unfortunately also this screening was not rewarded with 
success and provided a similar outcome as before (Entries 10–13, Table 2). Next, an excess 
of the inorganic base NaHCO3 was incorporated into the reaction system instead of the 
organic base 2,6-lutidine, leading to poor reaction conversion and mainly to recovery of the 
starting material (Entry 14, Table 2). The same holds for the peptide coupling without 
addition of a base (Entry 15, Table 2). Unable to optimize the reaction conditions with 
DEPBT as coupling reagent, yet another alternative coupling reagent was sought after, 
identifying 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) 
(Figure 22) to be the ideal promoter for the peptide coupling reaction of amine 2.72 and acid 
2.47. With DMTMM as coupling reagent and NMM as base,[49] the coupling was completed 
after only two hours resulting in an excellent yield of 87% with no observable elimination of 
HCl. 
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Figure 22 Peptide coupling reagents: PyBOP, PyBrOP, HATU, DEPBT and DMTMM.  
 
5.3.1. Racemization and elimination mechanism for the peptide coupling 
The elimination of HCl during the peptide coupling might proceed via the two following 
E1cB mechanism pathways:[50–52] In pathway A (Scheme 14, right), activation of the acid of 
dipeptide 2.47 leads to the active ester 2.76. Abstraction of the D-proton by the base gives 
enolate 2.77, leading to racemization of the amino acid. With the chlorine atom in E-position, 
there is a good leaving group present. Consequently, not only racemization – as in other 
peptide couplings – but also elimination of HCl in an E1 fashion becomes possible. Thus, 
D,E-unsaturated active ester 2.78 is obtained, which is subsequently attacked by the secondary 
amine of Xyl-L-Choi derivative 2.72 yielding tripeptide 2.75. Active ester 2.76 is again the 
first intermediate formed in pathway B (Scheme 14, left), as described before for pathway A. 
In this pathway, carboximidate 2.79 is produced which allows for an intramolecular attach on 
the active ester to form oxazolone intermediate 2.80. Oxazolone 2.80 can now be readily 
deprotonated to anionic intermediate 2.81 due to a stabilization of the anion caused by a 
mesomeric effect. Further, elimination of HCl gives intermediate 2.82 which is opened by the 
amine of Xyl-L-Choi derivative 2.72, again providing D,E-unsaturated tripeptide 2.75. 
Pathway B is more probable to occur, as the deprotonation of oxazolone 2.80 is more likely to 
happen compared to the D-deprotonation of active ester 2.77. Consequently, it is 
recommendable to synthesize a polypeptide starting from the C-terminus rather than from the 
N-terminus, since in this case oxazolone formation is prevented due to the missing carbonyl 
function at the J-position. Our established route for the synthesis of aeruginosin 828A was 
started from the N-terminus due to the more straightforward synthesis of Pla-Cleu-OH 
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dipeptide 2.47 with respect to the synthesis of the Cleu amino acid. In addition, the 
incorporation of Pla-Cleu-OH as a dipeptide allows for a more convergent synthesis, 
shortening the total synthesis by two steps. An assembly of the different building blocks 
starting from the C-terminus might have had spared the problem of racemization but would 
have also extended the total synthesis (for more details see Section 3.3). 
 
Scheme 14 Possible mechanistic pathways for the elimination of HCl. [50–52]  
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5.4. Saponification and Attachment of the Adc Subunit  
The next synthetic step towards the preparation of aeruginosin 828A (2.1) comprised the 
saponification of the methyl ester of the L-Choi residue in 2.74 and the cleavage of the 
benzoyl protecting group from the O4 position of the xylose moiety, preparing the molecule 
for coupling with Adc subunit 2.63 (Scheme 15). The saponification was carried out by the 
treatment of 2.74 with LiOH to access acid 2.83 in a good yield of 77%. Close monitoring of 
the reaction progression by UPLC was crucial, to allow for timely quenching of the reaction 
(~12 h), since longer reaction times again led to elimination of HCl. The subsequent peptide 
coupling of tripeptide 2.83 with the amine of Adc subunit 2.63 was performed with PyBOP as 
coupling reagent and 2,6-lutidine as base, yielding tetrapeptide 2.84 in a moderate yield of 
60%. Among other factors, the arduous purification of tetrapeptide 2.84 was responsible for 
the relatively poor yield of the peptide coupling: Repeated flash column chromatography was 
required to separate the desired product 2.84 from tri(pyrrolidin-1-yl)phosphine oxide 
obtained as side product during the peptide coupling. 
 
Scheme 15 Saponification of methyl ester 2.74 and further peptide coupling to Adc subunit 
2.63. Reagents and conditions: a) 0.1 M LiOH, THF/H2O (5:3), r.t., 12 h, 77%; b) Adc subunit 
2.63, PyBOP, 2,6-lutidine, CH2Cl2, 0 °C to r.t., 5 h, 60%. 
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5.5. Sulfonation and Global Deprotection  
Tetrapeptide 2.84 with the free hydroxyl group on C4 position of the xylose moiety was 
treated with an excess of SO3·pyridine (50.0 eq.) to obtain the required sulfate group on the 
xylose residue (Scheme 16).[33] After completion of the reaction, sulfated tetrapeptide 2.85 
was directly used for the next step without purification. Cleavage of the two Boc, the MOM 
and the BDA protecting groups was performed in a single acidic global deprotection by 
treating a solution of tetrapeptide 2.85 in CH2Cl2 with TFA. The deprotection proceeded 
smoothly at room temperature as monitored by UPLC, which showed first the cleavage of the 
Boc groups, followed by the BDA group. Finally, after 5 h also the MOM group was entirely 
cleaved from the phenyllactic acid residue. Timely quenching of the deprotection reaction was 
important in order to prevent cleavage of the sulfate group, since this functionality is known 
to be labile under acidic conditions.[33][53] The obtained crude residue containing aeruginosin 
828A (2.1) was then subjected to HPLC purification, discussed in more detail in the following 
Section 5.6.  
 
Scheme 16 Sulfonation of intermediate 2.84 and global deprotection – synthesis of aeruginosin 
828A (2.1). Reagents and conditions: a) SO3·pyridine (50.0 eq.), pyridine, 50 °C, 15 h; 
b) CH2Cl2/TFA (10:1), r.t., 5 h, 72% over two steps. 
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5.6. Isolation of Aeruginosin 828A 
The crude residue obtained after deprotection was purified by reversed phase HPLC 
(MeCN/H2O + 0.1% formic acid). The HPLC chromatogram at 210 nm showed two main 
peaks: a minor one at 6.58 min and a major one at 8.32 min (Figure 23). The minor and major 
peaks corresponded to masses of m/z = 749+ and 829+ (ESI-MS), respectively. The mass of 
829+ could rapidly be assigned to the natural product aeruginosin 828A. Due to the mass 
difference of m/z = 80, an absence of the SO3 group was suggested in the case of the minor 
peak which was therefore assigned to the synthetic analogue aeruginosin 748A or a 
diastereoisomer thereof. The lack of the SO3 group might either be derived from an 
incomplete introduction of this functionality before the global deprotection step or from a 
partial cleavage of the group during acidic deprotection. Fractionated HPLC finally provided 
996  μg  of  aeruginosin  828A  (2.1) as a white amorphous solid.  
 
Figure 23 HPLC chromatogram at 210 nm of the isolation of aeruginosin 828A (2.1): peak 2* at 
8.32 min corresponds to a mass of 829+ assigned to the natural product A828A; peak 1* at 
6.58 min to a mass of 749+ assigned to a compound lacking the SO3 group. 
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5.7. Comparison of the 1H and 13C NMR Spectra of Natural and Synthetic A828A 
In general, the NMR spectra of aeruginosin 828A (2.1) proved to be very sensitive in a sense 
that the water and salt content of the sample as well as the counterion present had an influence 
on the chemical shifts. In the 1H NMR spectrum, the shifts of the O-H and N-H protons were 
affected the most. Also the C-H protons in close proximity to one of the ionic species of 2.1 – 
such as Adc-H5 and H6 – showed slight differences of 0.03 to 0.04 ppm in the chemical shift 
in a first measured sample (for numbering see Figure 24). Adjustment of the salt content in 
the NMR sample finally provided NMR spectra which were in an excellent accordance with 
the spectra of the isolated compound described in the literature (Table 3).[2] Most of the 
1H NMR shifts were either exactly the same or shifted by only +/–0.01 ppm, only the 
chemical shift of Adc N-H proton showed a difference of –0.02 ppm. For the 13C NMR 
spectra, the situation was similar: most of the carbon signals exhibited precisely the same 
chemical shift or were shifted by only +/–0.1 ppm. An exception was the 13C signal of Adc-
C3 displaying a difference of –0.2 ppm. The recorded 2D NMR experiments such as HMBC, 
HSQC, COSY, NOESY and TOCSY were also in superb agreement with the spectra reported 
in the literature.[2] Thus, it was possible to conclude without any doubt that aeruginosin 828A 
(2.1) had been successfully synthesized via the developed synthetic strategy. 
 
Figure 24 Atom numbering in aeruginosin 828A (2.1).  
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Table 3 Comparison of the 1H and 13C NMR shifts of natural[2] and synthetic A828A 
 1H shifts (ppm) 13C shifts (ppm) 
Subunit Position A828A natural 
A828A 
synthetic 'G 
A828A 
natural 
A828A 
synthetic 'G 
Xyl 1eq 4.94 4.94 0.00 95.0 95.0 0.0 
 2ax 3.28 3.28 0.00 71.8 71.8 0.0 
 3ax 3.57 3.57 0.00 71.4 71.4 0.0 
 4ax 3.93 3.93 0.00 74.7 74.7 0.0 
 5ax 3.36 3.36 0.00 59.3 59.3 0.0 
 5eq 3.67 3.66 –0.01 - - - 
 2-OH 4.41 4.40 –0.01 - - - 
 3-OH 4.96 4.95 –0.01 - - - 
Choi 1 - - - 171.1 171.1 0.0 
 2 4.18 4.17 –0.01 59.5 59.5 0.0 
 3 2.01 2.00 –0.01 30.5 30.6 +0.1 
 3' 1.81 1.80 –0.01 - - - 
 3a 2.25 2.24 –0.01 35.6 35.6 0.0 
 4 2.14 2.15 +0.01 19.1 19.1 0.0 
 4' 1.48 1.47 –0.01 - - - 
 5 1.49 1.49 0.00 24.4 24.5 +0.1 
 5' 1.54 1.54 0.00 - - - 
 6 3.83 3.83 0.00 68.4 68.4 0.0 
 7 1.58 1.57 –0.01 28.4 28.4 0.0 
 7' 2.25 2.25 0.00 - - - 
 7a 4.32 4.32 0.00 54.1 54.1 0.0 
Pla 1 - - - 172.5 172.3 –0.2 
 2 4.18 4.18 0.00 71.5 71.4 –0.1 
 3 2.79 2.79 0.00 39.7 39.8 +0.1 
 3' 2.96 2.96 0.00 - - - 
 4 - - - 137.9 137.8 –0.1 
 5,9 7.23 7.24 +0.01 129.5 129.5 0.0 
 6,8 7.26 7.26 0.00 127.7 127.7 0.0 
 7 7.18 7.18 0.00 125.8 125.8 0.0 
Cleu 1 - - - 167.4 167.3 –0.1 
 2 4.93 4.92 –0.01 50.9 51.0 +0.1 
 3 4.00 3.99 –0.01 68.6 68.6 0.0 
 4 1.71 1.71 0.00 27.3 27.4 +0.1 
 5 0.87 0.87 0.00 15.3 15.3 0.0 
 5' 0.86 0.86 0.00 20.6 20.6 0.0 
 NH 7.68 7.67 –0.01 - - - 
Adc 1 3.16 3.16 0.00 36.3 36.3 0.0 
 1' 3.23 3.24 +0.01 - - - 
 2,2’ 2.25 2.25 0.00 28.1 28.2 +0.1 
 3 - - - 136.1 135.9 –0.2 
 4 5.61 5.61 0.00 119.0 119.0 0.0 
 5 4.07 4.07 0.00 53.6 53.6 0.0 
 6 4.07 4.07 0.00 54.9 54.9 0.0 
 NH 8.00 7.98 –0.02 - - - 
 8 - -  154.9 154.9 0.0 
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5.8. Synthesis and Isolation of Synthetic Analogue Aeruginosin 748A 
Late stage intermediate 2.84 served as precursor for the synthetic analogue aeruginosin 748A 
(2.12). Global deprotection of tetrapeptide 2.84 by treatment with a diluted TFA solution in 
CH2Cl2 provided analogue A748A (2.12) as crude residue (Scheme 17). After fractionated 
HPLC purification, 1.0 mg of pure A748A (2.12) was obtained as a white amorphous solid in 
a good yield of 70%.  
 
Scheme 17 Preparation of synthetic analogue aeruginosin 748A (2.12). Reagents and conditions: 
a) CH2Cl2/TFA (10:1), r.t., 7 h, 70%. 
 
5.9. Comparison of the 1H and 13C NMR Spectra of A748A and A828A 
Confirmation of the obtained desired structure of A748A (2.12) was achieved by analysis of 
1D (1H and 13C) and 2D NMR spectra (HMBC, HSQC, COSY and NOESY) as well as by 
comparison of the spectra with those of A828A (2.1). Table 4 shows the compared values of 
the 1H and 13C chemical shifts of the Xyl moiety of A748A (2.12) and A828A (2.1), which is 
affected the most. Expected upfield shifts are observed for the Xyl-H4 and Xyl-C4 signals of 
–0.64 ppm and –4.9 ppm, respectively, caused by the electron-withdrawing nature of the SO3 
group at O4 position (see highlighted entries in Table 4). Minor shifts to higher field were 
also detected for all other proton signals within the Xyl residue. Further, expected deshielding 
effects for the carbon atoms in E position to O4 were observed for C3 (+1.9 ppm) and C5 
(+2.4 ppm), going from sulfated (A828A) to hydroxyl containing Xyl (A748A).[54] The 1H 
and 13C NMR signals of the L-Choi, Adc, Cleu and Adc residues of 2.12 showed very similar 
shifts and coupling constants to those of A828A (2.1), constituting that the desired compound 
A748A (2.12) had effectively been synthesized.  
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Table 4 Comparison of the 1H and 13C NMR shifts of the Xyl moieties of natural A828A (2.1) 
and synthetic analogue A748A (2.12). 
 1H shifts (ppm) 13C shifts (ppm) 
Subunit Position A828A A748A 'G A828A A748A 'G 
Xyl 1eq 4.94 4.96 –0.02 95.0 95.2 +0.2 
 2ax 3.28 3.24 –0.04 71.8 71.8 0.0 
 3ax 3.57 3.43 –0.14 71.4 73.3 +1.9 
 4ax 3.93 3.29 –0.64 74.7 69.8 –4.9 
 5ax 3.36 3.30 –0.16 59.3 61.7 +2.4 
 5eq 3.67 3.40 –0.27 - - - 
 
5.10. Synthesis of Aeruginoside 126A 
Following the strategy developed for the synthesis of aeruginosin 828A (2.1) and synthetic 
analogue aeruginosin 748A (2.12), the preparation and isolation of aeruginoside 126A (2.11) 
was investigated (Scheme 18). For the synthesis of 2.11, the Cleu-Pla-OH dipeptide 2.47, 
used for the synthesis of A828A (2.1), was replaced by Leu-Pla-OH dipeptide 2.53 in the first 
peptide coupling step to access tripeptide 2.86 in a moderate yield of 58%. For the peptide 
coupling the same conditions with DMTMM as coupling reagent were used as in the synthesis 
of A828A (2.1). Further, under basic conditions, the methyl ester of the xylosylated Pla-Cleu-
L-Choi tripeptide 2.86 was converted into the corresponding acid and the hydroxyl group at 
O4 position of the xylosyl moiety was liberated giving acid 2.87 in an excellent yield. The 
improved yield of 95% for the saponification and deprotection, compared to the 77% obtained 
in the synthesis of A828A (2.1), can be explained by the fact that an elimination reaction is 
not possible in tripeptide 2.86. Second peptide coupling of tripeptide 2.87 with Adc subunit 
2.63 promoted by PyBOP and 2-6-lutidine afforded tetrapeptide 2.88 in a yield of 64%. The 
only step missing to complete the total synthesis of aeruginoside 126A (2.11) was the global 
removal of the protecting groups, which was carried out in a diluted TFA/CH2Cl2 solution. 
The reaction progression was followed by UPLC showing a fast cleavage of the Boc and the 
BDA groups, whereas the MOM group proved to be more stable. After seven hours the 
reaction was stopped in order to prevent side reactions regardless of the incomplete 
deprotection of the MOM group. The obtained crude residue was subjected to fractionated 
HPLC purification leading to a separation of A126A (2.11) from the product which still 
contained the MOM protecting group on the Pla residue. Doing so, 1.3 mg of A126A (2.11) 
could be isolated as a white amorphous solid.  
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Scheme 18 Synthesis of aeruginoside 126A (2.11). Reagents and conditions: a) DMTMM, 
NMM, CH2Cl2, 0 °C to r.t., 3 h, 58%; b) 0.1 M LiOH, THF/H2O (5:3), r.t., 12 h, 95%; c) Adc 
subunit 2.63, PyBOP, 2,6-lutidine, CH2Cl2, 0 °C to r.t., 4.5 h, 64%; d) CH2Cl2/TFA (10:1), r.t., 
7 h, 73%. 
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5.11. Comparison of 1H and 13C NMR Spectra of Natural and Synthetic A126A 
The NMR spectra obtained from our synthesized A126A (2.11) and the spectra from the 
isolation work were compared.[25] Both spectra showed the presence of two conformers, 
further referred to as rotamers, in a ratio of 3.5:1 and 3:1, respectively. The conformational 
behavior of the synthesized aeruginosins will be discussed in more detail in Section 5.14. 
Furthermore, the 1H NMR spectra of synthetic and natural A126A (2.11) revealed a good but 
not an excellent accordance (Table 5). All required proton signals from the 1H NMR 
spectrum of natural A126A (2.11)[25] could be assigned to signals in our recorded 1H NMR 
spectrum of synthetic A126A (2.11). Small differences in the chemical shifts were, however, 
observed (for the largest divergences see entries highlighted in red in Table 5). These 
chemical shift deviations are in a range of –0.08  ppm  for  Leu  H3’  to  +0.08  ppm  for  Pla  H3,  
except for the shift of Leu N-H which shows a difference of –0.23 ppm (for labeling and 
numbering see Figure 25). All necessary carbon signals of the literature[25] 13C NMR 
spectrum could also be assigned to signals in our recorded spectrum. The chemical shift 
differences in the 13C NMR spectrum lie in a range of –1.0 ppm for Pla C1 to +0.2 ppm for 
Leu C2 (for labeling and numbering see Figure 25). In general, the 13C signals of synthetic 
A126A (2.11) are shifted to lower frequency than the signals of natural A126A (2.11).[25] 
Examining the differences of the spectra in more detail, it was revealed that the Pla and Leu 
units showed the largest deviations. However, a wrong configuration of these units can be 
excluded: the absolute stereochemistry of the Pla and Leu units was determined after acidic 
hydrolysis by chromatography on a chiral stationary phase. By comparison of the retention 
times to those of authentic standards during isolation work, a D configuration of the Pla and 
Leu moieties was identified. In our synthetic work, the absolute stereochemistry of the Pla 
and Leu units was determined by comparison of the optical rotation values to those described 
in the literature: a positive value for the rotation of the Pla moiety and a negative value for the 
Leu unit were obtained, both corresponding to a D configuration. Another reason for the 
differences in the NMR spectra could be that natural A126A (2.11) incorporates a xylose 
moiety with L configuration instead of the D-xylose in synthetic A126A (2.11), since the 
absolute configuration of the xylose residue could not be determined during isolation work. 
Nevertheless, the scarcity of L-xylose in nature and the almost identical shifts of the 1H and 
13C signals in the xylose moiety of natural and synthetic A126A (2.11) suggest a 
D configuration of the xylose in natural A126A (2.11). Also the chemical shifts of the L-Choi 
and Adc units in the natural and synthetic A126A (2.11) were in a very good agreement with 
each other confirming the right confirmation of these units. So where do the observed 
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differences in the shifts of the NMR spectra arise from? As already described in Section 5.9, 
the recorded NMR spectra are sensitive with respect to water and salt concentration within the 
sample. Further, the counterion present in the compound can affect the chemical shifts of the 
signals. In the isolation work, HPLC purification was performed with aqueous acetonitrile 
containing 0.05% v/v TFA instead of the 0.1% v/v formic acid we used as eluent. Therefore, 
the counterions of natural and synthetic A126A (2.11) were not the same, which might be one 
explanation for differences in the shifts of the 1H and 13C spectra. Additionally, the spectra of 
the isolation work were recorded on a 500 MHz spectrometer[25] whereas our samples were 
measured on a 600 MHz spectrometer. Moreover, the temperature at which the NMR 
experiments were carried out is not apparent from the supporting information of the literature. 
A difference of the temperature could also be a reason for small deviations in the chemical 
shifts in the spectra (the influence of the temperature on the shifts of the rotamers will be 
discussed in more detail in Section 5.14.1). To conclude, the desired natural product A126A 
(2.11) was successfully synthesized with very high probability, regardless of the circumstance 
that the recorded NMR spectra were not in full agreement with those reported in literature.[25] 
However, definite confirmation could only be gained by either mixing equimolar amounts of 
synthetic and isolated samples for NMR experiments or by HPLC co-injection of both 
samples. 
 
Figure 25 Atom labeling and numbering in aeruginosin 126A (2.11).  
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Table 5 Comparison of the 1H and 13C NMR shifts of natural[25] and synthetic A126A (2.11) 
 1H shifts (ppm) 13C shifts (ppm) 
Subunit Position A126A natural 
A126A 
synthetic 'G 
A126A 
natural 
A126A 
synthetic 'G 
Xyl 1eq 4.81 4.81 0.00 96.5 96.4 –0.1 
 2ax 3.21 3.22 +0.01 71.9 71.7 –0.2 
 3ax 3.40 3.40 0.00 73.4 73.2 –0.2 
 4ax 3.28 3.28 0.00 70.0 69.8 –0.2 
 5ax 3.34 3.34 0.00 62.1 62.0 –0.1 
 5eq 3.39 3.40 +0.01 - - - 
Choi 1 - - - 171.4 170.8 –0.6 
 2 4.18 4.14 –0.04 59.8 59.7 –0.1 
 3 2.04 2.01 –0.03 30.5 30.4 –0.1 
 3' 1.78 1.77 –0.01 - - - 
 3a 2.28 2.31 +0.01 36.1 35.8 –0.3 
 4 2.08 2.09 +0.01 19.5 19.3 –0.2 
 4' 1.47 1.47 0.00 - - - 
 5 1.49 1.49 0.00 24.5 24.2 –0.3 
 5' 1.56 1.56 0.00 - - - 
 6 3.84 3.84 0.00 70.1 69.8 –0.3 
 7 1.57 1.61 +0.04 29.2 29.1 –0.1 
 7' 2.27 2.26 –0.01 - - - 
 7a 4.15 4.12 –0.03 54.1 53.7 –0.4 
Pla 1 - - - 173.2 172.2 –1.0 
 2 4.11 4.12 +0.01 72.0 71.5 –0.5 
 3 2.65 2.73 +0.08 40.4 39.9 –0.5 
 3' 2.95 2.99 +0.04 - - - 
 4 - - - 138.4 137.7 –0.7 
 5,9 7.21 7.22 +0.01 129.3 129.3 0.0 
 6,8 7.24 7.25 +0.01 127.9 127.6 –0.3 
 7 7.16 7.18 +0.02 125.9 125.7 –0.2 
Leu 1 - - - 169.9 - - 
 2 4.50 4.56 +0.06 48.6 47.8 –0.8 
 3 1.34 1.28 –0.06 41.0 41.2 +0.2 
 3’ 1.46 1.38 –0.08 - - - 
 4 1.48 1.48 0.00 24.1 24.2 +0.1 
 5 0.86 0.86 0.00 21.8 21.6 –0.2 
 5' 0.84 0.82 –0.02 23.3 23.3 0.0 
 NH 7.76 7.53 –0.23 - - - 
Adc 1 3.17 3.19 +0.02 36.6 36.3 –0.3 
 1' 3.21 3.19 –0.02 - - - 
 2 2.28 2.26 –0.02 28.2 28.1 –0.1 
 2’ 2.26 - - - - - 
 3 - - - 136.2 - - 
 4 5.61 5.62 +0.01 119.1 119.0 –0.1 
 5 4.10 4.07 –0.03 54.1 53.7 –0.4 
 6 4.09 4.07 –0.02 55.3 54.9 –0.4 
 NH 7.74 7.81 +0.07 - - - 
 8 - - - 154.2 - - 
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5.12. Synthesis and Isolation of Synthetic Analogue Aeruginosin 794A 
Late stage intermediate 2.88 figured also as precursor for the synthesis of aeruginosin 794A 
(2.13). Introduction of the SO3-group with a large excess of SO3·pyridine complex gave 
tetrapeptide 2.89. Further, global deprotection was carried out in a diluted TFA/CH2Cl2 
solution, closely monitored by UPLC. Subsequent fractionated HPLC purification afforded 
1.5 mg of the desired A794A (2.13) as a white amorphous solid in a yield of 75% over two 
steps (Scheme 19). 
 
Scheme 19 Sulfonation of intermediate 2.88 and global deprotection – synthesis of aeruginosin 
794A (2.13). Reagents and conditions: a) SO3·pyridine (50.0 eq.), pyridine, 50 °C, 15 h; 
b) CH2Cl2/TFA (10:1), r.t., 5 h, 75% over two steps. 
 
5.13. Comparison of the 1H and 13C NMR Spectra of A126A and A794A 
The structure of A794A (2.13) was confirmed by 1D (1H and 13C) and 2D (HMBC, HSQC, 
COSY and NOESY) NMR spectroscopies as well as by comparison of the spectra with those 
of A126A (2.11). Like A126A (2.11), A794A (2.13) showed the presence of two different 
rotamers in a ratio of 4:1 in the NMR spectra. Table 6 shows the comparison of the 1H NMR 
and 13C chemical shifts of the Xyl moieties of A126A (2.11) and A794A (2.13) which are 
affected the most. Expected downfield shifts are observed for the Xyl-H4 and Xyl-C4 signals 
of +0.64 ppm and +4.9 ppm, respectively, caused by the electron-withdrawing nature of the 
SO3 group at O4 position (see entries highlighted in red in Table 6). Minor shifts to higher 
field were detected for the other proton signals within the Xyl residue. Further, an expected 
shielding effect for the carbon atoms in E position to O4 was observed for C3 (–1.8 ppm) and 
C5 (–2.5 ppm), going from hydroxyl (A126A (2.11)) to sulfated Xyl (A794A (2.13)).[54] The 
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1H and 13C NMR signals of the L-Choi, Adc, Leu and Adc residues showed very similar shifts 
to those of A126A (2.13), corroborating that the desired compound A794A (2.13) had 
effectively been synthesized. 
 
Table 6 Comparison of the 1H and 13C NMR shifts of the Xyl moieties of synthetic A126A and 
synthetic analogue A794A. 
 
5.14. Conformational Analysis – The Presence of Rotamers  
An interesting feature observed during the synthesis of A828A (2.1) and its analogues was the 
modulating impact of the chlorine atom on the conformation of the entire molecule: All the 
late stage intermediates containing the Cleu moiety, including A828A (2.1) and A748A 
(2.12), appeared as a single or as a high excess of one rotamer (>50:1). The congeners lacking 
the chlorine atom, including A126A (2.11) and A794A (2.13), were on the other hand present 
as a rotameric mixture of around 3.5:1, as visible in the 1H and the 13C NMR spectra. The 
1H NMR spectra of A828A (2.1) and A794A (2.13) are illustrated in Figure 28; for the 
1H NMR spectra of A748A (2.12) and A126A (2.11), see Figure 29. The presence of two 
conformers is caused by a rotational equilibrium of the L-Choi-Leu peptide bond which can 
possess either cis or trans conformation (Figure 26). Analysis of the ROESY spectra of 
A828A (2.1) and A748A (2.12) revealed the existence of the trans rotamer in 2.1 and 2.12, as 
concluded   due   to   observed   NOEs   between   Cleu   H2   and   Choi   (H7,   H7’   and   H7a),  
respectively. As mentioned before, intermediates devoid of the chlorine atom appeared as a 
rotameric mixture. The presence of two rotamers in A126A (2.11) has already been reported 
in the isolation work of 2.11 by Dittmann and co-workers.[25] Additionally, it could be 
confirmed for A126A (2.11) and A794A (2.13) by exchange crosspeaks visible in the ROESY 
spectra between the methyl groups of both rotameric leucine units (Figure 27). Further, the 
trans rotamer was assigned as the major conformer, verified by similar NOEs as described 
before for 2.1 and 2.12. The minor cis rotamer was identified by an observed NOE between 
 1H shifts (ppm) 13C shifts (ppm) 
Subunit Position A126A A794A 'G A126A A794A 'G 
Xyl 1eq 4.81 4.81 0.00 96.4 96.2 –0.2 
 2ax 3.22 3.27 +0.04 71.7 71.8 +0.1 
 3ax 3.40 3.56 +0.16 73.2 71.4 –1.8 
 4ax 3.28 3.92 +0.64 69.8 74.7 +4.9 
 5ax 3.34 3.40 +0.06 62.0 59.5 –2.5 
 5eq 3.40 3.67 +0.27 - - - 
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Leu H2 and L-Choi H2. To conclude, the halogen atom appears to have a critical effect on the 
conformation of the different aeruginosins by restricting the torsion angle of the L-Choi-Leu 
amide bond. A related phenomenon has already been described earlier by Hanessian and co-
workers for unnatural aeruginosin hybrids.[15]  
 
Figure 26 Amide isomer equilibria of the L-Choi-Cleu (top) and the L-Choi-Leu (bottom) 
peptide bonds. 
 
 
Figure 27 Selected part of the 2D ROESY NMR spectrum of A126A (2.11); exchange cross-peaks 
between the methyl groups of both rotameric leucine units are highlighted in red. 
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Figure 28 1H NMR spectra of A828A (2.1) (top) and A794A (2.13) (bottom), showing the 
presence of two rotamers in A794A (2.13). 
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Figure 29 1H NMR spectra of A748A (2.12) (top) and A126A (2.11) (bottom), showing the 
presence of two rotamers in A126A (2.11). 
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5.14.1.  Variable temperature NMR spectroscopy of L-Choi-Leu-Pla 2.90 
For further investigations on the behavior of the two rotameric conformers, 1H NMR 
experiments were conducted at elevated temperatures (300–400 K). NMR experiments were 
performed with the model substrate L-Choi-Leu-Pla (2.90) (Figure 30) which lacks the Xyl 
and Adc units (for the synthesis of 2.90 see Section 8.2.1). The Adc and Xyl residues showed 
to exert a negligible influence on the conformation of the rotamers, observed during the 
synthesis of A126A (2.11) and A794A (2.13). Therefore, 2.90 was chosen as model substrate. 
First, the NMR spectra are more easily interpreted when lacking two units and second, 2.90 
should be more stable during the heating process since the Xyl and Adc units bear rather 
labile BDA and Boc protecting groups, respectively.[55] The proton signals of 2.90 showed 
sharp signals at room temperature and a rotameric mixture of 5:1. The most distinct effects 
upon increasing the temperature are illustrated with the following examples: The singlets of 
the L-Choi methyl esters of the cis and trans rotamers underwent a broadening of the peaks 
while increasing the temperature. At 400 K, just one broad merged signal for the methyl 
group was finally observed (highlighted in red, Figure 31). The signals for the Pla-H3’  proton  
first showed a pair of doublets of doublets caused by the two rotamers. Elevating the 
temperature first led to broadening and merging of the two signals (360 K). Higher 
temperatures (>360K) induced a sharpening of the two merged signals to one defined doublet 
of doublet (highlighted in blue, Figure 31). The two singlets corresponding to the acetate 
group only showed merging of the two signals to one sharp singlet at 360 K (highlighted in 
yellow, Figure 31). No broadening of the peaks was observed for this signal while heating. 
The most distinctive effect was observed for the doublets of the cis and trans Leu H5 and 
H5’,   respectively:  Heating   the  sample  did  not  only lead to merging of the signals of the cis 
and trans rotamers,  but  also  of   the  two  H5  and  H5’  doublets   to   just  one  signal,  when  going  
from 360 K to 380 K (highlighted in green, Figure 31). This effect is caused by a slow, 
restricted rotation of the Leu C3-C4 bond at room temperature, resulting in two doublets for 
H5  and  H5’.   Increasing   the  temperature  causes  a  faster  rotation  of   the  Leu  C3-C4 bond and 
the  formation  of  just  one  signal  for  H5  and  H5’.  Heating  the  sample to 400 K did not prove 
enough  in  order  to  access  a  sharp,  fully  merged  signal  for  H5  and  H5’,  since  a  small  shoulder  
could still be detected. Nevertheless, the tendency of a merging process of the signals is 
clearly evident. Higher temperatures than 400 K were avoided to prevent the sample from 
decomposition. 
CHAPTER I: TOXICITY AND SYNTHESIS OF AERUGINOSIN CHLOROSULFOPEPTIDES 
 
 
 
71 
 
Figure 30 Atom labeling and numbering in L-Choi-Leu-Pla derivative 2.90. 
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Figure 31 Selected region of the 1H NMR spectra of 2.90 at different temperatures, from 300 to 
400 K, with intervals of 20 K (top to bottom). Proton signals showing distinctive effects upon 
increasing temperature are shown in color. The 1H NMR spectra were recorded in DMSO-d6 on 
a 500 MHz spectrometer.  
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6. Evaluating the Toxicity of A828A, A126A, A748A and A794A  
For the evaluation of the environmental toxicity of natural products A828A (2.1) and A126A 
(2.11) as well as for synthetic analogues A748A (2.12) and A794A (2.13), a standard assay 
with the sensitive freshwater crustacean Thamnocephalus platyurus was conducted. 
Following the standard procedure, six concentrations ranging from 0.41 µM to 100 µM for 2.1 
and 1.2 µM to 150 µM for 2.11, 2.12, and 2.13 were prepared and tested in an acute toxicity 
assay (24 h). For every concentration, three to four experiments with 10 to 16 animals per 
experiment were performed. The mortality rates of the test organisms were determined by 
visual inspection of the animals after exposing them to a certain concentration for 24 h in the 
dark (Figure 32). A first topic of interest was the confirmation of the toxicity reported for 2.1 
by Blom et al., who indicated an LC50 value of 22.4 µM for 2.1 against T. platyurus.[2] In fact, 
our assay with synthetic aeruginosin 828A (2.1) showed a reproducible toxicity with an LC50 
value of 34.5 µM. Therefore, it could be proven that 2.1 is indeed responsible for the toxicity 
and that the toxicity assigned to 2.1 by Blom et al. had not been derived from a contamination 
with other toxins during isolation. The next focus lay on the evaluation of the effect of the 
chlorine atom and the sulfate group on the bioactivity. Conducting the assay with synthetic 
analogue A748A (2.12), which lacks the sulfate group, showed a toxicity of 24.2 µM, which is 
in the same range as that of A828A (2.1). Further, tests with dechloro derivative A794A 
(2.13) revealed an increased toxicity with an LC50 value of 12.8 µM, compared to 34.5 µM of 
A828A (2.1). As already discussed in Section 5.14, the chlorine substituent has a strong 
impact on the conformation of the aeruginosin. Reported SAR studies with unnatural 
aeruginosin hybrids bearing either a Cleu or a Leu residue revealed that the chlorine 
substituent in the leucine moiety is important for the inhibition of enzymes such as thrombin 
(for more details see Section 1.2.1).[15] In   terms  of   toxicity,   however,   this   “chlorine   effect”  
appears to be detrimental, which is likely due to restricted rotation around the L-Choi-Leu 
peptide bond, which could result in an entropic penalty. Most interestingly, the natural 
occurring A126A (2.11), which contains neither the sulfate group nor a chlorine substituent, 
showed a significantly lower toxicity with an LC50 of 57.7 µM. From the conducted toxicity 
assays, the following conclusions can be drawn: 1) the introduction of either chloride or 
sulfate functionalities leads to an increased toxicity, and 2) the chloride group in combination 
with the sulfate moiety results in a slight attenuation of the toxicity. These hypotheses go 
along with the ecological observations that chlorosulfopeptides such as A828A (2.1) are 
produced in microcystin deficient, but still toxic cyanobacteria, in contrast to non-chlorinated 
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and non-sulfated aeruginosins, like A126A (2.11), which are present in cyanobacteria strains 
able to produce microcystins.[1,23,24] Further, one can assume that the toxicity of aeruginosins 
is caused by a mode of action other than the inhibition of proteases like thrombin and trypsin, 
since chlorinated aeruginosins 2.1 and 2.12 showed no enhanced toxicity compared to 
dechloro congener 2.13. An enhanced protease inhibition can however be expected for 
chlorinated aeruginosins 2.1 and 2.12,  since  such  a  “chlorine  effect”  has  also  been  observed  
for similar aeruginosins[15] and strong protease inhibition has indeed been detected for A828A 
(2.1).[2] This hypothesis is supported by Blom and co-workers who reported on the absence of 
correlation between toxicity and protease inhibitory action of MCs.[3] However, this theory 
can only be proven by comparison of the enzyme inhibition of chlorinated aeruginosins 2.1 
and 2.12 with those of non-chlorinated 2.11 and 2.13. This dual use of A828A (2.1) – not only 
as strong protease inhibitor but also as toxin – might be the reason for the loss of MC 
production of certain bacteria strains, since MC production became obsolete in the presence 
of A828A (2.1). Therefore, the production of MCs provided no further advantage for the 
bacteria but only required a lot of energy to create. This might be an explanation for the 
evolutionary inactivation of the mcy gene cluster of some strains. All in all, the obtained 
results support the hypothesis that chlorosulfopeptides restore the toxic phenotype of 
cyanobacteria.  
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Figure 32 Mortality of T. platyurus as a function of the concentration of A828A (2.1), A126A 
(2.11), A748A (2.12) and A794A (2.13). Values are given as the mean of three independent 
experiments with 10 to 16 animals; error bars denote the standard error of the mean value.  
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7. Synthesis and Biological Activity of Aglycone A616A 
7.1. Synthesis of Aglycone A616A  
For further investigations on the toxicity and for studies on the influence of the xylose moiety, 
the aglycone A616A (2.91) of natural product A828A (2.1) was synthesized (Scheme 20): 
Cbz protected L-Choi derivative 2.35 was transferred to the corresponding free amine using a 
catalytic hydrogenation reaction with Pd/C to give amine 2.92 in a good yield.[27] The poor 
reactivity of the catalytic hydrogenation seen for the deprotection of Xyl-L-Choi-Cbz 2.71 (for 
details see Section 5.2.) was not observed for substrate 2.35. Therefore, the prevented 
reactivity of 2.71 against catalytic hydrogenation seems to be derived from the Xyl moiety 
attached to the L-Choi, caused e.g. by an increase of the sterical hindrance of the substrate. 
 
Scheme 20 Synthesis of aglycone A616A (2.91). Reagents and conditions: a) Pd/C, H2 (1 bar), 
MeOH, r.t., 3.5 h, 76%; b) Pla-Cleu-OH 2.47, DMTMM, NMM, CH2Cl2, 0 °C to r.t., 2 h, 83%; 
c) 0.1 M LiOH, THF/H2O (5:3), r.t., 12 h, 76%; d) Adc subunit 2.63, PyBOP, 2,6-lutidine, 
CH2Cl2, 0 °C to r.t., 5 h, 51%; e) CH2Cl2/TFA (10:1), r.t., 8 h, then K2CO3, H2O, r.t., 30 min, 
45%. 
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Peptide coupling of the obtained amine 2.92 with Pla-Cleu-OH subunit 2.47 provided 
tripeptide 2.93 in an excellent yield. Subsequent saponification of the methyl and acetyl ester 
in 2.93 to the corresponding acid and alcohol functionalities was carried out under basic 
conditions to afford Pla-Cleu-L-Choi-OH tripeptide 2.94. Attachment of the Adc subunit 2.63 
to the tripeptide 2.94 yielded tetrapeptide 2.95 in a moderate yield. Removal of the Boc and 
the MOM groups with a diluted TFA/CH2Cl2 solution was accompanied by the formation of 
trifluoroacetylated intermediate 2.96 (Scheme 21).[56] However, treatment of 2.96 with an 
aqueous K2CO3 solution for 30 min at room temperature finally provided aglycone A616A 
(2.91).  
 
Scheme 21 Conversion of the trifluoroacetate intermediate 2.96 into aglycone A616A (2.91). 
Reagents and conditions: a) K2CO3, H2O, r.t., 30 min. 
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7.2. Comparison of the NMR Spectra of A828A and A616A 
The comparison of the 1H and 13C NMR signals of A828A (2.1) and A616A (2.91) is shown 
in Table 7; for atom numbering see Figure 33. The chemical shifts of the Adc and Pla groups 
of A828A (2.1) and A616A (2.91) were almost identical with deviations of only –0.02 to 
+0.03 ppm in the proton and –0.2 to +0.2 ppm in the carbon NMR spectra. The small 
chemical shift differences are due to the long distance of at least seven bonds of the Pla and 
Adc units from the site of xylosylation. Consequently, the signals of the L-Choi unit should be 
affected the most, which was confirmed by the recorded spectra, showing a deviation for the 
L-Choi ranging from –0.20 to +0.06 ppm in the proton and from –4.8 to +4.6 ppm in the 
carbon NMR spectra. The most distinct differences in the carbon NMR of the L-Choi unit are 
assigned to the signals of C5, C6 and C7. This agrees well with the theory which predicts a 
shielding of the carbon atom in D position, C6 (–4.8 ppm), and a deshielding of the carbon 
atoms in E position, C5 (+1.4 ppm) and C7 (+4.6 ppm), going from an acetal (A828A (2.1)) to 
a hydroxyl (A616A (2.91)) group.[54] Concerning the chemical shifts of the proton signals, 
shielding of the D position and deshielding of the E positions are expected for the aglycone.[54] 
Indeed, the recorded 1H NMR spectrum showed a downfield shift for H6 (+0.06 ppm) and 
upfield shifts for H5 (–0.07 ppm),  H5’  (–0.11  ppm)  and  H7’  (–0.20 ppm). Only for the signal 
of H7 (+0.05 ppm), a reversed shift was observed. The Cleu unit exhibited minor differences 
in the chemical shifts which can be explained by the cis configuration of the molecule, 
bringing the Cleu and the Xyl moiety in close proximity to each other, as is confirmed by 
NOEs arising between Cleu-H5 and Xyl (H2, H3 and 2-OH). In conclusion, the NMR spectra 
were in perfect agreement with the predictions, proving that aglycone A616A (2.91) had 
successfully been synthesized. 
 
Figure 33 Atom numbering and labeling of A828A (2.1) and A616A (2.91).  
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Table 7 Comparison of the 1H and 13C NMR spectra of aglycone A616A (2.91) and natural 
product A828A (2.1). Most distinct deviations are highlighted in red.  
 1H shifts (ppm) 13C shifts (ppm) 
Subunit Position A828A A616A 'G A828A A616A 'G 
Choi 1 - - - 171.1 171.0 –0.1 
 2 4.17 4.17 +0.03 59.5 59.5 0.0 
 3 2.00 1.98 –0.02 30.6 30.5 –0.1 
 3' 1.80 1.79 –0.01 - - - 
 3a 2.24 2.19 –0.05 35.6 35.6 0.0 
 4 2.15 2.02 –0.13 19.1 18.7 –0.4 
 4' 1.47 1.41 –0.06 - - - 
 5 1.49 1.42 –0.07 24.5 25.9 +1.4 
 5' 1.54 1.43 –0.11 - - - 
 6 3.83 3.89 +0.06 68.4 63.6 –4.8 
 7 1.57 1.62 +0.05 28.4 33.0 +4.6 
 7' 2.25 2.05 –0.20 - - - 
 7a 4.32 4.27 –0.05 54.1 54.4 +0.3 
Pla 1 - - - 172.3 172.1 –0.2 
 2 4.18 4.20 +0.02 71.4 71.4 0.0 
 3 2.79 2.82 +0.03 39.8 39.7 –0.1 
 3' 2.96 2.96 0.00 - - - 
 4 - - - 137.8 137.8 0.0 
 5,9 7.24 7.22 –0.02 129.5 129.5 0.0 
 6,8 7.26 7.25 –0.01 127.7 127.6 –0.1 
 7 7.18 7.19 +0.01 125.8 125.8 0.0 
Cleu 1 - - - 167.3 167.6 +0.3 
 2 4.92 4.89 –0.03 51.0 50.8 –0.2 
 3 3.99 3.94 –0.05 68.6 68.8 +0.2 
 4 1.71 1.65 –0.06 27.4 27.3 –0.1 
 5 0.87 0.85 –0.02 15.3 14.9 –0.4 
 5' 0.86 0.84 –0.02 20.6 20.4 –0.2 
 NH 7.67 7.55 –0.12 - - - 
Adc 1 3.16 3.17 +0.01 36.3 36.3 0.0 
 1' 3.24 3.24 0.00 - - - 
 2,2’ 2.25 2.24 –0.01 28.2 28.1 –0.1 
 3 - - - 135.9 136.1 +0.2 
 4 5.61 5.61 0.00 119.0 119.0 0.0 
 5 4.07 4.07 0.00 53.6 53.7 +0.1 
 6 4.07 4.07 0.00 54.9 54.9 0.0 
 NH 7.98 7.96 –0.02 - - - 
 8 - -  154.9 - - 
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7.3. Toxicity of Aglycone 616A 
For the evaluation of the environmental toxicity of A616A (2.91), a standard assay with the 
sensitive freshwater crustacean Thamnocephalus platyurus was conducted. Six concentrations 
of A616A (2.91) ranging from 1.2 µM to 150 µM were prepared and tested in an acute toxicity 
assay (24 h); the results are shown in Figure 34. For each concentration, three experiments 
with ten animals were performed. The mortality rate of the test organisms was determined by 
visual inspection of the animals after exposing them to a defined concentration for 24 h in the 
dark. The thus obtained LC50 value of 21.0 µM for A616A (2.91) was in the same range as the 
toxicity of A828A (2.1) and A748A (2.12). Therefore, the bioassay supports the hypothesis 
that the Xyl residue has a negligible effect on the toxicity of the aeruginosin. However, 
incorporation of the Xyl residue leads to a better solubility in water of the corresponding 
aeruginosin. Since the tested concentrations of 1.2 µM to 150 µM corresponded to high 
dilution, solubility was not an issue in this case. A possible advantageous effect of the Xyl 
moiety on the toxicity might hence be only observed at higher concentrations. Another reason 
for the incorporation of the Xyl residue in A828A (2.1) could be a facilitated cell uptake of 
the glycosylated aeruginosin compared to the aglycone. However, these hypotheses need to be 
investigated in more detail. 
 
Figure 34 Mortality of T. platyurus as a function of the concentration of A616A (2.91). Values 
are given as the mean of three independent experiments with 10 animals; error bars denote the 
standard error of the mean value.  
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8. Alternative Approaches – Synthesis of Aeruginosin 828B 
In the following sections alternative synthetic approaches, which were performed in the 
pursuit of the successful total synthesis of aeruginosin 828A (2.1), will be discussed. The 
focus was laid especially on an alternative introduction of the sulfate group and a different 
assembly of the building blocks, including a late stage glycosylation. 
8.1. Introduction of the Sulfate Group as a Protected Trichloroethyl (TCE) Ester 
One anticipated drawback in the synthetic strategy for the assembly of A828A (2.1), as 
described in Section 5, was the introduction of the sulfate group with subsequent global acidic 
deprotection, regarding that sulfate groups are known to be sensitive to acidic conditions.[57] 
This assumption was supported by first experiments which indeed indicated a loss of the 
sulfate group according to UPLC mass analysis. Moreover, using a large excess of 50 
equivalents of SO3·pyridine complex for the introduction of the sulfate group is inconvenient 
in terms of reaction conditions. A much more elegant way for the incorporation of the sulfate 
group would therefore constitute of its introduction in a masked form at an early stage of the 
synthetic pathway. Thus, the stability of the sulfate towards acidic conditions would be 
increased.[58] Following this strategy, the sulfate group would not be unmasked until the very 
end of the synthesis. The advantage of this approach is that intermediates containing the 
protected sulfate can be easily purified whereas purification of unmasked sulfate containing 
compounds can prove difficult. In the literature, a large scope of protecting groups is 
provided, e.g. for hydroxyls, amines and acids. However, protection/deprotection strategies 
for sulfates are rarely known and are largely unexplored, despite the important role sulfates 
play in a large variety of biologically active compounds.[59,60] In 1981, Penney and Perlin 
reported the introduction of a sulfate group as a protected phenyl sulfate, using phenyl 
chlorosulfate (left, Figure 35).[61] Unmasking of the sulfate by cleavage of the phenyl group 
was performed through catalytic hydrogenation. Due to the poor stability of the 
dihydropyrrole of the Adc unit with regard to hydrogenation conditions, the strategy of 
Penney and Perlin is not suitable for our substrate. Next, Flitsch and co-workers approached 
the problem of sulfate protection in 1997. Flitsch et al. described the formation of a 2,2,2-
trifluoroethyl sulfate ester by treating sulfate monoesters with 2,2,2-trifluorodiazoethane 
(center, Figure 35).[62] The fact that 2,2,2-trifluorodiazoethane is highly toxic and potentially 
explosive and that the unmasking conditions by treatment with potassium tert-butoxide at 
high temperatures are vigorous, resulted in a discharge of this protection strategy in our case. 
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In 2006 finally, Taylor et al. elaborated a convenient method for the masking and unmasking 
of sulfates by the introduction of a trichloroethyl (TCE) group (right, Figure 35).[63] TCE 
protected sulfate esters showed remarkable stabilities against various different reaction 
conditions: strongly acidic conditions among others, thereby allowing unmasking under 
highly selective and mild conditions using a methanolic zinc and ammonium formate 
solution.[63] Furthermore, TCE sulfate esters can be readily obtained by the reaction of an 
adequate alcohol with TCE imidazolium salt 2.97 under mild conditions. The reported 
advantages of the TCE group encouraged us to further investigate this protection strategy in 
our synthesis. 
 
Figure 35 Masking of the sulfate group with a phenyl group (left), trifluoroethyl ester (center) 
and trichloroethyl ester (right). 
 
8.1.1. Preparation of the trichloroethyl protected sulfuryl imidazolium salt 2.97 
To incorporate the TCE group in our synthesis, the TCE protected sulfuryl imidazolium salt 
2.97 had to be prepared first. According to the literature procedure,[63] sulfuryl chloride was 
reacted with 2,2,2-trichloroethanol (2.98) to give sulfurochloridate 2.99 in a high yield. 
Subsequent replacement of the chlorine atom of 2.99 by an imidazole substituent was 
achieved by treating 2.99 with imidazole to access imidazole sulfonate 2.100 in a good yield. 
Finally, 2.100 was transferred to the corresponding imidazolium salt 2.96 in an excellent yield 
using methyl triflate (Scheme 22). 
 
Scheme 22 Synthesis of trichloroethyl protected sulfuryl imidazolium salt 2.97. Reagents and 
conditions: a) sulfuryl chloride, pyridine, Et2O, 78 °C, 1 h, 85%; b) imidazole, THF, 0 °C to 
r.t., 1 h, 67%; c) methyl triflate, Et2O, 0 °C, 3 h, 89%. 
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8.1.2. Preparation of the TCE ester and stability testing under acidic conditions 
For the investigation of the stability of the TCE group under acidic conditions, as used in the 
global deprotection step, model substrate 2.102 was synthesized (Scheme 23). For this, 
thioglycoside 2.69 was treated with a methanolic NaOMe solution to access the free hydroxyl 
group at C4 position of the glycoside 2.101, thus allowing the introduction of the TCE sulfate 
ester. The preparation of TCE sulfate ester 2.102 was achieved in a high yield by the reaction 
of 2.101 with the prepared imidazolium salt 2.97. Further, TCE sulfate ester 2.102 was 
suspended in a diluted CH2Cl2/TFA solution for 20 h, in order to examine whether the TCE 
sulfate ester is stable under such acidic conditions. Pleasingly, exclusively deprotection of the 
BDA group was observed to give diol 2.103, whereas the TCE sulfate ester was not harmed 
(Scheme 23). Hence, the TCE sulfate ester proved to be an ideal candidate for our synthetic 
strategy. 
 
Scheme 23 Introduction and cleavage of the TCE protecting group. Reagents and conditions: 
a) NaOMe, MeOH, CH2Cl2, r.t., 2 h, 83%; b) 2.97, 1-methylimidazole, THF, r.t., 66 h, 88%; c) 
CH2Cl2/TFA (10:1), r.t., 20 h, quant. 
  
CHAPTER I: TOXICITY AND SYNTHESIS OF AERUGINOSIN CHLOROSULFOPEPTIDES 
 
 
 
84 
8.1.3. Incorporation of the TCE sulfate ester into late stage intermediates 
Encouraged by the results described in the previous section, several attempts were performed 
to introduce the TCE sulfate ester at a late stage of the synthesis (Scheme 24). First, 
introduction at the stage of tetrapeptide 2.84 was investigated, unfortunately resulting in no 
formation of TCE protected sulfate 2.105. Next, tripeptide intermediates 2.83 and 2.87 were 
subjected to the same protection conditions, yet again leading to no observable conversion to 
sulfate esters 2.106 and 2107, respectively. Tripeptides 2.83 and 2.87 contain the free acid 
function at the L-Choi moiety, which could interfere with the outcome of the reaction. Thus, 
tripeptide 2.104, containing a methyl ester instead of the free acid, was prepared. However, 
reaction of tripeptide 2.104 with reagent 2.97 showed no formation of the desired TCE sulfate 
ester 2.108 either. The reasons for the poor reactivity of the tested substrates regarding the 
protection with a TCE sulfate ester remain unclear and have to be further investigated. One 
explanation could be the complexity of the intermediates causing more steric interference, 
since the protection worked well and reliably with the much less complex model substrate 
2.101. In conclusion, introduction of the TCE sulfate ester did not prove successful at a late 
stage of the synthesis. 
 
Scheme 24 Introduction of the TCE sulfate ester at a late stage of the synthesis. Reagents and 
conditions: a) 2.97, 1-methylimidazole, THF, r.t., 42–86 h. 
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8.2. One Step Back – Incorporating the TCE Sulfate Ester before Glycosylation 
Since late stage introduction of the TCE sulfate ester was not successful, a new synthetic 
strategy had to be investigated. This new route incorporated the use of a xylosyl donor already 
bearing the TCE sulfate ester on C4 position of the glycoside for the glycosylation reaction. 
The straightforward synthesis of such a xylosyl donor had already been investigated in 
Section 8.1.2. Because subjecting TCE sulfate xylosyl donor 2.102 to the conditions used for 
removing the Cbz group from the L-Choi led to cleavage of the TCE group in a test 
experiment, another strategy for the assembly of the different subunits had to be considered 
(for cleavage of the Cbz group from the L-Choi see Section 5.2). The new assembly comprises 
a first peptide coupling of the L-Choi core unit 2.92 with Cleu-Pla-OH 2.47 and Leu-Pla-OH 
2.53, respectively. Subsequently, L-Choi-Cleu-Pla unit 2.109 and L-Choi-Leu-Pla unit 2.110 
serve as acceptors in the xylosylation step, building up the Xyl-L-Choi-Cleu-Pla and Xyl-L-
Choi-Leu-Pla fragments, respectively. With this assembling strategy, a possible cleavage of 
the TCE group during Cbz deprotection can be avoided. 
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8.2.1. Preparation of different acceptors 
The two acceptors 2.109 and 2.110 were synthesized in a straightforward manner starting 
from L-Choi derivative 2.92. Peptide coupling of amine 2.92 with Pla-Cleu-OH unit 2.47 and 
Pla-Leu-OH unit 2.53 using DMTMM and NMM gave the corresponding tripeptides L-Choi-
Cleu-Pla 2.93 and L-Choi-Leu-Pla 2.90 in a high yield. Selective saponification of the acetyl 
ester at L-Choi-C6 position was achieved by treatment with a methanolic K2CO3 suspension, 
which did not harm the L-Choi methyl ester (Scheme 25). Using these reaction conditions, 
acceptors 2.109 and 2.110 were obtained, ready to be used in the xylosylation step. 
 
Scheme 25 Preparation of L-Choi acceptors 2.109 and 2.110. Reagents and conditions: a) Pla-
Cleu-OH 2.47, DMTMM, NMM, CH2Cl2, 0 °C to r.t., 2 h, 83%; b) Pla-Leu-OH 2.53, DMTMM, 
NMM, CH2Cl2, 0 °C to r.t., 3.5 h, 80%; c) K2CO3, MeOH, r.t., 2–3.5 h, (2.109: 85% from 2.93; 
2.110: 61% from 2.90). 
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8.2.2. Preparation of different donors  
To increase the scope of the glycosylation reactions, several different xylosyl donors 
containing the TCE sulfate ester were synthesized starting from thioglycoside 2.102 (Scheme 
26): Xylosyl donor 2.111, bearing a bromine atom at the anomeric position, was obtained as 
an anomeric mixture D/E of 6:1 by treating 2.102 with bromine.[64] Introduction of the 
trichloroacetimidate was carried out by reaction of 2.102 with Cl3CCN under basic conditions 
to access trichloroacetimidate 2.112 in a mixture D/E of 2:1.[65] Oxidation of the thiophenol 
group of 2.102 with m-CPBA gave the corresponding sulfoxide xylosyl donor 2.113 as a 1:1 
diastereomeric mixture.[66] Hydrolysis of the thiophenol group of 2.102 to the alcohol yielded 
xylosyl donor 2.114 as a mixture D/E of 2:1.[67] Fluorination of the anomeric position of 2.102 
using diethylaminosulfur trifluoride (DAST) provided fluorinated xylosyl donor 2.115.[68] All 
prepared xylosyl donors were then tested in the glycosylation step together with acceptors 
2.109 and 2.110 (Section 8.3.3.). 
 
Scheme 26 Synthesis of the different xylosyl donors. Reagents and conditions: a) Br 2, CH2Cl2, 
r.t., 1 h, 86%; b) Cl3CCN, DBU, CH2Cl2, r.t., 2 h, 55%; c) m-CPBA, KF, MeCN/H2O (5:1), 
0 °C, 5 min, 71%; d) NBS, acetone/H2O (9:1), 10 °C, 2 h, 53%; e) DAST, NBS, CH2Cl2, 
15 °C, 2 h, 76%. 
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8.3. Late Stage Glycosylation 
8.3.1. A closer look on the mechanism of glycosylations 
The elaboration of effective glycosylation methods with a manageable control over the 
diasteromeric outcome of the formed O-glycosidic linkage has been challenging organic 
chemists ever since the first reported glycosylation by Michael in 1879.[69] The term 
glycosylation generally describes the condensation of an alcohol, sometimes referred to as the 
acceptor, with a glycoside group bearing a leaving group (LG) at the anomeric position, 
referred to as the donor. Usually the glycosyl donor is activated with a promotor (E+X−), 
which transfers the substituent at the anomeric position into a better leaving group (LG-E+), 
thus enabling a facilitated cleavage thereof. Through cleavage of the activated leaving group 
an oxocarbenium ion is formed as active intermediate (highlighted in red, Figure 36). The 
creation of this oxocarbenium ion is the reason why the stereochemical control of a 
glycosylation is so difficult to manage and predict, since many parameters are involved in the 
stabilization of the oxocarbenium ion leading to different possible pathways. Pathway A: The 
former leaving group of the donor stays in close proximity to the oxocarbenium ion, thus, 
forming a contact ion pair (CIP). Depending on the nature of the leaving group, different 
orientations of the leaving group can be accessed in the CIP, favoring either an α  or  β  attack  
of the alcohol. A solvent-separated ion pair of the LG− with the oxocarbenium ion is also 
possible.[70] Pathway B: The solvent (S) participates by forming weak covalent bonds to the 
oxocarbenium ion, this behavior has been observed with acetonitrile and diethyl ether, for 
example.[71] Depending on the preferred position of the solvent donor, an α  or  β  attack  of  the  
alcohol is favored. The used solvent exerts a tremendous impact on the outcome of the 
glycosylation in any case, since polar solvents can lead to a stabilization of the oxocarbenium 
ion.[70] Path C: The counter ion (X−) of the promoter affects the stereochemical outcome of 
the glycosylation by forming either a CIP or a covalent bond with the oxocarbenium ion.[70] 
Concluding, the diasteromeric outcome of a glycosylation reaction depends on the leaving 
group, promoter, solvent and temperature. Determined by the reaction conditions, one 
intermediate will be dominant and hence responsible for the stereochemical outcome.  
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Figure 36 Possible intermediates occurring during a glycosylation reaction. LG = leaving group; 
P = nonparticipating substituent; EX = promoter (electrophile and leaving group), S = solvent.  
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8.3.2. The principle of armed and disarmed glycosyl donors 
The reactivity and selectivity of a glycosylation is also affected by the substituents the 
glycosyl donor is decorated with. Freiser-Reid and co-workers first described an enhanced 
reactivity rate of benzyl-protected donors compared to acetyl-protected donors during 
glycosylations reactions (Figure 37).[72,73] They  introduced  the  terms  “armed”  and  “disarmed”  
for donors with enhanced and reduced reactivity. The increased reactivity of an armed donor 
can be explained by the electron-pushing nature of e.g. benzyl groups, which stimulates the 
dissociation of the bond between the leaving group and the anomeric carbon atom by a 
stabilization of the positive charge of the obtained oxocarbenium ion intermediate. On the 
contrary, electron-withdrawing moieties such as acetyl protecting groups lead to a 
destabilization of the oxocarbenium ion intermediate. The principle of armed and disarmed 
donors especially meets applications in the oligosaccharide one-pot-synthesis, since it allows 
for directing the reactivity of two co-existing donors. 
 
Figure 37 Armed and disarmed glycosyl donors. 
 
8.3.3. Glycosylations with TCE-protected sulfate  
With the L-Choi-Cleu-Pla (2.109) and L-Choi-Leu-Pla (2.110) acceptors in hand, coupling to 
the Xyl donors was investigated. First attempts using thioglycoside donor 2.102 and the 
conditions developed for the glycosylation step during the synthesis of A828A (2.1) 
(Section 5.1.) led to no conversion (Entry 1, Table 8). Changing the activator/promoter system 
from NIS/AgOTf to Tf2O/Ph2SO/SnCl4[74] showed no improvement, leading to no conversion, 
but only decomposition (Entry 2, Table 8). As described in Section 8.3.2, the introduction of 
electron-withdrawing substituents leads to disarming of the corresponding donor. The poor 
reactivity of the glycosylations can therefore be explained by the electron-withdrawing nature 
of the TCE sulfate ester, leading to disarming of the Xyl donors. Next, donor 2.114, with a 
hydroxyl leaving group, was treated with acceptors 2.109 and 2.110 under Appel-like 
conditions.[75] Again, no conversion was observable for both reactions (Entries 3 and 4, Table 
8). Further, the reactivity of fluorinated donor 2.115 was investigated.  
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Table 8 Conditions for the glycosylation of different Xyl donors with acceptors 2.109 and 2.110
 
Entry Donor Acceptor Conditionsa Observationb α/βc 
1 SPh 2.109 NIS, AgOTf, Et2O, r.t. no reaction - 
2 SPh 2.110 Tf2O, Ph2SO, SnCl4, CH2Cl2, 78 °C decomposition - 
3 OH 2.110 CBr4, PPh3, DMF, r.t. no reaction - 
4 OH 2.109 CBr4, PPh3, DMF, r.t. no reaction - 
5 F 2.110 SnCl2, AgClO4, Et2O, r.t.d no reaction - 
6 F 2.110 SnCl2, AgClO4, Et2O, r.t.e no reaction - 
7 F 2.109 NIS, AgOTf, CH2Cl2, r.t. decomposition - 
8f OCNHCCl3 2.109 TMSOTf, DTBMP, CH2Cl2, 20 °C conversion 1:5 
9g OCNHCCl3 2.109 TMSOTf, DTBMP, CH2Cl2, 20 °C conversion 1:5 
10 S(O)Ph 2.109 Tf2O, DTBMP, PhMe, 78 °C conversion 1:2 
11 S(O)Ph 2.109 Tf2O, DTBMP, CH2Cl2, 78 °C conversion 1:4 
12 Br 2.110 AgOTf, DTBMP, Et2O, r.t. hydrolysis - 
13 Br 2.110 AgOTf, DTBMP, MeCN, r.t. hydrolysis - 
14 Br 2.109 AgOTf, DTBMP, Et2O, r.t. full conversion 1:5 
15 Br 2.109 AgOTf, DTBMP, CH2Cl2, r.t. full conversion 1:5 
16 Br 2.109 AgOTf, DTBMP, MeCN, r.t. decomposition - 
17 Br 2.109 AgOTf, DTBMP, PhMe, r.t. full conversion 1:20 
18 Br 2.109 Ag2O, CH2Cl2, r.t no reaction - 
19 Br 2.109 Ag2O, PhMe, r.t no reaction - 
20 Br 2.109 AgClO4, CH2Cl2, r.t full conversion 3:5 
aThe reactions were carried out under careful exclusion of water and in the presence of 4 Å molecular sieves. bThe 
screening was performed with small amounts, thus the yield was not always determined, but the conversion was 
monitored by TLC and/or UPLC. cThe anomeric ratio was determined either by the isolated yields or by integration 
of the characteristic shifts of the anomeric proton signals in the crude 1H NMR spectra. d2.50 equivalents of SnCl2 
and AgClO4 were used. e6.0 equivalents of SnCl2 and AgClO4 were used. fAn anomeric mixture of α/β (2:1) of donor 
2.112 was used. gβ anomer of donor 2.112 was used. 
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Nicolaou and co-workers reported the use of fluorinated donors in the synthesis of the natural 
product avermectin B1a. They used SnCl2 and AgClO4 as promoter system for linking a 
sterically demanding secondary alcohol with a fluorinated glycosyl donor.[68] The fact that 
these reaction conditions did not result in any conversion supports the assumption that the 
problem lies in the poor reactivity of the different donors, since Nicolaou successfully used a 
much less reactive acceptor in his glycosylation (Entries 5 and 6, Table 8).[68] Furthermore, by 
changing to a stronger activator/promoter system with NIS/AgOTf, only decomposition could 
be observed (Entry 7, Table 8). As a next step, the use of trichloroacetimidate donor 2.112 
was explored. Trichloroacetimidates were first introduced by Schmidt and co-workers in the 
1980s and have since become a useful tool in glycosyl chemistry.[65] Indeed, by using the 
Schmidt conditions the formation of the O-glycosidic linkage between acceptor 2.109 and 
donor 2.112 was achieved, although the undesired β   anomer  was   favored   in   a   ratio   of   5:1  
(Entry 8, Table 8).[67] Since an anomeric mixture of α/β  2:1  of donor 2.112 had been used in 
the previous experiment, the pure β  anomer  of  2.112 was tested next. With this experiment, it 
was investigated whether the configuration of the donor has an influence on the 
stereochemical  outcome.  Unfortunately,   the  observed  ratio  of  α/β  did  not change and stayed 
1:5  in  favor  of  the  β  anomer, indicating that the glycosylation reaction undergoes a pure SN1 
reaction pathway (Entry 9, Table 8). Seeing that the Schmidt conditions favored the formation 
of the β   anomer,   other   donors   and   conditions   were   investigated   in   order   to   access   the  
formation  of   the   favored  α   anomer.  Kahne  and  co-workers reported a rapid method for the 
glycosylation of unreactive substrates by the use of sulfoxides as donors, promoted by Tf2O 
and 2,6-di-tert-butyl-4-methylpyridine (DTBMP). Further, they could control the 
stereochemical  outcome  of  the  glycosylation  by  changing  the  solvent  from  toluene  (α/β  20:1),  
to CH2Cl2 (α/β   1:3)   and   to   propionitrile   (α/β   1:8).[76] Kahne’s   conditions   led   to   good  
conversion of donor 2.113 and acceptor 2.109 in toluene in combination with an anomeric 
ratio α/β  of  1:2,  which  were  the  best  results  obtained  so  far  (Entry 10, Table 8). Since Kahne 
et al. reported the strong influence of the solvent on the stereochemical outcome of this 
reaction, the solvent was switched from toluene to CH2Cl2, to find the same tendency such as 
that  more  polar   solvents   favor   the   formation  of   the  β  anomer   (Entry 11, Table 8). Last, the 
traditional Koenigs-Knorr conditions were investigated by the use of brominated donor 2.111. 
Brominated donors are known to be very reactive, therefore donor 2.111 was formed in situ 
during the glycosylation, since purification of donor 2.111 already led to its hydrolysis.[64] 
First attempts with acceptor 2.110 and AgOTf/DTBMP as activator/promoter system were 
accompanied by hydrolysis of the xylosyl donor (Entries 12 and 13, Table 8). Careful 
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exclusion of water finally led to a clean reaction in Et2O under full conversion of donor 2.113 
and acceptor 2.109 with a preference for the β  anomer  of  5:1  (Entry 14, Table 8). Knowing 
about the influence of the solvent on the stereochemical outcome, a screening of different 
solvents was performed (Entries 15, 16 and 17, Table 8). While the use of CH2Cl2 led to a 
comparable ratio as before (Entry 15), the use of MeCN showed only decomposition products 
(Entry   16).   Surprisingly,   toluene   induced   an   even   more   pronounced   favoritism   for   the   β  
anomer of 20:1 (Entry 17),   which   is   in   contradiction   to   the   results   obtained  with   Kahne’s  
method (Entries 10 and 11, Table 8).[76] This exemplifies the difficulty assigned to 
glycosylations, which is that general predictions of the stereochemical outcome are difficult to 
predict. Albeit in the literature[77] some tendencies for the stereochemical outcome are 
described by changing a specific parameter, these tendencies can heavily vary for each 
condition and as shown before, even the opposite can occur. This demonstrates the great 
importance of experimental synthetic work. Since the brominated donor proved to be very 
active, a weak activator/promoter system with Ag2O instead of AgOTf/DTBMP was 
investigated. However, neither in CH2Cl2 nor in toluene any conversion was observed (Entries 
18 and 19, Table 8). Finally, the best results were obtained using the moderate activator 
AgClO4 with  full  conversion  and  an  anomeric  ratio  α/β  of  3:5.  Because  in  the  meantime  the  
approach described in Section 5 gave rise to the successful synthesis of A828A, this approach 
with the late stage glycosylation using TCE sulfate ester donors was not further optimized. 
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8.4. Synthesis of Aeruginosin 828B 
Disregarding the success of the glycosylation step described in the previous section, we were 
interested in the endgame of the synthesis A828A (2.1). Since only very little amounts of the 
α  anomer  of  Xyl-L-Choi-Cleu-Pla 2.116 were obtained, the last steps of the synthesis were 
performed  with   the   β   anomer   of  2.116 (Scheme 27). Due to the poor stability of the TCE 
group under basic conditions, the general conditions for the saponification of the L-Choi 
methyl ester could not be used. Instead, milder conditions were used by treatment of 2.116 
with an excess of Me3SnOH,[78,79] resulting in a slow reaction rate.  
 
Scheme 27 Synthesis of aeruginosin 828B. Reagents and conditions: a) Me 3SnOH, DCE, 85 °C, 
90 h, 34% (97% brsm); b) Adc subunit 2.63, PyBOP, 2,6-lutidine, CH2Cl2, 0 °C to r.t., 4 h, 
95%; c) CH2Cl2/TFA (10:1), r.t., 10 h; d) Zn powder, ammonium formate, MeOH, r.t., 2 h, 44% 
over two steps. 
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Even after several days a yield of only 34% of acid 2.118 was observed, accompanied by the 
recovery of 63% of starting material 2.116. Acid 2.118 was further coupled with Adc subunit 
2.63 to give tetrapeptide 2.119 in an excellent yield. Cleavage of the Boc, BDA and MOM 
protecting groups was performed in a diluted TFA/CH2Cl2 solution, giving access to 
tetrapeptide 2.120. Final unmasking of the sulfate group in 2.120 was performed in a 
methanolic zinc powder/ammonium formate solution. Thus, 350 µg of aeruginosin 828B 
(2.121) could be obtained in 44% yield over the last two deprotection steps and after HPLC 
purification. It has to be mentioned that the five last steps were performed only once and on a 
very small scale, which leaves room for optimizations. Nevertheless, the feasibility of this 
synthetic strategy could be undoubtedly demonstrated. 
 
8.4.1. Comparison of the 1H NMR spectra of A828A and A828B 
Due to the small quantities obtained for A828B (2.121), no 2D NMR spectra were recorded. 
Therefore, the full assignment of the signals of A828B (2.121) could not be conducted. In 
general, the proton signals of the L-Choi, Adc, Cleu and Pla units of A828A (2.1) and A828B 
(2.121) are very similar. Differences were observed of course for the proton signals of the Xyl 
residue going from A828A (2.1) to A828B (2.121). 
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9. Conclusion 
In this chapter, the first total synthesis of the cyanobacterial toxin aeruginosin 828A (2.1) was 
reported. In the beginning, the synthesis of all required building blocks for the synthesis of 
A828A (2.1) was accomplished. The subsequent assembly of the building blocks featured a 
stereoselective α-xylosylation of L-Choi building block 2.37 with xylosyl donor 2.69. By 
screening different coupling reagents and conditions, the problem of HCl elimination during 
the peptide coupling of Xyl-L-Choi-H 2.72 with Pla-Cleu-OH dipeptide 2.47 was solved using 
DMTMM as coupling reagent. Completion of the total synthesis was achieved by another 
peptide coupling of xylosylated Pla-Cleu-L-Choi-OH 2.83 with Adc unit 2.63, followed by 
sulfonation and global deprotection. In summary, A828A (2.1) was successfully synthesized 
over a longest linear sequence of 18 steps incorporating 50 synthetic steps in total. 
Further, the developed synthetic strategy for A828A (2.1) was successfully adopted in the 
synthesis of the natural congener aeruginoside 126A (2.11) and the synthetic analogues 
A748A (2.12) and A794A (2.13). Comparison of the NMR spectra of chlorinated congeners 
A828A (2.1) and A748A (2.12) with non-chlorinated A126A (2.11) and A794A (2.13) 
revealed an interesting modulating effect of the chlorine atom on the conformation of the 
particular aeruginosins. While A828A (2.1) and A748A (2.12) appeared as a single rotamer, 
A126A (2.11) and A794A (2.13) were present as a rotameric mixtures of around 4:1, which 
was proven by 2D ROESY and variable temperature 1H NMR experiments. The synthesized 
compounds A828A (2.1), A794A (2.13), A748A (2.12) and A126A (2.11) were tested with 
regard to their toxicity against the freshwater crustacean T. platyurus, demonstrating that the 
sulfate   group   has   a   critical   effect   on   the   toxicity,   whereas   a   “chlorine   effect”   like   in   the  
inhibition of proteases was not observed. This finding led to the assumption that the toxicity 
of the chlorosulfopeptides has to be explained by another mode of action than the inhibition of 
protease enzymes. Further, the findings support the hypothesis that chlorosulfopeptides have 
to be considered not only as potent protease inhibitors but also as cyanobacterial biotoxins. 
This dual function of chlorosulfopeptides such as A828A (2.1) might be the reason for the 
inactivation of the mcy gene cluster in some cyanobacteria strains, which resulted in the loss 
of microcystin production in these strains. Therefore, MC formation became obsolete in 
cyanobacteria strains which produced chlorosulfopeptidic toxins like A828A (2.1). Further, 
aglycone A616A (2.91) of A828A (2.1) was synthesized. The determined potent toxicity of 
aglycone A616A (2.91) revealed that the aglycone of each particular aeruginosin has to be 
considered as cyanobacterial toxin, too. 
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In the course of the total synthesis of A828A (2.1) alternative approaches were also 
investigated. These incorporated a late stage glycosylation with a xylosyl donor bearing a 
masked sulfate group. This alternative approach resulted in the synthesis of aeruginosin 828B 
(2.121) which contains a β linkage to the xylosyl residue. In general, the work described in 
this chapter contributes to a better understanding of the toxicity related to chlorosulfopeptides 
produced by particular cyanobacterium strains. 
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1. Introduction 
In this chapter, the results of a purely synthesis driven research project are described. The 
efforts which were made in order to elucidate strategies for the synthesis of the recently 
isolated aeruginosin KT608A (3.1) are summarized. A special focus was laid on the efficient 
synthesis of the D-diepi-Choi unit present in KT608A (3.1). 
1.1. Isolation and Bioactivity of Aeruginosins KT608A, KT608B and KT650  
In 2012, Carmeli and co-workers reported the isolation of aeruginosin KT608A (3.1), 
KT608B (3.2) and KT650 (3.3) from Microcystis aeruginosa bloom material obtained from 
Lake Kinneret in Israel.[1] The especialness of these three isolated aeruginosins is the presence 
of a novel D-diepi-Choi motif instead of the L-Choi moiety usually observed in 
aeruginosins.[2] Further, Carmeli et al. investigated the inhibitory activities against serine 
proteases trypsin and thrombin of 3.1, 3.2 and 3.3. While aeruginosin KT608A (3.1) and 
KT608B (3.2) revealed a potent inhibition of trypsin with IC50 values of 1.9 and 1.3 µM, 
KT650 (3.3) showed an activity an order of magnitude lower with an IC50 value of 19.9 µM.[1] 
Interestingly, KT608A (3.1) induced an enhanced thrombin activity of 30% at a concentration 
of 45.5 µM, whereas KT608B (3.2) and KT650 (3.3) inhibited the activity of thrombin by 
50% at this concentration.[1] 
  
Figure 38 Elucidated structures of aeruginosin KT608A (3.1), KT608B (3.2) and KT650 (3.3) 
by Carmeli and co-workers.[1] 
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1.2. Previous Syntheses 
In this section, previously described syntheses of aeruginosins performed by other research 
groups will be discussed. Thereby, the focus is laid on the reported strategies for the 
preparation of the different Choi units. 
1.2.1. Bonjoch’s  contributions  to  the  syntheses  of  aeruginosins 
Bonjoch and co-workers effectively synthesized a variety of different aeruginosins.[3–7] The 
total syntheses of Bonjoch et al. build on a straightforward synthesis of the L-Choi core, 
which they had already developed in 1996.[8] This synthesis was later successfully 
implemented in the first total synthesis of aeruginosin 298A (1).[3] Bonjoch’s  preparation  of  
the L-Choi unit commenced with the Birch reduction of L-tyrosine derivative 3.4 to give 
compound 3.5. Further, the methoxy ether of 3.5 was cleaved under acidic conditions and the 
in situ formed α,β-unsaturated ketone was attacked intramolecularly by the amine in an aza 
Michael type addition providing a diasteromeric mixture of ketone 3.6 (Scheme 28).   
 
Scheme 28 Bonjoch’s  synthesis of L-Choi derivative 3.9 and L-diepi-Choi building block 3.10. 
Reagents and conditions: a) Li, NH3, THF/tBuOH,   ‒78   °C;;   b)   MeOH,   7.5   N HCl, 35 °C; c) 
BnBr, NaHCO3, EtOH, 70 °C; d) MeOH, 8 N HCl, 65 °C, 44% over four steps; e) H2, Pd(OH)2; 
f) Boc2O, EtOAc; g) LS-Selectride,  THF,  ‒78  °C,  42%  over  three  steps;;  h)  TFA,  CH2Cl2, 0 °C, 
quant.; i) NaBH4,  MeOH,    ‒78  °C,  72%. 
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Subsequent benzyl protection yielded ketones 3.7 and 3.8. Under acidic conditions, ketone 3.7 
could be isomerized to 3.8. For the completion of the L-Choi synthesis, the Bn group was 
replaced by a Boc group, followed by diastereoselective reduction of the ketone to the 
octahydroindole. Removal of the Boc group finally gave access to L-Choi derivative 3.9 
(Scheme 28). Usage of L-Choi building block 3.9 subsequently led to the total synthesis of 
aeruginosins 298A (1)[3] and 298B (8)[5] and microcin SF608 (7)[4]. (For the structures of the 
different aeruginosins see pages 5 and 8 in the general introduction). Branching off at 
intermediate 3.7 provided L-diepi-Choi building block 3.10, which was implemented in the 
synthesis of aeruginosin EI461 (Scheme 28).[6] Bonjoch et al. also reported the so far only 
synthesis of a D-diepi-Choi building block. For this, they used the same synthetic strategy as 
for the L-Choi synthesis, yet starting from D-tyrosine derivative 3.11 instead of L-tyrosine. 
Consequently, ketone 3.12, the enantiomer of intermediate 3.8 from the L-Choi synthesis, 
could be prepared. Further, reduction of ketone 3.12 followed by protection of the hydroxyl 
group and deprotection of the amine gave D-diepi-Choi building block 3.13 (Scheme 29). 
 
 
Scheme 29 Bonjoch’s   synthesis  of  D-diepi-Choi building block 3.13. Reagents and conditions: 
a) NaBH4, MeOH, 80%; b) Ac2O, DMAP, PyBOP, 95%; c) TFA, CH2Cl2, 0 °C, quant. 
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1.2.2. Wipf’s  contribution to the syntheses of aeruginosins 
Instead of the reductive route described by Bonjoch,[3] Wipf and co-workers reported an 
oxidative route starting from Cbz-L-Tyr (3.14) (Scheme 30). Oxidative amination of 3.14 
induced by a hypervalent iodine species provided bicyclic intermediate 3.15. Protection of the 
tertiary alcohol of 3.15 yielded compound 3.16, which could be isomerized under basic 
conditions to the thermodynamically more stable isomer 3.17. Further, reductive cleavage of 
the benzoyl ester gave access to intermediate 3.18. Hydrogenation of the alkene function in 
3.18 provided cis fused bicyclic system 3.19. The ketone of 3.19 could be diastereoselectively 
reduced to the alcohol in a similar fashion as described by Bonjoch.[3] Subsequent protection 
of the hydroxyl group with a TBS group finally provided the fully protected L-Choi building 
block 3.20 (Scheme 30). First, Wipf et al. incorporated building block 3.20 in the synthesis of 
aeruginosin 298A (1).[9] Later, they could also adopt the same strategy for the total synthesis 
of the natural product tuberostemonin.[10] 
 
Scheme 30 Wipf’s   synthesis   of   the   fully   protected   L-Choi building block 3.20. Reagents and 
conditions: a) PhI(OAc)2, NaHCO3, MeOH, 55%; b) Bz2O, DMAP, pyridine, CH2Cl2, 90%; c) 
NaHCO3, DMSO, 90 °C, 78%; d) Zn dust, AcOH/THF, 65 °C, 75%; e) H2, PtO2, AcOH/EtOH, 
0 °C, 95%; f) L-Selectride, THF, ‒78 °C; g) TBSOTf, imidazole, CH2Cl2, 87% over two steps. 
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1.2.3. Hanessian’s  contributions  to  the  syntheses  of  aeruginosins 
Besides the work of Bonjoch, the group of Hanessian probably contributed the most to the 
synthesis and structural confirmation of aeruginosins.   Hanessian’s   efforts   led   to   the  
preparation of numerous aeruginosins, e.g. oscillarin (3)[11], dysinosin A (49)[12], 
chlorodysinosin A (50)[13] and aeruginosin 205A (38) and B (39)[14] (for the structures of the 
different aeruginosins see pages 7, 10 and 11 in the general introduction). The successful 
syntheses of the above mentioned aeruginosins build on a facile synthesis of the L-Choi 
moiety (Scheme 31). To start with, N-Protected glutamate 3.21 was transformed to the 
terminal olefin 3.22. Deprotection of the amine of 3.22 followed by an intramolecular lactame 
formation in refluxing toluene with subsequent Boc protection provided lactame 3.23. 
Reduction of lactame 3.23 with superhydride and successive acetyl protection of the alcohol 
provided intermediate 3.24. The key step consisted of a N-acyloxyiminium ion aza-Prins 
halocarbocyclization of 3.24 leading to the second ring closure and thus to octahydroindole 
structure 3.25. Replacement of the bromine substituent at C6 position with an OAc group 
under inversion of the stereochemical configuration provided acetyl ester 3.26. Removal of 
the Boc group of 3.26 finally gave access to L-Choi building block 3.27. 
 
Scheme 31 Hanessian’s   synthesis   of   L-Choi building block 3.27. Reagents and conditions: 
a) LiHMDS,  THF,  ‒78   °C,   then  3-butenol triflate, 85%; b) TFA, CH2Cl2, then toluene, reflux, 
92% over two steps; c) Boc2O, Et3N, DMAP, CH2Cl2, 90%; d) LiHBEt3,  THF,  ‒78  °C;;  e)  Ac2O, 
Et3N, DMAP, CH2Cl2, 91% over two steps; f) SnBr4,  DCM,  ‒78  °C,  5  min, 78%; g) Bu4NOAc, 
toluene, 50 °C, 78%; h) TFA, CH2Cl2. 
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1.2.4. Carreira’s  synthesis  of  microcin  SF608 
Carreira and his group also provided a synthetic route for the synthesis of the L-Choi core, 
developed during the synthesis of microcin SF608 (7) (Scheme 32).[15,16] Carreira’s  synthesis  
features E-α,β-unsaturated ester (3.28)[17] which upon diasteroselective epoxidation and 
lactone formation was transformed into intermediate 3.29. Azidation of lactone 3.29 provided 
azidolactone 3.30, which was subsequently opened with O-TBDPS-protected 4-aminobutanol. 
Reduction of the azide followed by Cbz protection of the obtained amine afforded 
intermediate 3.31. Further, regioselective reduction of the epoxide of 3.31 yielded compound 
3.32. Acetylation of the secondary alcohol in 3.32 was followed by deoxygenation of the 
tertiary alcohol to give intermediate 3.33. By removal of the Cbz protecting group followed 
by intramolecular nucleophilic opening of the oxabicyclo[2.2.1]heptane by the obtained 
amine, octahydroindole 3.34 was gained with the desired L-Choi configuration. Intermediate 
3.34 was further converted into microcin SF608 (7) over ten additional synthetic steps. 
 
Scheme 32 Carreira’s   synthesis   of  microcin  SF608   (7). Reagents and conditions: a) m-CPBA, 
CH2Cl2, 93%; b) H2, Pd/C, then K2CO3,  MeOH,  78%;;  c)  LiHMDS,  ‒78  °C,  then  TrisN3,  ‒45 °C, 
then AcOH/KOAc, CH2Cl2, 58%; d) O-TBDPS-4-amino-1-butanol, CH2Cl2, 94%; e) H2, Pd/C, 
MeOH, then CbzCl, NaHCO3, EtOAc/H2O 1:1, 88%; f) Cp2TiCl2, Zn, 1,4-cyclohexadiene, THF, 
0 °C, 75% brsm; g) Ac2O, Et3N, DMAP, CH2Cl2, 99%; h) m-CF3-C6H4COCl, Et3N, DMAP, 
CH2Cl2, 91%; i) hν (UV), N-methylcarbazole, 1,4-cyclohexadiene, THF/H2O 1:1, 68%; j) H2, 
Pd/C, MeOH, 93%; k) TMSOTf, Et3N, CH2Cl2, 81%. 
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1.2.5. Trost’s  synthesis  of  aeruginosin  95B 
In the total synthesis of aeruginosin 98B (2), Trost and co-workers used a Pd-catalyzed 
asymmetric allylic alkylation (AAA) of late stage intermediates 3.39a and 3.39b to form the 
bicyclic backbone of the L-Choi unit (Scheme 33).[18] Intermediates 3.39a and 3.39b were 
synthesized starting from 4-methoxyphenol (3.35), which was reduced in a first step under 
Birch conditions, followed by TIPS protection of the alcohol and diastereoselective 
D-hydroxylation to give racemic 3.36. TES protection of 3.36 followed by treatment with 
Comin’s   reagent   afforded   triflate   3.37. Heck coupling of the obtained triflate 3.37 with 
N-Boc-3-iodalanine methyl ester provided intermediates 3.38a and 3.38b, which could be 
further converted over three synthetic steps into the AAA reaction precursors 3.39a and 
3.39b. The obtained bicyclic AAA reaction product 3.40 was finally transferred over two 
steps into L-Choi derivative 3.41 (Scheme 33). 
 
Scheme 33 Trost’s   synthesis   of   aeruginosin   98B   (2). Reagents and conditions: a) Li, NH3, EtOH, 
−78 °C, then TIPSOTf, 2,6-lutidine, CH2Cl2, 0 °C, then OsO4, NMO, THF/H2O 3:1, 0 °C, 96%; b) 
TESCl, imidazole, DMAP, CH2Cl2, 97%;;  c)  LiHMDS,  Comin’s  reagent,  ‒78 °C  to  ‒40  °C,  88%;;  d)  N-
Boc-3-iodalanine methyl ester, Zn, TMSCl, Pd(PPh3)4, LiCl, DMA, 60 °C, 87%; e) HF-pyridine, 
CH2Cl2, 0 °C, 93%; f) methyl chloroformate, pyridine, DMAP, CH2Cl2, 0 °C, 98%; g) TFA, CH2Cl2, 
−10 °C; h) [(η3-C3H5)PdCl]2, racemic L1, TFA, THF, 60 °C, 96%; i) BnBr, Et3N, MeCN, then TBAF, 
89%; j) H2, Pd/C, MeOH, 92%. 
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1.2.6. Baudoin’s  contributions to the syntheses of aeruginosins  
The most recent contribution to the total synthesis field of aeruginosins arose from Baudoin 
and his group. Already in 2012, Baudoin et al. showed that the octahydroindole core of the 
Choi can be readily accessed via an intramolecular Csp3-H alkenylation.[19] Based on this 
work, Baudoin and co-workers established an efficient, scalable synthesis for the L-Choi 
motif (Scheme 34). The synthesis was commenced with commercially available 
dihomoallylalcohol 3.42, which after TBDPS protection of the alcohol and ring-closing 
metathesis afforded cyclopentenol 3.43. Subsequent dibromocyclopropanation[20] provided 
cyclopropane 3.44 which upon thermal electrocyclic ring expansion furnished 
dibromocyclohexene 3.45. Nucleophilic substitution with a TBS-protected L-alaninol 
derivative followed by trifluoroacetylation of the amine yielded 3.46. Intramolecular Csp3-H 
alkenylation of 3.46 catalyzed by [Pd(PCy3)2] rendered hexahydroindole 3.47. Hydrogenation 
of the alkene in 3.47 provided octahydroindole 3.48, which was oxidized to the corresponding 
methyl ester 3.49 after deprotection of the alcohol. Cleavage of the trifluoroacetate finally 
furnished L-Choi derivative 3.50 (Scheme 34). Following this readily scalable synthetic 
strategy, Baudoin and co-workers were able to synthesize up to 700 mg of aeruginosin 
298A (1).[21] Furthermore, the development of an intermolecular Csp3-H arylation allowed the 
synthesis of halogenated Hpla fragments, which could be successfully incorporated in the 
synthesis of aeruginosin 98A(16) and C (17) (for the structures of the different aeruginosins 
see pages 5 and 8 in the general introduction).[22] 
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Scheme 34 Baudoin’s   synthesis   of   L-Choi building block 3.50. Reagents and conditions: 
a) TBDPSCl, imidazole, CH2Cl2,   0   °C,   quant.;;   b)   Grubbs’   first generation catalyst, CH2Cl2, 
quant.; c) CHBr3, NaOH, Et3BnNCl, CH2Cl2, ultrasound; d) 130 °C (neat), 88% over four steps; 
e) (S)-1-((tert-butyl dimethylsilyl)oxy)propan-2-amine, K2CO3, DMF, 20 °C to 90 °C; f) 
(CF3CO)2O, pyridine, CH2Cl2, 38% over two steps; g) Pd(PCy3)2, K2CO3, tBuCO2K, toluene, 
120 °C, 71%; h) H2, Rh/C, EtOAc, then HCl, MeOH, 95%; i) Jones’  reagent,  acetone,  86%;;   j)  
Me3SiCHN2, MeOH, 0 °C, 97%; k) NaBH4,  MeOH,  ‒10  °C  to  20  °C,  83%. 
 
1.2.7. Comparison of the different synthetic strategies 
As seen in the last sections, the groups of Bonjoch, Wipf, Carreira and Trost used a final 
formation of the C7a-N bond for the construction of the octahydroindole skeleton of the 
L-Choi (Figure 39). On the other hand, Hanessian described the formation of the C7-C7a bond 
via an aza-Prins halocarbocyclization to access the L-Choi. Most recently, Baudoin developed 
a Csp3-H alkenylation, building up the L-Choi through formation of the C3-C3a bond  
(Figure 39). 
 
Figure 39 Comparison of the different reported syntheses of the L-Choi moiety with the main 
disconnections of the respective synthetic strategies marked in red.  
  
CHAPTER II: SYNTHETIC STUDIES ON AERUGINOSIN KT608A 
 
 
 
113 
2. Aim and Retrosynthetic Considerations 
The aim of this project was the investigation of efficient synthetic strategies for the 
preparation of the D-diepi-Choi motif present in aeruginosins KT608A (3.1) and B (3.2) and 
KT650 (3.1). Further, the prepared D-diepi-Choi building block should be incorporated in the 
total syntheses of the natural products mentioned above. For the preparation of the 
octahydroindole core of the D-diepi-Choi we envisioned a straightforward synthesis from an 
enantiopure D-indoline precursor. Heterogeneous hydrogenation of this D-indoline precursor 
should allow for diastereoselective installation of the hydrogen atoms at C3a, C6 and C7a 
position, induced by substrate control from the carboxyl group of the indoline (Scheme 35). 
For the synthesis of suitable enantiopure indolines we considered two possible strategies. The 
first pathway comprises the condensation of an α-azido ester with anisaldehyde leading to an 
indole after intramolecular amination. Further, enantioselective hydrogenation of the indole 
should allow for the formation of enantioenriched indoline. The second strategy consists of 
using a starting material from the chiral pool, namely D-tyrosine, which is decorated with 
suitable protection and directing groups. Subsequent C-H activation should enable 
intramolecular amination and thus formation of the desired indoline (Scheme 35). 
 
Scheme 35 Retrosynthetic analysis of D-diepi-Choi. 
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3. Synthesis of Aeruginosin KT608A – 1st Generation 
3.1. D-diepi-Choi Synthesis 
3.1.1. Preparation of the indole  
The synthesis of aeruginosin KT608A commenced with the preparation of indole 3.55 which 
was needed for the later enantioselective reduction to access the required indoline. For the 
synthesis of indole 3.55, commercially available p-anisaldehyde (3.51) was reacted with 
ethyl-2-azidoacetate (3.52), which had been prepared from ethyl bromoacetate (3.53),[23] in an 
aldol condensation.[24] First attempts using commercially available NaOEt led to low 
conversion and a poor yield of condensated product 3.54. The poor reactivity of the aldol 
condensation could be enhanced by using freshly prepared NaOEt from solid Na and EtOH. 
With this modification, a yield of up to 70% on a small scale (~1 g) and 57% on a larger scale 
(~5.5 g) was achieved for the aldol condensation of 3.51 and 3.52. The next step was the 
Hemetsberger-Knittel cyclization[25] of azide 3.54 to the corresponding indole. Initial attempts 
by catalyzing the intramolecular C-H amination with Rh2(OAc)4 at room temperature resulted 
only in moderate conversion and yield.[26,27] Besides the poor reactivity, the use of expensive 
Rh catalysts is not convenient for reactions on a larger scale. However, azidoacrylate 3.54 
could be converted into the indole in an excellent yield of 93% without the addition of any 
catalyst by simply stirring 3.54 in refluxing o-xylene for 1.5 h.[28] The obtained indole was 
subsequently protected with an acetyl group to give indole derivative 3.55 in a good yield 
(Scheme 36).  
 
Scheme 36 Synthesis of indole 3.55. Reagents and conditions: a) NaN3, H2O/acetone (1:3), r.t., 
1 h,  quant.;;  b)  Na,  EtOH,  −15 °C, 7 h, 57%; c) o–xylene, 144 °C, 1.5 h, 93%; d) Ac2O, DMAP, 
Et3N, CH2Cl2, 50 °C, 16 h, 75%. 
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3.1.2. Enantioselective hydrogenation of the indole to the indoline  
With indole 3.55 in hand, the focus was laid on the enantioselective hydrogenation to access 
the D-indoline derivative. Since the investigation of catalytic asymmetric hydrogenation 
reactions was a dynamic field in chemistry in the last two decades, a big diversity of different 
catalysts and ligands for a variety of specific substrates has been explored. In the early 2000s 
Kuwano and Ito were the first to achieve the asymmetric reduction of indoles in a highly 
enantioselective fashion, providing indolines with up to 95% ee.[29] Kuwano and Ito used a 
rhodium catalyst with a chiral di-ferrocenyl ligand for their asymmetric reduction (left, Figure 
40). They successfully applied their catalytic system to a broad scope of 2-substituted indoles 
including 2-carboxylated indoles and thereby could optimize the reaction conditions to yield 
indolines with an ee of up to 99%.[30,31] Agbossou-Niedercorn and co-workers pursued a 
similar strategy to the one of Kuwano and Ito for their asymmetric reduction of indoles by 
using rhodium catalysts with chiral Walphos ligands (second from left, Figure 40). 
Agbossou-Niedercorn et al. achieved yields up to 85% and ees up to 80% using these 
Walphos ligands.[32] Rueping and co-workers developed the first metal-free asymmetric 
hydrogenation of 3H-indoles by applying a reaction system with chiral Brønsted acids in 
combination  with  Hantzsch’s  ester  as  hydrogen  source  (second  from right, Figure 40). With 
their catalytic system, Rueping et al. were able to access indolines with up to 99% ee and 99% 
yield from the corresponding 3H-indoles.[33] In 2010, Pfaltz and Baeza reported the use of 
Ir-PHOX catalysts for the asymmetric hydrogenation of 2-, 3- and 5-substituted indoles (right, 
Figure 40). With their Ir-PHOX catalysts, Pfaltz and Baeza could transfer 2-carboxylated 
indoles with 97% conversion and 99% ee into the corresponding indolines.[34] 
  
Figure 40 Different ligands and catalysts developed for the enantioselective reduction of indoles 
and 3H-indoles.  
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Of all the described enantioselective reduction methods, the one of Agbossou-Niedercorn, 
using chiral Walphos ligands, gave the lowest ee values and yields. Therefore, the use of this 
catalytic system was not investigated. Further, the asymmetric hydrogenation of the Rueping 
group only works with 3H-indoles and was therefore not suitable for our substrate, an indole. 
Most promising were the methods from Kuwano and Pfaltz, both using similar substrates to 
our indole for their asymmetric reductions. Both groups reported high ee values and yields. 
Since the Pfaltz group was located in the same department at the University of Basel, they 
generously provided us with their Ir-PHOX catalysts, whereas the di-ferrocenyl ligands used 
by Kuwano were not available and are cumbersome to prepare.[35] Therefore, the reduction 
developed by Pfaltz was investigated further for the asymmetric hydrogenation of indole 3.55 
(Table 9). First, a racemic reduction of indole 3.55 was performed using Pd on carbon as 
catalyst at 75 bar H2 pressure to access racemic indoline 3.56 (Entry 1). Racemic indoline 
3.56 was needed as a reference for the later determination of the ee of the asymmetric 
hydrogenations via chiral HPLC. The first asymmetric reduction was carried out with 2 mol% 
Ir-PHOX catalyst A under a H2 pressure of 100 bar at 60 °C. With these conditions an ee of 
99% and a yield of 27% were achieved (Entry 2). Since already the first tried conditions gave 
almost enantiopure indoline 3.56, the focus was laid on improving the yield. For this, the 
temperature was increased from 60 to 80 °C which indeed furnished a higher yield of 50% 
(Entry 3). Beside the isolation of the desired indoline, also starting material 3.55 and 
deprotected indole could be recovered. To further enhance the yield of the reaction, the 
catalyst loading was raised from 2 mol% to 3 and 4 mol%. By doing so, the yield was 
increased from 50% to 80% (Entries 4 and 5). Because no distinct effect was observed going 
from 3 to 4 mol%, a further increase of the catalyst loading was not tested. Next, the 
feasibility of the reduction on a larger scale was explored, going from a 0.04 mmol to a 0.4 
mmol scale. Unfortunately, scaling up the reaction led to a significant drop of the yield, 
providing only 10% of the desired indoline 3.56, with 2 mol% catalyst loading (Entry 6). As 
mentioned before, the Ir-PHOX catalyst was kindly provided by the research group of Pfaltz. 
However, the large molecular weight of the Ir-PHOX catalysts (>1600 g/mol) in combination 
with the relatively high required catalyst loading of up to 4 mol%, results in a catalyst loading 
of 25% w/w. For smaller scales these 25% w/w of catalyst were accessible, but not for larger 
scales. Therefore, the performance of Ir-PHOX catalyst B was investigated, since this catalyst 
was commercially available in a larger amount from Sigma-Aldrich. First, a catalyst loading 
of 2 mol% of catalyst B was applied, resulting only in traces of the desired product 3.56 
(Entry 7). Raising the catalyst loading from 2 to 4 mol% allowed the isolation of 35% of 
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indoline 3.56. However, chiral HPLC revealed a moderate ee of only 60% for catalyst B 
(Entry 8). Further increasing the catalyst loading to 6 mol% provided 50% of indoline 3.56 
(Entry 9). Due to the moderate ee in combination with the required high catalyst loadings, the 
use of catalyst B was not further investigated. To conclude, the asymmetric hydrogenation 
was achieved with a high ee and yield using Ir-PHOX catalyst A, albeit only on a very small 
scale.  
Table 9 Conditions tested for the asymmetric hydrogenation of indole 3.55 to access indoline 
3.56 
 
Entry Catalyst mol% Conditionsa Observationb eec 
1 Pd/C 10 CH2Cl2, H2 (75 bar), r.t. quant. - 
2d A 2 CH2Cl2, H2 (100 bar), 60 °C 27% 99 
3d A 2 DCE, H2 (100 bar), 80 °C 50%e n.d. 
4d A 3 DCE, H2 (100 bar), 80 °C 80%e n.d. 
5d A 4 DCE, H2 (100 bar), 80 °C 80%e n.d. 
6f A 2 DCE, H2 (100 bar), 80 °C 10%e n.d. 
7 B 2 DCE, H2 (100 bar), 80 °C traces n.d. 
8 B 4 DCE, H2 (100 bar), 80 °C 35% 60 
9 B 6 DCE, H2 (100 bar), 80 °C 50% n.d. 
aAll reactions were carried out in a high pressure autoclave, solvents were filtered over aluminium oxide prior to 
use. bThe yield was determined by isolation of the product and the conversion by integration of the 1H NMR 
signals in the crude product. cThe ee was determined by chiral HPLC. dThe reaction was carried out on a 0.04 
mmol scale. eCleavage of the acetyl group was observed. f The reaction was carried out on a 0.4 mmol scale. 
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3.2. D-diepi-Choi Formation, 1st Approach 
3.2.1. Reduction of the indoline to the octahydroindole  
The next sequence of the total synthesis involved the formation of the octahydroindole core of 
D-diepi-Choi. For the reduction of indoline 3.56 to octahydroindole 3.57, a heterogeneous 
catalysis was envisioned. The use of a heterogeneous catalyst poses the advantage that all 
hydrogen atoms are introduced from the side facing the surface of the catalyst, thus, allowing 
for stereochemical control of the three obtained chiral centers at C3a, C6 and C7a position. 
Alongside the induced syn addition of the hydrogen atoms by the heterogeneous catalyst, 
substrate control triggered by the carboxylate substituent at C2 position of the indoline takes 
place. The stereochemical configuration of the carboxylate substituent directs the binding of 
the indoline to the metal surface. These effects are responsible for the formation of a single 
diastereoisomer out of eight possible isomers. The groups of Vincent[36], Kim[37] and 
Cativiela[38–40] have reported on the highly diastereoselective outcome of prepared 
octahydroindoles from 2-substituted indolines. While the group of Vincent used Pd on carbon 
as catalyst, the groups of Kim and Cativiela applied PtO2 as the heterogeneous catalyst. 
However, all the conditions described in the literature led to no conversion with our substrate. 
Pleasingly, indoline 3.56 could be converted into octahydroindole 3.57 using Rh on carbon as 
catalyst at 50 bar hydrogen pressure, according to a patented procedure (Scheme 37).[41] 
Beside quantitative conversion, the reaction also displayed a high stereoselectivity featuring 
almost exclusively the formation of the desired compound 3.57. The correct relative 
configuration of octahydroindole 3.57 was confirmed by X-ray crystallographic analysis 
which revealed the syn configuration of the hydrogen atoms at positions C2, C3a, C6 and C7a 
(crystal structure numbering: C1, C3, C6 and C8, respectively), as shown in Figure 41. 
 
Scheme 37 Reduction of indoline 3.56 to octahydroindole 3.57. Reagents and conditions: a) H2 
(50 bar), Rh/C, MeOH, r.t., 9 h, 99%. 
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Figure 41 Structure of the D-enantiomer present in the asymmetric unit of racemic 3.57, 
ellipsoids plotted at 40% probability level. Selected bond parameters: N1–C9 = 1.3488(15), O1–
C9 = 1.2333(15) Å; C1–N1–C8 = 111.65(9), C1–N1–C9 = 119.75(10), N1–C9–O1 = 
121.10(11)°. 
 
3.2.2. Deprotection of the octahydroindole  
Octahydroindole 3.57 already contained the whole carbon backbone of the D-diepi-Choi core 
structure. Therefore, only global deprotection was required to access D-diepi-Choi building 
block 3.59. First, cleavage of the methoxy ether was investigated. Initial attempts based on the 
classical method for this transformation using the strong Lewis acid BBr3 resulted in no 
conversion.[42,43] The addition of 18-crown-6-ether and NaI to BBr3 could not enhance the 
reactivity either.[44,45] Similar results were obtained when employing SiCl4 and NaI for the 
deprotection.[46] Finally, a deprotection method utilizing TMSCl and NaI, which has been 
described by Zutter and co-workers, led to the formation of the desired alcohol 3.58 in a very 
good yield.[47] Further, removal of the acetyl group and saponification of the ethyl ester were 
achieved by treating 3.58 with an aqueous 6 M HCl solution giving the hydrochloride salt of 
D-diepi-Choi 3.59 (Scheme 38). 
 
Scheme 38 Synthesis of D-diepi-Choi hydrochloride salt 3.59. Reagents and conditions: a) 
TMSCl, NaI, MeCN, 40 °C, 16 h, 77%; b) 6 M HCl, H2O, reflux, 5 h, quant. 
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3.3. Octahydroindole Formation, 2nd Approach 
In the course of the D-diepi-Choi synthesis, alternative approaches were also investigated. 
Since methoxy ethers connected to an sp3 carbon center are more stable than their analogues 
linked to an sp2 carbon center, cleavage of the ether at an earlier stage of the synthesis was 
examined. Indeed, indoline 3.56 showed an enhanced reactivity compared to that of 
octahydroindole 3.57 towards the cleavage of the methoxy ether. Treating indoline 3.56 with 
BBr3 afforded the desired free alcohol 3.60 in a good yield. However, the following reduction 
of indoline 3.60 with the conditions developed in Section 3.2.1 led to no conversion. Neither 
increasing the temperature or the H2 pressure nor the use of other heterogeneous catalysts 
such as PtO2 could convert indoline 3.60 into octahydroindole 3.58 (Scheme 39). Since the 
free hydroxyl group of indoline 3.60 seemed to be responsible for decreasing the reactivity 
towards hydrogenations, the alcohol of 3.60 was protected with a MOM group to 
counterbalance this effect. Doing so, the reduction of indoline 3.61 proceeded smoothly using 
the conditions described in Section 3.2.1. Further, global acidic deprotection provided diepi-
Choi core 3.59 in quantitative yield (Scheme 39). Due to the ready availability of racemic 
indoline 3.60, all the reactions described in this section were performed with racemic 
substrates. However, the feasibility of this approach could be proven. 
 
Scheme 39 Synthesis of racemic diepi-Choi hydrochloride salt 3.59. Reagents and conditions: 
a) BBr3, CH2Cl2, 78 °C, 3 h, 85%; b) MOMCl, DIPEA, CH2Cl2, 0 °C to r.t., 20 h, 87%; c) H2 
(50 bar), Rh/C, MeOH, r.t., 14 h, 99%; d) 6 M HCl, H2O, reflux, 5 h, quant. 
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3.4. Synthesis of the Different Building Blocks 
3.4.1. Agmantin side chain 
The agmantin side chain was synthesized from commercially available 2-methyl-2-
thiopseudourea hemisulfate (3.62) according to literature known procedures. Protection of the 
imine and the amine of 3.62 with Boc2O afforded pseudothiourea derivative 3.63.[48] 
Replacement of the methyl thioether in 3.63 by 1,4-butanediamine gave access to agmantin 
side chain 3.64 in an excellent yield (Scheme 40).[49] 
 
Scheme 40 Synthesis of the agmantin side chain 3.64. Reagents and conditions: a) Boc2O, 
NaHCO3, CH2Cl2, r.t., 18 h, 92%; b) 1,4-butanediamine, THF, 50 °C, 1 h, 97%. 
3.4.2. L-Hpla building block 
The L-Hpla-OH building block 3.67 was prepared via a literature known two-step sequence 
starting from L-Tyr-OH (3.65). Protection of the hydroxyl group of 3.65 with a benzyl group 
furnished amino acid 3.66.[50] Further transformation of 3.66 into phenyllactic acid derivative 
3.67 was achieved by treating 3.66 with isoamyl nitrite and NaOAc (Scheme 41).[51]  
 
Scheme 41 Synthesis of L-Hpla-OH unit 3.67. Reagents and conditions: a) BnBr, NaOH, 
CuSO4, MeOH/H2O (5:1), r.t., 16 h, 62%; b) isoamyl nitrite, AcOH, NaOAc, r.t. , 24 h, 69%. 
3.4.3. Boc-D-Phe-OH building block 
Boc-D-Phe-OH (3.69) was accessed through protection of the amine of commercially 
available D-Phe-OH (3.68) (Scheme 42). 
 
Scheme 42 Synthesis of Boc-D-Phe-OH (3.69). Reagents and conditions: a) Boc2O, NaOH, 
dioxane/H2O (2:1), 0 °C to r.t., 16 h, quant. 
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3.5. Assembly of the Different Building Blocks 
The assembly of the different building blocks is shown in Scheme 43. The preparation of 
aeruginosin KT608A (3.1) commenced with the esterification of D-diepi-Choi building block 
3.59 to give the hydrochloride salt of methyl ester 3.70. Peptide coupling of the obtained 
methyl ester 3.70 with Boc-D-Phe-OH fragment 3.69 delivered dipeptide 3.71. In the 1H and 
13C NMR spectra, three sets of signals in a ratio of 3:1:1 were observed for dipeptide 3.71. 
Two of those sets could be assigned to the occurrence of two rotameric conformers of 3.71, in 
a ratio of 3:1. Nonetheless, the third set of signals in the NMR spectra indicated the presence 
of another diastereoisomer of dipeptide 3.71 in the sample probe. The reason for the 
formation of this second diastereoisomer remains under further investigation, but has to be 
derived either from a racemization process during peptide coupling or from the use of a non-
enantiopure D-diepi-Choi building block. Separation of the two diastereoisomers through 
flash column chromatography was not possible; therefore, the 4:1 diastereomeric mixture was 
used for the subsequent steps of the assembly. Acidic removal of the Boc protecting group of 
dipeptide 3.71 provided amine 3.72 which was coupled to L-Hpla building block 3.67 giving 
tripeptide 3.73 in a yield of 60% over two steps. Simultaneous saponification of the D-diepi-
Choi methyl ester and the L-Hpla acetyl ester of tripeptide 3.73 gave access to acid 3.74. 
Subsequent coupling of acid 3.74 to agmantin side chain 3.64 using PyBOP and NMM 
furnished tetrapeptide 3.75 in a yield of 61% over two steps. For completion of the total 
synthesis of KT608A (3.1), only global deprotection was required. First, the two Boc groups 
of the agmantin side chain were removed under acidic conditions, followed by cleavage of the 
benzyl group of the L-Hpla residue using catalytic hydrogenation (Scheme 43). The crude 
residue obtained from the deprotection steps was subjected to fractionated HPLC purification 
leading to the isolation of 1.0 mg of KT608A (3.1). 
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Scheme 43 Synthesis of aeruginosin KT608A (3.1). Reagents and conditions: a) SOCl2, MeOH, 
60 °C, 4 h, quant.; b) Boc-D-Phe-OH 3.69, PyBOP, NMM, CH2Cl2, r.t., 72 h, 64%; c) TFA, 
CH2Cl2, 0 °C, 1 h; d) L-Hpla-OH 3.67, PyBOP, NMM, CH2Cl2, r.t., 36 h, 60% over two steps; e) 
0.1 N LiOH, THF, r.t., 20 h; f) agmantin side chain 3.64, PyBOP, NMM, DMF, r.t., 48 h, 61% 
over two steps; g) 1 N HCl, MeCN, r.t., 24 h; h) H2, Pd/C, EtOAc/MeOH (1:1), r.t., 36 h, 37% 
over two steps. 
 
3.6. Comparison of the NMR Spectra of Isolated and Synthesized AKT608A  
The synthesized aeruginosin KT608A (3.1) was characterized by 1H and 13C NMR as well as 
COSY, HMBC, HSQC and NOESY 2D NMR experiments. Comparison of our recorded 
NMR spectra with the spectra of the isolated product reported in the literature[1] revealed 
significant deviations (Figure 43, Table 10). The most apparent difference is displayed by the 
ratio of the two rotamers present in the different samples. While the NMR spectra of the 
isolation work showed a ratio of almost 1:1 of cis and trans rotamers, our measured spectra 
indicated the presence of a 3:1 ratio favoring the trans rotamer. As already described in 
Chapter I, the NMR spectra of aeruginosins are strongly influenced by the water and salt 
concentration of the recorded sample, as well as by the counterion present. However, the 
influence of these parameters only affected the chemical shifts of the signals, whereas the 
equilibrium of the cis and trans rotamers stayed constant under different conditions. Changing 
the temperature also exerts a negligible effect on the ratio of the two rotamers, as shown in 
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Section 5.14.1 of Chapter I. The ratio of the two rotameric conformations therefore displays a 
characteristic feature of a particular aeruginosin. For this reason, the distinct deviation of the 
recorded rotameric ratios of 3.1 foreboded the existence of two different structures of the 
isolated and synthesized aeruginosin KT608A (3.1). Beside the nonconformity of the 
rotameric ratios, the chemical shifts in the 1H and 13C NMR spectra also showed tremendous 
differences (Table 10, page 126). The most pronounced discrepancies in the 1H NMR shifts 
were found for the signals of the D-diepi-Choi unit, namely H7 ('G = –0.77 ppm),  H7’  ('G = 
+1.07 ppm), H3 ('G = –0.57 ppm) and H2 ('G = –0.58 ppm) (for atom labeling and 
numbering of 3.1 see Figure 42). Further distinct differences were found for Phe-H2 ('G = 
+0.43 ppm), Agm-NH-1 ('G = +0.32 ppm) and Agm-NH-4 ('G = +0.40 ppm). Comparison of 
the 13C NMR spectra resembles the situation described for the 1H NMR spectra: The largest 
chemical shift deviations were observed for the signals of the D-diepi-Choi unit (C7: 'G = 
+1.8 ppm; C3a: 'G = +3.0 ppm; C3: 'G = –3.3 ppm) and for Phe-C3 ('G = +1.3 ppm). The 1H 
and 13C signals for the Hpla, Phe (except for H2 and C2) and Agm (except for N-H) units 
were in accordance with each other and showed only minor differences. To conclude, 
comparison of the NMR spectra indicated that the structures of the isolated and synthesized 
aeruginosin KT608A (3.1) were not identical. This provoked the assumption that either the 
structure of 3.1 was wrongly assigned during the isolation work or that a mistake had slipped 
in during the total synthesis. Possible missteps in the synthesis or assignment will be 
discussed in the following section.  
 
Figure 42 Atom labeling and numbering in aeruginosin KT608A (3.1). 
  
CHAPTER II: SYNTHETIC STUDIES ON AERUGINOSIN KT608A 
 
 
 
125 
 
Figure 43 1H NMR spectra of synthetic aeruginosin KT608A (3.1) (top) and isolated 
aeruginosin KT608A (3.1) (bottom). 
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Table 10 Comparison of the 1H and 13C NMR spectra of natural and synthetic KT608A (3.1) 
 1H shifts (ppm) 13C shifts (ppm) 
Subunit Position KT608A natural 
KT608A 
synthetic 'G 
KT608A 
natural 
KT608A 
synthetic 'G 
Choi 1 - - - 172.3 171.1 –1.2 
 2 4.82 4.24 –0.58 59.6 59.8 +0.2 
 3 2.38 1.81 –0.57 33.6 30.3 –3.3 
 3' 1.70 1.96 +0.26 - - - 
 3a 2.23 2.13 –0.10 32.7 35.7 +3.0 
 4 1.63 1.57 –0.06 22.7 22.4 –0.3 
 4' 1.56 1.67 +0.09 - - - 
 5 1.56 1.60 +0.04 29.9 29.0 –0.9 
 5' 1.19 1.20 +0.01 - - - 
 6 3.30 3.36 +0.06 67.0 66.9 –0.1 
 7 2.37 1.60 –0.77 36.1 37.9 +1.8 
 7' 0.83 1.90 +1.07 - - - 
 7a 4.04 4.24 +0.20 56.8 57.3 +0.5 
Hpla 1 - - - 173.5 173.0 –0.5 
 2 3.85 3.93 +0.08 72.0 72.0 0.0 
 3 2.33 2.43 +0.10 39.5 39.5 0.0 
 3' 2.55 2.64 +0.09 - - - 
 4 - - - 128.5 128.2 –0.3 
 5,9 6.82 6.87 +0.05 130.4 130.2 –0.2 
 6,8 6.57 6.59 +0.02 114.9 114.6 –0.3 
 7 - - - 155.7 155.6 –0.1 
 2-OH 5.05 5.32 +0.27 - - - 
 7-OH 9.06 9.28 +0.22 125.8 125.8 0.0 
Phe 1 - - - 170.0 169.3 –0.7 
 2 4.20 4.66 +0.46 51.8 50.9 –0.9 
 3 2.84 2.91 +0.07 36.5 37.8 +1.3 
 3’ 2.81 2.82 +0.01 - - - 
 4   - 138.4 137.4 –1.0 
 5,9 7.12 7.20 +0.08 129.2 129.2 0.0 
 6,8 7.19 7.25 +0.06 128.2 128.2 0.0 
 7 7.14 7.20 +0.06 126.4 126.4 0.0 
 NH 7.97 7.94 –0.03 - - - 
Agm 1 3.18 3.09 –0.09 38.6 37.8 –0.8 
 1' 3.06 3.09 +0.03 - - - 
 2 1.45 1.46 +0.01 26.2 25.8 –0.4 
 3 1.41 1.47 +0.06 26.4 26.3 –0.1 
 4 3.08 3.07 –0.01 40.6 40.3 –0.3 
 5 - - - 156.9 157.3 +0.4 
 1-NH 8.29 8.61 +0.32 - - - 
 4-NH 7.52 7.92 +0.40 154.9 - -  
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3.6.1. Elucidation of possible mistakes 
Possible mistakes during the total synthesis of KT608A 
Since the total synthesis of a natural product is a complex construct, possible mistakes can be 
manifold. As the analytical data for the building blocks Agm 3.64,[48,49] L-Hpla-OH 3.67[50,51] 
and Boc-D-Phe-OH (3.69) were in accordance with the literature, a fault in the synthesis of 
these units can be excluded. This assumption is supported by the NMR data, which show 
minor differences for the signals of these building blocks (Table 10). Therefore, possible 
mistakes have to have occurred in the synthesis of D-diepi-Choi unit 3.59 or during assembly 
of the building blocks. The relative configuration of the D-diepi-Choi was confirmed by X-ray 
crystallographic analysis of compound 3.57, displaying the syn configuration of the hydrogen 
atoms at C2, C3a, C6 and C7a (Figure 41, page 119). However, crystallization of 
octahydroindole 3.57 was carried out starting from a racemic sample, thus not allowing for 
definition of the absolute configuration of 3.57. Hence, determination of the absolute 
configuration of indoline 3.57 builds on the work of Baeza and Pfaltz, who reported on the 
exclusive formation of the R indoline 3.77 from indole 3.76 using Ir-PHOX catalyst A 
(Scheme 44).[34] As in our synthesis the other enantiomer of catalyst A was used, the indoline 
with D configuration should be obtained (R corresponds to an L configuration, S to a D 
configuration). Since our substrate for the enantioselective hydrogenation was not exactly the 
same as the one of Baeza and Pfaltz,[34] there remains a possibility that the absolute 
configuration of the obtained indoline is reversed to that of the literature,[34] though such an 
inversion would be unusual. However, definite confirmation of the absolute configuration of 
indoline 3.57 could only be done by comparison of the optical rotation value of 3.57 with that 
of an authentic substrate with known absolute configuration. The synthesis of such a reference 
substrate will be discussed in more detail in Section 4. 
 
Scheme 44 Asymmetric hydrogenation reported by Baeza and Pfaltz, including the confirmation 
of the absolute configuration of the obtained indoline 3.77.[34] 
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A more probable misstep in the total synthesis would be that the asymmetric hydrogenation of 
indole 3.55 did not provide enantiopure indoline 3.56, since the ee was not determined by 
chiral HPLC for each reaction condition (Section 3.1.2). According to this theory, a mixture 
of the D-diepi-Choi and L-6-epi-Choi could have been present in building block 3.59 (for the 
nomenclature of the different Choi isomers see Figure 45). This hypothesis is supported by 
the fact that indeed a 4:1 diastereomeric mixture of Phe-D-diepi-Choi dipeptide 3.71 was 
obtained (Section 3.5). The isolation of KT608A diastereoisomer 3.78, containing an L-6-epi-
Choi core instead of the D-diepi-Choi, can thus not be excluded (Figure 44). To prevent the 
formation of diastereoisomers, the incorporation of an enantiopure D-diepi-Choi building 
block is required. Doing so, the possibility of a wrong diastereoisomer isolated during final 
HPLC purification can be excluded. Studies on such a synthesis will be discussed in 
Section 5. 
 
Figure 44 Compound 3.78 displays a possible diastereoisomer of KT608A (3.1) which might 
have been isolated instead of 3.1 during the final HPLC purification of the total synthesis. 
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Possible mistakes in the assignment of the structure of KT608A 
As already described in the general introduction of this thesis, there have been various 
misassignments in the structural elucidation of compounds from the aeruginosin family. 
Among others, Carmeli and co-workers have also contributed to the number of misassigned 
aeruginosins with the wrong determination of the structure of aeruginosin EI461.[6,52]  
The absolute configuration of the Phe and Hpla units of KT608A (3.1) were confirmed via 
acidic hydrolysis of the peptide bonds of 3.1 followed  by  the  application  of  Marfey’s  method  
and chiral-phase HPLC on the obtained fragments. Thus, the L configuration of the Hpla 
moiety and the D configuration of the Phe could be confirmed.[1] A potential wrong 
assignment of the Carmeli group can therefore be restricted to the conformation of the Choi 
core, which is supported by the NMR data, revealing large deviations only in the Choi unit 
signals (Table 10). Four relative configurations of the Choi motif are possible, assuming that 
the hydrogen atoms at C3a and C7a positions have to be in a syn relationship, caused by the 
biosynthetic pathway of the Choi fragment and the large ring strain of trans-fused Choi 
derivatives.[53,54] These four relative configurations can adopt either an L or D absolute 
configuration (Figure 45). Beside the D-diepi-Choi, only the L-Choi (present in the majority 
of isolated aeruginosins[2]), the L-diepi-Choi (present in aeruginosin EI461[6]) and the L-6-epi-
Choi (present in aeruginosin DA594A, DA511 and KB676) have been detected in natural 
aeruginosins. 
 
Figure 45 Configurations of the Choi unit: four relative configurations with L and four relative 
configurations with D absolute configuration are possible. The nomenclature results on the one 
hand from the configuration at the C2 center (L or D) and on the other hand from the 
epimerization of centers C3a, C6 and C7a with respect to the L-Choi. Therefore, the enantiomer 
of e.g. L-Choi is named D-triepi-Choi. Aeruginosins consisting of the specific Choi structure are 
shown in brackets. 
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Now, which one is which member in the Choi family? 
The best way to distinguish between the different relative configurations of the Choi family is 
to analyze the respective 1H NMR spectra. First, we make the assumption that the relative 
configuration of the Choi motif has a more distinct influence on the chemical shifts than the 
absolute configuration. Thus, both enantiomers of a relative Choi configuration, e.g. L-Choi 
and D-triepi-Choi, will have similar shifts, although the decoration of the Choi with chiral 
substituents provides different diastereoisomers with slightly different NMR spectra. One 
example for how the different isomers can be identified is by considering the Choi-H6 signal. 
The Choi-H6 chemical shift is heavily influenced by the relative configuration of the Choi 
(Figure 46): In D-diepi-Choi and L-diepi-Choi, the hydroxyl group at Choi-C6 occupies an 
equatorial position, leading to chemical shifts of the Choi-H6 of around 3.30 ppm. In D-triepi-
Choi and L-triepi-Choi, however, the hydroxyl group is found in an axial position, so that the 
1H NMR signal of Choi-H6 is shifted downfield to around 3.90 to 4.00 ppm. Since the Choi-
H6 chemical shift of the isolated aeruginosin KT608A (3.1) was reported to be 3.30 ppm, a 
D-triepi-Choi and L-triepi-Choi configuration, as well as their respective enantiomers (L-Choi 
and D-Choi), can be excluded. Aeruginosin KT608A (3.1) therefore has to contain either a 
D-diepi-Choi, L-diepi-Choi, L-6-epi-Choi or D-6-epi-Choi core unit. The differences in the 
1H NMR spectra of D-diepi-Choi and L-diepi-Choi and L-6-epi-Choi and D-6-epi-Choi, 
respectively, will be discussed in the next section. 
 
Figure 46 The four possible relative configurations of the Choi family. For a better overview, 
only one enantiomer of each relative configuration is shown. The chemical shifts were obtained 
from the following examples reported in the literature: D-diepi-Choi from the synthesis of 
originally proposed aeruginosin EI461 by Bonjoch,[6] L-diepi-Choi from the revised structure of 
aeruginosin EI461 (53),[6] D-triepi-Choi from aeruginosin 298A (1)[55] and microcin SF608 (7)[4] 
and L-triepi-Choi  from  a  side  product  obtained  in  Wipf’s  and  Methot’s  synthesis  of  aeruginosin  
298A (1).[9] The Choi-H6 atom is highlighted in red. 
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D-diepi-Choi vs. L-diepi-Choi 
Comparing the 1H NMR spectra of aeruginosin EI461[6] containing an L-diepi-Choi core with 
those of KT608A (3.1) reveals good accordance of the chemical shifts (Table 11, page 133). 
Nonetheless, Carmeli and co-workers excluded the presence of an L-diepi-Choi unit in 
aeruginosin KT608A due to observed NOE cross-peaks between Choi H2 and H3a. Carmeli 
attributed these cross-peaks to a syn configuration of H2 and H3a (as in D-diepi-Choi). 
Therefore, Carmeli proposed the presence of a D-diepi-Choi instead of an L-diepi-Choi unit in 
aeruginosin KT608A (3.1). Figure 47 shows the ROESY spectrum of KT608A (3.1) recorded 
by Carmeli with the highlighted Choi H2-H3a cross-peaks (Figure 47). The conclusion that 
these cross-peaks are proof for the syn configuration of H2 and H3a is problematic in several 
respects: First, the intensity of the discussed cross-peaks is very low, therefore they might 
arise from a 4JH-H COSY coupling, since long-range couplings are possible for rigid bicyclic 
systems with a W shape orientation.[56] Second, from our X-ray crystal structure of the 
D-diepi-Choi core derivative 3.57 (Figure 41, page 119), the distance between protons H2 and 
H3a can be measured, revealing a value of 2.9 Å. This relatively short distance should result 
in more intense cross-peaks of H2 and H3a than those observed by Carmeli.[57] Further, the 
distance for an anti configuration of H2 and H3a can also be estimated from the crystal 
structure and should be less than 4.2 Å. This distance still allows the occurrence of NOE 
cross-peaks between H2 and H3a.[57] To conclude, the observed NOE cross-peaks between H2 
and H3a do not necessarily result from a relative syn configuration of these substituents, thus 
an L-diepi-Choi moiety in aeruginosin KT608A cannot be excluded. 
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Figure 47 Excerpt of the ROESY spectrum of aeruginosin KT608A, showing cross-peaks 
between Choi H2 and Choi H3a.[1] 
 
In the course of the structural elucidation of aeruginosin EI461, Carmeli had already proposed 
the presence of a D-diepi-Choi core.[52] However, the structure originally proposed by Carmeli 
was later revised by Bonjoch and co-workers,[6] who did indeed synthesize the proposed 
aeruginosin EI461 containing a D-diepi-Choi moiety. Bonjoch realized that the NMR spectra 
of the synthetic material and isolated EI461 were not in accordance with each other. To 
elucidate the correct structure of aeruginosin EI461, Bonjoch and co-workers synthesized a 
congener consisting of an L-diepi-Choi core. Comparison of the NMR spectra of the 
synthesized analogue containing the L-diepi-Choi core with those of naturally occurring 
EI461 proved that the L-diepi-Choi was the correct structural element present in aeruginosin 
EI461 (Figure 48).[6] 
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Figure 48 Structure originally proposed for aeruginosin EI461 by Carmeli and co-workers 
(left),[52] revised structure of aeruginosin EI461 by Bonjoch and co-workers (right).[6] 
 
Table 11 shows the 1H NMR data of revised aeruginosin EI461 containing an L-diepi-Choi 
moiety and the derivative with a D-diepi-Choi unit as well as those of isolated aeruginosin 
KT608A and our synthetic aeruginosin KT608A. There is a distinct similarity between EI461 
with its L-diepi-Choi unit and isolated KT608A, as well as between the originally proposed 
EI461 congener with a D-diepi-Choi motif and our synthetic KT608A. This supports the 
hypothesis that aeruginosin KT608A in fact does not contain the proposed D-diepi-Choi, but 
an L-diepi-Choi core instead. 
 
Table 11 Comparison of the 1H NMR spectra of the Choi moiety of natural and synthetic 
aeruginosin KT608A and aeruginosin EI461 and EI461 derivative synthesized by Bonjoch.  
 
Chemical shifts in ppm, multiplicity (coupling constant in Hz) 
KT608A natural EI461 
L-diepi-Choi KT608A synthetic 
EI461 derivative 
D-diepi-Choi 
2 4.82, d (9.5) 4.71, d (9) 4.23, t (8.8) 4.23, t (8.5) 
3 2.38, m (ax) 2.28, td (12.5, 9) 1.96, dt (12.3, 7.2) 2.02, m 
3' 1.70, dd (12, 6) 1.69, dd (12.0, 6.0) 1.83, dt (12.9, 10.1) 1.84, ddd (12, 10, 0.5) 
3a 2.23, m 2.18, m 2.15, m 2.16, ddddd 
4 1.63, m 1.63, m 1.57, m 1.70, m 
4' 1.63, m 1.63, m 1.67, m 1.70, m 
5 1.56, m (eq.) 1.54, m 1.60, m 1.62, m 
5' 1.19, m (ax) 1.21 dq (4.2, 12.8) 1.24, m 1.23, ddddd 
6 3.30, m 3.25, br t (11) 3.36, m 3.39, m 
7 2.37, m (eq.) 2.31, dd (12, 6) 1.90, m 1.96, m 
7' 0.83, q (12) 0.78, q (12) 1.60, m 1.57, m 
7a 4.04, ddd (12, 8, 6.5) 3.94 ddd, (12, 6.5, 5.5) 4.24, m 4.24, ddd (12, 6, 6) 
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One characteristic feature of the L-diepi-Choi is the presence of a high-field shifted pseudo-
quartet (~0.8 ppm for the cis and ~1.2 ppm for the trans rotamer) arising from H7 (ax). 
Bonjoch reported a shift of 1.57 ppm for H7 (ax) in the D-diepi-Choi of the originally 
synthesized EI461.[6] This is in accordance with the 1.60 ppm for H7 (ax) that we observed in 
our 1H NMR spectrum of KT608A (3.1). The dramatic downfield shift of the H7 signal (ax) 
when changing the L-diepi to a D-diepi configuration of the Choi unit can be explained by an 
influence of the peptide bond on the C-terminus. In D-diepi-Choi, the carboxyl oxygen of the 
amide bond lies in close proximity to H7 (ax), thus leading to a deshielding effect on H7 (ax) 
and an upfield shift of its 1H NMR signal. The X-ray structure of D-diepi-Choi derivative 3.57 
reveals a distance of 2.7 Å between these two atoms. In contrast, such a through-space 
deshielding effect of the carboxyl oxygen on the H7 (ax) proton is not possible in L-diepi-
Choi due to the large distance between these two atoms (Figure 49).  
 
Figure 49 Configuration of D-diepi-Choi and L-diepi-Choi, showing the respective distances of 
the carboxyl oxygen to H7 (ax). The chemical shifts were obtained from the following NMR 
examples described in the literature: D-diepi-Choi from aeruginosin EI461, L-diepi-Choi from 
the revised structure of aeruginosin EI461. The Choi-H2 and H7 (ax) atoms are highlighted in 
red. 
 
Furthermore, epimerization of D-diepi- to L-diepi-Choi does of course also strongly influence 
the chemical shift and the coupling pattern of the H2 signal in the 1H NMR spectrum. In 
D-diepi-Choi, the dihedral angles of H2-C2-C3-H3α and H2-C2-C3-H3β correspond to 20 and 
140°, respectively (Figure 50). According to the Karplus equation, these two angles induce 
similar coupling constants,[58,59] resulting in a pseudo-triplet multiplicity of the H2 signal in 
the 1H NMR spectrum of D-diepi-Choi (t, 4.23 ppm). On the other hand, the dihedral angles of 
H2-C2-C3-H3α and H2-C2-C3-H3β in L-diepi-Choi have values of 20 and 100°, respectively. 
Based on the Karplus equation, this leads to a large and a very small coupling constant for 
angles of H3α (dihedral angle = 20°) and H3β (dihedral angle = 100°), respectively. As a 
result, the signal appears as a doublet of doublet or just as a doublet, when the second 
coupling is too small to be resolved.[58,59] Indeed, the signal of L-diepi-Choi-H2 in aeruginosin 
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EI461 (53) is observed as a doublet at 4.71 ppm.[6] These observations are supported by the 
work of Bonjoch and co-workers, who reported on similar NMR characteristics for the 
Choi H2 in exo and endo cis-octahydroindole-2-carboxylic acid derivatives.[5] 
 
Figure 50 Newman projection of the Choi C2-C3 bond with selected dihedral angles. The 
dihedral angles for H2-C2-C3-H3α and H2-C2-C3-H3β in D-diepi-Choi were obtained from the 
X-ray structure of 3.57. The dihedral angles for H2-C2-C3-H3α and H2-C2-C3-H3β in L-diepi-
Choi were estimated by measuring the C1-C2-C3-H3α and C1-C2-C3-H3β dihedral angles in 
the X-ray structure of 3.57. 
 
All these observations strongly support the theory that in fact an L-diepi-Choi unit, or the 
enantiomeric D-6-epi-Choi, is present in aeruginosin KT608A (3.1). Of course, differentiation 
between the L-diepi-Choi and D-6-epi-Choi units cannot be achieved by NMR experiments 
without the use of chiral shift reagents. However, the fact that the L-diepi-Choi motif had 
already been identified in aeruginosin EI461 and that amino acids with L configuration are 
favorably formed in nature, hints at the presence of the L-diepi-Choi in aeruginosin KT608A 
(3.1). 
 
Isomerization of D-diepi-Choi 
For the investigation of the drastic shifting effect of the H7 (ax) NMR signal upon changing 
from a D-diepi-Choi to an L-diepi-Choi configuration, D-diepi-Choi derivative 3.57 was 
epimerized at its C2 position. First attempts using LDA as base did not bring about the desired 
epimerization and only led to decomposition of 3.57. However, treating 3.57 with NaH gave 
rise to epimerization at the C2 position and yielded an inseparable mixture of the D-diepi and 
L-diepi-Choi products (Scheme 45). Figure 51 shows a selected part of the 1H NMR 
spectrum of D-diepi-Choi derivative 3.57 (top) and the 1H NMR spectrum of the mixed 
D-diepi-Choi and L-diepi-Choi, obtained after epimerization (bottom). After epimerization, 
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the characteristic upfield-shifted pseudo-quartets at 1.20 ppm (trans rotamer) and 0.91 (cis 
rotamer) for H7 (ax) of the L-diepi-Choi were observed. This experiment further supports the 
hypothesis that an L-diepi-Choi instead of a D-diepi-Choi configuration is present in 
aeruginosin KT608A (3.1). However, final proof of this hypothesis can only be accomplished 
by the total synthesis of aeruginosin KT608A (3.1) containing an L-diepi-Choi moiety and by 
comparison of the NMR spectra to those of the isolated natural product KT608A (3.1). 
 
Scheme 45 Epimerization of D-diepi-Choi derivative 3.57. Reagents and conditions: a) NaH, 
THF, 78 °C to r.t., 20% as a diastereomeric mixture. 
 
 
Figure 51 Excerpt of the 1H NMR spectrum of D-diepi-Choi derivative 3.57 (top) and a mixture 
of D-diepi-Choi and L-diepi-Choi (bottom). The observed upfield-shifted signal for Choi-H7 
(ax) for the trans and cis rotamers in L-diepi-Choi are highlighted. 
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4. Indoline Synthesis via C-H Activation – Confirmation of the 
Absolute Configuration of the Indoline  
For the determination of the absolute configuration of indoline 3.56, an alternative synthetic 
approach was investigated. The new strategy featured an indoline formation by use of an 
intramolecular amination, starting from enantiopure L-tyrosine. Beginning with a compound 
with known absolute configuration is advantageous as the same absolute configuration will be 
found in indoline 3.56. 
4.1. Intramolecular Amination using Picolinamide as Directing Group 
In 2011, Chen and co-workers reported on the highly efficient synthesis of indolines via 
palladium-catalyzed intramolecular amination.[60] They introduced picolinamide as a directing 
group for the challenging amination of the G-C(sp2)-H bond. Catalyzed by Pd(OAc)2 as the 
PdII source and PhI(OAc)2 as stoichiometric oxidant, they were able to form indolines 3.81 
and 3.82 in excellent yields from 2-phenylethan-1-picolinamide (3.79) and phenylalanine 
methyl ester picolinamide (3.80), respectively (Scheme 46). Chen proposed a cyclic nine-
membered intermediate containing a PdIV center for the C-H activation mechanism. Reductive 
elimination of this cyclic intermediate provides the corresponding indolines.[61] Exchange of 
the phenylalanine moiety in 3.80 by an O-protected tyrosine picolinamide should therefore 
provide an indoline suitable for our total synthesis. The preparation of different picolinamide 
tyrosine derivatives and subsequent amination will be discussed in the following sections. 
 
Scheme 46 Chen’s   preparation   of   indolines   using   an   intramolecular amination reaction. The 
C-H activation proceeds via a PdIV species, with a picolinamide substituent as directing 
group.[60] 
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4.2. Preparation of Different Picolinamide Tyrosine Derivatives 
For the preparation of different picolinamide derivatives of tyrosine, the free amino group of 
L-tyrosine methyl ester (3.83) was coupled with 2-picolinic acid using HOBt and EDC as 
coupling reagents to give picolinamide 3.84 (Scheme 47). The low yield of 56% for this 
reaction can be explained by the formation of a side product in which both amino and 
hydroxyl groups of tyrosine were bound to picolinic acid. Alteration of the procedure by using 
Schotten-Baumann conditions,[62,63] including the usage of 2-picolinic acid chloride, did not 
lead to any improvement. Thus, the picolinamide tyrosine methyl ester (3.84) was protected 
on the phenol moiety. First, a TBS group was incorporated by the reaction of 3.84 with 
TBSCl to give silyl ether 3.85 in excellent yield. Further, 3.84 was protected with a MOM 
group by treatment with MOMCl providing MOM ether 3.86. Reaction of 3.84 with MeI 
afforded methyl ether 3.87 in very good yield (Scheme 47). Derivatives 3.85, 3.86 and 3.87 
were then subjected to the amination conditions described by Chen and co-workers, which 
will be discussed in the subsequent section in more detail. 
 
Scheme 47 Synthesis of picolinamide tyrosine derivatives 3.85, 3.86 and 3.87. Reagents and 
conditions: a) 2-picolinic acid, HOBt, EDC, DIPEA, CH2Cl2, 16 h, 56%; b) TBSCl, Et3N, 
DMAP, CH2Cl2/DMF (5:1), r.t., 16 h, 98%; c) MOMCl, DIPEA, CH2Cl2, 0 °C to r.t., 24 h, 75%; 
d) MeI, K2CO3, DMF, r.t., 17 h, 95%. 
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4.3. Investigation of the C-H Activation 
With the different picolinamide tyrosine derivatives in hand, their suitability for the 
intramolecular amination reaction was investigated (Table 12). First, silyl ether 3.85 and 
MOM ether 3.86 were subjected to the conditions described by Chen and co-workers. 
However, these conditions led to no conversion, but only the starting materials were 
recovered (Entries 1 and 2). In order to enforce the intramolecular amination to occur, the 
catalyst loading of Pd(OAc)2 was increased from 2 to 5 mol%. Indeed, with this change, 60% 
consumption of silyl ether 3.85 and 100% consumption of MOM ether 3.86 was observed 
(Entries 3 and 4). Indoline 3.89 containing the MOM ether was isolated in 60% yield, together 
with 20% of oxidized side product 3.89b. Since 100% consumption of the starting material 
had already been observed for derivative 3.86, further optimizations were carried out only for 
the cyclization of silyl ether 3.85. The catalyst loading was increased from 5 to 10 mol%, 
leading to an enhancement of the consumption from 60 to 80% (Entry 5). Because 10 mol% 
of catalyst already correspond to the upper limit of a convenient catalytic reaction, the catalyst 
loading was not further increased. Instead, the influence of the temperature on the outcome of 
the C-H activation was explored. Increasing the temperature from 60 to 110 °C furnished a 
90% consumption of silyl ether 3.85 to the corresponding indoline 3.88 already at 2 mol% 
catalyst loading (Entry 6). This observation suggests that our substrates required higher 
temperatures for the amination than the one investigated by Chen and his group. An increase 
of the catalyst loading to 5 and 10 mol%, respectively, finally led to full consumption of silyl 
ether 3.85 (Entires 7 and 8). However, the high temperature of 110 °C seemed to be too harsh 
conditions, provoking decomposition processes, since despite 100% consumption of the 
starting material only 60% of the desired indoline 3.88 was isolated. Therefore, the 
cyclization of methyl ether 3.87 was performed at a lower temperature of 60 °C, but with a 
high catalyst loading. Although the starting material was fully consumed, only 46% of 
methoxy indoline 3.90 were isolated (Entry 9). One reason for the low yields obtained despite 
full consumption of the starting material might be the formation of a pyridine N-oxide by 
reaction with the oxidant PhI(OAc)2, resulting in a very polar compound, which is difficult to 
elute during column chromatography. Therefore, the performance of an F+ oxidant[64] was 
investigated, to prevent the possible oxidation of the picolinamide nitrogen, but all attempts 
incorporating this oxidant led to no observable formation of the desired indoline (results not 
shown in Table 12).  
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Table 12 Different reaction conditions for the intramolecular amination of 3.85, 3.86 and 3.87. 
 
Entry Substrate Pd(OAc)2 Temperature 
Consumption of 
starting materiala Yield 
1 TBS 2 mol% 60 °C none - 
2 MOM 2 mol% 60 °C none - 
3 TBS 5 mol% 60 °C 60% n.d. 
4 MOM 5 mol% 60 °C 100% 60% + 20%b 
5 TBS 10 mol% 60 °C 80% n.d. 
6 TBS 2 mol% 110 °C 90% n.d. 
7 TBS 5 mol% 110 °C 100% 60% 
8 TBS 10 mol% 110 °C 100% 60% 
9c Me 10 mol% 60 °C 100% 46% 
All reactions were carried out by stirring in toluene for 16–20 h with 2.5 eq. of PhI(OAc)2 as oxidant. 
aConsumption of the starting material was determined using UPLC analysis. b20% of the oxidized product 3.89b 
were isolated. cOnly 2.0 eq. of PhI(OAc)2 were used. 
 
4.4. Synthesis of Indoline 3.56 and Confirmation of its Absolute Configuration 
Focusing on the determination of the absolute configuration of indoline 3.56, obtained after 
the enantioselective hydrogenation step described in Section 3.1.2, the transformation of 
methoxy indoline 3.90 to 3.56 was investigated. For this, the picolinamide group of 3.90 had 
to be replaced by an acetyl group and a transesterification from methyl to ethyl ester was 
required. First, the removal of the picolinamide substituent was explored. Chen and co-
workers described a facile elimination of the picolinamide auxiliary by subjecting the 
corresponding picolinamide product either to basic[60,61] or mildly acidic conditions.[65] 
However,  applying  Chen’s  conditions   to  our  substrate  3.90 led to no observable conversion 
under basic conditions. Treating 3.90 under acidic conditions, led to the cleavage of the 
picolinamide auxiliary, though in a very poor yield (Scheme 48). Although the picolinamide 
group has frequently been used in synthesis, for example as directing group for transition-
metal catalyzed C-H activation reactions[60,61,66,67] or as chelating ligand coordinated to 
different metal centers[68,69], only few methods have been established for the cleavage of this 
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group. Since picolinamides are known to strongly bind to CuII ions[70], Cu(OAc)2 was added 
to the reaction mixture under acidic conditions, in order to facilitate cleavage of the 
picolinamide group. Indeed, the picolinamide functionality was readily removed under these 
conditions, according to reaction control by TLC. However, purification and separation of the 
desired product from the CuII salts turned out to be challenging, due to good water solubility 
and large binding affinity to CuII of the obtained desired amino acid product. Therefore, no 
reasonable   yields  were  obtained.   In  May  2016,  O’Donovan  and   co-workers reported on the 
reductive cleavage of picolinamides by the reaction with zinc in aqueous HCl solution.[71] 
However, this deprotection method was published after we had stopped investigating cleavage 
of the picolinamide group in 3.90.  Further,   the  yields  of  O’Donovan   for   the   removal  of the 
picolinamide auxiliary range from 20 to 95%, revealing that this method cannot be universally 
used for the picolinamide deprotection either. Despite the problematic cleavage of the 
picolinamide group, synthesis of the desired indoline 3.56 was achieved: Esterification of the 
picolinamide deprotected amino acid with ethanol provided intermediate 3.91, followed by 
acetyl protection of the free amino group. The optical rotation of the obtained indoline 3.56 
was measured, revealing a negative value of 79.4°. Therefore, the negative optical rotation 
of indoline 3.56 can be attributed to an L-configuration, because the synthesis of 3.56 had 
started from enantiopure L-tyrosine. Since the indoline obtained via enantioselective 
hydrogenation displayed an optical rotation value of +78.8°, the D-configuration of this 
indoline could thus be confirmed (for details see Section 3.1.2). Consequently, the D-diepi-
Choi and not the L-6-epi-Choi had effectively been prepared in our previous synthesis of 
aeruginosin KT608A (3.1) (Section 3). Therefore, one possible mistake in our total synthesis 
of 3.1 could be excluded. Since picolinamide turned out to be problematic as directing group 
for the C-H activation to furnish reasonable amounts of indoline 3.56, the use of a different 
directing group for the intramolecular amination was investigated (Section 5). 
 
Scheme 48 Synthesis of indoline 3.56. Reagents and conditions: a) 6 N aq. HCl, 100 °C, 2 h; 
b) SOCl2, EtOH, 0 °C to 79 °C, 3 h, 14% over two steps; c) Ac2O, Et3N, DMAP, CH2Cl2, r.t., 
16 h, 71%. 
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5. Synthesis of Aeruginosin KT608A – 2nd Generation 
5.1. Intramolecular Amination using 2-Pyridinesulfonamide as Directing Group 
Already in 2008, Yu and co-workers had described the PdII-catalyzed formation of indolines 
and tetrahydroisoquinolines form arylethylamines.[72] Yu explored a tandem reaction 
incorporating a PdII-catalyzed iodination followed by a CuI-mediated amination, leading to 
the cyclization of a broad scope of arylethyltriflamides. Further investigations on this reaction 
showed that the iodination step is not necessarily required for C-H activation and that 
arylethyltriflamides can directly be transformed to the corresponding indolines.[73] A 
drawback of the C-H activation developed by Yu and co-workers was that the amines 
required a triflate protecting group to successfully undergo the amination. Due to the stability 
of triflamides and the harsh conditions which are required for their cleavage, e.g. using 
LiAlH4,[74] the liberation of the free amine can cause problems. Fortunately, Yu et al. later 
found a solution to circumvent this problem. Instead of using triflates for the protection of the 
amine, they incorporated pyridine-2-sulfonamide as the directing group.[75] The use of the 
pyridine-2-sulfonamide group combines the advantage of the high reactivity of triflamides 
regarding the C-H activation with the directing capability of the picolinamide group, as 
described by Chen. Further, Yu and co-workers explored a mild and selective deprotection 
method for the cleavage of the sulfonamide by simple treatment with a methanolic Mg0 
powder suspension (Scheme 49). An advantage of this mild deprotection method is that no 
racemization has been observed during the cleavage of sulfonamide 3.93 to give access to 
indoline 3.94 (Scheme 49). All these  benefits  encouraged  us  to  further  investigate  Yu’s  C-H 
activation strategy for our synthesis of the D-diepi-Choi. 
 
Scheme 49 Yu’s  amination  using  pyridine-2-sulfonamide as directing group and cleavage of the 
sulfonamide auxiliary by treatment with Mg0. 
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5.2. Preparation of Sulfonamides 3.98 and 3.100 
The synthesis of adequate sulfonamide precursors was started from commercially available 
D-tyrosine (3.95), which was transformed into methyl ester 3.96 (Scheme 50).[76] Further, the 
hydroxyl group of 3.96 was protected with a TBS group to give silyl ether 3.97.[76] For the 
formation of the pyridine-2-sulfonamide,  we   followed  Yu’s  method   by   treating   amine  3.97 
with sulfonyl chloride prepared from 2-mercaptopyridine and sodium hypochlorite in situ. 
However, this procedure did not furnish the desired product 3.98. Therefore, the sulfonamide 
was introduced by reaction with freshly prepared pyridine-2-sulfonyl chloride under basic 
conditions, giving pyridine-2-sulfonamide 3.98 in good yield[77] as starting material for the 
projected C-H activation. Furthermore, a pyridine-2-sulfonamide derivative was synthesized 
bearing an electron-withdrawing acetyl group instead of the electron-donating silyl group in 
order to investigate the influence of electronic properties on the C-H activation. Thus, silyl 
ether 3.98 was treated with a TBAF solution yielding the free phenol 3.99. Subsequent 
acetylation of 3.99 then provided pyridine-2-sulfonamide 3.100 (Scheme 50).  
 
Scheme 50 Preparation of sulfonamides 3.98 and 3.100. Reagents and conditions: a) SOCl2, 
MeOH, 0 °C to 66 °C, 12 h, quant.; b) TBSCl, imidazole, CH2Cl2, r.t., 16 h, 87%; c) pyridine-2-
sulfonyl chloride, Et3N, CH2Cl2, r.t., 2 h, 72%; d) TBAF, THF, 0 °C to r.t., 2 h, 79%; e) AcCl, 
DMAP, Et3N, CH2Cl2, r.t., 1 h, 86%. 
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5.3. Different Conditions for the C-H Activation of 3.98 and 3.100 
Both tyrosine sulfonamide derivatives 3.98 and 3.100 were tested for their suitability to react 
in the PdII-catalyzed intramolecular amination. The results of these experiments are 
summarized in Table 13. A first test reaction starting from silyl ether 3.98 with 2 mol% 
catalyst loading and a reaction temperature of 90 °C gave only traces of the desired indoline 
product 3.101 (Entry 1). Increasing the catalyst loading up to 15 mol% did not lead to a 
significant improvement of the conversion to indoline 3.101 (Entries 2-4). Since the C-H 
activation seemed to require higher temperatures than 90 °C, the temperature was raised to 
130 °C. However, with 5 mol% of catalyst, this did not change the results (Entry 5). Further, 
the catalyst loading was increased from 5 to 10 mol% and the dilution of the reaction mixture 
decreased from 0.01 M to 0.09 M. These changes provided 100% consumption of the starting 
material sulfonamide 3.98, although only 40% of the desired indoline 3.101 were isolated 
(Entry 6). The discrepancy between starting material consumption and isolated yield suggests 
the occurrence of side reactions leading to decomposition pathways. In order to diminish 
possible decomposition, the reaction time was reduced from 14 h to 10 h. Indeed, with this 
modification the isolated yield of 3.101 was raised from 40% to 54% (Entry 7). Next, 
acetylated tyrosine sulfonamide 3.100 was investigated as substrate. Knowing that 90 °C did 
not suffice to bring about intramolecular amination, we started our screening directly at a 
temperature of 130 °C. A first reaction with 10 mol% catalyst loading and 0.01 M substrate 
concentration provided 30% consumption of the starting material (Entry 8). As observed in 
the C-H activation of the silyl ether derivative, the dilution of the reaction mixture has a 
crucial impact on the outcome of the reaction. Therefore, the concentration was increased 
from 0.01 M to 0.1 M. This alteration of the reaction conditions resulted in an increased 
consumption of the starting material from 30 to 60% and furnished the isolation of 30% of 
indoline 3.102 (Entry 9). Since the reaction was not complete after 8 h (Entry 9), the reaction 
time was extended to 12 h (Entry 10). To reduce possible decomposition pathways, the 
dilution of the reaction was slightly increased from 0.1 M to 0.08 M. These adjustments of the 
reaction conditions led to 100% consumption of the starting material 3.100 accompanied by 
the isolation of 67% of the desired product 3.102 (Entry 10). A reduction of the reaction time 
from 12 to 11 h finally provided a yield of 80% of the desired indoline 3.102 (Entry 11). 
CHAPTER II: SYNTHETIC STUDIES ON AERUGINOSIN KT608A 
145 
Table 13 Different conditions for the amination of sulfonamides 3.98 and 3.100. 
Entry Substrate Pd(OAc)2 Temp. Time 
Consumption of 
starting materiala Yield 
1 TBS 2 mol% 90 °C 14 h <10% n.d.
2 TBS 5 mol% 90 °C 14 h <10% n.d.
3 TBS 10 mol% 90 °C 14 h <10% n.d.
4 TBS 15 mol% 90 °C 14 h <10% n.d.
5 TBSc 5 mol% 130 °Cb 6 h <10% n.d.
6 TBSd 10 mol% 130 °Cb 14 h 100% 40% 
7 TBSd 10 mol% 130 °Cb 10 h 100% 54% 
8 Acc 10 mol% 130 °Cb 8 h 30% n.d.
9 Acd 10 mol% 130 °Cb 8 h 60% 30% 
10 Acd 10 mol% 130 °Cb 12 h 100% 67% 
11 Acd 10 mol% 130 °Cb 11 h 100% 80% 
All reactions were carried out under exclusion of water in toluene with 2.0 eq. PhI(OAc)2 as the oxidant. 
aConsumption of the starting material was determined using UPLC analysis. bThe reaction was performed in a 
microwave reactor. cThe reaction was performed at a 0.01 M substrate concentration. dThe reactions were 
performed with a starting material concentration ranging from 0.08 to 0.1 M. 
5.4. Synthesis of the D-diepi-Choi, 1st Approach
With silyl ether indoline 3.101 in hand, the next focus lay on the cleavage of the sulfonamide 
auxiliary and reduction of the indoline to the octahydroindole unit (Scheme 51). For this, 
sulfonamide 3.101 was treated with a methanolic Mg0 powder suspension, as described by Yu
and co-workers.[75] Indeed under these mild conditions, the sulfonamide moiety in 3.101 was
smoothly cleaved to give indoline 3.103 in excellent yield. For the preparation of indoline 
3.103 as starting material for the subsequent reduction to the octahydroindole, the amine of 
indoline 3.103 was protected with a trifluoroacetate group yielding indoline 3.104. Baudoin 
and co-workers showed that amine trifluoroacetates can be readily and selectively cleaved in 
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the presence of a silyl ether and methyl ester by treatment with NaBH4,[21] whereas non-
fluorinated amides can only be cleaved under harsh acidic conditions (for more details see 
Section 3.2.2). Further, indoline 3.104 was subjected to the reduction conditions developed in 
our previous synthesis of the D-diepi-Choi (Section 3.2.1). Unfortunately, the applied 
conditions provoked degradation of the silyl ether, thus leading to a complex mixture of 
different products. Investigation of the synthetic strategy incorporating the TBS protecting 
group was therefore stopped and the focus was laid on the derivative bearing the acetyl group. 
The results obtained with this route will be the topic of the next section. 
 
Scheme 51 Studies towards the synthesis of octahydroindole 3.105. Reagents and conditions: 
a) Mg powder, MeOH, 0 °C, 3 h, then sat. aq. NH4Cl, Et2O, r.t., 1 h, 95%; b) trifluoroacetic 
anhydride, pyridine, CH2Cl2, 0 °C to r.t., 16 h, 89%; c) H2 (35 bar), Rh/C, MeOH, r.t.. 
 
5.5. Synthesis of the D-diepi-Choi, 2nd Approach 
Due to decomposition of the derivative bearing a TBS group (Section 5.4) under reducing 
conditions, the synthesis of the D-diepi-Choi was continued with acetylated indoline 3.102 
(Scheme 52). Not only did subjecting 3.102 to a methanolic Mg0 powder suspension induce 
the cleavage of the sulfonamide, but also of the acetyl ester to give indoline 3.106. Reduction 
of this unprotected indoline 3.106 to the corresponding octahydroindole using heterogeneous 
catalysis was not successful. Therefore, the amino group of indoline 3.106 was protected with 
a trifluoroacetyl group to provide indoline 3.107 (similar to Section 5.4). Since indoline 3.107 
could still not be converted into the corresponding octahydroindole via catalytic heterogenous 
hydrogenation, the hydroxyl group of 3.107 was protected with a MOM group. The poor 
reactivity of unprotected indolines towards hydrogenation has already been observed in our 
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previous synthesis of the D-diepi-Choi (for more details see Section 3.3). Fortunately, the 
trifluoroacetyl-protected indoline 3.108 could be converted into octahydroindole 3.109, 
although the yield of 56% (65% brsm) was moderate. The lower yield compared to the one 
achieved in our previous synthesis (Section 3.2.1) can be explained by the moderate stability 
of the trifluoroacetate under the applied conditions. However, optimization of the reaction 
conditions, e.g. by adjusting the H2 pressure, should prevent degradation of the 
trifluoroacetate and thus lead to an increased yield of 3.109. Removal of the trifluoroacetate 
functionality of 3.109 using the conditions described by Baudoin and co-workers finally gave 
access to D-diepi-Choi derivative 3.110 in a very good yield (Scheme 52). Compound 3.110 
was further used as a building block in the assembly of aeruginosin KT608A (3.1), which will 
be discussed in Section 5.7. 
 
Scheme 52 Synthesis of D-diepi-Choi derivative 3.110. Reagents and conditions: a) Mg powder, 
MeOH, 0 °C, 3 h, then sat. aq. NH4Cl, Et2O, r.t., 1 h; b) trifluoroacetic anhydride, pyridine, 
CH2Cl2, 0 °C to r.t., 16 h; c) MOMBr, DIPEA, CH2Cl2, 0 °C to r.t., 24 h, 62% over three steps; 
d) H2 (15 bar), Rh/C, MeOH, r.t., 4.5 h, 56% (65% brsm); e) NaBH4, MeOH, 0 °C, 1 h, 81%. 
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5.6. Synthesis of the Hpla-Phe-OH Dipeptide 
For the assembly of aeruginosin KT608A (3.1), we envisioned the incorporation of the D-Phe 
and L-Hpla-OH building blocks as a dipeptide, similar to the strategy described in the 
synthesis of aeruginosin 828A. Doing so, the step economy of the total synthesis is reduced 
by two synthetic steps. For the synthesis of Hpla-Phe-OH dipeptide 3.115, D-Phe-OMe 
(3.111) was coupled to the L-Hpla-OH unit (3.67) using PyBOP as coupling reagent, to access 
dipeptide 3.112 (Scheme 53). Since the acetyl ester of the L-Hpla unit was not orthogonal to 
the conditions used for the cleavage of the D-Phe methyl ester, the protecting group of this 
hydroxyl group had to be altered. That way, the problem of a free hydroxyl group which 
could possibly interfere by an intramolecular attack on the active ester in another peptide 
coupling was excluded. Thus, acetyl ester 3.112 was treated with K2CO3 to give the free 
hydroxyl group and dipeptide 3.113. Subsequent protection of the obtained hydroxyl group 
with TBSCl provided silyl ether 3.114. Finally, the synthesis of Hpla-Phe-OH dipeptide 3.115 
was accomplished by saponification of the D-Phe methyl ester in 3.114 (Scheme 53). The 
application of dipeptidic building block 3.115 in the assembly of aeruginosin KT608A (3.1) 
will be the content of the next section. 
 
Scheme 53 Synthesis of Hpla-Phe-OH dipeptide 3.115. Reagents and conditions: a) L-Hpla-OH 
3.67, PyBOP, 2,6-lutidine, CH2Cl2, 0 °C to r.t., 20 h, 77%; b) K2CO3, MeOH, r.t., 2 h, 84%; c) 
TBSCl, imidazole, DMAP, DMF, r.t., 18 h, 38% (94% brsm); d) LiOH, THF/H2O (5:3), r.t., 1 h, 
96%. 
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5.7. Assembly of the Different Building Blocks 
The assembly of the building blocks of aeruginosin KT608A commenced with the peptide 
coupling of D-diepi-Choi unit 3.110 to Hpla-Phe-OH dipeptide 3.115 (Scheme 54). For this 
coupling, the same conditions were applied as in the synthesis of aeruginosin 828A (Section 
5.3; Chapter I). Fortunately, these conditions provided tripeptide 3.116 in a high yield as a 
rotameric mixture of 4:1, without the occurrence of racemization. As tripeptide 3.116 was 
obtained as a single diastereoisomer (in contrast to the previously described synthesis of 
aeruginosin KT608A (3.1)), we can exclude the formation of an undesired stereoisomer in the 
course of this synthesis. Saponification of the methyl ester of the L-Choi moiety in tripeptide 
3.116 provided acid 3.117. Further, coupling of this acid 3.117 with the agmantin building 
block 3.64 gave access to tetrapeptide 3.118 (Scheme 54). At this stage, the desired natural 
product was fully assembled and global deprotection was required for completion of the total 
synthesis of KT608A (3.1). First, the Bn group of 3.118 was removed using catalytic 
hydrogenation to provide tetrapeptide 3.119 in excellent yield. Further, tetrapeptide 3.119 was 
treated with TFA in CH2Cl2 to cleave the acid-labile Boc, MOM and TBS groups. 
Surprisingly, the TBS group was not removed under these conditions. Therefore, the crude 
residue obtained after acidic treatment was additionally stirred for 1 h in a solution of HF in 
MeCN to ensure cleavage of the TBS group. During the treatment with diluted TFA solution, 
a trifluoroacetylated side product was formed as well. Thus, the obtained crude residue was 
stirred for 30 min in an aqueous Na2CO3 solution to cleave the trifluoroacetyl ester 
(analogously to the synthesis of aeruginosin 616A (Section 7.1, Chapter I)). After 
deprotection, 2.4 mg of the desired aeruginosin KT608A (3.1) were successfully isolated 
(Scheme 54). With the synthetic aeruginosin KT608A (3.1) in hand, 1H and 13C 1D NMR 
experiments as well as COSY, HMBC, HSQC and NOESY 2D NMR experiments were 
recorded. The obtained NMR spectra were then compared with those recorded by Carmeli[1] 
and with the NMR spectra from our previous total synthesis of KT608A (Section 3.6), 
revealing that the spectra of our previously synthesized KT608A and the synthesized KT608A 
of the 2nd generation were identical. This strongly supports the hypothesis that the desired 
aeruginosin does indeed contain a D-diepi-Choi core and that the assigned structure for 
aeruginosin KT608A by Carmeli and co-workers was incorrect. Of course, final prove of this 
hypothesis can only be accomplished by the total synthesis of aeruginosin KT608A 
containing the correct core structure. 
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Scheme 54 Assembly of the different building blocks – synthesis of aeruginosin KT608A (3.1). 
Reagents and conditions: a) Hpla-Phe-OH 3.115, DMTMM, NMM, CH2Cl2, 0 °C to r.t., 2 h, 
71%; b) 0.1 N LiOH, THF/H2O (5:3), r.t., 7 h, 77%; c) Agm 3.64, PyBOP, 2,6-lutidine, CH2Cl2, 
0 °C to r.t., 5 h, 55%; d) H2, Pd/C, MeOH/EtOAc (1:1), r.t., 24 h, 97%; e) CH2Cl2/TFA (10:1), 
r.t., 7 h; f) HF (aq.)/MeCN (1:9), r.t., 1 h, then Na2CO3, r.t., 30 min, 99% over two steps. 
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5.8. Isomerization of the D-diepi-Choi Unit 
As already exemplified in Section 3.6.1, the most probable candidate to be structurally 
identical with the natural product aeruginosin KT608A (3.1) is an aeruginosin consisting of 
the same L-Hpla, D-Phe and agmantin moieties, but with an L-diepi-Choi instead of the 
D-diepi-Choi core. Therefore, investigations towards the isomerization of the D-diepi-Choi to 
the L-diepi-Choi were carried out (Scheme 55). First attempts by treating D-diepi-Choi 
derivative 3.110 with LDA or NaH resulted either in no isomerization or in decomposition of 
3.110. Fortunately, a procedure by Wipf and co-workers,[9] developed for the epimerization of 
L-triepi-Choi to D-triepi-Choi, also led to the epimerization of our substrate. In general, the 
formation of the D-diepi-Choi is kinetically favored due the sterically less hindered 
protonation from the convex side compared to protonation from the concave side. Wipf took 
advantage of this effect by using sterically demanding tert-butyl alcohol for quenching and 
protonation, which gave the desired D-triepi-Choi in a 12:1 ratio. In order to minimize steric 
interaction of L-diepi-Choi with the proton source, we used methanol instead of tert-butyl 
alcohol to quench our epimerization reaction. With methanol as proton source, we observed a 
ratio of 3:1 of D-diepi-Choi to L-diepi-Choi. However, further inquiry of this epimerization 
and investigation of the separation of the two epimers have to be explored. 
 
Scheme 55 Isomerization of D-diepi-Choi derivative 3.110. Reagents and conditions: a) LiNEt2, 
10% HMPA/THF, 78 °C, 30 min, then MeOH, no product isolation. 
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6. Conclusion 
In this chapter, the development of two novel synthetic routes for the synthesis of the 
presumed D-diepi-Choi moiety in aeruginosins has been described. The first strategy 
comprises the homogeneous catalytic enantioselective hydrogenation, followed by 
heterogeneous catalytic hydrogenation to give the octahydroindole backbone of D-diepi-Choi. 
The second route includes C-H activation of a D-tyrosine derivative providing the 
corresponding indoline. As in the first strategy, heterogeneous catalytic hydrogenation 
provides the octahydroindole skeleton of the D-diepi-Choi. Both synthetic routes finally led to 
the total synthesis of the presumed structure of aeruginosin KT608A (3.1). However, analysis 
of the NMR spectra showed substantial differences between the data of our synthetic material 
and the isolated aeruginosin KT608A (3.1). Our synthetic work therefore resulted in a 
reconsideration of the proposed structure of KT608A, as described by Carmeli and co-
workers in the isolation work. Furthermore, by carefully comparing the NMR spectra of 
natural aeruginosin KT608A (3.1) with those of literature known aeruginosins, we have 
developed   a   closer   understanding   of   the   isomeric  Choi   core   units’   spectroscopic   properties  
and propose that aeruginosin KT608A (3.1) actually comprises an L-diepi-Choi moiety 
instead of the presumed D-diepi-Choi. This hypothesis was supported by epimerization 
experiments with D-diepi-Choi furnishing L-diepi-Choi. Further, it is to be expected that the 
structures of the other aeruginosins reported to contain such a D-diepi-Choi core – 
aeruginosins KT608B (3.2) and KT650 (3.3) – have also been wrongly assigned, since these 
natural products show the same characteristics in the NMR spectra as 3.1. These 
characteristics indicate the presence of an L-diepi-Choi motif in the natural products 3.2 and 
3.3 as well. All in all, the presence of a D-diepi-Choi unit in natural aeruginosins seems to be 
a myth from literature. Hence, the natural occurrence of the D-diepi-Choi unit has to be 
strongly questioned as no confirmed structure of a natural product containing this feature has 
been reported so far.  
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7. Outlook – Synthesis of Aeruginosin KT608A containing an 
L-diepi-Choi Moiety 
For future work, we envision the synthesis of our proposed revised structure of aeruginosin 
KT608A (3.121) containing an L-diepi-Choi core (Scheme 56). Careful investigation of the 
NMR spectra of our synthetic material with the isolated natural product indicates the presence 
of this stereoisomer of the Choi motif. Epimerization of the D-diepi-Choi derivative 3.110 
should give access to L-diepi-Choi building block 3.120. Further, assembly of the different 
building blocks can be performed by the same route as reported in section 5.7, with the only 
difference being the incorporation of L-diepi-Choi 3.120 instead of D-diepi-Choi derivative 
3.110. Once the synthesis of aeruginosin KT608A (3.121) will be successfully accomplished, 
the analysis of the NMR spectra of 3.121 and natural 3.1 should lead to the confirmation of 
our proposed structure of natural aeruginosin KT608A. 
 
Scheme 56 Planned synthesis of the proposed revised structure of aeruginosin KT608A ( 3.121), 
starting from L-diepi-Choi building block 3.120.  
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CONCLUSION 
In this thesis, our synthetic and biological studies on cyanobacterial aeruginosins were 
described.  
Intoxication of waters caused by cyanobacteria has emerged as an ever growing problem all 
over the world. Recently, chlorosulfopeptides such as aeruginosin 828A have been shown to 
exert toxic effects on aquatic organisms. In Chapter I, the first total synthesis of venomous 
A828A is described, incorporating 18 linear synthetic steps. Solutions for the challenging 
α-xylosylation and peptide coupling to the Pla-Cleu-OH dipeptide of the L-Choi moiety were 
reported. In order to get insights into the mode of action of A828A, three congeners with 
different permutations of the chloride and sulfate groups have successfully been prepared. The 
synthesized analogues include aeruginosin 748A and 794A, lacking the sulfate and the 
chloride substituent, respectively, and aeruginoside 126A, missing both sulfate and chloride 
residues. Performed toxicity tests against the crustacean Thamnocephalus platyurus revealed a 
distinct  effect  of  the  sulfate  group  on  increasing  the  toxicity.  Further,  no  ‘chlorine  effect’  was  
observed,  suggesting  that  the  mode  of  action  of  the  aeruginosins’  toxicity  differs  from  that  of  
protease inhibition. The results described in Chapter I therefore contribute to a more thorough 
understanding  of  the  chlorosulfopeptides’  role  as  cyanotoxins. 
In Chapter II, two different strategies for the synthesis of the D-diepi-Choi unit present in 
aeruginosins such as KT608A are described. The first approach involves a two-step sequence 
for the ready preparation of octahydroindoles from indoles. This sequence includes a 
homogeneous enantioselective hydrogenation reaction giving access to enantioenriched 
indolines followed by a stereocontrolled heterogeneous reduction. The second pathway 
comprises a C-H activation step providing the indoline intermediates which is again 
succeeded by a catalytic heterogeneous hydrogenation reaction. The synthesized D-diepi-Choi 
units were successfully incorporated in two independently performed total syntheses of 
presumed aeruginosin KT608A. Both synthetic materials revealed distinct deviations of the 
NMR data with respect to the isolated natural product, resulting in the structural revision of 
aeruginosin KT608A.  
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1. General Methods and Materials 
Reagents and Solvents were purchased from commercial suppliers (Acros, Fluorochem, 
Simga Aldrich or TCI) and were used in the reactions without any purification unless 
otherwise stated. Dry solvents were either purchased from Sigma Aldrich and Acros or 
were obtained from the Innovative Technology solvent drying system. Technical grade 
solvents were distilled prior to usage. 
 
Thin Layer Chromatography (TLC) was performed using Merck silica gel 60 F254 
plates, visualized with UV light or developed either with aqueous KMnO4/Na2CO3 or 
cerium ammonium molybdate (CAM) stain solution followed by heating.  
 
Flash Chromatography (FC) was carried out on silica gel 60 with a particle size of 
0.040.063 mm (230400 mesh) from Silicycle or Merck using a slight overpressure. 
 
Nuclear Magnetic Resonance spectroscopy (NMR) 1H NMR spectra were recorded on 
Bruker 400 MHz spectrometers, 500 MHz spectrometers or 600 MHz spectrometers 
(equipped with a cryo platform) at 298K or 300K in the indicated deuterated solvent. 
Data are reported as follow: chemical shift (δ, ppm), multiplicity (s, singulet; d, doublet; 
t, triplet; q, quartet; m, multiplet or not resolved signal; br, broad signal), coupling 
constant(s) (J, Hz), integration. All signals were referenced to the internal solvent signal 
as standard (CHCl3 = δ 7.26; DMSO-d6 = δ 2.50; MeOD-d4 = δ 3.31). 13C NMR spectra 
were recorded with 1H-decoupling on Bruker 101 MHz, Bruker 126 MHz or Bruker 150 
MHz spectrometers (equipped with a cryo platform) at 298 K or 300K in the indicated 
deuterated solvent. All signals were referenced to the internal solvent signal as standard 
(CHCl3 = δ 77.16; DMSO-d6 = δ 39.52; MeOD-d4 = 49.00). 19F NMR spectra were 
recorded with 1H-decoupling on Bruker 376 MHz spectrometers. 
 
Melting points (Mp) were determined using a Büchi B-545 apparatus in open capillaries 
and are uncorrected. 
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Infrared Spectroscopy (IR) was recorded on a Varian 800 FT-IR ATR spectrometer or on a 
Spectrum Two (UATR) FT-IR (Perkin Elmer). Data are reported in terms of frequency of 
absorption (ṽ, cm−1). 
 
Optical rotations [𝜶]𝑫𝑻  were recorded at the indicated tempereatre (T) on a Jasco P-2000 digital 
polarimeter with a path length of 1 dm, using the 589.3 nm D-line of sodium. Concentrations (c) 
are quoted in g/100 mL.  
 
High Resolution Mass Spectroscopy (HRMS) was recorded by Dr. Heinz Nadig at the 
University of Basel on a Bruker maXis 4G QTOF ESI mass spectrometer or by the mass 
spectroscopy service at University of Zurich on a Finnigan MAT95 MS. 
 
Ultra High Performance Liquid Chromatography with Mass Spectrometry (UHPLC-
MS) was performed on an Agilent 1290 Infinity instrument equipped with an Eclipse Plus 
C18 column and an Agilent 6130 ESI-MS detector using a formic acid buffered MeCN/H2O 
gradient.  
 
Chiral High Performance Liquid Chromatography (Chiral HPLC) was performed on a 
Dionex HPLC equipped with a UV-detecor and a chiralpak AS_H column, using isocratic n-
heptane/iPrOH or n-hexane/iPrOH eluents. 
 
Reversed-phase high-performance liquid chromatography (RP-HPLC) was performed on 
a Dionex HPLC equipped with a P680 HPLC Pump, an ASI-100 automated sample injector, a 
PDA-100 photodiode array detector, a MSQ- ESI mass spectrometric detector and a Gemini 
C18  5  μm  150x4.6  mm  column  using  formic  acid  buffered  H2O/MeCN gradients.  
 
X-ray single crystal structure determination was performed by Dr. Markus Neuburger on a 
Bruker APEX-II (University of Basel) and by Prof. Dr. Anthony Linden (University of 
Zurich) on a Nonius KappaCCD diffractometer. Data reduction, solution and refinement used 
the programs APEX[1] and SHELXL97.[2] Structure analysis was carried out using Mercury v. 
3.6.[3] 
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2. Experimental Procedures 
2.1. Toxicity and Synthesis of Aeruginosin Chlorosulfopeptides 
2.1.1. L-Choi synthesis  
Dimethyl (tert-butoxycarbonyl)-L-glutamate (2.25) 
L-Glutamic acid dimethyl ester hydrochloride (2.24) (5.80 g, 27.1 mmol, 
1.0 eq.) was dissolved in CH2Cl2 (45 mL). To this solution, NEt3 
(7.63 mL, 54.2 mmol, 2.0 eq.) and Boc2O (6.04 g, 27.1 mmol, 1.0 eq.) 
were added in small portions at 0 °C. The mixture was stirred for 30 min at 0 °C and further 
20 h at room temperature. The reaction mixture was quenched by the addition of sat. aq. 
Na2CO3 solution (25 mL). The layers were separated and the aqueous layer was extracted with 
CH2Cl2 (3 x 20 mL). The combined organic layers were dried over Na2SO4 and the solvent 
removed under reduced pressure. The crude product was purified by flash column 
chromatography (SiO2, pentane/EtOAc 2:1) to give N-Boc-glutamic acid dimethylester (2.25) 
(7.40 g, 26.9 mmol, 99%) a colorless solid. 
 
1H NMR (400 MHz, CDCl3) δ/ppm 5.11 (d, J = 8.4 Hz, 1H), 4.41–4.24 (m, 1H), 3.73 (s, 3H), 
3.66 (s, 3H), 2.54–2.32 (m, 2H), 2.17 (dq, J = 13.0, 7.5 Hz, 1H), 1.94 (td, J = 14.6, 8.2 Hz, 
1H), 1.42 (s, 9H); 13C NMR (101 MHz, CDCl3) δ/ppm 173.3, 172.8, 155.5, 53.0, 52.5, 51.9, 
30.2, 28.4, 27.9. 
Analytical data are in accordance with those reported in the literature.[4] 
 
But-3-en-1-yl trifluoromethanesulfonate 
To a solution of pyridine (5.60 mL, 69.1 mmol, 1.2 eq.) in CH2Cl2 (70 mL) was 
added dropwise Tf2O (9.90 mL, 57.6 mmol, 1.0 eq.) at –78 °C. The mixture was stirred for 
15 min at –78 °C before 3-butenol (5.00 mL, 57.6 mmol, 1.0 eq.) was added dropwise, 
followed by CH2Cl2 (20 mL). After stirring at –78 °C for 20 min, the mixture was diluted 
with CH2Cl2 (70 mL). The solution was washed with ice cold HCl solution (1 M, 40 mL), H2O 
(40 mL) and the organic layer was dried over Na2SO4. The solvent was removed under 
reduced pressure (300 mbar) at 24 °C. The crude residue was purified by flash column 
chromatography (SiO2, pentane/EtOAc 5:1) to give but-3-en-1-yl trifluoromethane-sulfonate 
(9.80 g, 48.0 mmol, 83%) as a colorless oil. 
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1H NMR (400 MHz, CDCl3) δ/ppm 5.85–5.67 (m, 1H), 5.23 (dq, J = 5.6, 1.4 Hz, 1H), 5.20 (t, 
J = 1.4 Hz, 1H), 4.56 (t, J = 6.6 Hz, 2H), 2.58 (qt, J = 6.6, 1.3 Hz, 2H); 13C NMR (101 MHz, 
CDCl3) δ/ppm 131.1, 119.7, 76.2, 33.6. 
Analytical data are in accordance with those reported in the literature.[4] 
 
Dimethyl (2S,4S)-2-(but-3-en-1-yl)-4-((tert-butoxycarbonyl)amino)pentanedioate (2.26) 
To a solution of N-boc-glutamic acid dimethylester (2.25) (6.60 g, 
24.0 mmol, 1.0 eq.) in THF (130 mL) was added slowly LiHMDS 
(48.0 mL, 1 M solution in THF, 48.0 mmol, 2.0 eq.) at –78 °C. The 
mixture was stirred for 45 min at –78 °C before but-3-en-1-yl 
trifluoromethanesulfonate (9.80 g, 48.0 mmol, 2.0 eq.) was added dropwise. After stirring for 
20 min at –78 °C the reaction was quenched by the addition of aq. NH4Cl solution (2 M, 
40 mL) and the mixture was allowed to warm to room temperature. The solvent was removed 
and the aqueous layer was extracted with CH2Cl2 (3 x 60 mL). The combined organic layers 
were dried over Na2SO4 and the solvent was removed under reduced pressure to obtain an 
orange oil. The crude residue was purified by flash column chromatography 
(SiO2, pentane/EtOAc 9:1) to give pentanedioate 2.26 (5.00 g, 15.2 mmol, 63%) as a colorless 
oil. 
 
1H NMR (400 MHz, CDCl3) δ/ppm 5.75 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 5.05–4.90 (m, 3H), 
4.40–4.28 (m, 1H), 3.72 (s, 3H), 3.67 (s, 3H), 2.50 (tt, J = 8.1, 5.8 Hz, 1H), 2.07–1.94 (m, 
4H), 1.72 (dtd, J = 13.6, 8.3, 6.9 Hz, 1H), 1.66–1.56 (m, 2H), 1.43 (s, 10H); 13C NMR 
(101 MHz, CDCl3) δ/ppm 176.2, 173.0, 155.4, 137.5, 115.6, 80.1, 52.5, 52.3, 51.9, 41.6, 34.6, 
31.7, 31.2, 28.4. 
Analytical data are in accordance with those reported in the literature.[4] 
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Methyl (2S,4S)-4-(but-3-en-1-yl)-5-oxopyrrolidine-2-carboxylate (2.27) 
Pentanedioate 2.26 (5.00 g, 15.2 mmol, 1.0 eq.) was dissolved in formic 
acid (38 mL) and stirred at room temperature for 5 h. The formic acid was 
removed under reduced pressure and the resulting oil was dissolved in 
toluene (180 mL) and refluxed for 1.5 h. The solvent was removed under reduced pressure to 
give pyrrolidinone 2.27 (3.00 g, 15.2 mmol, quant.) as a brown oil which was used in the next 
step without further purification. 
 
1H NMR (400 MHz, CDCl3) δ/ppm 6.41–6.11 (m, 1H), 5.89–5.67 (m, 1H), 5.07–4.95 (m, 
2H), 4.21 (t, J = 8.1 Hz, 1H), 3.78 (s, 2H), 2.66 (ddd, J = 12.8, 8.7, 7.9 Hz, 1H), 2.54–2.39 
(m, 1H), 2.24–2.13 (m, 1H), 2.13–1.96 (m, 2H), 1.82 (ddd, J = 12.9, 9.5, 8.2 Hz, 1H), 1.44 
(dddd, J = 13.8, 9.7, 8.2, 5.4 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ/ppm 176.0, 172.2, 
137.7, 115.6, 53.8, 52.7, 40.5, 31.6, 31.4, 30.1. 
Analytical data are in accordance with those reported in the literature.[4] 
 
1-Benzyl 2-methyl (2S,4S)-4-(but-3-en-1-yl)-5-oxopyrrolidine-1,2-dicarboxylate (2.29) 
To a solution of pyrrolidinone 2.27 (2.80 g, 14.2 mmol, 1.0 eq.) in THF 
(35 mL) at –78 °C was added dropwise a solution of LiHMDS (15.8 mL, 
1.0 M in THF, 15.8 mmol, 1.1 eq.). After stirring for 30 min at –78 °C, 
benzyl chloroformate (2.66 mL, 15.8 mmol, 1.1 eq.) was added and the resulting mixture 
stirred for 1 h at –78 °C. The excess of LiHMDS was quenched by the addition of aq. NH4Cl 
solution (2 N, 10 mL) and the resulting mixture was allowed to reach room temperature. THF 
and H2O were removed under reduced pressure and the obtained residue was dissolved in 
H2O (50 mL) and CH2Cl2 (50 mL). The layers were separated and the aqueous layer was 
extracted with CH2Cl2 (2 x 50 mL). The combined organic layers were washed with brine 
(10 mL), dried over Na2SO4 and the solvent was removed under reduced pressure. The crude 
residue was purified by flash column chromatography (SiO2, pentane/EtOAc 3:1) to give 
lactam 2.29 (3.35 g, 10.1 mmol, 71%) as a colorless oil. 
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1H NMR (400 MHz, CDCl3) δ/ppm 7.43–7.29 (m, 5H), 5.75 (ddt, J = 17.1, 10.2, 6.6 Hz, 1H), 
5.33 (d, J = 12.3 Hz, 1H), 5.19 (d, J = 12.3 Hz, 1H), 5.08–4.97 (m, 2H), 4.59–4.50 (m, 1H), 
3.64 (s, 2H), 2.64–2.50 (m, 2H), 2.26–2.14 (m, 1H), 2.13–2.06 (m, 1H), 2.05–1.96 (m, 1H), 
1.74–1.65 (m, 1H), 1.57–1.47 (m, 1H); 13C NMR (101 MHz, CDCl3) δ/ppm 174.7, 171.7, 
151.2, 137.2, 135.1, 128.7, 128.6, 128.3, 116.0, 68.5, 57.3, 52.7, 41.9, 31.2, 30.3, 28.1. 
Analytical data are in accordance with those reported in the literature.[5] 
 
1-Benzyl 2-methyl (2S,4S)-4-(but-3-en-1-yl)-5-hydroxypyrrolidine-1,2-dicarboxylate 
(2.29b) 
To a solution of lactam 2.29 (3.30 g, 10.0 mmol, 1.0 eq.) in THF (70 mL) 
at –78 °C was slowly added lithium triethylborohydride (11.1 mL, 1 M 
solution in THF, 11.1 mmol, 1.1 eq.). The reaction mixture was stirred for 
1 h at –78 °C and the excess of lithium triethylborohydride was quenched by the addition of 
aq. sat. NaHCO3 solution (5 mL). Three drops of H2O2 (30% w/w in H2O) were added and the 
solution concentrated under vacuum. The obtained residue was portioned between CH2Cl2 
(50 mL) and H2O (50 mL) and the aqueous layer extracted with CH2Cl2 (2 x 50 mL). The 
combined organic layers were washed with brine (20 mL), dried over Na2SO4 and the solvent 
removed under reduced pressure to obtain lactol 2.29b (3.33 g, 10.0 mmol, quant.) as a 
colorless oil (dr = 3:1). The crude residue was used in the next step without further 
purification. 
 
1-Benzyl 2-methyl (2S,4S)-5-acetoxy-4-(but-3-en-1-yl)pyrrolidine-1,2-dicarboxylate 
(2.31a and 2.31b) 
Lactol 2.29b (3.33 g, 10.0 mmol, 1.0 eq.) was 
dissolved in CH2Cl2 (25 mL) and Et3N (2.81 mL, 
20.0 mmol, 2.0 eq.), Ac2O (2.82 mL, 30.0 mmol, 
3.0 eq.) and DMAP (122 mg, 1.0 mmol, 0.10 eq.) were added. The mixture was stirred at 
room temperature for 16 h before additional Et3N (0.70 mL, 5.00 mmol, 0.50 eq.), Ac2O 
(0.70 mL, 7.50 mmol, 0.75 eq.) and DMAP (30 mg, 0.25 mmol, 0.030 eq.) were added. The 
mixture was stirred for further 3 h at room temperature. The reaction was quenched with sat. 
aq. NaHCO3 solution (20 mL), the resulting layers separated and the aqueous layer extracted 
with CH2Cl2 (2 x 70 mL). The combined organic layers were washed with brine (20 mL), 
dried over Na2SO4 and the solvent removed under reduced pressure. The crude residue was 
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purified by flash column chromatography (SiO2, pentane/EtOAc 5:1) to give in a first fraction 
a rotameric mixture of acetylated lactol 2.31a (0.600 g, 1.60 mmol, 16%) and in a second 
fraction a rotameric mixture of acetylated lactol 2.31b (2.10 g, 5.60 mmol, 56%) as colorless 
oils. Both diastereoisomers were combined (2.70 g, 7.20 mmol, 72%) and were used as a 
mixture in the next step. 
 
2.31a: 1H NMR (400 MHz, CDCl3, major rotamer) δ/ppm 7.43–7.27 (m, 5H), 6.77–6.63 (m, 
1H), 5.85–5.62 (m, 1H), 5.29–4.93 (m, 4H), 4.42–4.24 (m, 1H), 3.91–3.46 (m, 3H), 2.43 (dt, 
J = 12.1, 7.2 Hz, 1H), 2.35–1.96 (m, 6H), 1.94–1.68 (m, 1H), 1.68–1.50 (m, 1H), 1.36 (dq, 
J = 14.8, 7.7 Hz, 1H); 13C NMR (101 MHz, CDCl3, major rotamer) δ/ppm 170.0, 153.7, 
137.7, 128.6, 128.2, 127.9, 115.5, 82.6, 67.7, 59.2, 52.5, 43.2, 32.9, 31.8, 27.4, 21.1. 
 
2.31b: 1H NMR (400 MHz, CDCl3, major rotamer) δ/ppm 7.49–7.26 (m, 5H), 6.43–6.32 (m, 
1H), 5.85–5.67 (m, 1H), 5.41–5.11 (m, 2H), 5.10–4.94 (m, 3H), 4.55–4.38 (m, 1H), 3.84–3.73 
(m, 2H), 3.63–3.50 (m, 2H), 2.65–2.49 (m, 1H), 2.22–2.07 (m, 5H), 1.82–1.64 (m, 1H), 1.47–
1.32 (m, 1H); 13C NMR (101 MHz, CDCl3, major rotamer) δ/ppm 172.5, 154.1, 137.8, 128.6, 
128.1, 128.0, 115.3, 87.7, 67.6, 58.9, 52.6, 44.9, 31.6, 30.5, 21.0, 20.7. 
 
1-Benzyl 2-methyl (2S,3aS,6S,7aS)-6-bromooctahydro-1H-indole-1,2-dicarboxylate 
(2.33) 
To a solution of protected lactols 2.31a and 2.31b (2.25 g, 6.00 mmol, 
1.0 eq.) in CH2Cl2 (100 mL) at –78 °C was added dropwise a solution of 
SnBr4 (5.26 g, 12.0 mmol, 2.0 eq.) in CH2Cl2 (60 mL). After stirring for 
30 min at –78 °C, the solution was quenched with aq. NaHCO3 solution (10% w/w, 200 mL). 
The reaction mixture was allowed to warm to room temperature, the layers were separated 
and the aqueous layer extracted with CH2Cl2 (3 x 200 mL). The combined organic layers were 
dried over Na2SO4 and the solvent removed under reduced pressure. The crude residue was 
purified by flash column chromatography (SiO2, pentane/EtOAc 5:1) to give a 1:1 rotameric 
mixture of 6-bromooctahydroindole derivative 2.33 (2.00 g, 5.04 mmol, 84%) as a colorless 
oil. 
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1H NMR (400 MHz, CDCl3, mixture of rotamers) δ/ppm 7.37–7.20 (m, 10H), 5.11 (dd, J = 
16.2, 12.3 Hz, 2H), 4.96 (dd, J = 25.8, 12.4 Hz, 2H), 4.26 (ddd, J = 16.8, 9.7, 7.3 Hz, 2H), 
3.96 (dt, J = 10.9, 6.3 Hz, 1H), 3.86 (dt, J = 11.4, 6.5 Hz, 1H), 3.82–3.74 (m, 1H), 3.71 (s, 
3H), 3.50 (s, 3H), 2.74 (ddd, J = 12.5, 6.3, 3.0 Hz, 1H), 2.60 (ddd, J = 13.2, 6.1, 2.8 Hz, 1H), 
2.28 (dt, J = 13.6, 6.8 Hz, 2H), 2.12 (dt, J = 12.4, 7.2 Hz, 2H), 2.07–1.88 (m, 6H), 1.83–1.53 
(m, 7H); 13C NMR (101 MHz, CDCl3, mixture of rotamers) δ/ppm 173.3, 173.1, 154.3, 
153.7, 136.6, 136.4, 128.7, 128.5, 128.3, 128.2, 128.1, 128.0, 67.4, 67.3, 59.4, 59.3, 58.2, 
57.7, 52.5, 52.3, 47.1, 39.2, 38.6, 35.7, 35.0, 32.5, 32.2, 32.1, 31.4, 25.7, 25.6. 
Analytical data are in accordance with those reported in the literature.[5] 
 
1-Benzyl 2-methyl (2S,3aS,6R,7aS)-6-acetoxyoctahydro-1H-indole-1,2-dicarboxylate 
(2.35) 
To a solution of 6-bromooctahydroindole derivative 2.33 (1.59 g, 
4.00 mmol, 1.0 eq.) in toluene (47 mL) was added Bu4NOAc (18.1 g, 
60.0 mmol, 15 eq.). The mixture was stirred at 44 °C for 3 h. The 
reaction mixture was allowed to reach room temperature and was diluted with cyclohexane 
(200 mL). The solution was washed with H2O (150 mL) and brine (150 mL), dried over 
Na2SO4 and the solvent was removed under reduced pressure. The crude residue was purified 
by flash column chromatography (SiO2, pentane/EtOAc 5:1) to give a 1:1 rotameric mixture 
of octahydroindole 2.35 (0.800 g, 2.13 mmol, 53%) as a colorless oil. 
 
1H NMR (400 MHz, CDCl3, mixture of rotamers) δ/ppm 7.34–7.20 (m, 10H), 5.17–4.92 (m, 
4H), 4.27 (dt, J = 16.4, 9.1 Hz, 2H), 4.22–4.12 (m, 1H), 4.10–4.03 (m, 1H), 3.69 (s, 3H), 3.50 
(s, 3H), 2.42–2.24 (m, 3H), 2.14 (dt, J = 13.9, 7.2 Hz, 2H), 2.01–1.98 (m, 3H), 1.96–1.83 (m, 
5H), 1.77–1.57 (m, 4H), 1.57–1.42 (m, 4H); 13C NMR (101 MHz, CDCl3, mixture of 
rotamers) δ/ppm 171.2, 170.5, 153.9, 136.9, 136.6, 128.5, 128.04, 127.96, 127.6, 69.4, 69.2, 
67.1, 67.0, 59.4, 59.3, 54.5, 54.1, 52.5, 52.2, 36.5, 35.8, 32.7, 31.7, 31.2, 30.7, 23.8, 21.4, 
20.1. 
Analytical data are in accordance with those reported in the literature.[5] 
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1-Benzyl 2-methyl (2S,3aS,6R,7aS)-6-hydroxyoctahydro-1H-indole-1,2-dicarboxylate 
(2.37) 
Acetylated ester 2.35 (220 mg, 0.586 mmol, 1.0 eq.) was dissolved in 
MeOH (12 mL). NaOMe (222 mg, 4.10 mmol, 7.0 eq.) was added and 
the mixture was stirred for 3 h at room temperature. The excess of 
NaOMe was quenched with sat. aq. NH4Cl solution (5 mL), the solvent was removed and the 
remaining mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were 
dried over Na2SO4 and the solvent was removed under reduced pressure. The crude mixture 
was purified by flash column chromatography (SiO2, pentane/EtOAc 1:1) to obtain a 1:1 
rotameric mixture of L-Choi derivative 2.37 (168 mg, 0.504 mmol, 86%) as colorless sticky 
oil. 
 
Rf = 0.34 (SiO2, pentane/EtOAc); Optical rotation [𝛼]஽ଶହ = −22.2 (c = 0.95, CHCl3); FTIR 
ṽ/cm−1 3461, 2946, 2890, 1748, 1700, 1417, 1355, 1289, 1199, 1176, 1113, 1012, 907, 746, 
699; 1H NMR (400 MHz, CDCl3) δ/ppm 7.40–7.27 (m, 5H), 5.21–4.97 (m, 2H), 4.40–4.18 
(m, 2H), 4.12 (br, 1H), 3.75 (s, 3H), 2.41–2.25 (m, 2H), 2.23–2.10 (m, 3H), 2.01–1.90 (m, 
1H), 1.76–1.64 (m, 1H), 1.60–1.45 (m, 3H); 13C NMR (101 MHz, CDCl3) δ/ppm 173.8, 
154.7, 136.9, 128.5, 128.0, 127.9, 67.0, 66.2, 59.4, 53.9, 52.4, 36.7, 33.9, 31.7, 26.6, 19.7; 
HRMS ESI m/z calc. for C18H23NO5Na [M+Na]+: 356.1468, found: 356.1474. 
 
1-(tert-Butyl) 2-methyl (2S,4S)-4-(but-3-en-1-yl)-5-oxopyrrolidine-1,2-dicarboxylate 
(2.28) 
To a solution of pyrrolidinone 2.27 (1.46 g, 7.40 mmol, 1.0 eq.) in CH2Cl2 
(20 mL) were added Et3N (3.12 mL, 22.2 mmol, 3.0 eq.), Boc2O (2.31 g, 
10.4 mmol, 1.4 eq.) and DMAP (90.4 mg, 0.740 mmol, 0.10 eq.) at 0 °C. 
The mixture was stirred for 20 min at 0 °C and further for 16 h at room temperature. Sat. aq. 
NH4Cl solution (10 mL) and H2O (10 mL) were added. The layers were separated and the 
aqueous layer was extracted with CH2Cl2 (2 x 20 mL). The combined organic layers were 
washed with brine (10 mL), dried over Na2SO4 and the solvent removed under reduced 
pressure. The crude residue was purified by flash column chromatography 
(SiO2, pentane/EtOAc 9:1 changing to 5:1) to give lactam 2.28 (1.50 g, 5.04 mmol, 68%) as a 
colorless oil. 
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1H NMR (400 MHz, CDCl3) δ/ppm 5.84–5.68 (m, 1H), 5.09–4.94 (m, 2H), 4.54–4.43 (m, 
1H), 3.77 (s, 3H), 2.60–2.46 (m, 2H), 2.27–1.95 (m, 3H), 1.72–1.60 (m, 1H), 1.56–1.44 (m, 
10H); 13C NMR (101 MHz, CDCl3) δ/ppm 175.1, 172.1, 149.5, 137.4, 115.9, 83.8, 57.5, 52.6, 
42.0, 31.2, 30.3, 28.00, 27.96. 
Analytical data are in accordance with those reported in the literature.[4] 
 
1-(tert-Butyl) 2-methyl (2S,4S)-5-acetoxy-4-(but-3-en-1-yl)pyrrolidine-1,2-dicarboxylate 
(2.30) 
To a solution of lactam 2.28 (1.49 g, 5.00 mmol, 1.0 eq.) in THF (35 mL) 
at –78 °C was slowly added lithium triethylborohydride (5.55 mL, 1 M 
solution in THF, 5.55 mmol, 1.1 eq.). The reaction mixture was stirred for 
1 h at –78 °C before the excess of lithium triethylborohydride was quenched by the addition 
of aq. sat. NaHCO3 solution (2 mL). One drop of H2O2 (30% w/w in H2O) was added and the 
solution was concentrated under vacuum. The obtained residue was portioned between 
CH2Cl2 (50 mL) and H2O (50 mL), the layers separated and the aqueous layer extracted with 
CH2Cl2 (2 x 50 mL). The combined organic layers were washed with brine (20 mL), dried 
over Na2SO4 and the solvent removed under reduced pressure to obtain a diastereomeric 
mixture of the corresponding lactol as a colorless solid. The obtained crude product was 
dissolved in CH2Cl2 (20 mL). To this solution Et3N (1.40 mL, 10.0 mmol, 2.0 eq.), Ac2O 
(1.40 mL, 15.0 mmol, 3.0 eq.) and DMAP (61.0 mg, 0.500 mmol, 0.10 eq.) were added and 
the mixture was stirred at room temperature for 16 h. Additional Et3N (0.70 mL, 5.00 mmol, 
1.0 eq.) and Ac2O (0.70 mL, 7.50 mmol, 1.50 eq.) were added and the mixture stirred for 
further 5 h at room temperature. The reaction was quenched with sat. aq. NaHCO3 solution 
(10 mL), the layers separated and the aqueous layers extracted with CH2Cl2 (2 x 20 mL). The 
combined organic layers were washed with brine (10 mL), dried over Na2SO4 and the solvent 
removed under reduced pressure. The crude residue was purified by flash column 
chromatography (SiO2, pentane/EtOAc 7:1) to give acetylated lactol 2.30 as a mixture of 
diastereoisomers (0.750 g, 2.20 mmol, 44%) as a colorless oil. Further, the unprotected lactol 
(0.250 g, 0.850 mmol, 17%) could be isolated as a colorless oil. 
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1-(tert-Butyl) 2-methyl (2S,3aS,6S,7aS)-6-bromooctahydro-1H-indole-1,2-dicarboxylate 
(2.32) 
To a solution of protected lactol 2.30 (574 mg, 1.68 mmol, 1.0 eq.) in 
CH2Cl2 (11.5 mL) at –78 °C was added dropwise a solution of SnBr4 
(957 mg, 2.18 mmol, 1.3 eq.) in CH2Cl2 (2 mL). After stirring for 10 min 
at –78 °C, the solution was diluted with CH2Cl2 (5 mL) and quenched with sat. aq. NaHCO3 
solution (0.5 mL). The reaction mixture was allowed to warm to room temperature, filtered 
over Celite which was subsequently washed with CH2Cl2 (2 x 5 mL). The filtrate was 
washed with brine (15 mL), dried over Na2SO4 and the solvent removed under reduced 
pressure. A 4:3 rotameric mixture of 6-bromooctahydroindole derivative 2.32 (0.530 g, 
1.46 mmol, 87%) was obtained as a colorless oil which was used for the next step without 
further purification.  
 
1H NMR (400 MHz, CDCl3, mixture of rotamers) δ/ppm 4.21 (dd, J = 10.0, 7.7 Hz, 0.75H), 
4.15 (dd, J = 10.1, 7.5 Hz, 1H), 3.91–3.73 (m, 3.5H), 3.69 (s, 2.25H), 3.68 (s, 3H), 3.68–3.64 
(m, 1.75H), 2.73 (dddd, J = 13.1, 6.0, 3.7, 2.4 Hz, 1H), 2.60–2.53 (m, 0.75H), 2.35–2.20 (m, 
1.75H), 2.15–2.00 (m, 4.5H), 1.99–1.86 (m, 4.5H), 1.83–1.64 (m, 5.25H), 1.39 (s, 6.75H), 
1.32 (s, 9H); 13C NMR (101 MHz, CDCl3, mixture of rotamers) δ/ppm 173.6, 173.4, 153.6, 
153.0, 80.29, 80.26, 59.5, 59.0, 57.7, 57.4, 52.3, 52.2, 47.5, 47.4, 39.2, 38.8, 35.6, 34.9, 32.3, 
32.2, 32.1, 31.4, 28.5, 28.3, 25.7, 25.6. 
Analytical data are in accordance with those reported in the literature.[4] 
 
1-(tert-Butyl) 2-methyl (2S,3aS,6R,7aS)-6-acetoxyoctahydro-1H-indole-1,2-dicarboxylate 
(2.34) 
To a solution of 6-bromooctahydroindole derivative 2.32 (0.500 g, 
1.38 mmol, 1.0 eq.) in toluene (12 mL) was added Bu4NOAc (6.20 g, 
20.7 mmol, 15.0 eq.). The mixture was stirred at 47 °C for 2 h. The 
reaction mixture was allowed to reach room temperature and was diluted with cyclohexane 
(75 mL). The organic layer was washed with H2O (30 mL), brine (30 mL), dried over Na2SO4 
and the solvent was removed under reduced pressure. The crude residue was purified by flash 
column chromatography (SiO2, pentane/EtOAc 6:1) to give octahydroindole 2.34 (0.260 g, 
0.850 mmol, 62%) in a rotameric mixture of 3:1 as a colorless oil. 
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1H NMR (400 MHz, CDCl3, major rotamer) δ/ppm 5.03 (s, 1H), 4.27–4.13 (m, 1H), 4.13–
4.01 (m, 1H), 3.67 (s, 3H), 2.38–2.18 (m, 2H), 2.10 (dt, J = 12.4, 7.3 Hz, 1H), 1.95–1.83 (m, 
3H), 1.75–1.58 (m, 2H), 1.56–1.44 (m, 2H), 1.42–1.29 (m, 9H); 13C NMR (101 MHz, CDCl3, 
major rotamer) δ/ppm 174.1, 171.2, 153.2, 80.0, 69.2, 59.5, 53.6, 52.1, 35.7, 32.5, 30.8, 28.3, 
23.8, 21.1, 20.0. 
Analytical data are in accordance with those reported in the literature.[4] 
 
1-(tert-Butyl) 2-methyl (2S,3aS,6R,7aS)-6-hydroxyoctahydro-1H-indole-1,2-
dicarboxylate (2.36) 
A solution of octahydroindole 2.34 (0.270 g, 0.780 mmol, 1.0 eq.) in 
MeOH (9.5 mL) was treated with a solution of NaOMe (0.300 g, 
5.46 mmol, 7.0 eq.) in MeOH (11 mL). After stirring at room 
temperature for 6 h, the reaction mixture was diluted with sat. aq. NH4Cl solution (5 mL). The 
MeOH was removed under reduced pressure and the obtained aqueous residue extracted with 
EtOAc (3 x 30 mL). The combined organic layers were dried over Na2SO4 and the solvent 
removed under reduced pressure. The crude residue was purified by flash column 
chromatography (SiO2, pentane/EtOAc 3:2) to give octahydroindole 2.36 (0.200 g, 
0.670 mmol, 86%) as a colorless solid. 
 
Mp = 160.2−162.1   °C;;  Optical rotation [𝛼]஽ଶହ = −29.2 (c = 0.23, CHCl3); FTIR ṽ/cm−1 
3453, 2973, 2934, 2892, 1751, 1689, 1479, 1402, 1366, 1255, 1197, 1167, 1143, 1116, 1015, 
912, 882, 860, 777, 606, 555; 1H NMR (400 MHz, CDCl3, major rotamer) δ/ppm 4.28–4.06 
(m, 3H), 3.71 (s, 3H), 2.39–2.23 (m, 2H), 2.19–2.06 (m, 2H), 1.99–1.85 (m, 1H), 1.72–1.44 
(m, 4H), 1.41–1.33 (m, 9H); 13C NMR (101 MHz, CDCl3, major rotamer) δ/ppm 174.2, 80.0, 
66.0, 59.5, 53.6, 52.1, 45.2, 36.0, 33.8, 32.6, 28.4, 26.5, 19.6; HRMS ESI m/z calc. for 
C15H25NO5Na [M+Na]+: 322.1625, found: 322.1624. 
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2.1.2. Synthesis of Pla-Cleu-OH dipeptide 2.47 
Ethyl (E)-4-methylpent-2-enoate (2.38) 
To a solution of NaH (3.68 g, 92.1 mmol, 1.2 eq.) in benzene (110 mL) was 
slowly added isobutyraldehyde (2.21) (5.53 g, 76.7 mmol, 1.0 eq.) at room 
temperature. The mixture was stirred for 30 min before triethyl phosphonoacetate (1.94 g, 
86.7, 1.1 eq.) was added, leading to the formation of a white slurry. The reaction mixture was 
heated at 70 °C for 1.5 h and was quenched by the addition of H2O (40 mL). The layers were 
separated and the organic layer was washed with brine (40 mL), dried over Na2SO4 and the 
solvent was removed under reduced pressure. The obtained crude product was purified by 
distillation (85 °C, 50 mbar) to give ethyl (E)-4-methylpent-2-enoate (2.38) (7.12 g, 
49.9 mmol, 65%) as a colorless liquid. 
 
Bp: 85 °C (50 mbar); 1H NMR (400 MHz, CDCl3) δ/ppm 6.94 (dd, J = 15.7, 6.6 Hz, 1H), 
5.76 (dd, J = 15.7, 1.5 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 2.59–2.22 (m, 1H), 1.28 (t, J = 
7.1 Hz, 3H), 1.05 (d, J = 6.8 Hz, 6H). 
Analytical data are in accordance with those reported in the literature.[6] 
 
(E)-4-Methylpent-2-en-1-ol (2.39) 
Ethyl (E)-4-methylpent-2-enoate (2.38) (7.00 g, 49.1 mmol, 1.0 eq.) was 
dissolved in CH2Cl2 (210 mL) and cooled to –78 °C. Then DIBAL (149 mL, 
1 M solution in CH2Cl2, 143 mmol, 2.9 eq.) was added over a period of 20 min and the 
mixture stirred for 1.5 h before sat. aq. NH4Cl solution (100 mL) and aq. HCl solution (1 M, 
200 mL) were added at 0 °C. The mixture was diluted with CH2Cl2 (250 mL), the layers were 
separated and the aqueous layer was extracted with CH2Cl2 (3 x 250 mL). The combined 
organic layers were washed with brine (100 mL) and dried over Na2SO4. The solvent was 
removed and the obtained crude product purified by distillation (60 °C, 20 mbar) to give 
(E)-4-methylpent-2-en-1-ol (2.39) (3.70 g, 36.8 mmol, 75 %) as a colorless oil. 
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Bp: 60 °C (20 mbar); 1H NMR (400 MHz, CDCl3) δ/ppm 5.60 (dd, J = 15.5, 6.1 Hz, 1H), 
5.52 (dt, J = 16.4, 5.6 Hz, 1H), 4.02 (d, J = 5.6 Hz, 2H), 2.31–2.15 (m, 1H), 1.39 (s, J = 2.9 
Hz, 1H), 0.93 (d, J = 6.8 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ/ppm 140.3, 125.9, 63.9, 
30.79, 22.2. 
Analytical data are in accordance with those reported in the literature.[6] 
 
((2R,3R)-3-Isopropyloxiran-2-yl)methanol (2.40) 
To a suspension of powdered 4 Å molecular sieves in CH2Cl2 (60 mL) were 
added a solution of D(−)-diethyl tartrate (6.20 mL, 36.0 mmol, 0.60 eq.) in 
CH2Cl2 (10 mL) and Ti(OiPr)4 (8.99 mL, 30.0 mmol, 0.50 eq.) at 0 °C. The solution was 
stirred  for  20  min  at  the  same  temperature  before  cooling  to  −20  °C. tBuOOH (16.4 mL, 5.5 M 
solution in decane, 90.0 mmol, 1.5 eq.) was slowly added over a period of 10 min. The 
resulting   solution   was   stirred   for   30   min   at   −20   °C   before   allylalcohol   2.39 (6.01 g, 
60.0 mmol, 1.0 eq.) dissolved in CH2Cl2 (10 mL) was added dropwise over 20 min. The 
mixture was stirred at −20 °C for further 14 h and was quenched by the addition of aq. NaOH 
solution (35% w/w, 5 mL, sat. with NaCl). The reaction mixture was filtered over Celite® and 
the filtrate was concentrated under reduced pressure at room temperature. The obtained 
residue was purified by flash column chromatography (SiO2, pentane/Et2O 1:1) to give 
((2R,3R)-3-isopropyloxiran-2-yl)methanol (2.40) (3.20 g, 27.6 mmol, 46%) as a colorless oil. 
 
1H NMR (400 MHz, CDCl3) δ/ppm 3.85 (dd, J = 12.6, 2.5 Hz, 1H), 3.55 (dd, J = 12.6, 4.4 
Hz, 1H), 2.91 (dt, J = 4.7, 2.5 Hz, 1H), 2.69 (dd, J = 6.9, 2.3 Hz, 1H), 1.60–1.43 (m, 1H), 0.96 
(d, J = 6.7 Hz, 3H), 0.90 (d, J = 6.9 Hz, 3H). 
Analytical data are in accordance with those reported in the literature.[6] 
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(2S,3R)-2-Azido-4-methylpentane-1,3-diol (2.40a) and (2S,3S)-3-azido-4-methylpentane-
1,2-diol (2.40b) 
Epoxide 2.40 (1.63 g, 14.0 mmol, 1.0 eq.), NaN3 (9.10 g, 140 mmol, 10 eq.) 
and NH4Cl (1.50 g, 28.0 mmol, 2.0 eq.) were suspended in MeOEtOH 
(20 mL). H2O (1 mL) was added and the suspension heated at 120 °C for 24 h. 
The mixture was let to cool to room temperature and the solvent was removed 
under reduced pressure. The obtained brown oil was suspended in H2O 
(40 mL) and EtOAc (100 mL). The layers were separated, the aqueous layer was extracted 
with EtOAc (2 x 100 mL) and the combined organic layers were dried over Na2SO4. The 
solvent was removed under reduced pressure to obtain a regioisomeric mixture of azides 
2.40a and 2.40b as an amber oil (2.25 g, 14.0 mmol, quant.). The crude residue containing 
azides 2.40a and 2.40b was directly used for the next step without further purification.  
 
(2S,3R)-2-Azido-1-((tert-butyldimethylsilyl)oxy)-4-methylpentan-3-ol (2.41) and (2S,3S)-
3-azido-1-((tert-butyldimethylsilyl)oxy)-4-methylpentan-2-ol (2.42) 
Crude azides 2.40a and 2.40b (2.25 g, 14.0 mmol, 1.0 eq.) were dissolved in 
CH2Cl2 (21 mL). To this solution Et3N (2.83 mL, 20.3 mmol, 1.5 eq.), 
DMAP (40.0 mg, 0.328 mmol, 0.023 eq.) and TBSCl (2.27 g, 15.4 mmol, 
1.1 eq.) were added at 0 °C and the mixture was stirred for 2 h at 0 °C. The 
reaction mixture was diluted with CH2Cl2 (100 mL) and washed with aq. 
HCl solution (1 M, 20 mL). The organic layer was dried over Na2SO4 and the solvent was 
removed under reduced pressure. The obtained crude product was purified by flash column 
chromatography (SiO2, pentane/EtOAc 15:1 to 1:1) to give a 1:1 regioisomeric mixture of 
azides 2.41 and 2.42 (3.40 g, 12.4 mmol, 89% over two steps) as a colorless oil. 
 
2.41: 1H NMR (400 MHz, CDCl3) δ/ppm 3.97 (dd, J = 10.6, 4.0 Hz, 1H), 3.92 (dd, J = 10.6, 
5.9 Hz, 1H), 3.50–3.43 (m, 1H), 3.39 (td, J = 6.2, 3.9 Hz, 1H), 2.30 (d, J = 4.6 Hz, 1H), 1.93–
1.80 (m, 1H), 0.98 (d, J = 1.0 Hz, 3H), 0.96 (d, J = 1.2 Hz, 3H), 0.92 (s, 9H), 0.11 (s, 6H); 
13C NMR (101 MHz, CDCl3) δ/ppm  63.99,   63.91,   30.4,   26.0,   25.9,   19.6,   18.3,   16.9,   −5.4,  
−5.5. 
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2.42: 1H NMR (400 MHz, CDCl3) δ/ppm 3.78 (dd, J = 10.0, 3.3 Hz, 1H), 3.70 (dd, J = 10.1, 
5.6 Hz, 1H), 3.60 (s, 1H), 3.28 (dd, J = 8.0, 4.4 Hz, 1H), 2.51 (s, 1H), 2.09 (septd, J = 6.8, 4.5 
Hz, 1H), 1.05 (d, J = 6.9 Hz, 3H), 0.95 (d, J = 6.7 Hz, 3H), 0.92 (s, 9H), 0.11 (s, 3H), 0.11 (s, 
3H); 13C NMR (101 MHz, CDCl3) δ/ppm  71.4,  69.9,  64.0,  29.4,  26.0,  20.6,  18.4,  16.9,  −5.2,  
−5.3. 
 
(2R,3S)-2-(((tert-Butyldimethylsilyl)oxy)methyl)-3-isopropylaziridine (2.43) 
Azides 2.41 and 2.42 (3.40 g, 12.4 mmol, 1.0 eq.) and PPh3 (3.60 g, 
13.6 mmol, 1.1 eq.) were dissolved in MeCN (25 mL) and the mixture was 
stirred for 2 h at room temperature and further for 18 h at 50 °C. The 
solvent removed under reduced pressure and the obtained residue was diluted with Et2O 
(50 mL) and filtered over a short pad of Celite® to remove precipitated triphenylphosphine 
oxide. The pad of Celite® was washed with Et2O (2 x 30 mL) and the filtrate was concentrated 
under reduced pressure. The obtained crude residue was purified by flash column 
chromatography (SiO2, pentane/EtOAc 4:1) to give aziridine 2.43 (2.20 g, 9.80 mmol, 79%) 
as a colorless oil. 
 
Optical rotation [𝛼]஽ଶହ = 19.0 (c = 0.30, CHCl3); 1H NMR (400 MHz, CDCl3) δ/ppm 3.85–
3.63 (m, 1H), 1.88 (q, J = 3.7 Hz, 1H), 1.63 (dd, J = 7.9, 3.2 Hz, 1H), 1.31–1.18 (m, 1H), 
1.17–1.07 (m, 1H), 1.02 (d, J = 6.6 Hz, 1H), 0.96 (d, J = 6.8 Hz, 1H), 0.88 (s, J = 2.9 Hz, 4H), 
0.05 (d, J = 0.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ/ppm 63.0, 40.9, 37.4, 31.9, 25.9, 
20.4,  20.0,  18.3,  −5.33,  −5.36. 
Analytical data are in accordance with those reported in the literature.[7] 
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(2R,3S)-2-(((tert-Butyldimethylsilyl)oxy)methyl)-1-(tert-butylsulfinyl)-3-isopropyl-
aziridine (2.43a) 
Aziridine 2.43 (2.18 g, 9.50 mmol, 1.0 eq.) was dissolved in CH2Cl2 (35 mL) 
and cooled to 0 °C. Freshly distilled Et3N (9.61 mL, 95.0 mmol, 10.0 eq.) 
was slowly added and the solution was stirred for 5 min before tert-
butylsulfinyl chloride (2.81 g, 20.0 mmol, 2.1 eq.) was added dropwise. The reaction was 
further stirred at 0 °C for 2 h and then quenched by the addition of aq. Na2CO3 soln. 
(10% w/w, 35 mL). The layers were separated and the aqueous layer was extracted with 
CH2Cl2 (50 mL). The combined organic layers were washed with H2O (25 mL), dried over 
Na2SO4 and the solvent was removed under reduced pressure. The obtained crude residue was 
purified by flash column chromatography (SiO2, pentane/EtOAc 9:1) to give a 1:1 
diastereomeric mixture of protected aziridine 2.43a (3.20 g, 9.50 mmol, quant.) as a colorless 
oil. 
 
1H NMR (400 MHz, CDCl3, diastereomeric mixture) δ/ppm 4.01 (dd, J = 11.0, 4.3 Hz, 1H), 
3.86 (dd, J = 11.1, 7.4 Hz, 1H), 3.79 (s, 1H), 3.55 (s, 1H), 2.71–2.59 (m, 2H), 2.49 (dt, J = 
7.5, 4.2 Hz, 1H), 2.20 (dd, J = 7.5, 3.9 Hz, 1H), 1.92–1.79 (m, 2H), 1.61 (s, 3H), 1.46 (s, 3H), 
1.26 (s, 6H), 1.21 (s, 12H), 1.08 (d, J = 6.6 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H), 0.88 (d, J = 1.1 
Hz, 18H), 0.05 (d, J = 1.5 Hz, 12H); 13C NMR (101 MHz, CDCl3, diastereomeric mixture) 
δ/ppm 62.5, 57.0, 56.8, 48.8, 46.9, 31.7, 29.6, 27.8, 26.0, 23.9, 22.9, 22.7, 20.3, 19.8, 18.4, 
18.3,  −5.16,  −5.20,  −5.21,  −5.22. 
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(2R,3S)-2-(((tert-Butyldimethylsilyl)oxy)methyl)-1-(tert-butylsulfonyl)-3-isopropyl-
aziridine (2.44) 
The diastereomeric mixture of sulfoxides 2.43a (3.20 g, 9.58 mmol, 1.0 eq.) 
was dissolved in CH2Cl2 (22 mL) and cooled to 0 °C. m-CPBA (2.58 g, 
11.5 mmol, 1.2 eq.) was added and the reaction mixture was stirred for 1.5 h 
at 0 °C. The mixture was filtered over a short pad of Celite® and the Celite® 
pad was washed with CH2Cl2 (100 mL). The filtrate was washed with sat. aq. NaHCO3 
solution (50 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 
(50 mL). The combined organic layers were dried over Na2SO4 and the solvent was removed 
under reduced pressure. The crude residue was purified by flash column chromatography 
(SiO2, pentane/EtOAc 10:1) to give sulfone 2.44 (2.80 g, 8.05 mmol, 84%) as a colorless oil. 
 
Optical rotation [𝛼]஽ଶହ = +34.0 (c = 0.26, CHCl3); 1H NMR (400 MHz, CDCl3) δ/ppm 4.04 
(dd, J = 10.7, 3.9 Hz, 1H), 3.72 (dd, J = 10.9, 7.1 Hz, 1H), 2.73 (dt, J = 7.1, 4.6 Hz, 1H), 2.52 
(dd, J = 7.0, 4.5 Hz, 1H), 1.93 (dsept, J = 13.5, 6.6 Hz, 1H), 1.47 (s, 9H), 1.13 (d, J = 6.6 Hz, 
3H), 0.95 (d, J = 6.8 Hz, 3H), 0.89 (s, J = 3.0 Hz, 9H), 0.06 (s, J = 2.9 Hz, 6H); 13C NMR 
(101 MHz, CDCl3) δ/ppm 62.1,  60.0,  52.3,  46.8,  28.5,  25.8,  24.3,  20.6,  18.2,  −5.4. 
Analytical data are in accordance with those reported in the literature.[7] 
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N-((2R,3S)-1-((tert-Butyldimethylsilyl)oxy)-3-chloro-4-methylpentan-2-yl)-2-methyl-
propane-2-sulfonamide (2.45) 
Sulfone 2.44 (2.62 g, 7.50 mmol, 1.0 eq.) was dissolved in MeCN (20 mL). To 
this solution, CeCl3·H2O (8.38 g, 22.5 mmol, 3.0 eq.) was added in portions 
over 36 h (1.0 eq. every 12 h) under reflux. The reaction mixture was heated at 
reflux for additional 48 h. The mixture was let to cool to room temperature and 
filtered over a pad of Celite®. The filtrate was concentrated under reduced pressure and the 
obtained crude residue recrystallized from CH2Cl2/cyclohexane to give chlorinated sulfone 
2.45 (1.10 g, 4.05 mmol, 54%) as a white crystalline solid. 
 
Optical rotation [𝛼]஽ଶହ = 4.5 (c = 0.29, CHCl3); 1H NMR (400 MHz, CDCl3) δ/ppm 4.51 (s, 
J = 8.9 Hz, 1H), 4.06–3.68 (m, 4H), 2.12 (tq, J = 13.2, 6.5 Hz, 2H), 2.09 (br s, 1H), 1.43 (s, 
9H), 1.08 (pseudo-t, J = 7.0 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ/ppm 72.3, 62.2, 60.3, 
57.7, 31.8, 24.6, 24.4, 20.5, 19.6; Crystallography C10H22ClNO3S, M = 271.81, colorless 
needle, orthorhombic, space group C2221, a = 7.5819(6), b = 20.4433(18), c = 18.8420(16) Å, 
U = 2920.5(2) Å3, Z = 8, Dc = 1.236 Mg m–3, µ(Cu-Kα) = 3.618 mm−1, T = 123 K. Total 
12499 reflections, 2661 unique, Rint = 0.051. Refinement of 2548 reflections (152 parameters) 
with I >2σ (I) converged at final R1 = 0.0430 (R1 all data = 0.0438), wR2 = 0.0468 (wR2 all 
data = 0.0490), gof = 1.0492. 
Analytical data are in accordance with those reported in the literature.[7] 
 
(R)-N-((2S,3R)-3-Chloro-1-hydroxy-4-methylpentan-2-yl)-2-(methoxymethoxy)-3-
phenylpropanamide (2.46) 
Sulfone 2.45 (70.0 mg, 0.26 mmol, 1.0 eq.) was dissolved in CH2Cl2 
(13 mL). To this solution were added trifluoromethanesulfonic acid 
(0.11 mL, 1.29 mmol, 5.0 eq.) and anisole (0.56 mL, 5.16 mmol, 
20 eq.) at 0 °C. The mixture was stirred for 20 min at 0 °C and further for 16 h at room 
temperature. All volatiles were removed under reduced pressure and the obtained crude 
residue was suspended in H2O (10 mL). The aqueous layer was washed with Et2O (3 x 5 mL), 
frozen and lyophilized to give the triflate salt of the deprotected amine, which was directly 
used for the next step without further purification. The crude amine salt was suspended in 
CH2Cl2 (2 mL). To this suspension, PyBOP (143 mg, 0.280 mmol, 1.1 eq.), Pla-OH derivative 
2.51 (52.6 mg, 0.260 mmol, 1.0 eq.) and 2,6-lutidine (0.20 mL, 1.75 mmol, 7.0 eq.) were 
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added at 0 °C. The reaction mixture was allowed to warm to room temperature and was 
further stirred for 16 h. CH2Cl2 (15 mL) was added and the mixture was washed with aq. HCl 
solution (1 M, 5 mL), sat. aq. Na2CO3 solution (5 mL) and brine (5 mL). The organic layers 
were dried over Na2SO4 and the solvent was removed under reduced pressure. The obtained 
crude residue was purified by flash column chromatography (SiO2, pentane/EtOAc 1:1) to 
give the desired dipeptide 2.46 (59.0 mg, 0.170 mmol, 68%) as a colorless oil. 
Optical rotation [𝛼]஽ଶହ = +69.4 (c = 0.73, CHCl3); 1H NMR (400 MHz, CDCl3) δ/ppm 7.45–
7.17 (m, 1H), 6.92 (d, J = 9.3 Hz, 1H), 4.66 (d, J = 6.5 Hz, 1H), 4.56 (d, J = 6.5 Hz, 1H), 4.34 
(dd, J = 7.0, 3.8 Hz, 1H), 4.20 (dddd, J = 9.4, 7.9, 4.6, 3.2 Hz, 1H), 3.97 (dd, J = 11.4, 4.6 Hz, 
1H), 3.73 (dd, J = 7.9, 4.9 Hz, 1H), 3.71 (dd, J = 11.4, 3.2 Hz, 1H) 3.25 (s, 1H), 3.18 (dd, J = 
14.1, 3.8 Hz, 1H), 3.00 (dd, J = 14.1, 7.0 Hz, 1H), 2.49 (s, 1H), 1.71 (dsept, J = 6.7, 4.8 Hz 
1H), 0.97 (dd, J = 7.5, 6.7 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ/ppm 171.6, 136.8, 129.8,
128.3, 126.8, 96.5, 78.7, 68.6, 62.4, 56.1, 52.5, 38.7, 30.4, 20.8, 17.3. 
Analytical data are in accordance with those reported in the literature.[5]
(2S,3R)-3-Chloro-2-((R)-2-(methoxymethoxy)-3-phenylpropanamido)-4-methyl-
pentanoic acid (2.47) 
To an ice-cooled solution of dipeptide 2.46 (49.9 mg, 0.150 mmol, 
1.0 eq.) dissolved in MeCN (0.83 mL) was added a solution of CrO3 
(1.00 mg, 10.0 µmol, 0.66 eq.) in 0.9 mL of 0.4 M H5IO6 in wet 
MeCN (MeCN/H2O, 99.3:0.7). The mixture was stirred for 1 h at 0 °C before sat. aq. 
NaHCO3 solution (1 mL) was added. The solvent was removed under reduced pressure and 
the aqueous mixture was treated with aq. NaOH solution (0.5 M, 0.3 mL). The aqueous layer 
was washed with Et2O (2 x 5 mL) and acidified with aq. HCl solution (1 M, 10 mL). The 
aqueous layer was extracted with CH2Cl2 (2 x 20 mL). The combined organic layers were 
dried over Na2SO4 and the solvent was removed under reduced pressure to obtain 
Pla-Cleu-OH dipeptide 2.47 (47.0 mg, 0.130 mmol, 90%) as a colorless sticky oil, which was 
used in the next step without further purification. 
EXPERIMENTAL PART 
 
 
 
 182
 
Optical rotation [𝛼]஽ଶହ = +34.8 (c = 0.37, CHCl3); 1H NMR (400 MHz, CDCl3) δ/ppm 9.84 
(s, 1H), 7.36 (d, J = 8.9 Hz, 1H), 7.30–7.20 (m, 5H), 5.03 (dd, J = 8.9, 4.3 Hz, 1H), 4.62 (d, J 
= 6.8 Hz, 1H), 4.55 (d, J = 6.8 Hz, 1H), 4.41 (dd, J = 7.4, 3.6 Hz, 1H), 3.47 (dd, J = 8.5, 4.3 
Hz, 1H), 3.20–3.15 (m, 4H), 2.97 (dd, J = 14.1, 7.4 Hz, 1H), 2.13–2.00 (m, 1H), 1.09 (d, J = 
6.7 Hz, 3H), 1.03 (d, J = 6.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ/ppm 172.2, 171.9, 
136.7, 129.9, 128.4, 127.0, 96.2, 77.7, 69.7, 56.2, 54.2, 38.9, 31.9, 20.3, 20.0; HRMS ESI m/z 
calc. for C17H24ClNO5Na [M+Na]+: 380.1235, found: 380.1240. 
Analytical data are in accordance with those reported in the literature.[5] 
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2.1.3. Synthesis of Pla-Leu-OH dipeptide 2.53 
(R)-2-Hydroxy-3-phenylpropanoic acid (2.48) 
D-Phenylalanine (2.23) (3.30 g, 20.0 mmol, 1.0 eq.) was dissolved in aq. 
H2SO4 solution (2 M, 23 mL) and cooled to 0 °C. An aq. NaNO2 solution 
(40% w/w, 9 mL) was added over a period of 1 h at 0 °C. The mixture was 
stirred for 6 h at 0 °C and further 12 h at room temperature. Additional aq. H2SO4 solution 
(2 M, 5 mL) and aq. NaNO2 solution (40% w/w, 3 mL) were added as above and the mixture 
was stirred for another 4 h at room temperature. The reaction mixture was saturated with 
NaCl and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with 
brine (100 mL), dried over Na2SO4 and the solvent was removed under reduced pressure. The 
crude product was recrystallized from Et2O to obtain α-hydroxy acid 2.48 (0.733 g, 
4.41 mmol, 22%) as white crystals. The solvent of the mother liquor was removed under 
reduced pressure to obtain further α-hydroxy acid 2.48 with minor impurities (1.84 g, 
11.1 mmol, 55%) as white to light yellow crystals which were used for the next step without 
further purification. 
 
Mp = 121.0–123.0 °C; Rf = 0.11 (SiO2, pentane/EtOAc 4:1 + 0.1% AcOH); Optical rotation 
[𝛼]஽ଶହ = +37.5 (c = 0.61, CHCl3); FTIR ṽ/cm−1 3442, 2928, 1726, 1494, 1433, 1240, 1189, 
1089, 880, 794, 739, 699, 618; 1H NMR (400 MHz, CDCl3) δ/ppm 7.35–7.25 (m, 5H), 4.53 
(dd, J = 7.2, 4.3 Hz, 1H), 3.22 (dd, J = 14.0, 4.3 Hz, 1H), 3.01 (dd, J = 14.0, 7.2 Hz, 1H); 
13C NMR (101 MHz, CDCl3) δ/ppm 177.5, 135.9, 129.7, 128.8, 127.3, 71.1, 40.3. 
Analytical data are in accordance with those reported in the literature.[8] 
 
Methyl (R)-2-hydroxy-3-phenylpropanoate (2.49) 
α-Hydroxy acid 2.48 (2.40 g, 14.4 mmol, 1.0 eq.) was dissolved in 
MeOH/toluene (2:1, 36 mL). Conc. aq. HCl solution (32% w/w, 0.17 mL, 
1.73 mmol, 0.42 eq.) was added dropwise to this solution. The solution was 
stirred at 75 °C for 4 h. After cooling to room temperature, the mixture was neutralized with 
aq. NaHCO3 solution (5% w/w, 70 mL) and extracted with CH2Cl2 (3 x 50 mL). The 
combined organic layers were washed with H2O (100 mL), dried over Na2SO4 and the solvent 
was removed under reduced pressure to obtain  α-hydroxy ester 2.49 (2.49 g, 13.8 mmol, 96%) 
as a yellow sticky oil, which was used for the next step without further purification. 
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Rf = 0.26 (SiO2, pentane/EtOAc 4:1); Optical rotation [𝛼]஽ଶହ = +7.4 (c = 0.50, CHCl3); FTIR 
ṽ/cm−1 3029, 2951, 1744, 1433, 1341, 1272, 1210, 1104, 1015, 857, 744, 679; 1H NMR 
(400 MHz, CDCl3) δ/ppm 7.34–7.18 (m, 5H), 4.47 (td, J = 6.5, 4.5 Hz, 1H), 3.78 (s, 3H), 3.13 
(dd, J = 13.9, 4.4 Hz, 1H), 2.97 (dd, J = 13.9, 6.8 Hz, 1H), 2.70 (d, J = 6.2 Hz, 1H); 13C NMR 
(101 MHz, CDCl3) δ/ppm 174.7, 136.4, 129.6, 128.6, 127.1, 71.4, 52.6, 40.7. 
Analytical data are in accordance with those reported in the literature.[4] 
 
Methyl (R)-2-(methoxymethoxy)-3-phenylpropanoate (2.50) 
α-Hydroxy ester 2.49 (1.30 g, 7.21 mmol, 1.0 eq.) and DIPEA (3.58 mL, 
21.6 mmoL, 3.0 eq.) were dissolved in CH2Cl2 (15 mL) and the solution 
was cooled to 0 °C. MOMBr (1.77 mL, 21.6 mmol, 3.0 eq.) was added 
dropwise. The solution was stirred for 30 min at 0 °C and for 16 h at room temperature. The 
mixture was quenched with sat. aq. NH4Cl solution (20 mL), the layers were separated and 
the aqueous layer was extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were 
washed with brine (80 mL), dried over Na2SO4 and the solvent was removed under reduced 
pressure. The crude product was purified by flash column chromatography (SiO2, 
pentane/EtOAc 4:1) to obtain phenyllactic ester 2.50 (1.18 g, 5.28 mmol, 73%) as a colorless 
oil. 
 
Rf = 0.41 (SiO2, pentane/EtOAc 4:1); Optical rotation [𝛼]஽ଶହ = +64.3 (c = 0.41, CHCl3); 
FTIR ṽ/cm−1 2953, 2895, 1748, 1605, 1453, 1355, 1279, 1206, 1150, 1111, 1020, 919, 748, 
702, 630; 1H NMR (400 MHz, CDCl3) δ/ppm 7.34–7.20 (m, 5H), 4.64 (d, J = 7.0 Hz, 1H), 
4.51 (d, J = 7.0 Hz, 1H), 4.34 (dd, J = 9.0, 4.4 Hz, 1H), 3.73 (s, 3H), 3.11 (dd, J = 13.9, 4.5 
Hz, 1H), 3.07 (s, 3H), 2.99 (dd, J = 13.8, 9.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ/ppm 
172.7, 137.1, 129.6, 128.5, 126.9, 96.2, 76.5, 55.8, 52.2, 39.3. 
Analytical data are in accordance with those reported in the literature.[4] 
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(R)-2-(Methoxymethoxy)-3-phenylpropanoic acid (2.51) 
Ester 2.50 (1.30 g, 5.80 mmol, 1.0 eq.) was dissolved in THF/H2O (5:3, 
32 mL). LiOH (0.417 g, 17.4 mmol, 3.0 eq.) was added and the 
solution stirred for 1 h at room temperature. The mixture was cooled to 0 °C 
and was neutralized with aq. HCl solution (2 M, 5 mL). The aqueous layer was extracted with 
EtOAc (3 x 20 mL), the combined organic layers were washed with brine (50 mL) and dried 
over Na2SO4. The solvent was removed under reduced pressure to obtain the phenyllactic acid 
derivative 2.51 (1.19 g, 5.64 mmol, 97%) as a colorless to light yellow oil, which was used for 
the next step without further purification . 
 
Rf = 0.19 (SiO2, pentane/EtOAc 2:1 + 0.2% TFA); Optical rotation [𝛼]஽ଶହ = +62.8 (c = 0.57, 
CHCl3); FTIR ṽ/cm−1 3063, 2954, 2899, 1722, 1497, 1444, 1212, 1150, 1112, 1023, 918, 
701, 633; 1H NMR (400 MHz, CDCl3) δ/ppm 10.17 (br s, 1H), 7.35–7.20 (m, 5H), 4.67 (d, 
J = 7.0 Hz, 1H), 4.51 (d, J = 6.9 Hz, 1H), 4.39 (dd, J = 9.1, 3.9 Hz, 1H), 3.19 (dd, J = 14.0, 
4.0 Hz, 1H), 3.10 (s, 3H), 3.02 (dd, J = 14.0, 9.1 Hz, 1H); 13C NMR (101 MHz, CDCl3) 
δ/ppm 176.1, 136.7, 129.7, 128.6, 127.1, 96.5, 76.4, 56.1, 39.0. 
Analytical data are in accordance with those reported in the literature.[4] 
 
Methyl D-leucinate 
D-Leucine (1.50 g, 11.4 mmol, 1.0 eq.) was dissolved in MeOH (25 mL). 
SOCl2 (2.50 mL, 34.2 mmol, 3.0 eq.) was added dropwise at 0 °C. The 
reaction mixture was heated for 3 h under reflux. Then all volatiles were removed under 
reduced pressure. Semi-saturated aq. Na2CO3 soln. (20 mL) was added and the mixture 
extracted with CH2Cl2 (3 x 20 mL). The organic layers were combined and dried over 
Na2SO4. The solvent was removed under reduced pressure to obtain the H-D-Leu-OMe (1.30 
g, 8.97 mmol, 79%) as light yellow oil which was used without any further purification. 
 
Rf = 0.26 (SiO2, CH2Cl2/MeOH 20:1); Optical rotation [𝛼]஽ଶହ =   ‒12.4   (c = 0.51, CHCl3); 
FTIR ṽ/cm−1 3381, 2956, 2871, 1737, 1605, 1438, 1385, 1197, 1172, 1007, 835, 635; 
1H NMR (400 MHz, CDCl3) δ/ppm 3.72 (s, 3H), 3.49 (dd, J = 8.7, 5.6 Hz, 1H), 1.83–1.72 
(m, 3H), 1.61–1.53 (m, 1H), 1.48–1.39 (m, 1H), 0.93 (t, J = 6.6 Hz, 6H); 13C NMR (101 
MHz, CDCl3) δ/ppm 177.3, 53.0, 52.0, 44.3, 24.9, 23.1, 21.9. 
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Methyl ((R)-2-(methoxymethoxy)-3-phenylpropanoyl)-D-leucinate (2.52) 
H-D-Leu-OMe (250 mg, 1.72 mmol, 1.0 eq.) and phenyllactic aicd 
derivative 2.51 (470 mg, 2.24 mmol, 1.3 eq.) were dissolved in 
CH2Cl2 (12 mL). The solution was cooled to 0 °C and 2,6-lutidine 
(1.00 mL, 8.60 mmol, 5.0 eq.) and PyBOP (1.16 g, 2.24 mmol, 1.3 eq.) were added. The 
mixture was stirred for 20 min at 0 °C and further 20 h at room temperature. Then the reaction 
was diluted with CH2Cl2 (5.0 mL), washed with aq. HCl solution (1 M, 10 mL), sat. aq. 
Na2CO3 solution (10 mL) and brine (30 mL). The combined organic layers were dried over 
Na2SO4 and the solvent was removed under reduced pressure. The crude residue was purified 
by flash column chromatography (SiO2, pentane/EtOAc 3:1 changing to 1:1) to obtain 
Pla-Leu-OMe dipeptide 2.52 (0.471 g, 1.40 mmol, 81%) as a colorless oil. 
 
Rf = 0.63 (SiO2, pentane/EtOAc 1:1); Optical rotation [𝛼]஽ଶହ = +64.0 (c = 0.30, CHCl3); 
FTIR ṽ/cm−1 3317, 2955, 1744, 1667, 1520, 1453, 1339, 1273, 1208, 1151, 1103, 1036, 920, 
846, 702, 631; 1H NMR (400 MHz, CDCl3) δ/ppm 7.29–7.18 (m, 5H), 6.81 (d, J = 8.9 Hz, 
1H), 4.66–4.56 (m, 3H), 4.37 (dd, J = 7.3, 3.7 Hz, 1H), 3.70 (s, 3H), 3.21 (s, 3H), 3.18 (dd, 
J = 14.1, 3.7 Hz, 1H), 2.97 (dd, J = 14.1, 7.3 Hz, 1H), 1.59–1.51 (m, 1H), 1.45–1.37 (m, 1H), 
1.36–1.24 (m, 1H), 0.87 (d, J = 6.5 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ/ppm 173.5, 171.3, 137.1, 129.9, 128.3, 126.8, 96.0, 77.7, 56.2, 52.4, 50.1, 41.7, 
38.9, 24.6, 23.0, 21.9; HRMS ESI m/z calc. for C18H27NO5Na [M+Na]+: 360.1781, found: 
360.1785. 
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((R)-2-(Methoxymethoxy)-3-phenylpropanoyl)-D-leucine (2.53) 
Pla-Leu-OMe dipeptide 2.52 (340 mg, 1.01 mmol, 1.0 eq.) was 
dissolved in THF/H2O (5:3, 16 mL). LiOH (71.9 mg, 3.00 mmol, 
3.0 eq.) was added and the mixture was stirred for 2 h at room 
temperature. The reaction was cooled to 0 °C, neutralized with aq. HCl solution (2 M, 5 mL) 
and the THF was removed under reduced pressure. The residue was extracted with EtOAc 
(3 x 10 mL), the combined organic layers were washed with brine (50 mL) and dried over 
Na2SO4. The solvent was removed under reduced pressure to obtain Pla-Leu-OH 
dipeptide 2.53 (318 mg, 0.983 mmol, 98%) as colorless sticky oil. 
 
Rf = 0.12 (SiO2, pentane/EtOAc 1:1 + 0.5% AcOH); Optical rotation [𝛼]஽ଶହ = +62.1 (c = 
0.54, CHCl3); FTIR ṽ/cm−1 3408, 2955, 1728, 1637, 1529, 1453, 1351, 1268, 1201, 1150, 
1104, 1037, 920, 746, 700, 652, 621; 1H NMR (400 MHz, CDCl3) δ/ppm 7.30–7.18 (m, 5H), 
6.82 (d, J = 8.8 Hz, 1H), 4.65–4.55 (m, 3H), 4.39 (dd, J = 7.2, 3.7 Hz, 1H), 3.20–3.15 (m, 
4H), 2.97 (dd, J = 14.1, 7.2 Hz, 1H), 1.62 (ddd, J = 13.9, 9.7, 4.9 Hz, 1H), 1.45 (ddd, J = 13.7, 
9.7, 5.3 Hz 1H), 1.38–1.29 (m, 1H), 0.86 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CDCl3) 
δ/ppm 176.6, 172.1, 136.9, 129.9, 128.4, 126.8, 96.0, 77.7, 56.2, 50.2, 41.1, 38.8, 24.7, 23.0, 
21.8; HRMS ESI m/z calc. for C17H25NO5Na [M+Na]+: 346.1625, found: 346.1629. 
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2.1.4. Synthesis of Adc building block 2.63 
Methyl 4-hydroxy-2-methylenebutanoate (2.54) 
3-Methylenedihydrofuran-2-(3H)-one (2.17) (4.2 mL, 48.0 mmol, 1.0 eq.) 
was dissolved in MeOH (180 mL) and cooled to 0 °C. Fuming sulfuric acid 
(9.5 mL) was added dropwise and the solution was stirred for 16 h at room 
temperature. The mixture was neutralized with aq. NaOH solution (10 M, 50 mL) and the 
solvent was removed under reduced pressure at room temperature. The residue was extracted 
with EtOAc (3 x 150 mL). The combined organic layers were washed with H2O (200 mL), 
dried over Na2SO4 and the solvent was removed under reduced pressure at room temperature 
to obtain γ-hydroxy ester 2.54 (4.58 g, 35.2 mmol, 72%) as a colorless oil. The crude product 
was used for the next step without further purification. 
 
Rf = 0.43 (SiO2, pentane/EtOAc 10:1); 1H NMR (400 MHz, CDCl3) δ/ppm 6.27–6.23 (m, 
1H), 5.69–5.65 (m, 1H), 3.81–3.74 (m, 2H), 3.76 (s, 3H) 2.58 (t, J = 6.1 Hz, 2H); 13C NMR 
(101 MHz, CDCl3) δ/ppm 168.0, 137.5, 127.6, 61.8, 52.2, 35.7. 
 
Methyl 4-((tert-butyldiphenylsilyl)oxy)-2-methylenebutanoate (2.55)  
γ-Hydroxy ester 2.54 (4.58 g, 35.2 mmol, 1.0 eq.) was dissolved in 
DMF (150 mL) and cooled to 0 °C. TBDPSCl (9.20 mL, 35.5 mmol, 
1.0 eq.) and imidazole (4.85 g, 73.4 mmol, 2.1 eq.) were added. The 
solution was stirred for 16 h at room temperature. The solvent was removed under reduced 
pressure and the obtained residue dissolved in EtOAc (150 mL). The solution was washed 
with H2O (4 x 150 mL) and brine (100 mL) and dried over Na2SO4. The solvent was removed 
under reduced pressure and the crude residue purified by flash column chromatography (SiO2, 
pentane/EtOAc 15:1 changing to 1:1) to obtain TBDPS protected alcohol 2.55 (3.94 g, 
10.7 mmol, 30%) as a colorless oil. 
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Rf = 0.45 (SiO2, pentane/EtOAc 15:1); FTIR ṽ/cm−1 3071, 3050, 2954, 2932, 2858, 1722, 
1632, 1429, 1305, 1218, 1154, 1108, 998, 931, 821, 705, 631; 1H NMR (400 MHz, CDCl3) 
δ/ppm 7.67–7.63 (m, 4H), 7.45–7.35 (m, 6H), 6.22 (d, J = 1.3 Hz, 1H), 5.6–5.61 (m, 1H), 
3.79 (t, J = 6.4 Hz, 2H), 3.70 (s, 3H), 2.58 (t, J = 6.5 Hz, 2H), 1.03 (s, 9H); 13C NMR 
(101 MHz, CDCl3) δ/ppm 167.6, 137.4, 135.7, 133.9, 129.7, 127.7, 127.2, 62.7, 51.9, 35.3, 
27.0, 19.3. 
Analytical data are in accordance with those reported in the literature.[9] 
 
4-((tert-Butyldiphenylsilyl)oxy)-2-methylenebutan-1-ol (2.56) 
Ester 2.55 (3.85 g, 10.4 mmol, 1.0 eq.) was dissolved in CH2Cl2 (60 mL) 
and cooled to –78 °C. DIBAL (1 M, 26 mL, 26.5 mmol, 2.5 eq.) was 
added  dropwise   and   the   solution  was   stirred   for  1  h   at   ‒78   °C.  The   reaction  was  quenched  
with sat. aq. NH4Cl solution (10 mL). The solvent was removed under reduced pressure and 
the residue was dissolved in EtOAc (150 mL). The solution was washed with sat. aq. Rochelle 
salt solution (2 x 50 mL), H2O (100 mL), brine (100 mL) and dried over Na2SO4. The solvent 
was removed under reduced pressure and the crude product was purified by flash column 
chromatography (SiO2, pentane/EtOAc 4:1) to obtain alcohol 2.56 (3.19 g, 9.36 mmol, 90%) 
as a colorless oil. 
 
Rf = 0.45 (SiO2, pentane/EtOAc 4:1); FTIR ṽ/cm−1 3363, 3071, 2931, 2858, 1428, 1191, 
1109, 901, 822, 705, 632; 1H NMR (400 MHz, CDCl3) δ/ppm 7.69–7.65 (m, 4H), 7.46–7.36 
(m, 6H), 5.06 (d, J = 1.5 Hz, 1H), 4.90–4.88 (m, 1H), 4.08 (d, J = 6.1 Hz, 2H), 3.77 (t, J = 
6.2 Hz, 2H), 2.35 (t, J = 6.2 Hz, 2H), 2.23 (t, J = 6.2 Hz, 1H), 1.05 (s, 9H); 13C NMR 
(101 MHz, CDCl3) δ/ppm 146.8, 135.7, 133.5, 129.9, 127.8, 112.4, 66.5, 63.9, 36.7, 26.9, 
19.3.  
Analytical data are in accordance with those reported in the literature.[9] 
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N-Allyl-4-((tert-butyldiphenylsilyl)oxy)-2-methylenebutan-1-amine (2.57) 
Alcohol 2.56 (3.12 g, 9.16 mmol, 1.0 eq.) was dissolved in CH2Cl2 
(90 mL) and cooled to 0 °C. Et3N (1.4 mL, 9.96 mmol, 1.1 eq.) and 
methanesulfonyl chloride (0.80 mL, 10.3 mmol, 1.1 eq.) were added. After stirring for 2 h at 
0 °C, the mixture was allowed to warm to room temperature and prop-2-en-1-amine 
(3.43 mL, 45.8 mmol, 5.0 eq.) was added and the mixture stirred for 16 h at room 
temperature. The solvent was removed under reduced pressure and the crude product was 
purified by flash column chromatography (SiO2, CH2Cl2/MeOH 15:1 changing to 10:1) to 
obtain allyl amine 2.57 (2.64 g, 6.95 mmol, 76%) as a colorless oil. 
 
Rf = 0.40 (SiO2, CH2Cl2/MeOH 10:1); FTIR ṽ/cm−1 3071, 2931, 2858, 1647, 1463, 1428, 
1107, 997, 915, 823, 703, 613; 1H NMR (400 MHz, CDCl3) δ/ppm 7.69–7.65 (m, 4H), 7.45–
7.35 (m, 6H), 5.93–5.83 (m, 1H), 5.18–5.05 (m, 2H), 4.95 (q, J = 1.6 Hz, 1H), 4.86–4.84 (m, 
1H), 3.77 (t, J = 6.8 Hz, 2H), 3.19 (dt, J = 6.0, 1.4 Hz, 2H), 3.15 (s, 2H), 2.31 (t, J = 6.6 Hz, 
2H), 1.04 (s, 9H); 13C NMR (101 MHz, CDCl3) δ/ppm 145.1, 137.1, 135.7, 134.0, 129.7, 
127.8, 116.0, 111.9, 63.2, 54.1, 51.8, 37.7, 27.0, 19.3.  
Analytical data are in accordance with those reported in the literature.[9] 
 
tert-Butyl allyl(4-((tert-butyldiphenylsilyl)oxy)-2-methylenebutyl)carbamate (2.58) 
Allyl amine 2.57 (2.60 g, 6.85 mmol, 1.0 eq.) was dissolved in 
CH2Cl2 (38 mL). Et3N (1.25 mL, 8.91 mmol, 1.3 eq.) and Boc2O 
(1.65 g, 7.56 mmol, 1.1 eq.) were added and the solution was stirred for 1 h at room 
temperature. The solvent was removed under reduced pressure and the crude residue was 
purified by flash column chromatography (SiO2, pentane/EtOAc 10:1) to obtain Boc protected 
allyl amine 2.58 (3.14 g, 6.54 mmol, 96%) as a colorless oil. 
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Rf = 0.55 (SiO2, pentane/EtOAc 10:1); FTIR ṽ/cm−1 3072, 2931, 2858, 2360, 1695, 1405, 
1246, 1169, 1106, 997, 913, 823, 701, 612; 1H NMR (400 MHz, CDCl3) δ/ppm 7.68–7.64 (m, 
4H), 7.45–7.35 (m, 6H), 5.80–5.67 (m, 1H), 5.14–5.01 (m, 2H), 4.90–4.79 (m, 2H), 3.85–3.66 
(m, 6H), 2.24 (t, J = 6.1 Hz, 2H), 1.47–1.38 (m, 9H), 1.04 (s, 9H); 13C NMR (101 MHz, 
CDCl3) δ/ppm 155.7, 146.9, 142.2, 135.7, 133.9, 129.7, 127.8, 116.7, 112.4, 79.7, 62.7, 50.8, 
48.4, 36.8, 28.5, 27.0, 19.3.  
Analytical data are in accordance with those reported in the literature.[9] 
 
tert-Butyl 3-(2-((tert-butyldiphenylsilyl)oxy)ethyl)-2,5-dihydro-1-pyrrole-1-carboxylate 
(2.59) 
Allyl amine 2.58 (2.81 g, 5.86 mmol, 1.0 eq.) was dissolved in CH2Cl2 
(200 mL,   degassed).  Grubbs’   catalyst   2nd generation (100 mg, 0.120 mmol, 
0.020 eq.) was added and the black solution was stirred for 16 h at room 
temperature. The solvent was removed under reduced pressure and the crude 
residue was purified by flash column chromatography (SiO2, pentane/EtOAc 9:1) to obtain 
pyrroline 2.59 (2.42 g, 5.41 mmol, 92%) as a light brown oil. 
 
Rf = 0.49 (SiO2, pentane/EtOAc 9:1); FTIR ṽ/cm−1 3071, 2932, 2858, 1702, 1475, 1401, 
1365, 1253, 1164, 1110, 998, 824, 705, 632, 614; 1H NMR (400 MHz, CDCl3) δ/ppm 7.67–
7.63 (m, 4H), 7.46–7.34 (m, 6H), 5.44–5.37 (m, 1H), 4.12–3.95 (m, 4H), 3.75 (td, J = 6.4, 2.3 
Hz, 2H), 2.37–2.30 (m, 2H), 1.47 (s, 9H), 1.05 (d, J = 2.2 Hz, 9H); 13C NMR (101 MHz, 
CDCl3) δ/ppm 154.4, 137.3, 135.7, 133.7, 129.8, 127.8, 120.4, 79.3, 62.6, 55.5, 53.1, 32.5, 
28.7, 27.0, 19.3.  
Analytical data are in accordance with those reported in the literature.[9] 
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tert-Butyl 3-(2-hydroxyethyl)-2,5-dihydro-1H-pyrrole-1-carboxylate (2.60) 
Pyrroline 2.59 (2.30 g, 5.09 mmol, 1.0 eq.) was dissolved in THF (50 mL) and 
cooled to 0 °C. TBAF (7.70 mL, 1 M in THF, 7.70 mmol, 1.5 eq.) was added 
dropwise. The reaction mixture was stirred for 10 min at 0 °C and further for 1 h at 
room temperature. The mixture was quenched with sat. aq. NH4Cl solution 
(30 mL). The solvent was evaporated and the residue was diluted with H2O (10 mL) and 
extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were washed with brine 
(2 x 50 mL) and dried over Na2SO4. The solvent was removed under reduced pressure and the 
crude product was purified by flash column chromatography (SiO2, pentane/EtOAc 1:1) to 
obtain alcohol 2.60 (833 mg, 3.91 mmol, 77%) as a colorless oil. 
 
Rf = 0.29 (SiO2, pentane/EtOAc 1:1); FTIR ṽ/cm−1 3430, 2972, 2866, 1681, 1653, 1405, 
1367, 1250, 1169, 1118, 1050, 984, 873, 621; 1H NMR (400 MHz, CDCl3) δ/ppm 5.56–5.48 
(m, 1H), 4.16–4.02 (m, 4H), 3.80–3.74 (m, 2H), 2.42–2.34 (m, 2H), 1.47 (d, J = 1.5 Hz, 9H); 
13C NMR (101 MHz, CDCl3) δ/ppm 154.4, 136.5, 120.9, 79.5, 60.6, 55.2, 53.2, 32.4, 28.7.  
Analytical data are in accordance with those reported in the literature.[9] 
 
tert-Butyl 3-(2-azidoethyl)-2,5-dihydro-1H-pyrrole-1-carboxylate (2.61) 
Alcohol 2.60 (790 mg, 3.70 mmol, 1.0 eq.) and PPh3 (1.95 g, 7.40 mmol, 2.0 eq.) 
were dissolved in THF (27 mL) and cooled to 0 °C. DEAD (3.40 mL, 40% w/w 
solution in toluene, 7.40 mmol, 2.0 eq.) and diphenyl phosphorazidate (1.60 mL, 
7.40 mmol, 2.0 eq.) were added. The mixture was stirred for 15 min at 0 °C and 
further for 1 h at room temperature. The solvent was removed under reduced pressure and the 
crude product was purified by flash column chromatography (SiO2, pentane/EtOAc 6:1) to 
obtain azide 2.61 (633 mg, 2.66 mmol, 72%) as a colorless oil. 
 
Rf = 0.33 (SiO2, pentane/EtOAc 6:1); FTIR ṽ/cm−1 2976, 2858, 2095, 1697, 1399, 1255, 
1173, 1113, 988, 878, 652, 624; 1H NMR (400 MHz, CDCl3) δ/ppm 5.56–5.48 (m, 1H), 4.15–
3.99 (m, 4H), 3.42 (td, J = 6.9, 3.6 Hz, 2H), 2.43–2.35 (m, 2H), 1.47 (d, J = 2.3 Hz, 9H); 
13C NMR (101 MHz, CDCl3) δ/ppm 154.3, 135.9, 121.3, 79.5, 55.0, 53.2, 49.3, 28.7, 28.6; 
HRMS ESI m/z calc. for C11H18N4O2Na [M+Na]+: 261.1322, found: 261.1319. 
Analytical data are in accordance with those reported in the literature.[9] 
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tert-Butyl (E)-((3-(2-azidoethyl)-2,5-dihydro-1H-pyrrol-1-yl)((tert-butoxycarbonyl) 
imino)methyl)carbamate (2.62) 
Azide 2.61 (219 mg, 0.919 mmol, 1.0 eq.) was dissolved in CH2Cl2 
(16 mL). TFA (0.65 mL) was added dropwise to the solution, which turned 
black after a few minutes. After stirring for 4 h at room temperature, the 
solution was cooled to 0 °C and Et3N (1.30 mL, 9.40 mmol, 10 eq.) was 
added slowly. The solvent was removed under reduced pressure and the resulting dark oil was 
dissolved in chloroform (10 mL). To this solution Et3N (0.26 mL, 1.88 mmol, 2.1 eq.) and 
Goodman’s   reagent   (360  mg,   0.919 mmol, 1.0 eq.) were added and the mixture stirred for 
16 h at room temperature. The reaction mixture was diluted with chloroform (20 mL), washed 
with H2O (20 mL) and brine (20 mL) and dried over Na2SO4. The solvent was removed under 
reduced pressure and the crude product was purified by flash column chromatography (SiO2, 
pentane/EtOAc 4:1) to obtain the azide 2.62 (273 mg, 0.718 mmol, 78%) as a colorless oil. 
 
Rf = 0.26 (SiO2, pentane/EtOAc 4:1); FTIR ṽ/cm−1 2978, 2932, 2098, 1743, 1598, 1125; 
1H NMR (400 MHz, CDCl3) δ/ppm 10.27 (br s, 1H), 5.58–5.53 (m, 1H), 4.44–4.32 (m, 4H), 
3.43 (t, J = 6.9 Hz, 2H), 2.40 (t, J = 6.4 Hz, 2H), 1.50 (s, 18H); 13C NMR (101 MHz, CDCl3) 
δ/ppm 154.0, 134.9, 120.1, 80.6, 56.9, 55.4, 49.0, 31.2, 28.3; HRMS ESI m/z calc. for 
C17H29N6O4 [M+H]+: 381.2245, found: 381.2245. 
Analytical data are in accordance with those reported in the literature.[9] 
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tert-Butyl (E)-((3-(2-aminoethyl)-2,5-dihydro-1H-pyrrol-1-yl)((tert-butoxycarbonyl) 
imino)methyl)carbamate (2.63) 
Azide 2.62 (68.0 mg, 0.179 mmol, 1.0 eq.) was dissolved in MeOH 
(1.5 mL) and Lindlar catalyst (34.0 mg, 50% w/w) was added. The mixture 
was stirred at room temperature for 1.5 h under an atmosphere of H2. The 
mixture was filtered over a pad of Celite®, the filter cake was washed with 
MeOH (2.0 mL) and the filtrate concentrated under reduced pressure. After lyophilization, 
Adc subunit 2.63 (60.7 mg, 0.171 mmol, 96%) was obtained as a colorless solid. 
 
Mp = 109.7–110.4 °C; Rf = 0.11 (SiO2, CH2Cl2/MeOH 10:1 + 0.2% Et3N); FTIR ṽ/cm−1 
2977, 2934, 1746, 1603, 1479, 1367, 1289, 1241, 1137, 804; 1H NMR (400 MHz, MeOD) 
δ/ppm 5.72–5.69 (m, 1H), 4.35–4.24 (m, 4H), 3.11 (t, J = 7.3 Hz, 2H), 2.51 (t, J = 6.8 Hz, 
2H), 1.48 (s, 18H); 13C NMR (101 MHz, MeOD) δ/ppm 153.0, 137.7, 120.5, 81.3, 57.0, 53.7, 
40.2, 32.5, 28.6; HRMS ESI m/z calc. for C17H31N4O4 [M+H]+: 355.2340, found: 355.2340. 
Analytical data are in accordance with those reported in the literature.[9] 
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2.1.5. Synthesis of Xyl donor 2.69 
(2S,3R,4S,5R)-2-(Phenylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate (2.66) 
D-(+)-Xylose (5.00 g, 33.3 mmol, 1.0 eq.) was dissolved in pyridine 
(26.9 mL, 333 mmol, 10 eq.) and cooled to 0 °C. Acetyl chloride (23.8 mL, 
333 mmol, 10 eq.) was added slowly and the reaction mixture stirred for 24 h 
at 0 °C. The reaction mixture was poured into H2O (150 mL) and extracted with Et2O 
(2 x 150 mL). The combined organic layers were washed with sat. aq. NH4Cl solution 
(3 x 100 mL) and dried over Na2SO4. The solvent was removed under reduced pressure to 
give an anomeric mixture of (3R,4S,5R)-tetrahydro-2H-pyran-2,3,4,5-tetrayl tetraacetate 
(2.65) (10.0 g, 31.4 mmol, 94%) as a  brown syrup, which was used for the next step without 
further purification. The crude residue of acetylated xylose moiety 2.65 (2.20 g, 6.91 mmol, 
1.0 eq.) was dissolved in CH2Cl2 (9 mL). Thiophenol (0.86 mL, 8.29 mmol, 1.2 eq.) and 
boron trifluoro etherate (2.60 mL, 20.7 mmol, 3.0 eq.) were slowly added at 0 °C and the 
mixture was stirred for 20 min at 0 °C and further for 2 h at room temperature. The reaction 
mixture was diluted with CH2Cl2 (10 mL) and washed with sat. aq. NaHCO3 solution 
(2 x 25 mL) and H2O (2 x 15 mL). The organic layer was dried over Na2SO4 and the solvent 
was removed under reduced pressure to obtain thioxyloside 2.66 (2.50 g, 6.79 mmol, 98%) as 
a colorless, viscous oil.  
 
1H NMR (400 MHz, CDCl3) δ/ppm 7.50–7.46 (m, 2H), 7.34–7.29 (m, 3H), 5.18 (t, J = 8.1 
Hz, 1H), 4.97–4.88 (m, 2H), 4.80 (d, J = 8.3 Hz, 1H), 4.28 (dd, J = 11.8, 5.0 Hz, 1H), 3.42 
(dd, J =11.8, 8.7 Hz, 1H), 2.09 (s, 3H), 2.04 (s, 3H), 2.04 (s, 3H); 13C NMR (101 MHz, 
CDCl3) δ/ppm 170.0, 169.9, 169.4, 132.9, 132.4, 129.2, 128.4, 86.4, 72.1, 70.0, 68.5, 65.3, 
20.92, 20.86, 20.84. 
Analytical data are in accordance with those reported in the literature.[10] 
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(2S,3R,4S,5R)-2-(Phenylthio)tetrahydro-2H-pyran-3,4,5-triol (2.67) 
Acetylated thioxyloside 2.66 (2.50 g, 6.79 mmol, 1.0 eq.) was dissolved in 
MeOH (6 mL). NaOMe (124 mg, 2.30 mmol, 0.34 eq.) was added and the 
reaction mixture was stirred for 2 h at room temperature. Acidic Amberlite® 
resin 120 was added to neutralize the reaction solution (the resin was prewashed with H2O, 
1 M HCl and MeOH (2x) prior to use). The resin was filtered off and the solvent was removed 
under reduced pressure. The crude residue was recrystallized from cyclohexane/acetone (3:1) 
to afford thioxyloside 2.67 (1.00 g, 4.13 mmol, 61%) as colorless crystals. 
 
Mp = 123.0−124.0  °C;; Optical rotation [𝛼]஽ଶହ = +1.7 (c = 0.48, MeOH); FTIR ṽ/cm−1 3338, 
2932, 2907, 2862, 1568, 1478, 1436, 1345, 1306, 1235, 1092, 1042, 959, 928, 903, 837, 730, 
684; 1H NMR (400 MHz, MeOD) δ/ppm 7.59–7.47 (m, 2H), 7.39–7.23 (m, 3H), 4.55 (d, J = 
9.3 Hz, 1H), 3.94 (dd, J = 11.3, 5.2 Hz, 1H), 3.47 (ddd, J = 9.9, 8.7, 5.1 Hz, 1H), 3.37–3.32 
(m, 1H), 3.26–3.18 (m, 2H); 13C NMR (101 MHz, MeOD) δ/ppm 134.9, 133.2, 129.9, 128.5, 
90.1, 79.2, 73.7, 70.9, 70.4. 
Analytical data are in accordance with those reported in the literature.[10] 
 
(3R,4R,5R,6S)-4,5-Dihydroxy-6-(phenylthio)tetrahydro-2H-pyran-3-yl benzoate (2.68) 
BzCl (0.32 mL, 2.72 mmol, 1.1 eq.) was added dropwise to a stirred solution 
of thioxyloside 2.67 (598 mg, 2.47 mmol, 1.0 eq.), Me2SnCl2 (28.0 mg, 0.120 
mmol, 0.050 eq.) and DIPEA (0.82 mL, 4.94 mmol, 2.0 eq.) in THF/H2O 
(9:1, 11 mL). The mixture was stirred for 2 h at room temperature before additional Me2SnCl2 
(28.0 mg, 0.120 mmol, 0.050 eq.) was added. The mixture was stirred for further 2 h after 
which an aq. HCl solution (3% w/w, 100 mL) was added. The aqueous layer was extracted 
with EtOAc (3 x 100 mL), the combined organic layers were dried over Na2SO4 and the 
solvent was removed. The obtained crude product was purified by flash column 
chromatography (SiO2, pentane/EtOAc 1:1) to give thioxyloside 2.68 (650 mg, 1.88 mmol, 
76%) as a colorless solid. 
 
Rf = 0.51 (SiO2, pentane/EtOAc 1:1); Mp = 89.0−90.0  °C; Optical rotation  [𝛼]஽ଶହ = –40.7 (c 
= 1.09, CHCl3); FTIR ṽ/cm−1 3443, 3064, 2878, 1722, 1602, 1452, 1317, 1261, 1179, 1114, 
1086, 1061, 1043, 1026, 968, 906, 847, 804, 744, 708, 688; 1H NMR (400 MHz, CDCl3) 
δ/ppm 8.09–7.97 (m, 2H), 7.61–7.53 (m, 3H), 7.44 (dt, J = 7.5, 3.0 Hz, 2H), 7.37–7.30 (m, 
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3H), 5.07 (td, J = 9.7, 5.4 Hz, 1H), 4.58 (d, J = 9.3 Hz, 1H), 4.30 (dd, J = 11.4, 5.4 Hz, 1H), 
3.89 (t, J = 8.8 Hz, 1H), 3.52–3.41 (m, 2H); 13C NMR (101 MHz, CDCl3) δ/ppm 166.2, 
133.5, 133.2, 131.3, 129.8, 129.3, 129.2, 128.5, 128.5, 88.5, 75.5, 72.2, 71.5, 66.6; HRMS 
ESI m/z calc. for C18H19O5S [M+H]+: 369.0767; found: 369.0767. 
 
(2R,3R,4aR,5S,8R,8aS)-2,3-Dimethoxy-2,3-dimethyl-5-(phenylthio)hexahydro-5H-
pyrano[3,4-b][1,4]dioxin-8-yl benzoate (2.69) 
To a solution of thioxyloside 2.68 (600 mg, 1.73 mmol, 1.0 eq.) in MeOH 
(9.0 mL) were added 2,3-butanedione (0.19 mL, 2.08 mmol, 1.2 eq.), 
trimethyl orthoformate (0.57 mL, 5.20 mmol, 3.0 eq.) and CSA (4.07 mg, 
17.0 µmol, 0.010 eq.). The reaction mixture was heated at 66 °C for 40 h 
before additional 2,3-butanedione (0.19 mL, 2.08 mmol, 1.2 eq.), trimethyl orthoformate 
(0.57 mL, 5.20 mmol, 3.0 eq.) and CSA (4.07 mg, 17.0 µmol, 0.010 eq.) were added. The 
reaction mixture was stirred for additional 24 h at 66 °C. The precipitated product was filtered 
off and the filter cake was washed with ice cold MeOH (2 x 10 mL) to give the desired 
thioxyloside 2.69 (550 mg, 1.19 mmol, 69%) as white crystals. 
 
Rf = 0.66 (SiO2, pentane/EtOAc 10:1); Mp = 201.0–203.0 °C; Optical rotation [𝛼]஽ଶହ = –
208.2 (c = 0.50, CHCl3); FTIR ṽ/cm−1 2989, 2952, 2937, 2901, 2875, 2825, 1708, 1600, 
1450, 1379, 1336, 1316, 1288, 1267, 1203, 1128, 1108, 1044, 979, 924, 884, 850, 749, 708, 
691, 654; 1H NMR (400 MHz, CDCl3) δ/ppm 8.09–7.97 (m, 2H), 7.61–7.53 (m, 3H), 7.48–
7.41 (m, 2H), 7.33–7.25 (m, 3H), 5.22 (td, J = 9.7, 5.4 Hz, 1H), 4.85 (d, J = 9.3 Hz, 1H), 4.37 
(dd, J = 11.6, 5.4 Hz, 1H), 4.10 (t, J = 9.3 Hz, 1H), 3.89 (t, J = 9.7 Hz, 1H), 3.41 (dd, J = 
11.6, 8.9 Hz, 1H), 3.32 (s, 3H), 3.23 (s, 3H), 1.35 (s, 3H), 1.28 (s, 3H); 13C NMR (101 MHz, 
CDCl3) δ/ppm 165.5, 133.3, 133.2, 131.9, 129.6, 128.9, 128.5, 127.6, 100.3, 99.7, 86.0, 71.5, 
69.3, 68.2, 67.1, 48.2, 47.9, 17.61, 17.57; HRMS ESI m/z calc. for C24H28O7SNa [M+Na]+: 
483.1448, found: 483.1444; Crystallography C24H28O7S, M = 460.55, colorless needle, 
triclinic, space group P1, a = 5.6090(6), b = 8.5370(9), c = 12.7740(13) Å, α = 71.160(6), β = 
88.037(7), γ = 85.190(7)o, U = 576.85(6) Å3, Z = 1, Dc = 1.326 Mg m–3, µ(Cu-Kα) = 1.608 
mm−1, T = 123 K. Total 5847 reflections, 3451 unique, Rint = 0.025. Refinement of 3218 
reflections (290 parameters) with I >2σ (I) converged at final R1 = 0.0294 (R1 all data = 
0.0308), wR2 = 0.0334 (wR2 all data = 0.0350), gof = 1.1090. 
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2.1.6.  Assembly of the Different Building Blocks – Synthesis of A828A, A848A, A126A 
and A794A  
 
1-Benzyl 2-methyl (2S,3aS,6R,7aS)-6-(((2R,3R,4aR,5R,8R,8aS)-8-(benzoyloxy)-2,3-
dimethoxy-2,3-dimethylhexahydro-5H-pyrano[3,4-b][1,4]dioxin-5-yl)oxy)octahydro-1H-
indole-1,2-dicarboxylate (2.71) 
Xylosyl donor 2.69 (203 mg, 0.440 mmol, 1.1 eq.), L-choi 
derivative 2.37 (133 mg, 0.400 mmol, 1.0 eq.) and NIS 
(99.0 mg, 0.440 mmol, 1.1 eq.) were dissolved in Et2O 
(8.5 mL) containing powdered 4 Å molecular sieves. The 
mixture was stirred for 20 min at 0 °C before AgOTf 
(206 mg, 0.800 mmol, 2.0 eq.) was added. The mixture was 
stirred for another 20 min at 0 °C and further for 2 h at room 
temperature before four drops of pyridine were added. The mixture was filtered over Celite® 
and the filtrate was concentrated. The crude product was purified by flash column 
chromatography (SiO2,  pentane/EtOAc  4:1)  to  give  1:1  rotameric  mixtures  of  pure  α-anomer 
2.71 (135  mg,  19.8  mmol,  50%)  and  pure  β-anomer 2.71b (80.0 mg, 11.7 mmol, 29%). Both 
anomers were initially obtained as colorless oils, which solidified upon standing. 
 
2.71: Mp = 84.0−86.0 °C; Rf = 0.53 (SiO2, pentane/EtOAc 1:1); Optical rotation [𝛼]஽ଶହ = 
−107.4   (c = 0.13, CHCl3); FTIR ṽ/cm−1 2946, 1704, 1451, 1414, 1353, 1316, 1270, 1197, 
1175, 1137, 1111, 1034, 993, 938, 882, 847, 772, 748, 645; 1H NMR (400 MHz, CDCl3, 
mixture of rotamers) δ/ppm 8.02 (d, J = 7.0 Hz, 2H), 7.56 (t, J = 7.4 Hz, 1H), 7.43 (t, J = 
7.7 Hz, 2H), 7.36–7.75 (m, 5H), 5.28–5.02 (m, 3H), 5.00–4.80 (m, 1H), 4.41–4.24 (m, 3H), 
4.00 (br s, 1H), 3.95 (dd, J = 10.7, 5.7 Hz, 1H), 3.76 (s, 3H), 3.71–3.60 (m, 2H), 3.28 (s, 3H), 
2.96 (s, 3H), 2.51–2.35 (m, 2H), 2.26–2.14 (m, 2H), 2.06–1.93 (m, 1H), 1.75–1.66 (m, 1H), 
1.64–1.51 (m, 3H), 1.25 (s, 3H), 1.21 (s, 3H); 13C NMR (101 MHz, CDCl3, mixture of 
rotamers) δ/ppm 173.8, 165.7 154.8, 137.0, 136.7, 133.2, 130.0, 129.8, 128.5, 128.0, 127.8, 
127.6, 99.9, 99.6, 94.8, 94.3, 71.3, 70.5, 69.8, 68.3, 68.2, 67.0, 66.6, 66.5, 59.8, 59.5, 59.3, 
54.5, 53.8, 52.4, 52.1, 48.2, 47.7, 36.6, 36.0, 32.8, 31.9, 29.8, 29.6, 25.7, 20.4, 20.2, 17.8, 
17.7, 17.6; HRMS ESI m/z calc. for C36H45NO12Na [M+Na]+: 706.2834, found: 706.2833. 
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2.71b: Rf = 0. 46 (SiO2, pentane/EtOAc 1:1); Optical rotation [𝛼]஽ଶହ = ‒124.4 (c = 0.70, 
CHCl3); FTIR ṽ/cm−1 2950, 1705, 1416, 1354, 1271, 1176, 1138, 1113, 1037, 888, 755, 713; 
1H NMR (400 MHz, CDCl3, mixture of rotamers) δ/ppm 8.05–7.99 (m, 2H), 7.60–7.53 (m, 
1H), 7.47–7.40 (m, 2H), 7.35–7.27 (m, 5H), 5.22–4.95 (m, 3H), 4.55 (d, J = 7.4 Hz, 1H), 
4.37–4.25 (m, 2H), 4.18 (dt, J = 12.0, 6.5 Hz, 1H), 4.09–4.02 (m, 1H), 4.00–3.91 (m, 1H), 
3.75 (s, 3H), 3.71–3.58 (m, 1H), 3.30 (s, 3H), 3.21 (s, 3H), 3.19–3.12 (m, 1H), 2.51–2.30 (m, 
2H), 2.23–2.10 (m, 2H), 2.04–1.89 (m, 1H), 1.81–1.74 (m, 1H), 1.68–1.56 (m, 1H), 1.52–1.36 
(m, 2H), 1.28 (s, 3H), 1.26 (s, 3H); 13C NMR (101 MHz, CDCl3, mixture of rotamers) δ/ppm 
173.8, 165.6, 154.7, 136.7, 133.3, 133.2, 129.9, 129.7, 128.5, 128.4, 128.1, 127.9, 99.6, 99.0, 
98.6, 72.9, 72.0, 70.7, 70.1, 69.8, 69.6, 69.5, 67.1, 66.9, 63.8, 63.5, 59.8, 59.4, 59.2, 54.6, 
54.2, 52.4, 52.1, 47.9, 47.7, 36.5, 35.9, 32.8, 32.5, 32.0, 31.8, 23.4, 23.1, 19.6, 17.7, 17.6; 
HRMS ESI m/z calc. for C36H45NO12Na [M+Na]+: 706.2834, found: 706.2833. 
 
Methyl (2S,3aS,6R,7aS)-6-(((2R,3R,4aR,5R,8R,8aS)-8-(benzoyloxy)-2,3-dimethoxy-2,3-
dimethylhexahydro-5H-pyrano[3,4-b][1,4]dioxin-5-yl)oxy)octahydro-1H-indole-2-
carboxylate (2.72) 
To a solution of Xyl-L-Choi-Cbz derivative 2.71 (90.0 mg, 
13.1 mmol, 1.0 eq.) and PdCl2 (23.6 mg, 13.1 mmol, 1.0 eq.) 
in Et3SiH (1.5 mL) was added Et3N (37.1 µL, 26.2 mmol, 
2.0 eq.). The reaction was stirred for 2.5 h at room 
temperature and filtered over a short pad of Celite®. The filtrate was concentrated under 
reduced pressure and the crude product was purified by flash column chromatography (SiO2, 
CH2Cl2/MeOH 30:1) to give Xyl-L-Choi-H derivative 2.72 (64.0 mg, 11.6 mmol, 88%) as a 
colorless oil which solidified upon standing. 
 
Mp = 68.1–68.9 °C; Rf = 0.45 (SiO2, CH2Cl2/MeOH 20:1); Optical rotation [𝛼]஽ଶହ = –64.1 
(c = 0.58, CHCl3); FTIR ṽ/cm−1 2947, 1727, 1602, 1452, 1375, 1272, 1177, 1140, 1034, 943, 
884, 714; 1H NMR (400 MHz, CDCl3) δ/ppm 8.02 (d, J = 7.5 Hz, 2H), 7.56 (t, J = 7.4 Hz, 
1H), 7.43 (t, J = 7.6 Hz, 2H), 5.13 (td, J = 10.1, 5.7 Hz, 1H), 4.91 (d, J = 3.6 Hz, 1H), 4.26 (t, 
J = 9.9 Hz, 1H), 3.93 (dd, J = 10.8, 5.8 Hz, 1H), 3.87 (dt, J = 10.3, 5.4 Hz, 2H), 3.78 (dd, J = 
10.4, 3.5 Hz, 1H), 3.74 (s, 3H), 3.65 (t, J = 10.6 Hz, 1H), 3.45 (q, J = 5.0 Hz, 1H), 3.30 (s, 
3H), 3.24 (s, 3H), 3.00 (br s, 1H), 2.30–.20 (m, 1H), 2.10–2.00 (m, 2H), 1.88–1.77 (m, 2H), 
1.75–1.65 (m, 2H), 1.55–1.45 (m, 1H), 1.38–1.31 (m, 1H), 1.28 (s, 3H), 1.24 (s, 3H); 
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13C NMR (101 MHz, CDCl3) δ/ppm 176.0, 165.7, 133.2, 130.0, 129.8, 128.5, 99.9, 99.6, 
95.9, 73.2, 70.0, 68.4, 66.7, 59.6, 58.5, 58.4, 48.0, 47.8, 37.4, 35.7, 32.8, 31.2, 25.6, 17.9, 
17.7; HRMS ESI m/z calc. for C28H40NO10 [M+H]+: 550.2647, found: 550.2655. 
 
Ethyl (2S,3aS,6R,7aS)-6-(((2R,3R,4aR,5R,8R,8aS)-8-(benzoyloxy)-2,3-dimethoxy-2,3-
dimethylhexahydro-5H-pyrano[3,4-b][1,4]dioxin-5-yl)oxy)-1-((2S,3R)-3-chloro-2-((R)-2-
(methoxymethoxy)-3-phenylpropanamido)-4-methylpentanoyl)-octahydro-1H-indole-2-
carboxylate (2.74) 
To a solution of amine 2.72 (5.50 mg, 10.0 µmol, 1.0 eq.) 
and Cleu derivative 2.47 (5.37 mg, 15.0 µmol, 1.5 eq.) in 
CH2Cl2 (0.2 mL) at 0 °C were added DMTMM (4.15 mg, 
15.0 µmol, 1.5 eq.) and NMM (2.2 μL, 20.0 mmol, 2.0 eq.). 
After the addition, the reaction mixture was allowed to reach 
room temperature and stirred for 2 h. The solvent was 
removed under reduced pressure and the crude product 
directly purified by flash column chromatography (SiO2, pentane/EtOAc 1:1) to give pure 
tripeptide 2.74 (7.45 mg, 8.70 µmol, 87%) as a white solid. 
 
Mp = 218.0−220.0  °C; Rf = 0.41 (SiO2, pentane/EtOAc 1:1); Optical rotation [𝛼]஽ଶହ  = –29.3 
(c = 0.12, CHCl3); FTIR ṽ/cm−1 2954, 2927, 2855, 1749, 1727, 1682, 1646, 1505, 1451, 
1369, 1316, 1271, 1196, 1175, 1143, 1112, 1084, 1036, 939, 881, 803, 754, 713, 613; 1H 
NMR (400 MHz, CDCl3) δ/ppm 8.07–7.98 (m, 2H), 7.57 (tt, J = 7.4, 1.3 Hz, 1H), 7.44 (t, J = 
7.7 Hz, 2H), 7.29–7.18 (m, 5H), 6.92 (d, J = 10.2 Hz, 1H), 5.22 (d, J = 3.4 Hz, 1H), 5.17 (td, 
J = 10.2, 5.8 Hz, 1H), 4.95 (t, J = 10.4 Hz, 1H), 4.55 (s, 2H), 4.42–4.31 (m, 4H), 4.04 (br s, 
1H), 3.99 (ddd, J = 10.6, 3.8, 1.8 Hz, 2H), 3.90 (dd, J = 10.1, 3.4 Hz, 1H), 3.67 (s, 3H), 3.53 
(t, J = 10.6 Hz, 1H), 3.33 (s, 3H), 3.29 (s, 3H), 3.16 (s, 3H), 3.12 (dd, J = 14.2, 3.5 Hz, 1H), 
2.97 (dd, J = 14.2, 6.9 Hz, 1H), 2.53 (td, J = 12.5, 6.3 Hz, 1H), 2.47–2.39 (m, 1H), 2.35–2.25 
(m, 1H), 2.23–2.13 (m, 1H), 1.95 (dd, J = 23.2, 12.8 Hz, 2H), 1.76–1.69 (m, 1H), 1.56 (t, J = 
12.8 Hz, 3H), 1.50–1.42 (m, 1H), 1.30 (s, J = 10.7 Hz, 3H), 1.27 (s, 3H), 0.93 (d, J = 6.5 Hz, 
3H), 0.87 (d, J = 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ/ppm 172.7, 170.5, 168.7, 
165.8, 136.9, 133.2, 130.11, 130.06, 129.8, 128.5, 128.3, 126.8, 99.8, 99.6, 95.6, 93.5, 77.0, 
70.1, 68.5, 68.4, 68.1, 66.6, 59.7, 59.2, 56.2, 54.7, 52.2, 48.2, 47.8, 38.4, 36.9, 30.6, 29.8, 
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28.9, 27.9, 25.2, 20.9, 19.9, 18.0, 17.6, 16.0; HRMS ESI m/z calc. for C45H61ClN2O14Na 
[M+Na]+: 911.3704, found: 911.3707. 
 
 (2S,3aS,6R,7aS)-1-((2S,3R)-3-Chloro-2-((R)-2-(methoxymethoxy)-3-phenyl-propan-
amido)-4-methylpentanoyl)-6-(((2R,3R,4aR,5R,8R,8aS)-8-hydroxy-2,3-dimethoxy-2,3-
dimethylhexahydro-5H-pyrano[3,4-b][1,4]dioxin-5-yl)oxy)-octahydro-1H-indole-2-
carboxylic acid (2.83) 
Tripeptide 2.74 (7.20 mg, 8.09 µmol, 1.0 eq.) was dissolved in 
THF/H2O (5:3, 1.5 mL) and LiOH monohydrate (6.60 mg, 
0.160 mmol, 20 eq.) was added. The reaction was stirred for 
12 h at room temperature, H2O (1 mL) was added and the 
THF was removed under reduced pressure. Aq. citric acid 
solution (5% w/w, 3 mL) was added and the aqueous layer 
was extracted with CH2Cl2 (3 x 5 mL), the combined organic 
layers were dried over Na2SO4 and the solvent was removed under reduced pressure. The 
crude residue was purified by flash column chromatography (SiO2, CH2Cl2/MeOH 10:1) to 
obtain tripeptidic acid 2.83 (4.80 mg, 6.22 µmol, 77%) as a colorless solid. 
 
Mp = 183.5–185.0 °C; Rf = 0.31 (SiO2, CH2Cl2/MeOH 10:1); Optical rotation [𝛼]஽ଶହ = –13.9 
(c = 0.15, CHCl3); FTIR ṽ/cm−1 3405, 2953, 2927, 2362, 2342, 1741, 1680, 1631, 1510, 
1458, 1374, 1334, 1254, 1141, 1117, 1096, 1034, 941, 921, 880, 806, 754, 700, 670, 612; 1H 
NMR (400 MHz, CDCl3) δ/ppm 7.27–7.17 (m, 1H), 6.98 (d, J = 10.5 Hz, 1H), 5.14 (d, J = 
3.2 Hz, 1H), 5.03 (t, J = 10.5 Hz, 1H), 4.58–4.47 (m, 1H), 4.41–4.31 (m, 1H), 4.07–3.97 (m, 
1H), 3.87 (td, J = 9.9, 5.7 Hz, 1H), 3.75–3.69 (m, 1H), 3.51 (t, J = 10.7 Hz, 1H), 3.29 (s, 1H), 
3.27 (s, 1H), 3.17 (s, 1H), 3.12 (dd, J = 14.2, 3.5 Hz, 1H), 2.97 (dd, J = 14.1, 6.5 Hz, 1H), 
2.54–2.42 (m, 1H), 2.39–2.12 (m, 1H), 1.74 (d, J = 12.5 Hz, 1H), 1.59 (d, J = 9.1 Hz, 1H), 
1.46–1.37 (m, 1H), 1.32 (s, 1H), 1.29 (s, 1H), 0.88 (t, J = 7.2 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ/ppm 173.4, 170.7, 170.6, 136.7, 130.07, 128.3, 126.9, 99.8, 99.5, 95.8, 93.9, 69.9, 
68.4, 68.3, 68.0, 67.9, 62.3, 59.4, 56.2, 55.9, 52.1, 48.1, 48.0, 38.2, 36.0, 29.9, 29.2, 29.1, 
27.9, 24.9, 20.8, 19.8, 18.0, 17.7, 15.9; HRMS ESI m/z calc. for C37H55ClN2O13Na [M+Na]+: 
793.3285, found: 793.3284. 
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tert-Butyl ((Z)-((tert-butoxycarbonyl)imino)(3-(2-((2S,3aS,6R,7aS)-1-((2S,3R)-3-chloro-2-
((R)-2-(methoxymethoxy)-3-phenylpropanamido)-4-methylpentanoyl)-6-(((2R,3R,4aR, 
5R,8R,8aS)-8-hydroxy-2,3-dimethoxy-2,3-dimethylhexahydro-5H-pyrano[3,4-b][1,4] 
dioxin-5-yl)oxy)octahydro-1H-indole-2-carboxamido)ethyl)-2,5-dihydro-1H-pyrrol-1-yl) 
methyl)carbamate (2.84) 
To a solution of tripeptidic acid 2.83 (4.63 mg, 
6.00 µmol, 1.0 eq.), Adc side chain 2.63 
(4.25 mg, 12.0 µmol, 2.0 eq.) and PyBOP 
(6.24 mg, 12.0 µmol, 2.0 eq.) in CH2Cl2 
(0.2 mL) was added 2,6-lutidine (2.1 µL, 
18.0 µmol, 3.0 eq.) at 0 °C. The reaction 
mixture was stirred for 30 min at 0 °C and 
further for 5 h at room temperature. CH2Cl2 (3 mL) was added and the mixture was washed 
with sat. aq. NaHCO3 solution (1 mL) and brine (1 mL). The organic layer was dried over 
Na2SO4 and the solvent was removed. The crude product was purified by flash column 
chromatography (SiO2, CH2Cl2/MeOH 30:1) to give tetrapeptide 2.84 (4.00 mg, 3.61 µmol, 
60%) as a white amorphous solid. 
 
Rf = 0.40 (SiO2, CH2Cl2/MeOH 10:1); Optical rotation [𝛼]஽ଶହ = –43.0 (c = 0.10, CHCl3); 
FTIR ṽ/cm−1 2954, 2926, 2855, 2362, 2336, 1746, 1678, 1631, 1503, 1454, 1369, 1289, 1254, 
1141, 1035, 880, 755, 699; 1H NMR (400 MHz, CDCl3) δ/ppm 10.31 (br s, 1H), 7.25–7.16 
(m, 5H), 6.96 (br s, 1H), 6.47 (br s, 1H), 5.51 (s, 1H), 5.12 (d, J = 3.3 Hz, 1H), 4.94 (t, J = 
10.2 Hz, 1H), 4.60–4.49 (m, 2H), 4.44–4.27 (m, 5H), 4.09–3.96 (m, 3H), 3.91–3.82 (m, 1H), 
3.72 (ddd, J = 10.1, 4.4, 2.4 Hz, 2H), 3.52 (m, J = 10.7 Hz, 1H), 3.37–3.30 (m, 2H), 3.29 (s, 
3H), 3.26 (s, 3H), 3.16 (s, 3H), 3.11 (dd, J = 14.1, 3.6 Hz, 1H), 2.95 (dd, J = 14.1, 6.9 Hz, 
1H), 2.50–2.38 (m, 1H), 2.36–2.17 (m, 5H), 2.12–2.00 (m, 1H), 1.75–1.57 (m, 5H), 1.50 (s, 
18H), 1.32 (s, 3H), 1.29 (s, 3H), 0.91 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.6 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ/ppm 171.2, 170.5, 169.2, 136.7, 135.6 (HMBC), 129.9, 128.1, 126.7, 
119.4 (HSQC), 99.6, 99.3, 95.7, 93.9, 82.0 (HMBC), 79.5 (HMBC), 77.2 (HSQC), 69.7, 68.4, 
68.3, 68.2, 68.1, 62.2, 60.6, 56.2, 55.3, 52.2, 48.0, 47.8, 38.2, 36.2, 31.2, 29.8, 29.7, 28.9, 
28.6, 28.2, 27.9, 24.8, 20.7, 19.8, 17.9, 17.5, 15.8; HRMS ESI m/z calc. for C54H84ClN6O16 
[M+H]+: 1107.5627, found: 1107.5640. 
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Synthesis of A828A (2.1) 
To a solution of tetrapeptide 2.84 (1.80 mg, 
1.62 μmol,  1.0 eq.) in pyridine (0.5 mL) was added 
sulfur trioxide pyridine complex (12.8 mg, 
81.0 μmol,   50   eq.). The mixture was heated at 
50 °C for 15 h.  After cooling to room temperature, 
the pyridine was removed under reduced pressure. 
The crude residue was suspended in H2O (2 mL) 
and extracted with CH2Cl2 (4 x 3 mL). The 
combined organic layers were dried over Na2SO4 and the solvent was removed under reduced 
pressure to obtain sulfonated tetrapeptide 2.85 as an amorphous white solid, which was used 
for the next step without further purification. The crude sulfonated tetrapeptide 2.85 was 
dissolved in CH2Cl2 (1.5 mL) and TFA (0.15 mL) was added. After stirring for 5 h at room 
temperature, toluene (2 mL) was added and all volatiles were removed under reduced 
pressure. The crude product was purified by reversed phase HPLC (MeCN/H2O + 0.1% 
formic acid) to obtain aeruginosin 828A (2.1)   (996   μg,   1.16   μmol,   72%)   as   a   white  
amorphous solid.  
 
Optical rotation [𝛼]஽ଶହ = +23.9 (c = 0.023, MeOH); 1H NMR (600 MHz, DMSO-d6) δ/ppm 
8.51–8.41 (br s, 2H), 7.98 (t, J = 5.8 Hz, 1H), 7.67 (d, J = 9.6 Hz, 1H), 7.29–7.21 (m, 4H), 
7.21–7.15 (m, 1H), 5.99–5.93 (br s, 1H), 5.62 (s, 1H), 4.95 (m, 1H), 4.94 (d, J = 3.8 Hz, 2H), 
4.92 (pseudo-t, J = 10.0 Hz, 1H), 4.40 (d, J = 7.3 Hz, 1H), 4.32 (dt, J = 12.1, 6.3 Hz, 1H), 
4.21–4.14 (m, 2H), 4.11–4.04 (m, 4H), 3.99 (dd, J = 10.7, 1.8 Hz, 1H), 3.93 (ddd, J = 10.8, 
8.9, 5.9 Hz, 1H), 3.83 (s, 1H), 3.67 (dd, J = 10.8, 5.8 Hz, 1H), 3.58 (pseudo-td, J = 9.1, 2.4 
Hz, 1H), 3.36 (pseudo-t, J = 11.1 Hz, 1H), 3.28 (m, 1H), 3.29–3.22 (m, 1H), 3.21–3.12 (m, 
1H), 2.96 (dd, J = 13.9, 3.8 Hz, 1H), 2.82–2.77 (m, 1H), 2.29–2.22 (m, 2H), 2.19–2.10 (m, 
1H), 2.01 (dt, J = 12.3, 7.3 Hz, 1H), 1.80 (td, J = 12.7, 9.8 Hz, 1H), 1.70 (dsept, J = 6.3, 1.5 
Hz, 1H), 1.62–1.44 (m, 3H), 0.87 (d, J = 6.5 Hz, 3H), 0.86 (d, J = 6.6 Hz, 2H); 13C NMR 
(151 MHz, DMSO-d6, obtained from 2D NMR spectra) δ/ppm 172.3, 171.1, 167.3, 154.9, 
137.8, 135.9, 129.5, 127.7, 125.8, 119.0, 95.0, 74.7, 71.8, 71.4, 68.6, 68.4, 59.5, 59.3, 55.0, 
54.1, 53.6, 51.0, 39.8, 36.3, 35.6, 30.6, 28.4, 28.2, 27.4, 24.5, 20.6, 19.1, 15.3; HRMS ESI 
m/z calc. for C36H53ClN6O12SNa [M+Na]+: 851.3023, found: 851.3017. 
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Synthesis of A748A (2.12) 
Tetrapeptide 2.84 (2.10  mg,  1.90  μmol,  1.0  eq.)  was  
dissolved in CH2Cl2 (2.0 mL) before TFA (0.2 mL) 
was added. The solution was stirred for 7 h at room 
temperature. Toluene (2 mL) was added and all 
volatiles were removed under reduced pressure. 
The obtained crude product was purified by 
reversed phase HPLC (MeCN/H2O + 0.1% formic 
acid) to obtain aeruginosin 748A (2.12) (1.00 mg, 1.33 μmol,   70%)   as   a  white   amorphous  
solid. 
Optical rotation [𝛼]஽ଶହ = +61.0 (c = 0.050, MeOH); 1H NMR (600 MHz, DMSO-d6) δ/ppm
7.98 (t, J = 5.7 Hz, 1H), 7.71–7.57 (br s, 2H), 7.66 (d, J = 9.7 Hz, 1H), 7.28–7.21 (m, 4H), 
7.20–7.16 (m, 1H), 5.91 (s, 1H), 5.62 (d, J = 1.5 Hz, 1H), 4.96 (d, J = 3.8 Hz, 1H), 4.93 
(pseudo-t, J = 10.2 Hz, 1H), 4.33 (dt, J = 12.1, 6.3 Hz, 1H), 4.20–4.16 (m, 2H), 4.12–4.05 (m, 
4H), 4.00 (dd, J = 10.7, 1.9 Hz, 1H), 3.84 (s, 1H), 3.43 (pseudo-t, J = 8.6 Hz, 1H), 3.43–3.37 
(m, 1H), 3.35–3.28 (m, 2H), 3.28–3.21 (m, 2H), 3.20–3.13 (m, 1H), 2.96 (dd, J = 13.9, 3.8 
Hz, 1H), 2.79 (dd, J = 13.9, 7.4 Hz, 1H), 2.31–2.20 (m, 4H), 2.13 (ddt, J = 13.0, 9.4, 5.2 Hz, 
1H), 2.01 (dt, J = 12.0, 7.1 Hz, 1H), 1.81 (td, J = 12.8, 9.9 Hz, 1H), 1.71 (dsept, J = 6.6, 1.9 
Hz, 1H), 1.59 (pseudo-t, J = 12.9 Hz, 1H), 1.55–1.45 (m, 3H), 0.87 (d, J = 6.1 Hz, 3H), 0.86 
(d, J = 6.1 Hz, 3H); 13C NMR (151 MHz, DMSO-d6, obtained from 2D NMR spectra) δ/ppm
172.4, 171.1, 167.2, 137.8, 136.1, 129.4, 127.6, 125.8, 118.9, 95.2, 73.3, 71.8, 71.4, 69.8, 
68.6, 68.2, 61.7, 59.5, 54.9, 54.0, 53.7, 50.9, 39.7, 36.3, 35.6, 30.5, 28.4, 28.1, 27.3, 24.5, 
20.5, 19.1, 15.2; HRMS ESI m/z calc. for C36H54ClN6O9 [M+H]+: 749.3635, found:
749.3633. 
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Methyl (2S,3aS,6R,7aS)-6-(((2R,3R,4aR,5R,8R,8aS)-8-(benzoyloxy)-2,3-dimethoxy-2,3-
dimethylhexahydro-5H-pyrano[3,4-b][1,4]dioxin-5-yl)oxy)-1-(((R)-2-(methoxymethoxy)-
3-phenylpropanoyl)-D-leucyl)octahydro-1H-indole-2-carboxylate (2.86) 
Amine 2.72 (20.0 mg, 36.4 mmol, 1.0 eq.), Pla-Leu-OH 
dipeptide 2.53 (17.7 mg, 54.6 µmol, 1.5 eq.), NMM (8.0 µL, 
72.8 µmol, 2.0 eq.) and DMTMM (15.1 mg, 54.6 µmol, 
1.5 eq.) were dissolved in CH2Cl2 (0.8 mL) at 0 °C. The 
mixture was stirred for 30 min at 0 °C and further for 3 h at 
room temperature. The solvent was removed under reduced 
pressure and the crude product was purified by flash column 
chromatography (SiO2, pentane/EtOAc 1:1) to obtain a 4:1 rotameric mixture of tripeptide 
2.86 (18.1 mg, 21.0 µmol, 58%) as a white solid. 
 
Mp = 182.7–183.4 °C; Rf = 0.24 (SiO2, pentane/EtOAc 1:1); Optical rotation [𝛼]஽ଶହ = –65.1 
(c = 0.31, CHCl3); FTIR ṽ/cm−1 3411, 2953, 1726, 1643, 1513, 1450, 1368, 1270, 1140, 
1111, 1035, 917, 731; 1H NMR (400 MHz, CDCl3, major rotamer) δ/ppm 8.05–8.01 (m, 2H), 
7.59–7.42 (m, 1H), 7.47–7.40 (m, 2H), 7.25–7.18 (m, 5H), 6.97 (d, J = 9.4 Hz, 1H), 5.21–
5.09 (m, 2H), 4.82 (dt, J = 12.9, 6.5 Hz, 1H), 4.54–4.46 (m, 2H), 4.36–4.27 (m, 3H), 4.18 (dt, 
J = 11.8, 6.1 Hz, 1H), 4.04 (br s, 1H), 3.98 (dd, J = 10.7, 5.8 Hz, 1H), 3.90 (dd, J = 10.2, 3.5 
Hz, 1H), 3.67 (s, 3H), 3.55 (t, J = 10.6 Hz, 1H), 3.33 (s, 3H), 3.31 (s, 3H), 3.16 (dd, J = 14.0, 
3.4 Hz, 1H), 3.11 (s, 3H), 2.92 (dd, J = 14.0, 7.9 Hz, 1H), 2.55–2.44 (m, 2H), 2.37–2.13 (m, 
3H), 2.05–1.90 (m, 1H), 1.79–1.54 (m, 4H), 1.43–1.38 (m, 2H), 1.30 (s, 3H), 1.27 (s, 3H), 
0.92 (d, J = 5.9 Hz, 3H), 0.86 (d, J = 5.9 Hz, 3H); 13C NMR (101 MHz, CDCl3, major 
rotamer) δ/ppm 172.8, 170.6, 170.4, 165.8, 137.4, 133.2, 130.1, 129.9, 129.8, 128.5, 128.3, 
126.7, 99.9, 99.6, 95.9, 94.3, 77.7, 70.1, 69.7, 68.5, 66.7, 59.7, 59.4, 56.1, 54.6, 52.3, 48.2, 
48.1, 47.9, 42.6, 39.1, 37.3, 30.4, 29.6, 24.9, 24.8, 23.6, 22.9, 20.0, 18.0, 17.8; HRMS ESI 
m/z calc. for C45H62N2O14Na [M+Na]+: 877.4093, found: 877.4102. 
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(2S,3aS,6R,7aS)-6-(((2R,3R,4aR,5R,8R,8aS)-8-Hydroxy-2,3-dimethoxy-2,3-dimethyl-
hexahydro-5H-pyrano[3,4-b][1,4]dioxin-5-yl)oxy)-1-(((R)-2-(methoxymethoxy)-3-
phenylpropanoyl)-D-leucyl)octahydro-1H-indole-2-carboxylic acid (2.87) 
Tripeptide 2.86 (14.0 mg, 16.4 µmol, 1.0 eq.) was dissolved in 
THF/H2O (5:3, 4 mL) before LiOH monohydrate (17.6 mg, 
0.420 mmol, 26 eq.) was added. The reaction was stirred for 
12 h at room temperature, H2O (2.5 mL) was added and the 
THF was removed under reduced pressure. Aq. citric acid 
solution (5% w/w, 6 mL) was added and extracted with 
CH2Cl2 (3 x 10 mL). The combined organic layers were dried 
over Na2SO4 and the solvent was removed under reduced pressure. The crude residue was 
purified by flash column chromatography (SiO2, CH2Cl2/MeOH 15:1 changing to 5:1) to 
obtain a 10:1 rotameric mixture of acid 2.87 (11.5 mg, 15.6 µmol, 95%) as a colorless solid. 
 
Mp = 132.5–135.1 °C; Rf = 0.28 (SiO2, CH2Cl2/MeOH 15:1); Optical rotation [𝛼]஽ଶହ = –28.3 
(c = 0.17, CHCl3); FTIR ṽ/cm−1 3413, 2956, 2929, 1737, 1633, 1520, 1260, 1138, 1094, 
1032, 915, 802, 732; 1H NMR (400 MHz, CDCl3, major rotamer) δ/ppm 7.25–7.18 (m, 5H), 
6.97 (d, J = 9.0 Hz, 1H), 5.04 (d, J = 3.5 Hz, 1H), 4.90–4.82 (m, 1H), 4.55 (d, J = 6.7 Hz, 
1H), 4.52–4.46 (m, 2H), 4.30 (dd, J = 7.3, 3.6 Hz, 1H), 4.24 (dt, J = 11.4, 5.6 Hz, 1H), 4.03 
(br s, 1H), 4.00–3.93 (m, 1H), 3.86 (td, J = 9.8, 9.4, 5.6 Hz, 1H), 3.74–3.69 (m, 2H), 3.53 (t, 
J = 10.7 Hz, 1H), 3.29 (s, 3H), 3.28 (s, 3H), 3.16 (s, 3H), 3.13–3.10 (m, 1H), 2.92 (dd, J = 
14.0, 7.4 Hz, 1H), 2.56–2.46 (m, 1H), 2.43–2.35 (m, 2H), 2.27–2.08 (m, 3H), 1.80–1.57 (m, 
4H), 1.45–1.34 (m, 3H), 1.32 (s, 3H), 1.28 (s, 3H), 0.89 (d, J = 6.0 Hz, 3H), 0.86 (d, J = 6.2 
Hz, 3H); 13C NMR (101 MHz, CDCl3, major rotamer) δ/ppm 176.1, 173.7, 170.8, 137.1, 
129.9, 128.3, 99.9, 99.5, 96.1, 95.0, 77.8, 70.0, 69.9, 68.3, 68.3, 62.4, 59.8, 56.2, 56.0, 48.3, 
48.1, 48.0, 42.1, 38.9, 36.0, 29.9, 28.2, 24.8, 24.6, 23.5, 22.8, 19.9, 18.0, 17.8; HRMS ESI 
m/z calc. for C37H56N2O13Na [M+Na]+: 759.3675, found: 759.3688. 
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tert-Butyl ((Z)-((tert-butoxycarbonyl)imino)(3-(2-((2S,3aS,6R,7aS)-6-(((2R,3R,4aR,5R,8R, 
8aS)-8-hydroxy-2,3-dimethoxy-2,3-dimethylhexahydro-5H-pyrano[3,4-b][1,4]dioxin-5-
yl)oxy)-1-(((R)-2-(methoxymethoxy)-3-phenyl-propanoyl)-D-leucyl)octahydro-1H-indole-
2-carboxamido)ethyl)-2,5-dihydro-1H-pyrrol-1-yl)methyl)carbamate (2.88) 
Adc subunit 2.63 (4.00 mg, 5.43 µmol, 
1.0 eq.) and acid 2.87 (3.85 mg, 10.9 µmol, 
2.0 eq.) were dissolved in CH2Cl2 (0.6 mL). 
At 0 °C, 2,6-lutidine (2.0 µL, 17.2 µmol, 
3.2 eq.) and PyBOP (4.24 mg, 8.15 µmol, 
1.5 eq.) were added and the mixture was 
stirred for 20 min at 0 °C and further 4.5 h at 
room temperature. The mixture was diluted with CH2Cl2 (2 mL) and washed with sat. aq. 
NaHCO3 solution (2 mL) and brine (2 mL). The organic layer was dried over Na2SO4 and the 
solvent was removed under reduced pressure. The crude residue was purified by flash column 
chromatography (SiO2, CH2Cl2/MeOH 30:1 changing to 20:1) to obtain a 7:1 rotameric 
mixture of tetrapeptide 2.88 (3.70 mg, 3.45 µmol, 64%) as an amorphous colorless solid. 
 
Rf = 0.15 (SiO2, CH2Cl2/MeOH 20:1); Optical rotation [𝛼]஽ଶହ = –92.7 (c = 0.19, CHCl3); 
FTIR ṽ/cm−1 3348, 2957, 2929, 1747, 1640, 1453, 1369, 1288, 1140, 1034, 938, 846, 801; 
1H NMR (400 MHz, CDCl3, major rotamer) δ/ppm 10.21 (br s, 1H), 7.25–7.19 (m, 5H), 6.95 
(t, J = 5.7 Hz, 1H), 6.85 (d, J = 7.2 Hz, 1H), 5.50 (br s, 1H), 4.94 (d, J = 3.5 Hz, 1H), 4.59 (d, 
J = 6.7 Hz, 1H), 4.55–4.50 (m, 2H), 4.42 (t, J = 8.7 Hz, 1H), 4.36 (br s, 1H), 4.31 (br s, 1H), 
4.25 (dd, J = 7.6, 3.7 Hz, 1H), 4.13 (dt, J = 11.9, 5.9 Hz, 1H), 4.02 (br s, 1H), 3.96 (t, J = 9.6 
Hz, 1H), 3.85 (td, J = 9.7, 9.2, 5.5 Hz, 1H), 3.75–3.64 (m, 2H), 3.55 (t, J = 10.7 Hz, 1H), 3.41 
(td, J = 6.9, 3.4 Hz, 1H), 3.38–3.31 (m, 2H), 3.28 (s, 3H), 3.26 (s, 3H), 3.15 (s, 3H), 3.15–
3.10 (m, 1H), 2.92 (dd, J = 14.0, 7.6 Hz, 1H), 2.49–2.40 (m, 1H), 2.38–2.31 (m, 1H), 2.28–
2.24 (m, 2H), 2.22–2.10 (m, 3H), 2.02–1.93 (m, 1H), 1.77–1.72 (m, 1H), 1.65–1.55 (m, 4H), 
1.49 (s, 18H), 1.45–1.36 (m, 3H), 1.32 (s, 3H), 1.28 (s, 3H), 0.90 (t, J = 5.4 Hz, 6H); 
13C NMR (101 MHz, CDCl3, major rotamer) δ/ppm 171.9, 171.7, 171.4, 137.1, 136.0, 129.9, 
128.3, 126.8, 119.2, 99.9, 99.5, 96.1, 95.8, 83.2, 80.5, 77.9, 71.5, 70.0, 68.4, 68.3, 62.5, 60.2, 
59.5, 57.5, 56.2, 55.8, 55.4, 49.6, 48.1, 48.0, 41.3, 39.1, 37.6, 36.8, 30.2, 29.9, 28.3, 24.9, 
24.7, 23.6, 22.7, 20.1, 18.1, 17.8; HRMS ESI m/z calc. for C54H85N6O16 [M+H]+: 1073.6017, 
found: 1073.6032. 
EXPERIMENTAL PART 
 
 
 
 208
 
Synthesis of A126A (2.11) 
Tetrapeptide 2.88 (2.68 mg, 2.50  μmol,  1.0  eq.)  was  
dissolved in CH2Cl2 (2 mL) before TFA (0.2 mL) 
was added. The solution was stirred for 7 h at room 
temperature. Toluene (2 mL) was added and all 
volatiles were removed under reduced pressure. The 
obtained crude product was purified by reversed 
phase HPLC (MeCN/H2O + 0.1% formic acid) to 
obtain a 3.5:1 rotameric mixture of aeruginoside 126A (2.11) (1.30 mg, 1.82 μmol,  73%)  as  a  
white amorphous solid.  
 
Optical rotation [𝛼]஽ଶହ  = +39.1 (c = 0.070, MeOH); 1H NMR (600 MHz, DMSO-d6, major 
rotamer) δ/ppm 7.85 (t, J = 5.7 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.29–7.14 (m, 5H), 5.62 (s, 
1H), 4.83 (d, J = 3.7 Hz, 1H), 4.60–4.53 (m, 1H), 4.20–4.02 (m, 4H), 3.43–3.38 (m, 2H), 
3.37–3.32 (m, 1H), 3.30–3.25 (m, 1H), 3.23 (dd, J = 9.6, 3.4 Hz, 1H), 3.22–3.16 (m, 1H), 
2.99 (dd, J = 13.8, 3.7 Hz, 1H), 2.74 (dd, J = 13.8, 7.7 Hz, 1H), 2.33–2.23 (m, 4H), 2.15–2.07 
(m, 1H), 2.03 (dt, J = 12.2, 7.6 Hz, 1H), 1.84–1.75 (m, 1H), 1.66–1.54 (m, 2H), 1.54–1.44 (m, 
1H), 1.44–1.34 (m, 2H), 1.33–1.19 (m, 1H), 0.87 (d, J = 6.3 Hz, 3H), 0.82 (d, J = 6.2 Hz, 3H); 
13C NMR (151 MHz, DMSO-d6, major rotamer, obtained from 2D NMR spectra) δ/ppm 
172.2, 170.8, 137.7, 129.3, 127.6, 125.7, 119.0, 96.4, 73.2, 71.7, 71.5, 70.0, 69.8, 62.0, 59.7, 
54.9, 53.7, 53.7, 47.8, 41.2, 39.9, 36.3, 35.8, 30.4, 29.1, 28.1, 24.2 (2C), 23.3, 21.6, 19.3; 
HRMS ESI m/z calc. for C36H55N6O9 [M+H]+: 715.4025, found: 715.4026. 
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Synthesis of A794A (2.13) 
Sulfur trioxide pyridine complex (20.1 mg, 
126 μmol,   50 eq.) was added to a solution of 
tetrapeptide 2.88 (2.70 mg,   2.52   μmol,   1.0   eq)   in  
pyridine (0.6 mL). The mixture was heated at 50 °C 
for 15 h.  After cooling to room temperature, the 
pyridine was removed under reduced pressure. The 
crude residue was suspended in H2O (2 mL) and 
extracted with CH2Cl2 (4 x 3 mL). The combined 
organic layers were dried over Na2SO4 and the solvent was removed under reduced pressure 
to obtain sulfonated tetrapeptide 2.89 as an amorphous white solid, which was used for the 
next step without further purification. The crude sulfonated tetrapeptide 2.89 was dissolved in 
CH2Cl2 (2 mL) and TFA (0.2 mL) was added. After stirring for 7 h at room temperature, 
toluene (2 mL) was added and all volatiles were removed under reduced pressure. The crude 
product was purified by reversed phase HPLC (MeCN/H2O + 0.1% formic acid) to obtain a 
4:1 rotameric mixture of aeruginosin 794A (2.13) (1.50 mg, 1.89 μmol, 75%) as a white 
amorphous solid.  
 
Optical rotation [𝛼]஽ଶହ = +17.6 (c = 0.042, MeOH); 1H NMR (600 MHz, DMSO-d6, major 
rotamer) δ/ppm 7.81 (t, J = 5.8 Hz, 1H), 7.69–7.53 (br s, 2H), 7.53 (d, J = 8.2 Hz, 1H), 7.29–
7.15 (m, 5H), 5.61 (s, 1H), 5.41, (s, 1H), 4.81 (d, J = 3.7 Hz, 1H), 4.54 (td, J = 8.8, 4.4 Hz, 
1H), 4.19–4.02 (m, 7H), 3.93 (ddd, J = 10.6, 8.9, 5.8 Hz, 1H), 3.84 (br s, 1H), 3.68 (dd, J = 
10.8, 5.8 Hz, 1H), 3.57 (pseudo-t, J = 9.2 Hz, 1H), 3.40 (pseudo-t, J = 10.8 Hz, 1H), 3.27 (dd, 
J = 9.5, 3.6 Hz, 1H), 3.21–3.17 (m, 1H), 2.99 (dd, J = 13.7, 3.5 Hz, 1H), 2.73 (dd, J = 13.7, 
7.8 Hz, 1H), 2.34–2.19 (m, 3H), 2.13–2.07 (m, 1H), 2.02 (ddd, J = 12.4, 7.4, 7.4 Hz, 1H), 
1.82–1.71 (m, 1H), 1.63–1.56 (m, 1H), 1.41–1.35 (m, 1H), 1.31–1.20 (m, 2H), 0.86 (d, J = 6.0 
Hz, 3H), 0.82 (d, J = 6.3 Hz, 3H); 13C NMR (151 MHz, DMSO-d6, major rotamer, obtained 
from 2D NMR spectra) δ/ppm 172.9, 172.6, 171.2, 138.1, 136.1, 129.3, 127.6, 125.8, 119.0, 
96.2, 74.7, 71.8, 71.6, 71.4, 70.2, 59.6, 59.5, 54.9, 53.7, 53.0, 47.9, 41.2, 40.0, 36.3, 35.8, 
30.4, 29.1, 28.2, 24.2, 23.7, 23.1, 21.6, 19.2; HRMS ESI m/z calc. for C36H54N6O12SNa 
[M+Na]+: 817.3413, found: 817.3408. 
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2.1.7.  Synthesis of Aeruginosin 616A 
 
Methyl (2S,3aS,6R,7aS)-6-acetoxyoctahydro-1H-indole-2-carboxylate (2.92) 
L-Choi-Cbz derivative 2.37 (151 mg, 0.401 mmol, 1.0 eq.) and Pd/C 
(31.3 mg, 29.4 μmol, 0.070 eq.) were suspended in MeOH (7.5 mL). 
The mixture was stirred for 3.5 h at room temperature under an 
atmosphere of H2. The catalyst was filtered off over Celite® and the crude product was 
purified by flash column chromatography (SiO2, CH2Cl2/MeOH 20:1) to obtain L-Choi-H 
derivative 2.92 (73.9 mg, 0.306 mmol, 76%) as a colorless oil. 
 
Rf = 0.29 (SiO2, CH2Cl2/MeOH 20:1); Optical rotation [𝛼]஽ଶହ = ‒39.9 (c = 0.49, CHCl3); 
FTIR ṽ/cm−1 3350, 2945, 2864, 1731, 1437, 1365, 1243, 1031, 921, 839, 627; 1H NMR 
(400 MHz, CDCl3) δ/ppm 4.99 (tt, J = 8.5, 4.0 Hz, 1H), 3.80 (dd, J = 10.3, 5.7 Hz, 1H), 3.73 
(s, 3H), 3.33 (q, J = 5.0 Hz, 1H), 2.25–2.17 (m, 1H), 2.11 (d, J = 6.5 Hz, 1H), 2.05–2.03 (m, 
1H), 2.02 (s, 3H), 2.01–1.99 (m, 1H), 1.86–1.79 (m, 1H), 1.76–1.68 (m, 2H), 1.66–1.60 (m, 
1H), 1.44–1.35 (m, 2H); 13C NMR (101 MHz, CDCl3) δ/ppm 175.8, 170.6, 69.7, 58.5, 58.1, 
52.3, 37.3, 35.3, 32.9, 29.3, 25.0, 21.5; HRMS ESI m/z calc. for C12H20NO4 [M+H]+: 
242.1387, found: 242.1389. 
 
Methyl (2S,3aS,6R,7aS)-6-acetoxy-1-((2S,3R)-3-chloro-2-((R)-2-(methoxymethoxy)-3-
phenylpropanamido)-4-methylpentanoyl)octahydro-1H-indole-2-carboxylate (2.93) 
L-Choi derivative 2.92 (13.0 mg, 53.9 µmol, 1.0 eq.) and Pla-Cleu-OH 
dipeptide 2.47 (25.1 mg, 70.1 µmol, 1.3 eq.) were dissolved in CH2Cl2 
(1 mL) and cooled to 0 °C. DMTMM (19.4 mg, 70.1 µmol, 1.3 eq.) 
and NMM (11.9 PL, 0.108 mmol, 2.0 eq.) were added to the solution. 
The reaction mixture was stirred for 20 min at 0 °C and further for 2 h 
at room temperature. The solvent was removed under reduced 
pressure and the crude residue was directly purified by flash column 
chromatography (SiO2, pentane/EtOAc 1:1) to give tripeptide 2.93 (26.0 mg, 45.0 µmol, 83%) 
as a colorless oil. 
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Rf = 0.30 (SiO2, pentane/EtOAc 1:1); Optical rotation [𝛼]஽ଶହ = +23.4 (c = 0.50, CHCl3); 
FTIR ṽ/cm−1 3405, 3342, 2956, 2931, 2362, 1740, 1685, 1650, 1579, 1505, 1440, 1365, 1311, 
1251, 1198, 1177, 1152, 1100, 1019, 919, 820, 751, 702; 1H NMR (400 MHz, CDCl3) δ/ppm 
7.29–7.19 (m, 5H), 7.04 (d, J = 9.9 Hz, 1H), 5.08 (s, 1H), 4.98 (t, J = 10.4 Hz, 1H), 4.57–4.53 
(m, 1H), 4.46–4.37 (m, 1H), 4.39–4.33 (m, 2H), 3.83 (dd, J = 10.8, 1.9 Hz, 1H), 3.66 (s, 3H), 
3.19 (s, 3H), 3.14 (dd, J = 14.1, 3.7 Hz, 1H), 2.99 (dd, J = 14.1, 6.6 Hz, 1H), 2.51–2.41 (m, 
1H), 2.36–2.29 (m, 1H), 2.27–2.15 (m, 1H), 2.08 (s, 3H), 2.05–1.90 (m, 2H), 1.84 (d, J = 
14.9 Hz, 1H), 1.71 (ddd, J = 14.5, 11.7, 2.5 Hz, 1H), 1.66–1.56 (m, 2H), 1.56–1.44 (m, 2H), 
0.94 (d, J = 6.5 Hz, 3H), 0.88 (d, J = 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ/ppm 172.4, 
170.8, 170.2, 168.5, 136.8, 130.1, 128.3, 126.8, 95.7, 77.1, 69.3, 68.6, 58.8, 56.3, 54.9, 52.3, 
51.7, 38.3, 36.5, 31.2, 30.7, 28.2, 23.2, 21.3, 20.9, 19.8, 15.0; HRMS ESI m/z calc. for 
C29H41ClN2O8Na [M+Na]+: 603.2444, found: 603.2451. 
 
(2S,3aS,6R,7aS)-1-((2S,3R)-3-Chloro-2-((R)-2-(methoxymethoxy)-3-phenylpropan-
amido)-4-methylpentanoyl)-6-hydroxyoctahydro-1H-indole-2-carboxylic acid (2.94) 
Tripeptide 2.93 (5.81 mg, 10.0 µmol, 1.0 eq.) was dissolved in 
THF/H2O (5:3, 2 mL). To this solution was added LiOH monohydrate 
(8.40 mg, 0.200 mmol, 20 eq.) and the reaction mixture was stirred for 
12 h at room temperature. The reaction mixture was acidified with aq. 
citric acid solution (5% w/w, 3 mL) to a pH of around 3. The THF was 
removed under reduced pressure and the residue was extracted with 
CH2Cl2 (3 x 5 mL). The combined organic layers were washed with H2O 
(5 mL), dried over MgSO4 and the solvent removed under reduced pressure. The crude 
residue was purified by flash column chromatography (SiO2, CH2Cl2/MeOH 10:1) to give 
tripeptide 2.94 (4.00 mg, 8.00 µmol, 76%) as a colorless solid. 
 
FTIR ṽ/cm−1 3395, 2948, 2924, 2853, 1736, 1634, 1517, 1455, 1368, 1333, 1259, 1187, 1149, 
1098, 1079, 1033, 1014, 909, 874, 801, 730, 700, 648, 615, 492; 1H NMR (400 MHz, CDCl3) 
δ/ppm 7.30–7.20 (m, 5H), 7.11 (d, J = 10.1 Hz, 1H), 5.09 (t, J = 10.5 Hz, 1H), 4.59 (q, J = 
6.8 Hz, 2H), 4.55–4.49 (m, 2H), 4.39 (dd, J = 6.1, 3.9 Hz, 1H), 4.15 (s, 1H), 3.92 (dd, J = 
10.8, 1.9 Hz, 1H), 3.22 (s, 3H), 3.14 (dd, J = 14.2, 3.8 Hz, 1H), 3.01 (dd, J = 14.2, 6.1 Hz, 
1H), 2.47–2.32 (m, 2H), 2.25–2.05 (m, 2H), 1.71–1.53 (m, 3H), 1.50–1.43 (m, 1H), 1.45–1.33 
(m, 1H), 0.89 (d, J = 3.9 Hz, 3H), 0.87 (d, J = 4.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) 
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δ/ppm 172.6, 171.0, 170.8, 136.4, 130.1, 128.4, 127.0, 95.9, 67.8, 65.7, 59.4, 56.3, 56.1, 51.9, 
38.1, 35.8, 34.1, 29.0, 28.0, 25.7, 20.8, 19.1, 15.3; HRMS ESI m/z calc. for C26H38ClN2O7 
[M+H]+: 525.2362, found: 525.2365. 
 
tert-Butyl ((E)-((tert-butoxycarbonyl)imino)(3-(2-((2S,3aS,6R,7aS)-1-((2S,3R)-3-chloro-2-
((R)-2-(methoxymethoxy)-3-phenylpropanamido)-4-methylpentanoyl)-6-hydroxyocta 
hydro-1H-indole-2-carboxamido)ethyl)-2,5-dihydro-1H-pyrrol-1-yl)methyl)carbamate 
(2.95) 
To a solution of tripeptide 2.94 (2.99 mg, 57.0 µmol, 
1.0 eq.) and Adc subunit 2.63 (2.63 mg, 74.0 µmol, 
1.3 eq.) in CH2Cl2 (0.4 mL) were added PyBOP 
(3.86 mg, 74.0 µmol, 1.3 eq.) and 2,6-lutidine (2.0 PL, 
17.1 µmol, 3.0 eq.) at 0 °C. The reaction mixture was 
stirred for 20 min at 0 °C and further for 5 h at room 
temperature. CH2Cl2 (3 mL) was added and the organic 
layer was washed with sat. aq. NaHCO3 solution (1 mL) 
and brine (1 mL). The organic layer was dried over Na2SO4 and the solvent was removed 
under reduced pressure. The crude residue was purified by flash column chromatography 
(SiO2, CH2Cl2/MeOH 30:1) to give tetrapeptide 2.95 (2.50 mg, 3.00 µmol, 51%) as a white 
amorphous solid. 
 
FTIR ṽ/cm−1 3334, 3034, 2971, 2931, 1746, 1673, 1633, 1512, 1454, 1392, 1369, 1285, 1251, 
1235, 1149, 1051, 1037, 1016, 920, 841, 732, 701; 1H NMR (400 MHz, CDCl3) δ/ppm 10.35 
(br s, 1H), 7.30–7.20 (m, 5H), 7.09 (br s, 1H), 6.70 (br s, 1H), 5.51 (s, 1H), 4.99 (t, J = 10.2 
Hz, 1H), 4.59–4.54 (m, 2H), 4.51–4.38 (m, 5H), 4.37–4.32 (m, 1H), 4.16 (s, 1H), 3.94 (d, J = 
10.7 Hz, 1H), 3.33 (dd, J = 12.2, 6.0 Hz, 1H), 3.21 (s, 3H), 3.13 (dd, J = 14.1, 3.7 Hz, 1H), 
2.98 (dd, J = 14.1, 6.5 Hz, 1H), 2.33 (d, J = 26.3 Hz, 3H), 2.19–2.04 (m, 3H), 1.77–1.57 (m, 
4H), 1.50 (s, 18H), 0.90 (s, 3H), 0.89 (s, 3H); HRMS ESI m/z calc. for C43H65ClN5O11 
[M+H]+: 861.4523, found: 861.4524. 
Due to stability problems related to the partial cleavage of the Boc protection groups in the 
NMR tube, no 13C NMR spectrum could be measured.  
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Synthesis of A616A (2.91) 
Tetrapeptide 2.95 (2.50 mg, 3.00 µmol, 1.0 eq.) was 
dissolved in CH2Cl2 (2 mL) before TFA (0.2 mL) was 
added. The solution was stirred for 8 h at room 
temperature. Toluene (2 mL) was added and all volatiles 
were removed under reduced pressure. The obtained 
residue was dissolved in H2O (2 mL). To this solution 
K2CO3 (0.500 mg, 3.60 mmol, 1.2 eq.) was added and the 
reaction mixture was stirred for 30 min at room 
temperature. The H2O was removed under reduced pressure and the obtained crude product 
was purified by reversed phase HPLC (MeCN/H2O + 0.1% formic acid) to obtain aeruginosin 
616A (2.91) (0.800 mg, 1.30 μmol,  45%)  as  a  white  solid. 
 
1H NMR (600 MHz, DMSO-d6) δ/ppm 8.00 (br s, 1H), 7.95 (t, J = 5.7 Hz, 1H), 7.55 (d, J = 
9.4 Hz, 1H), 7.27–.16 (m, 6H), 6.04 (s, 1H), 5.61 (s, 1H), 4.89 (t, J = 10.1 Hz, 1H), 4.53–4.49 
(m, 1H), 4.27 (dt, J = 12.3, 6.3 Hz, 1H), 4.19 (s, 1H), 4.17 (dd, J = 10.1, 8.0 Hz, 1H), 4.07 (s, 
4H), 3.94 (dd, J = 10.8, 1.8 Hz, 1H), 3.89 (s, 1H), 3.24 (dq, J = 13.0, 6.7 Hz, 1H), 3.17 (td, 
J = 12.8, 6.4 Hz, 1H), 2.96 (dd, J = 13.9, 3.9 Hz, 1H), 2.82 (dd, J = 13.8, 6.9 Hz, 1H), 2.29–
2.16 (m, 3H), 2.07–1.95 (m, 3H), 1.83–1.76 (m, 1H), 1.68–1.59 (m, 2H), 1.48–1.38 (m, 3H), 
0.85 (dd, J = 6.7, 2.2 Hz, 7H); 13C NMR (151 MHz, DMSO-d6, obtained from 2D NMR 
spectra) δ/ppm 172.1, 171.0, 167.5, 137.8, 136.1, 129.7, 127.8, 126.1, 119.3, 71.6, 69.0, 63.8, 
59.8, 54.7, 55.1, 53.9, 51.0, 40.0, 36.5, 35.9, 33.2, 30.8, 28.4, 27.6, 26.1, 20.6, 18.9, 15.1; 
HRMS ESI m/z calc. for C31H46ClN6O5 [M+H]+: 617.3213, found: 617.3217. 
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2.1.8.  Alternative Approaches – Synthesis of Aeruginosin 828B 
2,2,2-Trichloroethyl sulfurochloridate (2.99) 
2,2,2-Trichloroethanol (2.98) (2.33 mL, 23.9 mmol, 1.0 eq.) and pyridine 
(1.93 mL, 23.9 mmol, 1.0 eq.) were dissolved in Et2O (40 mL) and cooled to 
−78 °C. To this mixture sulfuryl chloride (2.0 mL, 23.9 mmol, 1.0 eq.) was added 
over a period of 1 h and the mixture stirred for an additional hour at –78 °C. The 
mixture was allowed to reach room temperature and was stirred for further 3 h. The white 
precipitate was filtered off and the solvent removed from the filtrate, to give 
2,2,2-trichloroethyl sulfurochloridate (2.99) (5.06 g, 20.4 mmol, 85%) as a colorless oil.  
 
1H NMR (400 MHz, CDCl3) δ/ppm 4.92 (s, 2H); 13C NMR (101 MHz, CDCl3) δ/ppm 91.4, 
81.3. 
Analytical data are in accordance with those reported in the literature.[11] 
 
2,2,2-Trichloroethyl 1H-imidazole-1-sulfonate (2.100) 
A solution of 2,2,2-trichloroethyl sulfurochloridate (2.99) (1.86 g, 7.50 mmol, 
1.0 eq.) in THF (1 mL) was added dropwise to a solution of imidazole (1.00 g, 
15.0 mmol, 2.0 eq.) in THF (2.5 mL) at 0 °C. The reaction mixture was stirred 
for 1 h at 0 °C and further for 1 h at room temperature. The obtained 
precipitate was filtered off and the solvent removed from the filtrate. The obtained crude 
residue was purified by flash column chromatography (SiO2, pentane/EtOAc 2:1) to give 
2,2,2-trichloroethyl 1H-imidazole-1-sulfonate (2.100) (1.40 g, 5.01 mmol, 67%) as a colorless 
solid.  
 
1H NMR (400 MHz, CDCl3) δ/ppm 8.10–7.96 (m, 1H), 7.45–7.37 (m, 1H), 7.24–7.19 (m, 
1H), 5.01–4.30 (m, 2H); 13C NMR (101 MHz, CDCl3) δ/ppm 137.1, 131.8, 118.2, 91.8, 80.3. 
Analytical data are in accordance with those reported in the literature.[11] 
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3-Methyl-1-((2,2,2-trichloroethoxy)sulfonyl)-1H-imidazol-3-ium triflate (2.96) 
To a solution of 2,2,2-trichloroethyl 1H-imidazole-1-sulfonate (2.100) 
(1.06 g, 3.79 mmol, 1.0 eq.) in Et2O (14 mL) at 0 °C was added dropwise 
methyl triflate (0.50 mL, 4.29 mmol, 1.1 eq.). The reaction was stirred for 
3 h at 0 °C during which time a white precipitate was formed. The precipitate was filtered off 
and washed with ice cold Et2O (2 x 10 mL) to give triflate salt 2.96 (1.50 g, 3.38 mmol, 89%) 
as a colorless solid. 
 
1H NMR (400 MHz, MeOD) δ/ppm 10.12–9.85 (m, 1H), 8.47–8.24 (m, 1H), 8.03–7.74 (m, 
1H), 5.43–5.37 (m, 2H), 4.05 (s, 3H); 13C NMR (101 MHz, MeOD) δ/ppm 141.2, 127.3, 
122.3, 93.0, 83.5, 37.8. The triflate 13C signal was not resolved. 
Analytical data are in accordance with those reported in the literature.[11] 
 
(4aR,5S,8R,8aS)-2,3-Dimethoxy-2,3-dimethyl-5-(phenylthio)hexahydro-5H-pyrano[3,4-
b][1,4]dioxin-8-ol (2.101) 
Thioxyloside 2.69 (330 mg, 0.717 mmol, 1.0 eq.) was suspended in MeOH 
(3 mL) and subsequently dissolved in CH2Cl2 (4 mL). NaOMe (79.1 mg, 
1.46 mmol, 2.0 eq.) was added and the mixture was stirred for 2 h at room 
temperature. The solvents were removed under reduced pressure and the obtained residue was 
dissolved in CH2Cl2 (20 mL). The solution was washed with sat. aq. NH4Cl solution (20 mL), 
dried over Na2SO4 and the solvent was removed under reduced pressure. The crude product 
was purified by flash column chromatography (SiO2, pentane/EtOAc 3:1 changing to 2:1) to 
obtain alcohol 2.101 (212 mg, 0.595 mmol, 83%) as a colorless solid. 
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Mp = 164.6–165.7 °C; Rf = 0.26 (SiO2, pentane/EtOAc 2:1); Optical rotation [𝛼]஽ଶହ = ‒161.5 
(c = 0.79, CHCl3); FTIR ṽ/cm−1 3502, 2924, 2852, 1584, 1454, 1375, 1304, 1219, 1134, 
1107, 1068, 1006, 922, 879, 849, 741, 692; 1H NMR (400 MHz, CDCl3) δ/ppm 7.54–7.49 (m, 
2H), 7.33–7.21 (m, 3H), 4.76 (d, J = 9.4 Hz, 1H), 4.12 (dd, J = 11.3, 5.4 Hz, 1H), 3.96–3.84 
(m, 1H), 3.69 (t, J = 9.2 Hz, 1H), 3.60 (t, J = 9.5 Hz, 1H), 3.31–3.27 (m, 4H), 3.22 (s, 3H), 
2.23 (d, J = 2.9 Hz, 1H), 1.34 (d, J = 1.4 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ/ppm 133.4, 
131.9, 129.0, 127.6, 100.4, 99.8, 86.1, 75.0, 69.8, 68.1, 67.4, 48.3, 48.1, 17.80, 17.76; 
HRMS ESI m/z calc. for C17H24O6SNa [M+Na]+: 379.1186, found: 379.1191. 
 
(4aR,5S,8R,8aR)-2,3-Dimethoxy-2,3-dimethyl-5-(phenylthio)hexahydro-5H-pyrano[3,4-
b][1,4]dioxin-8-yl (2,2,2-trichloroethyl) sulfate (2.102) 
Alcohol 2.101 (200 mg, 0.584 mmol, 1.0 eq.) and triflate salt 2.96 
(519 mg, 1.17 mmol, 2.0 eq.) were dissolved in THF (6 mL). 
1-Methylimidazole (0.12 mL, 1.51 mmol, 2.6 eq.) was added at 0 °C 
and the mixture stirred for 66 h at room temperature. The solvent 
was removed under reduced pressure before H2O (50 mL) and EtOAc (50 mL) were added. 
The layers were separated and the organic layer was washed with sat. aq. NaHCO3 solution 
(30 mL) and brine (30 mL). The organic layer was dried over Na2SO4 and the solvent was 
removed under reduced pressure. The crude product was purified by flash column 
chromatography (SiO2, pentane/EtOAc 6:1 changing to 2:1) to obtain sulfate ester 2.102 
(293 mg, 0.516 mmol, 88%) as a colorless sticky oil. 
 
Rf = 0.79 (SiO2, pentane/EtOAc 4:1); Optical rotation [𝛼]஽ଶହ =  ‒168.1   (c = 0.49, CHCl3); 
FTIR ṽ/cm−1 2996, 2956, 1585, 1416, 1205, 1140, 1046, 1058, 1012, 964, 884, 774, 729, 
692; 1H NMR (400 MHz, CDCl3) δ/ppm 7.55–7.50 (m, 2H), 7.35–7.26 (m, 3H), 4.95 (d, J = 
10.5 Hz, 1H), 4.80–4.72 (m, 3H), 4.42 (dd, J = 11.8, 5.4 Hz, 1H), 3.97 (t, J = 9.6 Hz, 1H), 
3.69 (t, J = 9.7 Hz, 1H), 3.55 (dd, J = 11.9, 9.3 Hz, 1H), 3.30 (s, 3H), 3.23 (s, 3H), 1.35 (s, 
3H), 1.33 (s, 3H); 13C NMR (101 MHz, CDCl3) δ/ppm 132.6, 132.2, 129.1, 127.9, 100.5, 
100.2, 92.5, 86.0, 79.6, 78.4, 71.2, 68.1, 66.7, 48.4, 48.2, 17.6, 17.5; UPLC ESI m/z calc. for 
C19H25Cl3O9S2Na [M+Na]+: 589.0, found: 589.0. 
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(3R,4R,5R,6S)-4,5-Dihydroxy-6-(phenylthio)tetrahydro-2H-pyran-3-yl (2,2,2-trichloro-
ethyl) sulfate (2.103) 
BDA protected thioxyloside 2.102 (20.0 mg, 35.2 µmol, 1.0 eq.) was 
dissolved in CH2Cl2 (0.55 mL), TFA (0.05 mL) was added and the 
mixture stirred for 20 h at room temperature. Toluene (2 mL) was 
added and the solvents were removed under reduced pressure to obtain deprotected 
thioxyloside 2.103 (16.0 mg, 35.2 µmol, quant.) as a colorless solid. 
 
1H NMR (400 MHz, CDCl3) δ/ppm 7.60–7.48 (m, 2H), 7.41–7.31 (m, 3H), 4.94 (d, J = 10.8 
Hz, 1H), 4.77 (d, J = 10.7 Hz, 1H), 4.60 (ddd, J = 10.3, 9.1, 5.6 Hz, 1H), 4.46 (d, J = 9.6 Hz, 
1H), 4.40 (dd, J = 11.5, 5.5 Hz, 1H), 3.80 (t, J = 8.9 Hz, 1H), 3.50 (dd, J = 11.6, 10.4 Hz, 1H), 
3.36 (dd, J = 9.6, 8.7 Hz, 1H), 2.77 (s, 2H); 13C NMR (101 MHz, CDCl3) δ/ppm 133.6, 
130.5, 129.4, 129.2, 92.7, 88.6, 80.2, 80.0, 74.7, 72.3, 66.7. 
 
(4aR,8R,8aR)-5-Hydroxy-2,3-dimethoxy-2,3-dimethylhexahydro-5H-pyrano[3,4-b][1,4] 
dioxin-8-yl (2,2,2-trichloroethyl) sulfate (2.114) 
Thioxyloside 2.102 (9.00 mg, 15.8 µmol, 1.0 eq.) was dissolved in 
acetone/H2O (0.25 mL, 9:1) and cooled to ‒10 °C. NBS (8.50 mg, 
47.8 µmol, 3.0 eq.) was added and the mixture was stirred for 
45 min before additional NBS (2.80 mg, 15.8 µmol 1.0 eq.) was 
added. After stirring for 1 h at ‒10 °C, the mixture was quenched with sat. aq. NaHCO3 
solution (2 mL). The reaction mixture was concentrated under reduced pressure; the residue 
was diluted with EtOAc (20 mL) and washed with sat. aq. NaHCO3 solution (2 x 5 mL) and 
brine (2 x 5 mL). The organic layer was dried over Na2SO4 and the solvent was removed 
under reduced pressure. The crude product was purified by flash column chromatography 
(SiO2, pentane/EtOAc 4:1) to  obtain   an   anomeric  mixture  α/β  of  2:1  of  hydrolyzed  xylosyl  
donor 2.114 (4.00 mg, 8.00 µmol, 53%) as a white solid. 
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Rf = 0.16 (SiO2, pentane/EtOAc 4:1); FTIR ṽ/cm−1 3415, 2954, 2925, 1663, 1414, 1205, 
1141, 1037, 967, 883, 779, 729; 1H NMR (400 MHz, CDCl3, major diastereomer) δ/ppm 5.21 
(d, J = 3.1 Hz, 1H), 4.99–4.96 (m, 1H), 4.84–4.66 (m, 2H), 4.25 (t, J = 9.9 Hz, 1H), 4.08–3.97 
(m, 2H), 3.77 (ddd, J = 10.0, 3.5, 0.8 Hz, 1H), 3.61–3.51 (m, 1H), 3.29 (s, 3H), 3.25 (s, 3H), 
2.94 (br s, 1H), 1.34 (s, 3H), 1.30 (s, 3H). 
 
(4aR,8R,8aR)-5-Bromo-2,3-dimethoxy-2,3-dimethylhexahydro-5H-pyrano[3,4-b][1,4] 
dioxin-8-yl (2,2,2-trichloroethyl) sulfate (2.111) 
Thioxyloside 2.102 (5.50 mg, 9.93 µmol, 1.0 eq.) was dissolved in 
CH2Cl2 (0.1 mL) and cooled to 0 °C. Bromine (1.53 mL, 29.8 mmol, 
3.0 eq.) was added and the mixture was stirred for 30 min at 0 °C 
and further 1 h at room temperature. The mixture was quenched 
with aq. Na2S2O3 solution (10% w/w, 2 mL) and the aqueous layer was extracted with CHCl3 
(3 x 2 mL). The combined organic layers were washed with brine (5 mL), dried over Na2SO4 
and the solvent was removed under reduced pressure. Brominated xylosyl donor 2.111 
(4.5 mg, 8.58 µmol, 86%) was obtained as an anomeric mixture α/β of 6:1 as a yellow solid 
which was used without further purification. 
 
Rf = 0.63 (SiO2, pentane/EtOAc 4:1); 1H NMR (400 MHz, CDCl3, major diastereomer) 
δ/ppm 6.26 (d, J = 3.7 Hz, 1H), 4.96 (d, J = 10.5 Hz, 1H), 4.84–4.73 (m, 2H), 4.31–4.21 (m, 
2H), 4.05–3.92 (m, 1H), 3.78 (dd, J = 9.8, 3.7 Hz, 1H), 3.31 (s, 3H), 3.25 (s, 3H), 1.34 (s, 
3H), 1.31 (s, 3H). 
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(4aR,5S,8R,8aR)-5-Fluoro-2,3-dimethoxy-2,3-dimethylhexahydro-5H-pyrano[3,4-b][1,4] 
dioxin-8-yl (2,2,2-trichloroethyl) sulfate (2.115) 
Thioxyloside 2.102 (29.7 mg, 52.3 µmol, 1.0 eq.) was dissolved in 
CH2Cl2 (3.5 mL) and DAST (10.5 µL, 78.4 µmol, 1.5 eq.) and 
NBS (12.9 mg, 72.5 µmol, 1.4 eq.) were added at ‒15 °C. The 
reaction was stirred for 20 min at this temperature before additional 
NBS (13.0 mg, 73.0 µmol, 1.4 eq.) was added and the mixture was stirred for additional 2 h at 
‒15 °C. Sat. aq. NaHCO3 solution (6 mL) was added and the aqueous layer was extracted 
with Et2O (3 x 10 mL). The combined organic layers were washed with brine (15 mL), dried 
over Na2SO4 and the solvent was removed under reduced pressure. The crude product was 
purified by flash column chromatography (SiO2, pentane/EtOAc 4:1) to obtain an anomeric 
mixture   α/β   of   3:1   of   fluorinated xylosyl donor 2.115 (19.0   mg,   39.8   μmol,   76%)   was  
obtained as a sticky colorless oil.  
 
Rf = 0.74 (SiO2, pentane/EtOAc 4:1); Optical rotation [𝛼]஽ଶହ =  ‒89.8 (c = 0.24, CHCl3); 
FTIR ṽ/cm−1 2996, 2957, 2838, 1417, 1206, 1142, 1104, 1034, 973, 918, 881, 783, 730; 
1H NMR (400 MHz, CDCl3, major diastereomer) δ/ppm 5.54 (dd, J = 53.6, 2.4 Hz, 1H), 4.96 
(d, J = 10.5 Hz, 1H), 4.80–4.72 (m, 2H), 4.25–4.18 (m, 2H), 3.92 (t, J = 11.0 Hz, 1H), 3.78 
(ddd, J = 24.9, 10.2, 2.5 Hz, 1H), 3.30 (s, 3H), 3.26 (s, 3H), 1.35 (s, 3H), 1.31 (s, 3H); 
13C NMR (101 MHz, CDCl3, major diastereomer) δ/ppm 104.7 (d, J = 231.3 Hz), 100.6, 
100.4, 92.5, 79.8, 68.2, 68.0, 66.0, 61.3 (d, J = 3.6 Hz), 48.4, 48.3, 17.7, 17.6; 19F NMR (376 
MHz, CDCl3) δ/ppm ‒150.9. 
 
  
EXPERIMENTAL PART 
 
 
 
 220
 
(2R,3R,4aR,8R,8aR)-2,3-Dimethoxy-2,3-dimethyl-8-(((2,2,2-trichloroethoxy)sulfonyl)-
oxy)hexahydro-5H-pyrano[3,4-b][1,4]dioxin-5-yl 2,2,2-trichloroacetimidate (2.112) 
To  a  solution  of  an  α/β  2:1  anomeric  mixture  of  hydroxyl  xyloside 
2.114 (33.5 mg, 70.4 µmol, 1.0 eq.) in CH2Cl2 (0.5 mL) were added 
trichloroacetonitrile (44.5 µL, 0.440 mmol, 6.3 eq.) and DBU 
(10.5 µL, 70.4 µmol, 1.0 eq.) at room temperature. The reaction 
mixture was stirred for 2 h at room temperature. The solvent was 
removed and the crude product directly purified by flash column chromatography (SiO2, 
pentane/EtOAc 8:1) to obtain an α/β 2:1 anomeric mixture of trichloroacetimidate 2.112 
(24.0 mg, 39.0 µmol, 55%) as a colorless oil. A 2nd flash column chromatography (SiO2, 
pentane/EtOAc  8:1)  led  to  separation  of  the  α  and  β  anomers. 
 
1H NMR (400 MHz, CDCl3, mixture of diastereomers) δ/ppm 8.71 (s, 0.5H), 8.67 (s, 1H), 
6.28 (d, J = 3.2 Hz, 1H), 5.98 (d, J = 7.2 Hz, 0.5H), 4.99 (d, J = 10.5 Hz, 1H), 4.92 (d, J = 
10.5 Hz, 0.5H), 4.86–4.74 (m, 3H), 4.38 (dd, J = 7.8, 5.1 Hz, 0.5H), 4.33 (t, J = 10.0 Hz, 1H), 
4.21 (dd, J = 11.3, 5.9 Hz, 1H), 4.05 (dd, J = 10.8, 8.4 Hz, 0.5H), 3.97–3.86 (m, 3H), 3.31 (s, 
1.5H), 3.28 (s, 1.5H), 3.27 (s, 3H), 3.25 (s, 3H), 1.32 (s, 1.5H), 1.30 (s, 1.5H), 1.30 (s, 3H), 
1.25 (s, 3H); 13C NMR (101 MHz, CDCl3, mixture of diastereomers) δ/ppm 161.04, 160.96, 
100.3, 100.2, 100.0, 96.3, 93.5, 92.6, 92.5, 91.1, 90.9, 80.0, 79.8, 79.7, 77.9, 68.7, 68.0, 67.6, 
66.2, 64.4, 61.7, 48.4, 48.3, 48.2, 48.1, 17.7, 17.61, 17.59, 17.5. 
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(2R,3R,4aR,5S,8R,8aR)-2,3-Dimethoxy-2,3-dimethyl-5-((S)-phenylsulfinyl)hexahydro-
5H-pyrano[3,4-b][1,4]dioxin-8-yl (2,2,2-trichloroethyl) sulfate (2.113) 
Thioxyloside 2.102 (30.0 mg, 52.8 µmol, 1.0 eq.) and KF (6.14 mg, 
106 µmol, 2.0 eq.) were dissolved in MeCN/H2O (5:1, 0.25 mL) 
and stirred for 30 min at 0 °C. A solution of m-CPBA (26.0 mg, 
106 µmol, 2.0 eq.) in MeCN (0.1 mL) was slowly added and the 
reaction mixture stirred for 5 min at 0 °C before it was quenched with sat. aq. FeSO4 solution 
(2 mL). The aqueous layer was extracted with CH2Cl2 (3 x 2 mL) and the combined organic 
layers were washed with sat. aq. NaHCO3 solution (1 mL), dried over Na2SO4 and the solvent 
was removed under reduced pressure. The crude residue was purified by flash column 
chromatography (SiO2, pentane/EtOAc 4:1) to obtain a 1:1 diastereomeric mixture of 
sulfoxide 2.113 (22.0 mg, 38.0 µmol, 71%) as a colorless solid. 
 
Mp = 64.0–66.0 °C; Rf = 0.26 (SiO2, pentane/EtOAc 4:1); FTIR ṽ/cm−1 2995, 2956, 2922, 
2839, 1446, 1415, 1379, 1262, 1204, 1139, 1108, 1093, 1042, 1010, 964, 921, 881, 849, 778, 
747, 727, 690, 674, 622; 1H NMR (400 MHz, CDCl3, mixture of diastereomers) δ/ppm 7.66–
7.62 (m, 2H), 7.61–7.57 (m, 2H), 7.55–7.52 (m, 3H), 7.51–7.48 (m, 3H), 4.92 (d, J = 8.2 Hz, 
1H), 4.89 (d, J = 8.2 Hz, 1H), 4.79 (dd, J = 9.3, 5.4 Hz, 1H), 4.77–4.68 (m, 3H), 4.46 (dd, J = 
12.1, 5.3 Hz, 1H), 4.42–4.36 (m, 2H), 4.33–4.23 (m, 2H), 4.05–3.96 (m, 3H), 3.70 (dd, J = 
12.2, 8.0 Hz, 1H), 3.41 (dd, J = 6.6, 2.6 Hz, 1H), 3.41 (s, 3H), 3.37 (s, 3H), 3.31 (s, 3H), 3.23 
(s, 3H), 1.40 (s, 3H), 1.36 (s, 3H), 1.26 (s, 3H), 1.04 (s, 3H); 13C NMR (101 MHz, CDCl3, 
mixture of diastereomers) δ/ppm 140.0, 138.9, 131.5, 131.3, 129.3, 128.9, 125.08, 125.07, 
100.7, 100.6, 100.4, 100.0, 94.3, 92.5, 92.4, 90.9, 79.7, 78.4, 77.9, 70.7, 70.1, 68.2, 67.9, 64.3, 
63.9, 49.5, 48.9, 48.4, 48.2, 17.70, 17.67, 17.6, 17.2; HRMS ESI m/z calc. for C17H24O6SNa 
[M+Na]+: 606.8917, found: 606.8927. 
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Methyl (2S,3aS,6R,7aS)-6-acetoxy-1-(((R)-2-(methoxymethoxy)-3-phenylpropanoyl)-D-
leucyl)octahydro-1H-indole-2-carboxylate (2.90) 
Secondary amine 2.92 (15.1 mg, 62.7 µmol, 1.0 eq.), Pla-Leu-OH 
dipeptide 2.53 (26.4 mg, 81.7 µmol, 1.3 eq.), DMTMM (22.9 mg, 
82.8 µmol, 1.3 eq.) and NMM (14 µL, 125 µmol, 1.6 eq.) were 
dissolved in CH2Cl2 (2 mL) at 0 °C. The mixture was stirred for 
30 min at this temperature and further for 4 h at room temperature. 
The crude product was purified by flash column chromatography 
(SiO2, CH2Cl2/MeOH 15:1) to obtain a rotameric mixture of 5:1 of 
tripeptide 2.90 (27.4 mg, 50.1 µmol, 80%) as a colorless sticky oil. 
 
Rf = 0.42 (SiO2, CH2Cl2/MeOH 15:1); Optical rotation [𝛼]஽ଶହ = +0.3 (c = 0.46, CHCl3); 
FTIR ṽ/cm−1 3414, 2954, 2933, 1739, 1649, 1578, 1516, 1435, 1365, 1236, 1175, 1104, 1020, 
919, 817, 747, 702; 1H NMR (400 MHz, CDCl3, major rotamer) δ/ppm 7.30–7.20 (m, 5H), 
7.08 (d, J = 9.4 Hz, 1H), 5.15–5.10 (m, 1H), 4.80 (td, J = 10.0, 3.4 Hz, 1H), 4.60–4.50 (m, 
2H), 4.37–4.32 (m, 1H), 4.11 (dt, J = 12.0, 6.1 Hz, 1H), 3.96–3.72 (m, 1H), 3.69 (s, 3H), 
3.22–3.19 (m, 1H), 3.17 (s, 3H), 2.97 (dd, J = 14.0, 7.6 Hz, 1H), 2.49–2.38 (m, 2H), 2.25–
2.17 (m, 1H), 2.07 (s, 3H), 2.02–1.94 (m, 2H), 1.89–1.79 (m, 2H), 1.68–1.61 (m, 1H), 1.59–
1.52 (m, 1H), 1.50–1.42 (m, 1H), 1.35–1.29 (m, 1H), 1.25–1.20 (m, 1H), 0.98 (d, J = 6.3 Hz, 
3H), 0.86 (d, J = 6.5 Hz, 3H); 13C NMR (101 MHz, CDCl3, major rotamer) δ/ppm 172.6, 
171.1, 170.4, 170.1, 137.3, 129.9, 128.2, 126.6, 96.0, 77.7, 69.2, 59.1, 56.2, 54.4, 52.3, 48.0, 
43.1, 38.9, 37.0, 31.3, 30.5, 29.8, 24.4, 23.5, 21.5, 21.2, 19.8; HRMS ESI m/z calc. for 
C29H43N2O8 [M+H]+: 547.3014, found: 547.3018. 
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Methyl (2S,3aS,6R,7aS)-6-hydroxy-1-(((R)-2-(methoxymethoxy)-3-phenylpropanoyl)-D-
leucyl)octahydro-1H-indole-2-carboxylate (2.110) 
Tripeptide 2.90 (25.0 mg, 45.7 µmol, 1.0 eq.) and K2CO3 (20.4 mg, 
0.148 mmol, 3.2 eq.) were dissolved in MeOH (0.6 mL) at 0 °C. The 
reaction mixture was stirred for 5 min at this temperature and further for 
3.5 h at room temperature. The reaction was quenched with sat. aq. 
NH4Cl solution (4 mL) and the MeOH was removed under reduced 
pressure. The residue was extracted with CH2Cl2 (3 x 5 mL), the 
combined organic layers were dried over Na2SO4 and the solvent was 
removed under reduced pressure. The crude product was purified by flash column 
chromatography (SiO2, CH2Cl2/MeOH 30:1) to obtain a rotameric mixture (5:1) of glycosyl 
acceptor 2.110 (14.1 mg, 27.9 µmol, 61%) as colorless sticky oil. 
 
Rf = 0.46 (SiO2, CH2Cl2/MeOH 20:1); Optical rotation [𝛼]஽ଶହ = +17.0 (c = 0.71, CHCl3); 
FTIR ṽ/cm−1 3409, 2953, 2932, 1750, 1642, 1579, 1525, 1440, 1364, 1260, 1174, 1104, 1015, 
918, 817, 748, 702; 1H NMR (400 MHz, CDCl3, major rotamer) δ/ppm 7.30–7.19 (m, 5H), 
7.07 (d, J = 9.6 Hz, 1H), 4.85 (td, J = 9.7, 3.9 Hz, 1H), 4.58–4.50 (m, 2H), 4.37–4.30 (m, 2H), 
4.25 (dt, J = 12.1, 6.3 Hz, 1H), 4.19 (br s, 1H), 3.96–3.74 (m, 1H), 3.68 (s, 3H), 3.16 (s, 3H), 
2.96 (dd, J = 14.1, 7.5 Hz, 1H), 2.49–2.41 (m, 1H), 2.32–2.25 (m, 2H), 2.23–2.14 (m, 2H), 
2.01–1.90 (m, 1H), 1.81–1.73 (m, 1H), 1.70–1.63 (m, 1H), 1.61–1.53 (m, 2H), 1.48–1.41 (m, 
1H), 1.35–1.29 (m, 2H), 0.93 (d, J = 5.6 Hz, 3H), 0.85 (d, J = 5.8 Hz, 3H); 13C NMR 
(101 MHz, CDCl3, major rotamer) δ/ppm 172.7, 171.1, 170.2, 137.2, 129.9, 128.3, 126.7, 
95.9, 77.6, 65.7, 59.2, 56.2, 54.5, 52.2, 48.1, 42.7, 39.0, 37.3, 34.3, 30.5, 25.8, 24.5, 23.5, 
22.0, 19.3; HRMS ESI m/z calc. for C27H41N2O7 [M+H]+: 505.2908, found: 505.2915. 
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Methyl (2S,3aS,6R,7aS)-1-((2S,3R)-3-chloro-2-((R)-2-(methoxymethoxy)-3-phenyl-
propanamido)-4-methylpentanoyl)-6-hydroxyoctahydro-1H-indole-2-carboxylate (2.109) 
Tripeptide 2.93 (18.8 mg, 32.4 µmol, 1.0 eq.) and K2CO3 (13.4 mg, 
97.2 µmol, 3.0 eq.) were dissolved in MeOH (0.4 mL) at 0 °C. The 
reaction mixture was stirred for 5 min at the same temperature and 
further for 2 h at room temperature. Additional K2CO3 (4.30 mg, 
32.4 µmol, 1.0 eq.) was added and the reaction mixture was stirred for 
further 1.5 h. The reaction was quenched with sat. aq. NH4Cl solution 
(2 mL) and the MeOH was removed under reduced pressure. The 
residue was extracted with CH2Cl2 (3 x 5 mL), the combined organic layers were dried over 
Na2SO4 and the solvent was removed under reduced pressure. The crude product was purified 
by flash column chromatography (SiO2, pentane/EtOAc 1:2) to obtain glycosyl acceptor 2.109 
(14.9 mg, 28.0 µmol, 85%) as colorless foam.  
 
Rf = 0.21 (SiO2, pentane/EtOAc 1:1); Optical rotation [𝛼]஽ଶହ = +51.8 (c = 0.31, CHCl3); 
FTIR ṽ/cm−1 3399, 2929, 1750, 1640, 1513, 1452, 1361, 1255, 1197, 1176, 1148, 1113, 1035, 
919, 887, 804, 752, 701, 695, 667, 605; 1H NMR (400 MHz, CDCl3) δ/ppm 7.30–7.18 (m, 
5H), 7.03 (d, J = 10.1 Hz, 1H), 4.99 (t, J = 10.4 Hz, 1H), 4.61–4.55 (m, 2H), 4.46 (dt, J = 
12.2, 6.3 Hz, 1H), 4.42–4.36 (m, 2H), 4.16 (s, 1H), 3.88 (dd, J = 10.8, 1.9 Hz, 1H), 3.67 (s, 
3H), 3.21 (s, 3H), 3.14 (dd, J = 14.2, 3.8 Hz, 1H), 3.00 (dd, J = 14.2, 6.4 Hz, 1H), 2.45 (dq, 
J = 12.9, 6.3 Hz, 1H), 2.25–2.11 (m, 3H), 1.93 (td, J = 12.9, 10.2 Hz, 1H), 1.85 (s, 1H), 1.74–
1.61 (m, 1H), 1.59–1.50 (m, 1H), 1.46–1.37 (m, 1H), 1.29–1.23 (m, 2H), 0.91 (d, J = 6.5 Hz, 
3H), 0.86 (d, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ/ppm 172.6, 170.8, 168.4, 
136.7, 130.1, 128.3, 126.9, 95.6, 68.4, 65.9, 58.9, 56.4, 54.8, 52.2, 51.9, 38.3, 36.8, 34.3, 30.7, 
28.1, 25.8, 20.9, 19.3, 15.4; HRMS ESI m/z calc. for C27H39ClN2O7Na [M+Na]+: 561.2338, 
found: 561.2344. 
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Methyl (2S,3aS,6R,7aS)-1-((2S,3R)-3-chloro-2-((R)-2-(methoxymethoxy)-3-phenyl-
propanamido)-4-methylpentanoyl)-6-(((4aR,5S,8R,8aR)-2,3-dimethoxy-2,3-dimethyl-8-
(((2,2,2-trichloroethoxy)sulfonyl)oxy)hexahydro-5H-pyrano[3,4-b][1,4]dioxin-5-
yl)oxy)octahydro-1H-indole-2-carboxylate (2.116) 
Brominated xylosyl donor 2.111 (3.60 mg, 6.68 µmol, 
1.2 eq.), L-Choi-Cleu-Pla derivative 2.109 (3.00 mg, 
5.57 µmol, 1.0 eq.) and DTBMP (2.75 mg, 13.4 µmol, 
2.4 eq.) were dissolved in CH2Cl2 (0.3 mL) containing 
4 Å powdered molecular sieves. AgOTf (3.44 mg, 
13.4 µmol, 2.4 eq.) was added to this suspension at 0 °C 
and the mixture was stirred at the same temperature for 
30 min and further for 1 h at room temperature. Et3N 
(30 µL) was added and the reaction mixture was filtered over Celite®. The Celite® pad was 
washed with CH2Cl2 (2 x 5 mL) and the solvent removed from the filtrate. The crude product 
was purified by flash column chromatography (SiO2, pentane/EtOAc 1:2) to give in a first 
fraction   the   α-anomer of Xyl-L-Choi-Cleu-Pla derivative 2.116a (0.800 mg, 0.840 µmol, 
15%)   and   in   a   second   fraction   the   β-anomer of Xyl-L-Choi-Cleu-Pla derivative 2.116b 
(2.40 mg, 2.40 µmol, 43%) as colorless oils. 
 
2.116b: 1H NMR (250 MHz, CDCl3) δ/ppm7.26 (s, 5H), 6.98 (d, J = 10.1 Hz, 1H), 4.97 (t, J 
= 10.4 Hz, 1H), 4.97 (d, J = 10.5 Hz, 1H), 4.79 (d, J = 10.5 Hz, 1H), 4.74–4.65 (m, 1H), 
4.64–4.46 (m, 3H), 4.44–4.33 (m, 2H), 4.01 (s, 1H), 3.95 (dd, J = 10.3, 9.2, 1H), 3.81 (dd, J = 
10.8, 1.8 Hz, 1H), 3.74–3.67 (m, 1H), 3.65 (s, 3H), 3.57 (dd, J = 10.3, 7.5 Hz, 1H), 3.31 (s, 
3H), 3.27 (s, 3H), 3.20 (s, 3H), 3.13 (dd, J = 14.2, 3.9 Hz, 1H), 3.01 (dd, J = 14.1, 6.3 Hz, 
1H), 2.42 (d, J = 16.7 Hz, 2H), 2.16 (d, J = 7.8 Hz, 2H), 2.00–1.81 (m, 1H), 1.68 (d, J = 21.9 
Hz, 1H), 1.56 (s, 3H), 1.32 (s, 3H), 1.31 (s, 3H), 0.93 (d, J = 6.4 Hz, 3H), 0.85 (d, J = 6.7 Hz, 
3H). 
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(2S,3aS,6R,7aS)-1-((2S,3R)-3-Chloro-2-((R)-2-(methoxymethoxy)-3-phenylpropan-
amido)-4-methylpentanoyl)-6-(((4aR,5S,8R,8aR)-2,3-dimethoxy-2,3-dimethyl-8-(((2,2,2-
trichloroethoxy)sulfonyl)oxy)hexahydro-5H-pyrano[3,4-b][1,4]dioxin-5-yl)oxy)octa-
hydro-1H-indole-2-carboxylic acid (2.118) 
β-Xyl-L-Choi-Cleu-Pla methyl ester 2.116b (5.90 mg, 
5.92 µmol, 1.0 eq.) was dissolved in 1,2-dichloroethane 
(0.3 mL). Trimethyltin hydroxide (3.60 mg, 19.9 µmol, 
3.3 eq.) was added and the reaction mixture stirred for 14 h 
at 85 °C, before additional trimethyltin hydroxide 
(3.60 mg, 19.9 µmol, 3.3 eq.) was added. Additional 
trimethyltin hydroxide (3.60 mg, 19.9 µmol, 3.3 eq.) was 
again added after further 14 h. The reaction mixture was 
stirred for additional 68 h at 85 °C before it was partitioned 
between CH2Cl2 (2 mL) and aq. HCl solution (1 M, 1 mL). The layers were separated and the 
organic layer was washed with aq. HCl solution (1 M, 5 x 1 mL), dried over Na2SO4 and the 
solvent was removed under reduced pressure. The crude product was purified by flash column 
chromatography (SiO2, CH2Cl2/MeOH 10:1) to obtain Xyl-L-Choi-Cleu-Pla acid 2.118 
(2.00 mg, 2.01 µmol, 34%) as a colorless oil. Further, starting material 2.116b could be 
recovered (3.70 mg, 3.72 µmol, 63%). 
 
1H NMR (400 MHz, CDCl3) δ/ppm 7.31–7.19 (m, 5H), 7.08–7.00 (m, 1H), 5.06 (t, J = 
10.3 Hz, 1H), 4.97 (d, J = 10.5 Hz, 1H), 4.79 (d, J = 10.5 Hz, 1H), 4.71–4.57 (m, 2H), 4.51 
(dd, J = 12.4, 5.0 Hz, 1H), 4.39–4.33 (m, 1H), 3.99 (s, 1H), 3.94 (t, J = 9.8 Hz, 1H), 3.82 (d, 
J = 10.8 Hz, 1H), 3.66 (dd, J = 12.3, 9.0 Hz, 1H), 3.55 (dd, J = 10.2, 7.6 Hz, 1H), 3.30 (s, 
3H), 3.26 (s, 3H), 3.24 (s, 3H), 3.11–3.03 (m, 2H), 2.47–2.32 (m, 3H), 2.16–2.04 (m, 3H), 
1.80–1.72 (m, 1H), 1.63–1.49 (m, 1H), 1.32 (s, 3H), 1.31 (s, 3H), 1.40–1.21 (m, 4H), 0.89 (d, 
J = 6.3 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H). 
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(4aR,5S,8R,8aR)-5-(((2S,3aS,6R,7aS)-2-((2-(1-((Z)-N,N'-Bis(tert-butoxycarbonyl)-
carbamimidoyl)-2,5-dihydro-1H-pyrrol-3-yl)ethyl)carbamoyl)-1-((2S,3R)-3-chloro-2-
((R)-2-(methoxymethoxy)-3-phenylpropanamido)-4-methylpentanoyl)octahydro-1H-
indol-6-yl)oxy)-2,3-dimethoxy-2,3-dimethylhexahydro-5H-pyrano[3,4-b][1,4]dioxin-8-yl 
(2,2,2-trichloroethyl) sulfate (2.119) 
PyBOP (1.82 mg, 3.50 µmol, 2.0 eq.) was 
added to a solution of Xyl-L-Choi-Cleu-Pla 
acid 2.118 (1.70 mg, 1.75 µmol, 1.0 eq.) 
and Adc subunit 2.63 (1.24 mg, 3.50 µmol, 
2.0 eq.) in CH2Cl2 (50 µL) containing 
2,6-lutidine (0.6 µL, 5.15 µmol, 2.9 eq.) at 
0 °C. The reaction mixture was stirred for 
30 min at 0 °C and further for 4 h at room 
temperature. CH2Cl2 (2 mL) was added and 
the mixture was washed with sat. aq. NaHCO3 solution (1 mL) and brine (1 mL). The organic 
layer was dried over Na2SO4 and the solvent removed under reduced pressure. The crude 
product was purified by flash column chromatography (SiO2, CH2Cl2/MeOH 15:1) to obtain 
tetrapeptide 2.119 (2.20 mg, 1.67 µmol, 95%) as a colorless amorphous solid. 
 
Rf = 0.36 (SiO2, CH2Cl2/MeOH 15:1); 1H NMR (400 MHz, CDCl3) δ/ppm 10.24 (s, 1H), 
7.31–7.19 (m, 5H), 6.92 (d, J = 9.6 Hz, 1H), 6.65 (s, 1H), 5.49 (s, 1H), 4.97 (d, J = 10.5 Hz, 
1H), 4.94 (t, J = 9.5 Hz, 1H), 4.79 (d, J = 10.5 Hz, 1H), 4.67 (td, J = 9.0, 5.2 Hz, 1H), 4.61–
4.55 (m, 3H), 4.48 (dd, J = 12.3, 5.2 Hz, 1H), 4.42–4.25 (m, 4H), 4.00 (s, 1H), 3.94 (t, J = 9.7 
Hz, 1H), 3.82 (dd, J = 10.8, 1.9 Hz, 1H), 3.71–3.61 (m, 1H), 3.55 (dd, J = 10.2, 7.6 Hz, 1H), 
3.30 (s, 3H), 3.26 (s, 3H), 3.23 (s, 3H), 3.13 (dd, J = 14.1, 3.9 Hz, 1H), 3.02 (dd, J = 14.2, 6.2 
Hz, 1H), 2.41–2.29 (m, 2H), 2.28–2.20 (m, 2H), 2.11–2.00 (m, 1H), 1.81–1.70 (m, 1H), 1.50–
1.45 (m, 25H), 1.33–1.23 (m, 4H), 1.32 (s, 3H), 1.30 (s, 3H), 0.90 (d, J = 6.4 Hz, 3H), 0.86 (d, 
J = 6.7 Hz, 3H); LRMS ESI m/z calc. for C56H85Cl4N6O19S [M+H]+: 1317.4, found: 1317.6. 
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Synthesis of A828B (2.121) 
Tetrapeptide 2.119 (1.25 mg, 0.96 µmol, 1.0 eq.) 
was dissolved in CH2Cl2 (1 mL) and cooled to 0 °C. 
TFA (0.1 mL) was added and the mixture was 
stirred for 5 min at 0 °C and further for 10 h at room 
temperature. Solvent and TFA were removed under 
reduced pressure and the obtained crude residue 
was directly dissolved in MeOH (50 µL). 
Ammonium formate (0.59 µL, 11.5 µmol, 12 eq.) 
and zinc powder (0.980 mg, 14.4 µmol, 15 eq.) were added and the suspension was stirred for 
2 h at room temperature. The reaction mixture was diluted with MeOH (2 mL), filtered over 
Celite® and the filtrate was concentrated under reduced pressure. The crude product was 
purified by reversed phase HPLC (MeCN/H2O + 0.1% formic acid) to obtain aeruginosin 
828B (2.121)  (340  μg,  0.420  μmol,  44%)  as  a  white  amorphous  solid. 
 
1H NMR (600 MHz, DMSO-d6) δ/ppm 7.85 (t, J = 5.8 Hz, 1H), 7.51 (d, J = 9.0 Hz, 1H), 
7.26–7.12 (m, 5H), 5.84 (d, J = 5.8 Hz, 1H), 5.59 (s, 1H), 5.16 (d, J = 2.5 Hz, 1H), 4.96 (d, J 
= 5.1 Hz, 1H), 4.82 (t, J = 9.7, 1H), 4.25 (dt, J = 12.3, 6.3 Hz, 1H), 4.16–4.12 (m, 3H), 4.10–
4.03 (m, 4H), 3.98 (dd, J = 11.5, 5.5 Hz, 1H), 3.93–3.84 (m, 2H), 3.41–3.36 (m, 1H), 3.20–
3.12 (m, 2H), 2.93 (dd, J = 13.6, 3.7 Hz, 1H), 2.78 (dd, J = 13.9, 7.1 Hz, 1H), 2.33–2.14 (m, 
2H), 2.03–1.94 (m, 2H), 1.79–1.72 (m, 1H), 1.66–1.56 (m, 2H), 1.56–1.37 (m, 2H), 1.34–1.25 
(m, 1H), 0.85 (d, J = 6.5 Hz, 3H), 0.82 (d, J = 6.6 Hz, 3H); LRMS ESI m/z calc. for 
C36H54ClN6O12S [M+H]+: 829.3, found: 829.4. 
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2.2. Aeruginosin KT608A Synthesis 
2.2.1.  D-diepi-Choi Synthesis 
Ethyl 2-azidoacetate (3.52) 
Ethyl bromoacetate (3.53) (17.0 g, 102 mmol, 1.0 eq.) and sodium azide (13.3 g, 
204 mmol, 2.0 eq.) were dissolved in H2O/acetone (1:3, 300 mL) and stirred for 
1 h at room temperature. The reaction mixture was diluted with CH2Cl2 (100 mL), the layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The combined 
organic layers were dried over Na2SO4 and the solvent was removed under reduced pressure 
to obtain ethyl 2-azidoacetate (3.52) (13.0 g, 100 mmol, quant.) as a colorless oil, which was 
used without further purification. 
 
1H NMR (400 MHz, CDCl3) δ/ppm 4.26 (q, J = 7.2 Hz, 2H), 3.86 (s, 2H), 1.31 (t, J = 7.2 Hz, 
3H). 
Analytical data are in accordance with those reported in the literature.[12] 
 
Ethyl (Z)-2-azido-3-(4-methoxyphenyl)acrylate (3.54) 
Sodium (1.98 g, 85.2 mmol, 2.2 eq.) was dissolved in EtOH (100 mL) 
and  cooled  to  −15 °C. Ethyl 2–azidoacetate (3.52) (11.0 g, 85.2 mmol, 
2.2 eq.) dissolved in EtOH (20 mL) and p–anisaldehyde (3.51) 
(4.70 mL, 38.7 mmol 1.0 eq.)  dissolved  in  EtOH  (8  mL)  were  added  dropwise  at  −15 °C. The 
reaction mixture was stirred for 7 h at  −15 °C and quenched by the addition of sat. aq. NH4Cl 
solution (30 mL). The aqueous layer was extracted with Et2O (2 x 50 mL) and the combined 
organic layers were washed with H2O (15 mL), dried over Na2SO4 and the solvent was 
removed under reduced pressure. The obtained crude residue was purified by flash column 
chromatography (SiO2, pentane/EtOAc 4:1) to give ethyl (Z)-2-azido-3-(4-methoxy-
phenyl)acrylate (3.54) (5.50 g, 22.2 mmol, 57%) as a yellow oil. 
 
Rf = 0.63 (SiO2, pentane/EtOAc 4:1); 1H NMR (400 MHz, CDCl3) δ/ppm 8.06–7.63 (m, 1H), 
7.04–6.43 (m, 1H), 4.36 (q, J = 7.1 Hz, 1H), 3.84 (s, 2H), 1.39 (t, J = 7.1 Hz, 2H); 13C NMR 
(101 MHz, CDCl3) δ/ppm 163.9, 160.6, 132.5, 126.2, 125.5, 123.5, 114.0, 62.2, 55.4, 14.4. 
Analytical data are in accordance with those reported in the literature.[13] 
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Ethyl 6-methoxy-1H-indole-2-carboxylate (3.54b) 
Azide 3.54 (6.00 g, 24.3 mmol, 1.0 eq.) was dissolved in o–xylene 
(180 mL) and added dropwise over a period of 1 h to refluxing 
o-xylene (240 mL). The reaction mixture was heated at reflux for 1.5 
h. The solvent was removed under reduced pressure to give pure indole 3.54b (4.95 g, 
22.6 mmol, 93%) as a yellow solid which was used without further purification. 
 
Rf = 0.48 (SiO2, pentane/EtOAc 3:1); Mp = 130.3–131.5 °C; FTIR ṽ/cm−1  2980, 2940, 2906, 
1706, 1613, 1347, 1213, 1184, 1110, 1025, 842, 806; 1H NMR (400 MHz, CDCl3) δ/ppm 
8.97 (s, 1H), 7.55 (dt, J = 8.5, 0.8 Hz, 1H), 7.17 (dd, J = 2.1, 0.8 Hz, 1H), 6.85–6.83 (m, 1H), 
6.81 (d, J = 2.2 Hz, 1H), 4.40 (q, J = 7.1 Hz, 2H), 3.85 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H); 
13C NMR (101 MHz, CDCl3) δ/ppm 162.2, 159.0, 138.1, 126.5, 123.5, 122.0, 112.4, 109.1, 
93.9, 60.9, 55.6, 14.6. 
Analytical data are in accordance with those reported in the literature.[14] 
 
Ethyl 1-acetyl-6-methoxy-1H-indole-2-carboxylate (3.55) 
Indole 3.54b (4.95 g, 24.3 mmol, 1.0 eq.) was dissolved in CH2Cl2 
(170 mL), then DMAP (30.0 mg, 0.240 mmol, 0.010 eq.), acetic 
anhydride (3.10 g, 30.3 mmol, 1.3 eq.) and Et3N (8.50 mL, 60.8 mmol, 
2.5 eq.) were added and the mixture was stirred for 70 min at 40 °C. Additional DMAP 
(30.0 mg, 0.240 mmol, 0.010 eq.) and Et3N (8.50 mL, 60.8 mmol, 2.5 eq.) were added. After 
stirring for 16 h at 50 °C, additional DMAP (300 mg, 24.3 mmol, 0.10 eq.), acetic anhydride 
(7.5 mL, 80.0 mmol, 3.3 eq.) and Et3N (2.0 mL, 15.2 mmol, 0.63 eq.) were added and the 
reaction mixture was stirred for 16 h at 50 °C. The mixture was washed with sat. aq. NaHCO3 
solution (2 x 200mL) and the combined aqueous layers were extracted with CH2Cl2 (50 mL). 
The combined organic layers were dried over Na2SO4 and the solvent was removed under 
reduced pressure. The obtained crude residue was purified by flash column chromatography 
(SiO2, pentane/EtOAc 4:1) to give indole 3.55 (4.77 g, 18.3 mmol, 75%) as a yellow oil. 
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Rf = 0.57 (SiO2, pentane/EtOAc 8:1); FTIR ṽ/cm−1 2980, 2940, 2906, 1706, 1613, 1347, 
1213, 1184, 1110, 1025, 842, 806; 1H NMR (400 MHz, CDCl3) δ/ppm 7.62 (d, J = 2.3 Hz, 
1H), 7.38 (d, J = 8.7 Hz, 1H), 7.21 (d, J = 0.8 Hz, 1H), 6.81 (dd, J = 8.7, 2.3 Hz, 1H), 4.29 (q, 
J = 7.1 Hz, 2H), 3.78 (s, 3H), 2.50 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ/ppm 212.8, 202.7, 201.9, 181.4, 169.4, 164.2, 161.9, 160.5, 155.4, 139.4, 102.6, 
96.8, 68.5, 55.5; HRMS ESI m/z calc. for C14H15NO4Na [M+Na]+: 284.0893, found: 
284.0893. 
 
Ethyl (R)-1-acetyl-6-methoxyindoline-2-carboxylate (3.56) 
For enantiomerically enriched (+)-3.56: Indole derivate 3.55 (20.0 mg, 
76.5 µmol, 1.0 eq.) and IrPHOX cat. A (1.20 mg, 0.765 µmol, 0.010 eq.) 
were dissolved in DCE (0.3 ml). The reaction mixture was stirred at 80 
°C for 16 h under H2 pressure (100 bar) in an autoclave, the pressure was released and the 
system allowed to cool to room temperature. Additional IrPHOX cat. A (1.20 mg, 
0.765 µmol, 0.010 eq.) was added and the reaction mixture was stirred at 80 °C for further 
24 h under H2 pressure (100 bar). The pressure was released and the system was allowed to 
cool to room temperature. The residue was diluted with Et2O/EtOAc (1:1, 2 mL) and filtered 
over a short pad of silica gel. The solvents were removed under reduced pressure and the 
obtained crude residue was purified by flash column chromatography (SiO2, pentane/EtOAc 
10:1 changing to 2:1) to give enantiomerically enriched indoline 3.56 (10.1 mg, 38.3 µmol, 
50%) as a colorless solid. Further, starting material 3.55 (2.00 mg, 7.65 µmol, 10%) and 
deprotected indole 3.54b (1.90 mg, 8.42 µmol, 11%) could be recovered. 
 
Mp = 89.0–90.1 °C; Rf = 0.37 (SiO2, pentane/EtOAc 4:1); Optical rotation [𝛼]஽ଶହ = +78.8 (c 
= 0.10, MeOH); FTIR ṽ/cm−1 3129, 2985, 2833, 1727, 1655, 1596, 1495, 1445, 1217, 1171, 
1020, 848; 1H NMR (400 MHz, CDCl3, major rotamer) δ/ppm 7.91 (s, 1H), 7.01 (d, J = 8.2 
Hz, 1H), 6.58 (d, J = 9.2 Hz, 1H), 4.89 (d, J = 10.1 Hz, 1H), 4.30–4.12 (m, 2H), 3.81 (s, 3H), 
3.55 (dd, J = 16.0, 10.9 Hz, 1H), 3.18 (d, J = 16.0 Hz, 1H), 2.17 (s, 3H), 1.27 (t, J = 7.1 Hz, 
3H); 13C NMR (101 MHz, CDCl3, major rotamer) δ/ppm 171.5, 169.1, 159.9, 144.0, 124.5, 
120.3, 110.5, 103.4, 62.4, 62.2, 55.7, 33.0, 23.9, 14.2; HRMS ESI m/z calc. for C14H17NO4Na 
[M+Na]+: 286.1050, found: 286.1050. 
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For racemic 3.56: Indole derivate 3.55 (100 mg, 0.383 mmol, 1.0 eq.) 
and activated Pd/C (5% w/w, 81.5 mg, 38.3 µmol, 0.10 eq.) were 
dissolved in CH2Cl2 (5 ml). The reaction mixture was stirred for 8 h at 
room temperature under H2 pressure (75 bar) in an autoclave. The pressure was released and 
the catalyst was filtered off over a short pad of silica gel, the silica gel was washed with Et2O 
(2 x 10 mL) and the solvent was removed under reduced pressure. The obtained crude residue 
was purified by flash column chromatography (SiO2, pentane/EtOAc 10:1 changing to 5:1) to 
give racemic indoline 3.56 (80.0 mg, 0.304 mmol, 79%) as a colorless solid. 
 
Ethyl (2R,3aR,6R,7aR)-1-acetyl-6-methoxyoctahydro-1H-indole-2-carboxylate (3.57) 
Rh/C (5% w/w, 73.5 mg, 35.3 µmol, 0.10 eq.) was added to a solution 
of indoline 3.56 (94.0 mg, 0.353 mmol, 1.0 eq.) in MeOH (3 mL). The 
reaction mixture was stirred for 9 h at room temperature under H2 
pressure (50 bar). The catalyst was filtered off over Celite®, the Celite® was washed with 
MeOH (2 x 5 mL) and the solvent was removed under reduced pressure. The obtained crude 
residue was purified by flash column chromatography (SiO2, pentane/EtOAc 1:3) to give a 
3:1 rotameric mixture of octahydroindole 3.57 (94.0 mg, 0.353 mmol, 99%) as a colorless oil 
which crystallized upon storing in the refrigerator. 
 
Rf = 0.40 (SiO2, pentane/MeOH 1:3); Optical rotation [𝛼]஽ଶହ = +42.7 (c = 0.12, MeOH); 
FTIR ṽ/cm−1 2938, 2826, 1731, 1646, 1406, 1182, 1121, 1020; 1H NMR (400 MHz, CDCl3, 
major rotamer) δ/ppm 4.36–4.29 (m, 1H), 4.20–4.09 (m, 2H), 3.80 (dt, J = 12.0, 6.2 Hz, 1H), 
3.30 (s, 3H), 3.05 (tt, J = 11.5, 3.8 Hz, 1H), 2.35–2.20 (m, 1H), 2.16–2.07 (m, 1H), 2.06 (s, 
3H), 1.94–1.72 (m, 3H), 1.69–1.51 (m, 2H), 1.24–1.19 (m, 5H); 13C NMR (101 MHz, CDCl3, 
major rotamer) δ/ppm 172.2, 168.4, 77.1, 61.0, 59.1, 58.5, 55.7, 37.0, 33.7, 30.7, 25.8, 22.9, 
21.6, 14.1; HRMS ESI m/z calc. for C14H23NO4Na [M+Na]+: 292.1519, found: 292.1525; 
Crystallography C14H23NO4, M = 269.33, colorless prism, monoclinic, space group P21/n, a 
= 6.81580(10), b = 19.4328(3), c = 11.29430(10) Å, β = 106.5055(8)°, U = 1434.29(3) Å3, Z 
= 4, Dc = 1.247 Mg m–3, µ(Mo-Kα) = 0.091 mm−1, T = 160 K. Total 31512 reflections, 3396 
unique, Rint = 0.0477. Refinement of 3392 reflections (176 parameters) with I >2σ (I) 
converged at final R1 = 0.0415 (R1 all data = 0.0536), wR2 = 0.1008 (wR2 all data = 0.1099), 
gof = 1.026. 
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Ethyl (2R,3aR,6R,7aR)-1-acetyl-6-hydroxyoctahydro-1H-indole-2-carboxylate (3.58) 
To a suspension of NaI (211 mg, 1.41 mmol, 4.0 eq.) in MeCN 
(0.6 mL) was added H2O (2 µL) and the suspension was stirred for 
30 min at 40 °C. TMSCl (0.18 mL, 1.41 mmol, 4.0 eq.) was added and 
the reaction mixture was stirred for further 30 min at 40 °C before a solution of 
octahydroindole 3.57 (95.0 mg, 0.353 mmol, 1.0 eq.) in MeCN (0.4 mL) was added. The 
reaction mixture was stirred for further 16 h at 40 °C. EtOAc (15 mL) was added and the 
organic layer was washed with H2O (5 mL), sat. aq. Na2S2O3 solution (5 mL) and brine 
(5 mL). The organic layer was dried over Na2SO4 and the solvent was removed under reduced 
pressure. The obtained crude residue was purified by flash column chromatography 
(SiO2, EtOAc/MeOH 8:1) to give a 4:1 rotameric mixture of octahydroindole 3.58 (69.0 mg, 
0.270 mmol, 77%) as a yellow oil. 
 
Rf = 0.40 (SiO2, EtOAc/MeOH 15:1); FTIR ṽ/cm−1 3399, 2935, 2865, 1739, 1622, 1415, 
1182, 1049, 826; 1H NMR (400 MHz, CDCl3, major rotamer) δ/ppm 4.35 (dd, J = 10.1, 8.1 
Hz, 1H), 4.24–4.06 (m, 2H), 3.84 (dt, J = 12.1, 6.3 Hz, 1H), 3.53 (tt, J = 11.8, 3.7 Hz, 1H), 
2.40–2.27 (m, 1H), 2.26–2.18 (m, 1H), 2.17–2.09 (m, 1H), 2.08 (s, 3H), 2.01–1.89 (m, 1H), 
1.82–1.72 (m, 2H), 1.72–1.58 (m, 2H), 1.42–1.29 (m, 2H), 1.25 (t, J = 7.2 Hz, 3H); 13C NMR 
(101 MHz, CDCl3, major rotamer) δ/ppm 172.6, 168.7, 68.5, 61.2, 59.1, 58.5, 37.2, 36.7, 
30.9, 29.6, 23.1, 21.6, 14.2; HRMS ESI m/z calc. for C13H21NO4Na [M+Na]+: 278.1368, 
found: 278.1363. 
 
Ethyl 1-acetyl-6-hydroxyindoline-2-carboxylate (3.60) 
Racemic indoline 3.56 (75.0 mg, 0.285 mmol, 1.0 eq.) was dissolved in 
CH2Cl2 (7.5 mL) and cooled to 78 °C. BBr3 (1.99 mL, 1 M solution in 
CH2Cl2, 1.99 mmol, 7.0 eq.) was added dropwise to this solution and the 
reaction mixture was stirred for 3 h at 78 °C. Pentane (10 mL) was added, leading to 
precipitation of the desired product. Filtration afforded indoline 3.60 (60.0 mg, 0.241 mmol, 
85%) as a 3:1 rotameric mixture as a colorless solid, which was used without further 
purification. 
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1H NMR (400 MHz, MeOD, major rotamer) δ/ppm 7.71–7.62 (m, 1H), 6.98 (d, J = 8.2 Hz, 
1H), 6.48 (dd, J = 8.1, 2.5 Hz, 1H), 5.09 (dd, J = 10.8, 2.5 Hz, 1H), 4.28–4.14 (m, 2H), 3.53 
(dd, J = 16.1, 10.9 Hz, 1H), 3.17 (dd, J = 15.9, 2.7 Hz, 1H), 2.16 (s, 3H), 1.27 (t, J = 7.3 Hz, 
3H). 
 
Ethyl 1-acetyl-6-(methoxymethoxy)indoline-2-carboxylate (3.61) 
Indoline 3.60 (75.0 mg, 0.301 mmol, 1.0 eq.) and MOMCl (45.7 µL, 
0.602 mmol, 2.0 eq.) were dissolved in CH2Cl2 (6 mL) and cooled to 
0 °C. DIPEA (149 µL, 0.903 mmol, 3.0 eq.) was added at 0 °C and the 
reaction mixture was stirred for 20 h at room temperature. The solvent was removed under 
reduced pressure and the crude residue was directly purified by flash column chromatography 
(SiO2, CH2Cl2/EtOAc 10:1) to give a 3:2 rotameric mixture of racemic indoline 3.61 
(77.0 mg, 0.263 mmol, 87%) as a colorless solid.  
 
1H NMR (400 MHz, CDCl3, major rotamer) δ/ppm 7.98 (s, 1H), 7.05 (dd, J = 17.7, 8.0 Hz, 
1H), 6.72 (dd, J = 8.2, 2.3 Hz, 1H), 5.16 (s, 2H), 4.94–4.84 (m, 1H), 4.21 (td, J = 11.7, 8.8, 
4.8 Hz, 2H), 3.61–3.49 (m, 1H), 3.48 (s, 3H), 3.19 (d, J = 16.1 Hz, 1H), 2.16 (s, 3H), 1.27 (t, 
J = 7.1 Hz, 3H). 
 
Ethyl 1-acetyl-6-(methoxymethoxy)octahydro-1H-indole-2-carboxylate (3.61b) 
Rh/C (5% w/w, 52.9 mg, 25.7 µmol, 0.10 eq.) was added to a solution 
of racemic indoline 3.57 (75.0 mg, 0.257 mmol, 1.0 eq.) in MeOH 
(1.2 mL). The reaction mixture was stirred for 14 h at room 
temperature under H2 pressure (50 bar). The catalyst was filtered off 
over Celite®, the Celite® was washed with MeOH (2 x 5 mL) and the 
solvent was removed under reduced pressure to obtain a 2:1 rotameric 
mixture of racemic octahydroindole 3.61b (76.5 mg, 0.257 mmol, quant.) as a colorless oil.  
 
1H NMR (400 MHz, MeOD, major rotamer) δ/ppm 4.69 (s, 2H), 4.36 (dd, J = 10.2, 8.1 Hz, 
1H), 4.17 (qd, J = 7.1, 3.0 Hz, 2H), 4.05 (dt, J = 12.1, 6.3 Hz, 1H), 3.52 (tt, J = 11.5, 3.7 Hz, 
1H), 3.36 (s, 3H), 2.49–2.32 (m, 1H), 2.32–2.23 (m, 1H), 2.19 (ddd, J = 12.6, 8.2, 6.8 Hz, 
1H), 2.11 (s, 3H), 2.04–1.93 (m, 1H), 1.88–1.80 (m, 2H), 1.80–1.70 (m, 1H), 1.61 (q, J = 12.1 
Hz, 1H), 1.45–1.32 (m, 1H), 1.27 (t, J = 7.1 Hz, 3H). 
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D-diepi-Choi (3.59) 
From 3.58: Octahydroindole 3.58 (37.5 mg, 0.14 mmol, 1.0 eq.) was 
suspended in aq. HCl solution (6 M, 1.9 mL) and heated at reflux for 5 h. 
The H2O was removed under reduced pressure to give D-diepi-Choi 
hydrochloride salt (3.59) (26.0 mg, 0.140 mmol, quant.) as a colorless solid, which was used 
without further purification. 
 
From racemic 3.61b: Octahydroindole 3.61b (35.9 mg, 0.120 mmol, 1.0 eq.) was suspended 
in aq. HCl solution (6 M, 1.6 mL) and heated at reflux for 5 h. The H2O was removed under 
reduced pressure to give racemic diepi-Choi hydrochloride salt (3.59) (26.6 mg, 0.120 mmol, 
quant.) as a colorless solid. 
 
1H NMR (400 MHz, MeOD) δ/ppm 4.45 (dd, J = 11.8, 4.2 Hz, 1H), 4.12–4.05 (m, 1H), 3.80 
(dd, J = 4.5 Hz, 1H), 2.63 (ddd, J = 13.5, 11.7, 6.6 Hz, 1H), 2.45–2.37 (m, 1H), 2.18–2.03 (m, 
2H), 1.97 (ddd, J = 15.1, 4.3, 2.8 Hz, 1H), 1.86–1.73 (m, 1H), 1.67–1.56 (m, 3H); 13C NMR 
(101 MHz, MeOD) δ/ppm 172.9, 65.9, 61.1, 58.7, 37.3, 35.3, 31.0, 30.6, 21.6. 
 
2.2.2.  Synthesis of the Agmantin Side Chain 
1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (3.63) 
2-Methyl-2-thiopseudourea hemisulfate (3.62) (0.630 g, 4.49 mmol, 1.0 eq.) 
was dissolved in CH2C12 (15 mL). Boc2O (2.40 g, 10.8 mmol, 2.4 eq.) and sat. 
aq. NaHCO3 solution (14.4 mL) were added to this solution at room temperature. The reaction 
mixture was stirred for 18 h at room temperature and was then diluted with CH2Cl2 (20 ml). 
The layers were separated and the aqueous layer was extracted with CH2Cl2 (2 x 20 mL) and 
the combined organic layers were washed with brine (10 mL), dried over Na2SO4 and the 
solvent was removed under reduced pressure. The crude product was purified by flash column 
chromatography (SiO2, pentane/EtOAc 15:1) to give thiopseudourea derivative 3.63 (1.20 g, 
4.13 mmol, 92%) as a colorless solid. 
 
1H NMR (400 MHz, CDCl3) δ/ppm 2.40 (s, 3H), 1.51 (s, 18H); 13C NMR (101 MHz, CDCl3) 
δ/ppm 171.6, 28.2, 14.6. The remaining 13C signals could not be resolved. 
Analytical data are in accordance with those reported in the literature.[15] 
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tert-Butyl (Z)-(N-(4-aminobutyl)-N'-(tert-butoxycarbonyl)carbamimidoyl)-O2-azane-
carboxylate (3.64) 
A solution of thiopseudourea derivative 3.63 (0.200 g, 0.689 mmol, 
1.0 eq.) in THF (1.7 mL) was added dropwise to a solution of 
1,4-butanediamine (0.17 mL, 1.72 mmol, 2.5 eq.) in THF (2.6 mL) and H2O (0.1 mL) at room 
temperature. The resulting mixture was stirred for 1 h at 50 °C. CHCl3 (20 mL) and sat. aq. 
NaHCO3 solution (20 mL) were added, the layers were separated and the aqueous layer was 
extracted with CHCl3 (2 x 20 mL). The combined organic layers were dried over MgSO4 and 
the solvent was removed under reduced pressure to give agmantin side chain 3.64 (0.220 g, 
0.666 mmol, 97%) as a colorless solid. 
 
Mp = 86.7–87.5 °C; FTIR ṽ/cm−1 3335, 3134, 2979, 2933, 2866, 1715, 1633, 1611, 1568, 
1475, 1452, 1413, 1392, 1366, 1324, 1286, 1251, 1227, 1152, 1125, 1051, 1024, 926, 877, 
852, 808, 757, 663, 617, 505, 461; 1H NMR (400 MHz, CDCl3) δ/ppm 11.49 (s, 1H), 8.33 (s, 
1H), 3.43 (td, J = 7.1, 5.2 Hz, 2H), 2.72 (t, J = 6.9 Hz, 2H), 1.67–1.57 (m, 2H), 1.55–1.45 (m, 
2H) 1.50 (s, 9H), 1.49 (s, 9H); 13C NMR (101 MHz, CDCl3) δ/ppm 163.8, 156.3, 153.5, 83.2, 
79.4, 42.0, 40.9, 31.1, 28.5, 28.2, 26.6; HRMS ESI m/z calc. for C15H31N4O4 [M+H]+: 
331.2340, found: 331.2336. 
Analytical data are in accordance with those reported in the literature.[16]  
2.2.3.  Synthesis of the L-Hpla building block 
(S)-2-Amino-3-(4-(benzyloxy)phenyl)propanoic acid (3.66) 
L-Tyrosine (3.65) (3.10 g, 17.1 mmol, 1.0 eq.) was dissolved in aq. 
NaOH solution (2 M, 17 mL). A solution of CuSO4·5H2O (2.13 g, 
8.55 mmol, 0.50 eq.) in H2O (12.8 mL) was added and the reaction 
mixture was stirred for 15 min at room temperature. The mixture was diluted with MeOH 
(64 mL) and additional aq. NaOH solution (2 M, 2.6 ml) was added. After stirring for 30 min 
at room temperature, benzyl bromide (2.05 mL, 17.1 mmol, 1.0 eq.) was added and the 
mixture was stirred for 16 h. The blue-violet precipitate was filtered off and the filter cake 
was washed with H2O/MeOH (3:1, 40 mL) and MeOH (5 mL). The solid was washed with aq. 
HCl solution (1 M, 6 x 15 mL), H2O (2 x 10 mL), aq. NH4OH solution (2 M, 5 x 10 mL) and 
H2O (2 x 10 mL) to give tyrosine derivative 3.66 (3.37 g, 12.4 mmol, 62%) as a colorless 
solid which was used without further purification. 
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(S)-2-Acetoxy-3-(4-(benzyloxy)phenyl)propanoic acid (3.67) 
Isoamyl nitrite (1.74 mL, 12.9 mmol, 3.5 eq.) and NaOAc (1.06 g, 
12.9 mmol, 3.5 eq.) were slowly added to a solution of tyrosine 
derivative 3.66 (1.0 g, 3.69 mmol, 1.0 eq.) in glacial acetic acid 
(15 mL). The reaction mixture was stirred for 24 h at room temperature before the acetic acid 
was removed under reduced pressure. The obtained residue was partitioned between aq. HCl 
solution (1 M, 20 mL) and EtOAc (20 mL). The layers were separated and the aqueous layer 
was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with H2O 
(10 mL) and brine (10 mL), dried over MgSO4 and the solvent was removed under reduced 
pressure. The crude product was purified by flash column chromatography 
(SiO2, pentane/EtOAc/AcOH 1:9:1) to give L-Hpla building block 3.67 (0.800 g, 2.55 mmol, 
69%) as a colorless solid.  
 
Optical rotation [𝛼]஽ଶହ = 4.7 (c = 0.44, CHCl3); FTIR ṽ/cm−1 3033, 1742, 1611, 1585, 
1513, 1454, 1375, 1235, 1178, 1114, 1075, 1042, 1026, 917, 829, 736, 697, 609, 525; 
1H NMR (400 MHz, CDCl3) δ/ppm 7.46–7.32 (m, 6H), 7.20–7.13 (m, 2H), 6.96–6.84 (m, 
2H), 5.21 (dd, J = 8.7, 4.1 Hz, 1H), 5.05 (s, 2H), 3.17 (dd, J = 14.5, 4.2 Hz, 1H), 3.07 (dd, J 
= 14.4, 8.7 Hz, 1H), 2.09 (s, 3H); 13C NMR (101 MHz, CDCl3) δ/ppm 170.5, 158.1, 137.1, 
130.5, 128.7, 128.1, 127.6, 115.0, 72.8, 70.2, 36.5, 20.7. 
Analytical data are in accordance with those reported in the literature.[17] 
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2.2.4.  Assembly of the Different Building Blocks – Synthesis of AKT608A 
Methyl (2R,3aR,6R,7aR)-1-((tert-butoxycarbonyl)-D-phenylalanyl)-6-hydroxyoctahydro-
1H-indole-2-carboxylate (3.71) 
SOCl2 (30.0 µL, 0.150 mmol, 1.1 eq.) was added dropwise to a 
solution of D-diepi-Choi hydrochloride salt (3.59)  (26.0 mg, 
0.140 mmol, 1.0 eq.) in MeOH (0.9 mL) at 0 °C. The reaction mixture 
was stirred for 4 h at 70 °C. The solvent was removed under reduced 
pressure to give the corresponding D-diepi-Choi methyl ester 
hydrochloride salt (3.70) which was dissolved in CH2Cl2 (3.0 mL). Boc-D-Phe-OH (3.69) 
(48.3 mg, 0.180 mmol, 1.3 eq.) was added to this solution. The mixture was cooled to 0 °C 
before PyBOP (94.7 mg, 0.180 mmol, 1.3 eq.) and NMM (53.9 µL, 0.490 mmol, 3.5 eq.) were 
added. The reaction mixture was stirred for 30 min at 0 °C and further for 72 h at room 
temperature The solvent was removed under reduced pressure and the crude residue directly 
purified by flash column chromatography (SiO2, pentane/EtOAc 1:1) to give a 3:1 rotameric 
mixture of dipeptide 3.71 (40.2 mg, 90.0 µmol, 64%) as a colorless, viscous oil. 
 
Rf = 0.43 (SiO2, pentane/EtOAc 1:1); Optical rotation[𝛼]஽ଶହ = +8.7 (c = 0.10, CHCl3); FTIR 
ṽ/cm−1 2933, 2866, 1741, 1703, 1635, 1498, 1439, 1366, 1249, 1053, 1022, 984, 844, 700, 
661; 1H NMR (400 MHz, CDCl3, major rotamer) δ/ppm 7.28–7.13 (m, 5H), 5.31 (dd, J = 
12.8, 8.7 Hz, 1H), 5.02 (d, J = 9.4 Hz, 1H), 4.51 (q, J = 7.1 Hz, 1H), 4.38 (dd, J = 10.4, 
8.0 Hz, 1H), 4.23–4.09 (m, 1H), 3.70 (s, 3H), 3.41 (tq, J = 11.7, 4.0 Hz, 1H), 3.35–3.26 (m, 
1H), 3.08 (dd, J = 13.0, 6.6 Hz, 1H), 2.96 (dd, J = 12.8, 4.6 Hz, 1H), 2.83–2.78 (m, 1H), 2.26 
(dt, J = 13.0, 6.4 Hz, 1H), 2.06 (dt, J = 12.5, 7.4 Hz, 1H), 1.88 (dd, J = 12.9, 10.4 Hz, 1H), 
1.76–1.40 (m, 3H), 1.30 (s, 9H); 13C NMR (101 MHz, CDCl3, major rotamer) δ/ppm 172.4, 
171.3, 155.4, 136.7, 129.8, 129.5, 128.6, 126.9, 80.0, 68.3, 59.3, 57.8, 53.0, 52.4, 37.7, 36.6, 
29.2, 28.5, 28.4, 22.9; HRMS ESI m/z calc. for C24H35N2O6 [M+H]+: 447.2490, found: 
447.2493. 
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Methyl (2R,3aR,6R,7aR)-1-(((S)-2-acetoxy-3-(4-(benzyloxy)phenyl)propanoyl)-D-
phenylalanyl)-6-hydroxyoctahydro-1H-indole-2-carboxylate (3.73) 
Dipeptide 3.71 (34.6 mg, 80.0 µmol, 1.0 eq.) was 
dissolved in CH2Cl2 (1.0 mL) and cooled to 0 °C. TFA 
(0.2 mL) was added and the mixture was stirred for 1 h at 
0 °C. TFA and CH2Cl2 were removed under reduced 
pressure to obtain crude dipeptide 3.72. The obtained residue was dissolved in CH2Cl2 (0.5 
mL) and NMM (14.0 µL, 0.130 mmol, 1.6 eq.) was added. The obtained solution was treated 
with an ice-cooled solution of L-Hpla-OH derivate 3.67 (30.2 mg, 96.0 µmol, 1.2 eq.) in 
CH2Cl2 (1 mL) which had been stirring for 30 min at 0 °C with PyBOP (50.0 mg, 96.0 µmol, 
1.2 eq.) and NMM (17.6 µL, 0.160 mmol, 2.0 eq.). The reaction mixture was stirred for 36 h 
at room temperature. CH2Cl2 (5 mL) was added and the solution was washed with aq. HCl 
solution (1 M, 3 x 2 mL), sat. aq. NaHCO3 solution (2 mL) and brine (2 mL). The organic 
layer was dried over Na2SO4 and the solvent was removed under reduced pressure. The crude 
residue was purified by flash column chromatography (SiO2, pentane/EtOAc 1:1) to give a 
3:1 rotameric mixture of tripeptide 3.73 (31.0 mg, 48.2 µmol, 60%) as a colorless, viscous oil.  
 
Rf = 0.31 (SiO2, pentane/EtOAc 1:2); Optical rotation[𝛼]஽ଶହ = –3.84 (c = 0.25, CHCl3); 
FTIR ṽ/cm−1 3276, 3063, 3036, 2360, 2342, 1743, 1678, 1627, 1512, 1254, 1370, 1299, 1232, 
1177, 1059, 1027, 920, 755, 700, 669, 607; 1H NMR (400 MHz, CDCl3, major rotamer) 
δ/ppm 7.38–7.28 (m, 4H), 7.27–7.15 (m, 4H), 7.14–7.02 (m, 2H), 6.98–6.93 (m, 2H), 6.79–
6.74 (m, 2H), 6.48 (d, J = 8.5 Hz, 1H), 5.26 (dt, J = 7.9, 4.8 Hz, 1H), 5.18 (dd, J = 7.7, 4.4 
Hz, 1H), 4.95 (s, 2H), 4.82–4.72 (m, 1H), 4.34 (dd, J = 10.4, 8.0 Hz, 1H), 4.14 (dt, J = 12.2, 
6.1 Hz, 1H), 3.68 (s, 3H), 3.49–3.39 (m, 1H), 3.07 (dd, J = 13.8, 7.1 Hz, 1H), 2.97 (dd, J = 
14.4, 4.5 Hz, 1H), 2.86 (dd, J = 14.4, 7.7 Hz, 1H), 2.78 (dd, J = 13.8, 6.6 Hz, 1H), 2.29–2.19 
(m, 1H), 2.10–1.97 (m, 2H), 1.91 (s, 3H), 1.77–1.52 (m, 3H), 1.40–1.13 (m, 3H); 13C NMR 
(101 MHz, CDCl3, major rotamer) δ/ppm 172.3, 169.8, 169.4, 168.9, 157.9, 137.1, 135.9, 
130.6, 129.9, 128.70, 128.66, 128.2, 128.1, 127.7, 127.64, 127.61, 127.2, 114.8, 74.3, 70.1, 
68.4, 59.3, 57.9, 52.4, 51.2, 39.2, 37.7, 37.1, 36.7, 29.2, 22.9, 20.9; HRMS ESI m/z calc. for 
C37H43N2O8 [M+H]+: 643.3014, found: 643.3017. 
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(2R,3aR,6R,7aR)-1-(((S)-3-(4-(Benzyloxy)phenyl)-2-hydroxypropanoyl)-D-phenylalanyl) 
-6-hydroxyoctahydro-1H-indole-2-carboxylic acid (3.74) 
At 0 °C, a solution of LiOH (2.87 mg, 0.120 mmol, 3.0 eq.) in 
H2O (1.2 mL) was added dropwise to a solution of tripeptide 
methyl ester 3.73 (25.7 mg, 40.0 µmol, 1.0 eq.) in THF (1 mL). 
The obtained suspension was stirred for 20 h at room 
temperature. The solvents were removed under reduced pressure 
and the obtained residue was dissolved in H2O (5 mL) and 
washed with Et2O (2 x 5 mL). The aqueous layer was acidified with aq. HCl solution (1 M, 
0.2 mL) and extracted with CH2Cl2/iPrOH (4:1, 4 x 5 mL). The combined organic layers were 
dried over Na2SO4 and the solvent was removed under reduced pressure to give carboxyl 
tripeptide 3.74 (23.5 mg, 0.120 mmol, quant.) as a colorless solid, which was used without 
further purification. 
 
tert-Butyl ((Z)-N-(4-((2R,3aR,6R,7aR)-1-(((S)-3-(4-(benzyloxy)phenyl)-2-hydroxypropan-
oyl)-D-phenylalanyl)-6-hydroxyoctahydro-1H-indole-2-carboxamido)butyl)-N'-(tert-but-
oxycarbonyl)carbamimidoyl)-O2-azanecarboxylate (3.75) 
Crude tripeptidic acid 3.74 (23.5 mg, 
40.0 µmol, 1.0 eq.) and agmantine side chain 3.64 
(17.6 mg, 53.2 µmol, 1.3 eq.) were dissolved in DMF 
(1 mL) and cooled to 0 °C. PyBOP (20.8 mg, 
40.0 mmol, 1.0 eq.) and NMM (11.0 µL, 0.100 mmol, 
2.5 eq.) were added and the mixture was stirred for 
30 min at 0 °C and further 48 h at room temperature. EtOAc (10 mL) was added and the 
solution was washed with sat. aq. NaHCO3 solution (5 mL) and H2O (4 x 5 mL). The 
combined aqueous layers were extracted with EtOAc (5 mL) and the combined organic layers 
were dried over Na2SO4. The solvent was removed under reduced pressure and the crude 
residue was purified by flash column chromatography (SiO2, EtOAc/MeOH 50:1) to give a 
3:1 rotameric mixture of tetrapeptide 3.75 (22.0 mg, 24.0 µmol, 61%) as a colorless 
amorphous solid. 
 
Rf = 0.72 (SiO2, EtOAc/MeOH 2:1); FTIR ṽ/cm−1 3391, 2928, 2860, 1720, 1627, 1511, 1455, 
1416, 1367, 1330, 1230, 1134, 1053, 1027, 801, 752, 698, 668, 649, 611; 1H NMR 
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(400 MHz, CDCl3, major rotamer) δ/ppm 11.49 (s, 1H), 8.31 (t, J = 5.4 Hz, 1H), 7.46–7.34 
(m, 4H), 7.33–7.19 (m, 4H), 7.18–7.13 (m, 1H), 7.12–7.04 (m, 2H), 6.96–6.83 (m, 2H), 6.65 
(t, J = 5.9 Hz, 1H), 5.03 (s, 2H), 4.87 (q, J = 8.0 Hz, 1H), 4.43 (t, J = 8.8 Hz, 1H), 4.31–4.18 
(m, 2H), 3.52–3.36 (m, 2H), 3.34–3.02 (m, 3H), 2.99–2.86 (m, 1H), 2.81–2.68 (m, 1H), 2.37 
(td, J = 12.9, 9.1 Hz, 1H), 2.24–2.13 (m, 1H), 2.03–1.72 (m, 2H), 1.69–1.53 (m, 1H), 1.49 (s, 
9H), 1.47 (s, 9H); 13C NMR (101 MHz, CDCl3, major rotamer) δ/ppm 172.5, 170.9, 170.7, 
163.7, 158.1, 156.3, 153.4, 137.1, 136.1, 130.6, 129.5, 128.9, 128.8, 128.74, 128.70, 128.1, 
127.7, 127.5, 115.2, 83.3, 79.4, 72.9, 70.2, 68.6, 59.9, 58.8, 51.9, 40.7, 40.0, 39.5, 39.3, 37.3, 
36.3, 29.8, 28.4, 28.2, 27.0, 26.8, 23.0; HRMS ESI m/z calc. for C49H67N6O10 [M+H]+: 
899.4913, found: 899.4919. 
 
Aeruginosin KT608A (3.1) 
Tetrapeptide 3.75 (4.00 mg, 4.45 µmol, 1.0 eq.) was 
dissolved in MeCN (0.3 mL). Aq. HCl solution (6 M, 60 
µL) was added and the reaction mixture was stirred for 
24 h at room temperature. The solvent was removed 
under reduced pressure and the obtained residue was 
dissolved in EtOAc/MeOH (1:1, 0.3 mL). Pd/C 
(10% w/w, 1.70 mg, 1.60 µmol, 0.36 eq.) was added and the reaction mixture was stirred for 
12 h under a H2 atmosphere. Additional Pd/C (10% w/w, 1.70 mg, 1.60 µmol, 0.36 eq.) was 
added and the reaction mixture was stirred for 24 h at room temperature. The catalyst was 
filtered off over a short pad of Celite® and the Celite® was washed with MeOH (2 x 3 mL). 
The solvents were removed under reduced pressure and the obtained crude residue was 
purified by reversed phase HPLC (MeCN/H2O + 0.1% formic acid) to obtain a 3:1 rotameric 
mixture of aeruginosin KT608A (3.1) (1.00 mg, 1.65 µmol, 37%) as a white amorphous solid. 
 
1H NMR (600 MHz, DMSO-d6, major rotamer) δ/ppm 9.27 (s, 1H), 8.61 (s, 1H), 7.97–7.90 
(m, 2H), 7.32–7.18 (m, 6H), 6.87 (d, J = 8.4 Hz, 2H), 6.61–6.56 (m, 2H), 5.32 (s, 1H), 4.66 
(td, J = 8.9, 4.6 Hz, 1H), 4.27–4.21 (m, 2H), 4.02–3.84 (m, 1H), 3.39–3.31 (m, 1H),  3.13–
3.01 (m, 3H), 2.91 (dd, J = 14.1, 4.5 Hz, 1H), 2.82 (dd, J = 14.1, 9.3 Hz, 1H), 2.64 (dd, J = 
13.9, 3.9 Hz, 1H), 2.43 (dd, J = 13.8, 8.3 Hz, 1H), 2.17–2.08 (m, 1H), 2.01–1.94 (m, 1H), 
1.92–1.86 (m, 1H), 1.86–1.78 (m, 1H), 1.77–1.66 (m, 1H), 1.64–1.54 (m, 2H), 1.53–1.42 (m, 
2H), 1.31–1.17 (m, 1H).; 13C NMR (151 MHz, DMSO-d6, major rotamer) δ/ppm 173.1, 
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171.1, 169.3, 157.3, 155.6, 137.4, 130.2, 129.2, 128.24, 128.16, 126.4, 114.6, 72.0, 66.9, 59.8, 
57.3, 50.9, 40.3, 39.9, 37.9, 37.8, 36.0, 30.6, 29.2, 26.3, 25.8, 22.7. LRMS ESI m/z calc. for 
C32H45N6O6 [M+H]+: 609.3, found: 609.3.
2.2.5.  Synthesis of Indoline 3.56 via C-H Activation 
Methyl picolinoyl-L-tyrosinate (3.84) 
Tyrosine methyl ester (3.83) (3.51 g, 18.0 mmol, 1.0 eq.) was 
dissolved in CH2Cl2 (90 mL). 2-picolinic acid (2.44 g, 19.8 mmol, 
1.1 eq.), benzotriazol-1-ol (2.68 g, 19.8 mmol, 1.1 eq.), EDC (3.80 g, 
19.8 mmol, 1.1 eq.) and DIPEA (8.89 mL, 53.8 mmol, 2.9 eq.) were 
added and the reaction mixture was stirred for 16 h at room temperature. H2O (40 mL) was 
added, the layers were separated and the aqueous layer was extracted with CH2Cl2 
(2 x 60  mL). The combined organic layers were washed with H2O (20 mL) and brine (20 mL) 
and dried over Na2SO4. The solvent was removed under reduced pressure and the residue was 
purified by flash column chromatography (SiO2, pentane/EtOAc 1:1) to give methyl 
picolinoyl-L-tyrosinate (3.84) (3.00 g, 9.99 mmol, 56%) as a very viscous, colorless oil. 
Rf = 0.39 (SiO2, pentane/EtOAc 1:1); Optical rotation [𝛼]஽ଶହ = +45.9 (c = 0.23, CHCl3);
FTIR ṽ/cm−1 3366, 3067, 3011, 2950, 1739, 1658, 1615, 1513, 1465, 1434, 1364, 1267, 1215,
1172, 1109, 998, 841, 820, 748, 734, 698, 620, 535, 490; 1H NMR (400 MHz, CDCl3) δ/ppm
8.55 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 8.51 (d, J = 8.6 Hz, 1H), 8.14 (ddd, J = 7.8, 0.9 Hz, 1H), 
7.83 (td, J = 7.7, 1.7 Hz, 1H), 7.42 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 7.07–6.99 (m, 2H), 6.78–
6.68 (m, 2H), 5.03 (ddd, J = 8.5, 6.6, 5.7 Hz, 1H), 3.73 (s, 3H), 3.20 (dd, J = 14.0, 5.7 Hz, 
1H), 3.11 (dd, J = 14.0, 6.7 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ/ppm 172.1, 164.3,
155.2, 149.3, 148.5, 137.5, 130.5, 127.8, 126.6, 122.5, 115.7, 53.8, 52.5, 37.7; HRMS ESI 
m/z calc. for C16H17N2O4 [M+H]+: 301.1183, found: 301.1180.
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Methyl (S)-3-(4-methoxyphenyl)-2-(picolinamido)propanoate (3.87) 
A suspension of methyl picolinoyl-L-tyrosinate (3.84) (2.22 g, 
7.40 mmol, 1.0 eq.) and K2CO3 (1.33 g, 9.62 mmol, 1.3 eq.) in DMF 
(5 mL) was treated with MeI (0.51 mL, 8.14 mmol, 1.1 eq.) and 
stirred at room temperature for 17 h. The solvent was removed under 
reduced pressure and the residue was suspended in H2O (50 mL). The aqueous layer was 
extracted with EtOAc (3 x 50 mL) and the combined organic layers were washed with brine 
(20 mL), dried over Na2SO4 and the solvent was removed under reduced pressure. The 
obtained crude residue was purified by flash column chromatography (SiO2, pentane/EtOAc 
5:1) to give picoline tyrosinate derivative 3.87 (2.20 g, 7.00 mmol, 95%) a colorless oil. 
 
Rf = 0.20 (SiO2, pentane/EtOAc 5:1); Optical rotation [𝛼]஽ଶହ = +57.5 (c = 1.09, CHCl3); 
FTIR ṽ/cm−1 3385, 3006, 2955, 1739, 1674, 1612, 1509, 1465, 1433, 1362, 1301, 1246, 1213, 
1177, 1112, 1032, 998, 839, 820, 750, 699, 620, 539; 1H NMR (400 MHz, CDCl3) δ/ppm 
8.55 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 8.52–8.48 (m, 1H), 8.16 (dt, J = 7.8, 1.1 Hz, 1H), 7.84 
(td, J = 7.7, 1.7 Hz, 1H), 7.43 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 7.10 (d, J = 8.7 Hz, 2H), 6.81 (d, 
J = 8.7 Hz, 2H), 5.02 (dt, J = 8.3, 6.1 Hz, 1H), 3.77 (s, 3H), 3.73 (s, 3H), 3.24–3.13 (m, 2H); 
13C NMR (101 MHz, CDCl3) δ/ppm 172.0, 164.0, 158.8, 149.4, 148.3, 137.5, 130.4, 128.1, 
126.5, 122.5, 114.1, 55.3, 53.8, 52.4, 37.6; HRMS ESI m/z calc. for C17H19N2O4 [M+H]+: 
315.1339, found: 315.1339. 
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Methyl (S)-6-methoxy-1-picolinoylindoline-2-carboxylate (3.90) 
PhI(OAc)2 (653 mg, 1.99 mmol, 2.5 eq.) and Pd(OAc)2 (17.8 mg, 
80.0 mmol, 0.10 eq.) were added to a solution of picoline tyrosinate 
derivative 3.87 (250 mg, 0.795 mmol, 1.0 eq.) in toluene (8 mL). The 
reaction mixture was stirred for 20 h at 60 °C. The solvent was 
removed under reduced pressure and the obtained residue purified by flash column 
chromatography (SiO2, pentane/EtOAc 3:2) to give indoline 3.90 (113 mg, 0.360 mmol, 46%) 
as a colorless oil.  
 
Rf = 0.53 (SiO2, pentane/EtOAc 1:1); Optical rotation [𝛼]஽ଶହ = 46.7 (c = 1.03, CHCl3); 
FTIR ṽ/cm−1 3006, 2959, 2833, 1742, 1648, 1497, 1436, 1387, 1334, 1284, 1232, 1199, 1174, 
1160, 1105, 1030, 1010, 997, 911, 852, 811, 728, 691; 1H NMR (400 MHz, CDCl3) δ/ppm 
8.52 (d, J = 3.4 Hz, 1H), 8.18–8.04 (m, 2H), 7.85 (t, J = 7.8 Hz, 1H), 7.38 (t, J = 6.3 Hz, 1H), 
7.07 (d, J = 8.2 Hz, 1H), 6.66 (d, J = 8.3 Hz, 1H), 5.83 (d, J = 11.0 Hz, 1H), 3.86 (s, 3H), 3.63 
(s, 3H), 3.56 (dd, J = 15.9, 11.1 Hz, 1H), 3.18 (d, J = 15.9 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ/ppm 172.9, 165.5, 159.7, 153.2, 147.2, 144.9, 137.3, 125.5, 125.2, 124.5, 121.1, 
111.3, 104.1, 63.6, 55.7, 52.4, 33.2; HRMS ESI m/z calc. for C17H17N2O4 [M+H]+: 313.1183, 
found: 313.1185. 
 
Ethyl (S)-6-methoxyindoline-2-carboxylate (3.91) 
Indoline 3.90 (40.0 mg, 0.128 mmol, 1.0 eq.) was dissolved in aq. HCl 
solution (6 M, 3 mL) at room temperature and stirred at 100 °C for 2 h. 
The reaction mixture was let to cool to room temperature and the solvent was removed under 
reduced pressure to give (S)-6-methoxyindoline-2-carboxylic acid as crude product which was 
subsequently dissolved in EtOH (5 mL) and cooled to 0 °C. SOCl2 (28.0 µL, 0.384 mmol, 
3.0 eq.) was added dropwise and the reaction mixture was stirred for 3 h at 79 °C. The solvent 
was removed under reduced pressure and the obtained crude residue was purified by flash 
column chromatography (SiO2, pentane/EtOAc 1:1) to give indoline ethyl ester 3.91 
(4.00 mg, 18.0 µmol, 14%) as a colorless oil. 
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1H NMR (400 MHz, CDCl3) δ/ppm 6.97 (dt, J = 8.4, 1.2 Hz, 1H), 6.40 (d, J = 2.3 Hz, 1H), 
6.34 (dd, J = 8.1, 2.3 Hz, 1H), 4.43 (dd, J = 10.3, 5.2 Hz, 1H), 4.21 (qd, J = 7.1, 1.0 Hz, 2H), 
3.75 (s, 3H), 3.36 (ddd, J = 15.6, 10.3, 1.1 Hz, 1H), 3.25 (dd, J = 15.5, 5.2 Hz, 1H), 1.29 (t, 
J = 7.1 Hz, 3H). 
 
Ethyl (S)-1-acetyl-6-methoxyindoline-2-carboxylate (3.56) 
Indoline 3.91 (4.00 mg, 18.0 µmol, 1.0 eq.) was dissolved in CH2Cl2 
(0.5 mL) and acetic anhydride (4.37 µL, 45.3 µmol, 2.5 eq.), Et3N 
(6.36 µL, 45.3 µmol, 2.5 eq.) and DMAP (0.220 mg, 1.81 µmol, 
0.10 eq.) were added. The reaction mixture was stirred for 16 h at room temperature before 
CH2Cl2 (5 mL) was added. The organic layer was washed with sat. aq. NaHCO3 solution 
(2 mL), dried over MgSO4 and the solvent was removed under reduced pressure. The obtained 
crude residue was purified by flash column chromatography (SiO2, pentane/EtOAc 4:1) to 
give a 2:1 rotameric mixture of ()-indoline 3.56 (3.40 mg, 13.0 µmol, 71%) as a colorless 
solid. 
 
Rf = 0.37 (SiO2, pentane/EtOAc 4:1); Optical rotation [𝛼]஽ଶହ = 79.4 (c = 0.17, CHCl3); 
1H NMR (400 MHz, CDCl3, major rotamer) δ/ppm 7.91 (s, 1H), 7.01 (d, J = 8.1 Hz, 1H), 
6.57 (d, J = 8.9 Hz, 1H), 4.89 (dd, J = 10.8, 2.6 Hz, 1H), 4.32–4.09 (m, 2H), 3.80 (s, 3H), 
3.55 (dd, J = 16.0, 10.8 Hz, 1H), 3.18 (d, J = 16.5 Hz, 1H), 2.16 (s, 3H), 1.27 (t, J = 7.1 Hz, 
3H); 1H NMR (400 MHz, CDCl3, minor rotamer) δ/ppm 7.08 (d, J = 8.3 Hz, 1H), 6.76 (s, 
1H), 6.61–6.54 (m, 1H), 5.13 (d, J = 10.7 Hz, 1H), 4.32–4.09 (m, 2H), 3.80 (s, 3H), 3.39 (dd, 
J = 16.2, 10.9 Hz, 1H), 3.00 (d, J = 16.0 Hz, 1H), 2.47 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H). 
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2.2.6.  Synthesis of D-diepi-Choi 3.110 
D-Tyrosine methyl ester hydrochloride (3.96) 
SOCl2 (4.01 mL, 55.2 mmol, 2.0 eq.) was added dropwise to a 
suspension of D-tyrosine (3.95) (5.00 g, 27.6 mmol, 1.0 eq.) in 
MeOH (37 mL) at 0 °C. The solution was stirred for 20 min at 0 °C 
and further 12 h at 67 °C. The reaction mixture was allowed to reach room temperature and 
the solvent was removed under reduced pressure to obtain D-tyrosine methyl ester 
hydrochloride (3.96) (6.40 g, 27.6 mmol, quant.) as a colorless solid which was used without 
further purification. 
 
1H NMR (400 MHz, MeOD) δ/ppm 7.14–7.02 (m, 2H), 6.82–6.75 (m, 2H), 4.24 (dd, J = 7.3, 
6.0 Hz, 1H), 3.81 (s, 3H), 3.17 (dd, J = 14.5, 6.0 Hz, 1H), 3.08 (dd, J = 14.5, 7.4 Hz, 1H); 
13C NMR (101 MHz, MeOD) δ/ppm 170.5, 158.4, 131.5, 125.6, 116.9, 55.4, 53.5, 36.6. 
Analytical data are in accordance with those reported in the literature.[18] 
 
Methyl (R)-2-amino-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)propanoate (3.97) 
Imidazole (4.14 g, 60.8 mmol, 2.2 eq.) and TBSCl (5.80 mL, 
33.2 mmol, 1.2 eq.) were added to a solution of D-tyrosine methyl 
ester hydrochloride (3.97) (6.40 g, 27.6 mmol, 1.0 eq.) in CH2Cl2 
(90 mL). The reaction mixture was stirred at room temperature for 16 h before quenching 
with sat. aq. NH4Cl solution (50 mL). The layers were separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 100 mL). The combined organic layers were dried over MgSO4 
and the solvent was removed under reduced pressure to obtain TBS protected tyrosine methyl 
ester 3.97 (7.40 g, 23.9 mmol, 87%) as a very viscous colorless oil which was used without 
further purification. 
  
1H NMR (400 MHz, CDCl3) δ/ppm 7.10–6.95 (m, 2H), 6.86–6.70 (m, 2H), 3.70 (s, 3H), 3.00 
(dd, J = 13.6, 5.3 Hz, 1H), 2.80 (dd, J = 13.6, 7.7 Hz, 1H), 1.43 (s, 2H), 0.97 (s, 9H), 0.18 (s, 
6H).  
Analytical data are in accordance with those reported in the literature.[18] 
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Pyridine-2-sulfonyl chloride 
A two necked flask was charged with 2-mercaptopyridine (5.00 g, 45.0 mmol, 
1.0 eq.) and sulphuric acid (96-98% w/w, 73 mL). The reaction mixture was cooled 
to 0 °C in an ice bath and aq. sodium hypochlorite solution (13% w/w, 220 mL) was 
slowly added with a dropping funnel over a period of 1.5 h. Vigorous chlorine gas evolution 
was observed upon addition. After the addition was complete, the reaction mixture was stirred 
for 20 min at 0 °C before CH2Cl2 (400 mL) was added. The layers were separated and the 
aqueous layer was extracted with CH2Cl2 (400 mL). The combined organic layers were 
washed with brine (100 mL), dried over MgSO4 and the solvent was removed under reduced 
pressure to give pyridine-2-sulfonyl chloride (5.40 g, 30.4 mmol, 67%) as a colorless oil 
which was used without further purification. 
 
1H NMR (400 MHz, CDCl3) δ/ppm 8.88–8.78 (m, 1H), 8.12 (ddt, J = 7.9, 1.5, 0.8 Hz, 1H), 
8.06 (ddd, J = 8.0, 7.5, 1.7 Hz, 1H), 7.69 (ddd, J = 7.5, 4.7, 1.3 Hz, 1H); 13C NMR 
(101 MHz, CDCl3) δ/ppm 159.4, 150.8, 139.2, 129.2, 122.1. 
Analytical data are in accordance with those reported in the literature.[19] 
 
Methyl (R)-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2-(pyridine-2-sulfonamido)-
propanoate (3.98) 
Et3N (4.76 mL, 33.9 mmol, 1.50 eq.) was added to a solution of TBS 
protected tyrosine methyl ester 3.97 (6.99 g, 22.6 mmol, 1.0 eq.) and 
pyridine-2-sulfonyl chloride (4.39 g, 24.9 mmol, 1.1 eq.) in CH2Cl2 
(70 mL). The reaction mixture was stirred for 16 h at room 
temperature, then the solvent was removed under reduced pressure. The crude product was 
purified by flash column chromatography (SiO2, pentane/EtOAc 1:1) to give sulfonamide 
3.98 (7.30 g, 16.2 mmol, 72%) as a very viscous, colorless oil. 
 
  
EXPERIMENTAL PART 
 
 
 
 248
 
Rf = 0.61 (SiO2, pentane/EtOAc 1:1); Optical rotation [𝛼]஽ଶହ = –5.9 (c = 1.0, CHCl3); FTIR 
ṽ/cm−1 3723, 2955, 2931, 2856, 1739, 1510, 1428, 1345, 1251, 1216, 1175, 1121, 1109, 1086, 
992, 910, 838, 778, 738, 688, 620, 594, 537, 468; 1H NMR (400 MHz, CDCl3) δ/ppm 8.62 
(ddd, J = 4.7, 1.7, 0.9 Hz, 1H), 7.92 (dt, J = 7.9, 1.2 Hz, 1H), 7.86 (dt, J = 7.5, 1.7 Hz, 1H), 
7.45 (ddd, J = 7.5, 4.7, 1.3 Hz, 1H), 7.02–6.92 (m, 2H), 6.76–6.65 (m, 2H), 5.29 (d, J = 
8.8 Hz, 1H), 4.58 (dt, J = 8.9, 5.8 Hz, 1H), 3.54 (s, 3H), 3.12–2.99 (m, 2H), 0.97 (s, 9H), 0.17 
(s, 6H); 13C NMR (101 MHz, CDCl3) δ/ppm 171.4, 157.9, 155.0, 149.9, 138.1, 130.5, 127.7, 
126.8,   121.8,   120.3,   57.8,   52.4,   39.1,   25.8,   18.3,   −4.3;;   HRMS ESI m/z calc. for 
C21H31N2O5SSi [M+H]+: 451.1718, found: 451.1719. 
 
Methyl (pyridin-2-ylsulfonyl)-D-tyrosinate (3.99) 
Sulfonamide 3.98 (4.82 g, 10.7 mmol, 1.0 eq.) was dissolved in THF 
(90 mL) and cooled to 0 °C. TBAF (1 M solution in THF, 16.0 mL, 
16.0 mmol, 1.5 eq.) was added dropwise and the reaction mixture was 
stirred for 10 min at 0 °C and further 2 h at room temperature. The 
reaction mixture was quenched by the addition of sat. aq. NH4Cl solution (150 mL). The 
layers were separated and the aqueous layer was extracted with EtOAc (3 x 100 mL). The 
combined organic layers were washed with brine (2 x 25 mL), dried over MgSO4 and the 
solvent was removed under reduced pressure. The crude product was purified by flash column 
chromatography (SiO2, pentane/EtOAc 1:2) to give sulfonamide 3.99 (2.84 g, 8.44 mmol, 
79%) as a colorless solid. 
 
Rf = 0.43 (SiO2, pentane/EtOAc 1:2); Mp = 137.4–138.4 °C; Optical rotation  [𝛼]஽ଶହ = –6.2 
(c = 0.50, CHCl3); FTIR ṽ/cm−1 3277, 1736, 1514, 1427, 1339, 1331, 1248, 1232, 1172, 
1108, 1082, 851, 822, 781, 741, 619, 607, 569, 550, 533, 486; 1H NMR (400 MHz, MeOD) 
δ/ppm 8.54 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 7.94 (td, J = 7.8, 1.8 Hz, 1H), 7.80 (dt, J = 7.9, 
1.1 Hz, 1H), 7.54 (ddd, J = 7.6, 4.7, 1.2 Hz, 1H), 7.08–6.87 (m, 2H), 6.66–6.54 (m, 2H), 4.30 
(dd, J = 8.3, 6.1 Hz, 1H), 3.52 (s, 3H), 2.94 (dd, J = 13.8, 6.2 Hz, 1H), 2.80 (dd, J = 13.8, 
8.3 Hz, 1H); 13C NMR (101 MHz, MeOD) δ/ppm 173.3, 159.3, 157.3, 150.7, 139.6, 131.3, 
128.2, 127.9, 122.7, 116.2, 59.7, 52.6, 39.2; HRMS ESI m/z calc. for C15H17N2O5S [M+H]+: 
337.0853, found: 337.0855. 
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Methyl (R)-3-(4-acetoxyphenyl)-2-(pyridine-2-sulfonamido)propanoate (3.100) 
Et3N (1.63 mL, 11.6 mmol, 1.4 eq.) and DMAP (50.6 mg, 0.410 mmol, 
0.050 eq.) were added to a solution of sulfonamide 3.99 (2.80 g, 
8.29 mmol, 1.0 eq.) in CH2Cl2 (44 mL). The reaction mixture was 
stirred for 5 min at room temperature before acetyl chloride (0.59 mL, 
8.29 mmol, 1.0 eq.) was added. The reaction mixture was stirred for 1 h at room temperature 
before quenching by the addition of sat. aq. NH4Cl solution (50 mL). The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (2 x 50 mL). The combined 
organic layers were dried over MgSO4 and the solvent was removed under reduced pressure. 
The crude product was purified by flash column chromatography (SiO2, pentane/EtOAc 1:1) 
to give sulfonamide 3.100 (2.29 g, 7.16 mmol, 86%) as colorless crystals. 
 
Rf = 0.30 (SiO2, pentane/EtOAc 1:1); Mp = 129.8–130.8 °C; Optical rotation  [𝛼]஽ଶହ = –7.0 
(c = 0.72, CHCl3); FTIR ṽ/cm−1 3178, 1742, 1353, 1217, 1197, 1182, 1170, 1155, 1124, 
1111, 1087, 912, 776, 741, 737, 622, 604, 570, 534, 527, 509; 1H NMR (400 MHz, CDCl3) 
δ/ppm 8.61 (ddd, J = 4.7, 1.7, 1.0 Hz, 1H), 7.91 (dt, J = 7.9, 1.1 Hz, 1H), 7.87 (dt, J = 7.6, 
1.7 Hz, 1H), 7.45 (ddd, J = 7.4, 4.7, 1.4 Hz, 1H), 7.18–7.09 (m, 2H), 7.01–6.89 (m, 2H), 5.30 
(d, J = 8.6 Hz, 1H), 4.63 (dt, J = 8.7, 5.9 Hz, 1H), 3.58 (s, 3H), 3.27–2.96 (m, 2H), 2.28 (s, 
3H); 13C NMR (101 MHz, CDCl3) δ/ppm 171.3, 169.5, 157.9, 150.03, 149.98, 138.2, 132.8, 
130.6, 126.9, 121.81, 121.77, 57.6, 52.6, 39.3, 21.3; HRMS ESI m/z calc. for C17H19N2O6S 
[M+H]+: 379.0958, found: 379.0970. 
 
Methyl (R)-6-((tert-butyldimethylsilyl)oxy)-1-(pyridin-2-ylsulfonyl)indoline-2-carboxy-
late (3.101) 
PhI(OAc)2 (1.22 g, 3.78 mmol, 2.0 eq.) and Pd(OAc)2 (42.4 mg, 
0.189 mmol, 0.10 eq.) were added to a solution of sulfonamide 3.98 
(852 mg, 1.89 mmol, 1.0 eq.) in toluene (20 mL). The reaction 
mixture was heated for 10 h at 130 °C in a microwave reactor. The 
solvent was removed under reduced pressure and the crude residue purified by flash column 
chromatography (SiO2, pentane/EtOAc 2:1) to give indoline 3.101 (460 mg, 1.03 mmol, 54%) 
as a colorless, viscous oil. 
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Rf = 0.33 (SiO2, pentane/EtOAc 2:1); Optical rotation [𝛼]஽ଶହ = –132.5 (c = 0.29, CHCl3); 
FTIR ṽ/cm−1 2955, 2931, 2887, 2858, 1757, 1612, 1592, 1579, 1566, 1494, 1473, 1452, 1428, 
1391, 1360, 1282, 1257, 1197, 1179, 1153, 1122, 1101, 1086, 1027, 991, 937, 859, 840, 801, 
780, 737, 667, 622, 602, 567; 1H NMR (400 MHz, CDCl3) δ/ppm 8.58 (ddd, J = 4.7, 1.7, 
0.9 Hz, 1H), 7.95 (dt, J = 7.9, 1.0 Hz, 1H), 7.81 (td, J = 7.8, 1.8 Hz, 1H), 7.41 (ddd, J = 7.7, 
4.7, 1.2 Hz, 1H), 7.02 (d, J = 2.1 Hz, 1H), 6.87 (dt, J = 8.2, 1.1 Hz, 1H), 6.42 (dd, J = 8.1, 
2.3 Hz, 1H), 5.54 (dd, J = 10.9, 4.2 Hz, 1H), 3.78 (s, 3H), 3.48 (ddd, J = 15.8, 10.9, 1.1 Hz, 
1H), 3.11 (dd, J = 16.0, 4.2 Hz, 1H), 0.94 (s, 9H), 0.14 (s, 6H); 13C NMR (101 MHz, CDCl3) 
δ/ppm 172.0, 156.8, 155.8, 150.3, 142.0, 137.8, 127.1, 125.1, 123.3, 122.4, 116.2, 107.9, 64.5, 
52.9,   32.7,   25.8,   18.3,   −4.3,   −4.4;;   HRMS ESI m/z calc. for C21H29N2O5SSi [M+H]+: 
449.1561, found: 449.1558. 
 
Methyl (R)-6-((tert-butyldimethylsilyl)oxy)indoline-2-carboxylate (3.103) 
Magnesium powder (250 mg, 10.3 mmol, 10 eq.) was added to a 
solution of indoline 3.101 (462 mg, 1.03 mmol, 1.0 eq.) in MeOH 
(30 mL) at 0 °C. The reaction mixture was stirred for 3 h at 0 °C. Sat. 
aq. NH4Cl solution (25 mL) and Et2O (25 mL) were added and the mixture was stirred for 1 h 
at room temperature until the remaining magnesium powder was quenched. The layers were 
separated and the aqueous layer was extracted with Et2O (3 x 25 mL). The combined organic 
layers were dried over MgSO4 and the solvent was removed under reduced pressure to give 
indoline 3.103 (302 mg, 0.983 mmol, 95%) as a very viscous, brown syrup which was used 
without further purification. 
 
Rf = 0.77 (SiO2, pentane/EtOAc 2:1); Optical rotation [𝛼]஽ଶହ = +3.2 (c = 0.42, CHCl3); FTIR 
ṽ/cm−1 3375, 2955, 2930, 2895, 1740, 1618, 1594, 1498, 1472, 1463, 1390, 1362, 1321, 1298, 
1254, 1203, 1160, 1093, 1008, 973, 940, 877, 840, 799, 780, 688, 661, 587; 1H NMR 
(400 MHz, CDCl3) δ/ppm 6.92–6.85 (m, 1H), 6.24–6.20 (m, 2H), 4.38 (dd, J = 10.2, 5.5 Hz, 
1H), 3.75 (s, 3H), 3.31 (ddd, J = 15.6, 10.3, 0.9 Hz, 1H), 3.22 (ddd, J = 15.6, 5.6, 0.8 Hz, 1H), 
0.97 (s, 9H), 0.17 (s, 6H); 13C NMR (101 MHz, CDCl3) δ/ppm 174.8, 156.0, 151.4, 124.7, 
119.5, 111.2, 102.9, 60.6, 52.6, 33.2, 25.9, 18.3, −4.3; HRMS ESI m/z calc. for C16H26NO3Si 
[M+H]+: 308.1677, found: 308.1674. 
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Methyl (R)-6-((tert-butyldimethylsilyl)oxy)-1-(2,2,2-trifluoroacetyl)indoline-2-carboxy-
late (3.104) 
Pyridine (0.30 mL, 3.77 mmol, 4.0 eq.) and trifluoroacetic anhydride 
(0.53 mL, 3.77 mmol, 4.0 eq.) were added to a solution of indoline 
3.103 (290 mg, 0.940 mmol, 1.0 eq.) in CH2Cl2 (15 mL) at 0 °C. The 
reaction mixture was stirred for 20 min at 0 °C and further 16 h at room temperature. The 
mixture was diluted with CH2Cl2 (10 mL) and quenched with sat. aq. NaHCO3 solution 
(25 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 
(3 x 20 mL). The combined organic layers were washed with H2O (15 mL) and brine (15 mL), 
dried over MgSO4 and the solvent was removed under reduced pressure. The crude product 
was purified by flash column chromatography (SiO2, pentane/EtOAc 6:1) to give indoline 
3.104 (337 mg, 0.840 mmol, 89%) as a viscous, colorless oil. 
 
Rf = 0.54 (SiO2, pentane/EtOAc 6:1); Optical rotation [𝛼]஽ଶହ = +60.7 (c = 0.65, CHCl3); 
FTIR ṽ/cm−1 2957, 2932, 2888, 2860, 1757, 1702, 1610, 1490, 1474, 1440, 1392, 1362, 1349, 
1304, 1282, 1265, 1240, 1195, 1155, 1100, 1079, 1010, 964, 940, 876, 862, 841, 819, 801, 
783, 750, 729, 698, 667, 633, 585, 527, 458; 1H NMR (400 MHz, CDCl3) δ/ppm 7.78 (d, J = 
2.2 Hz, 1H), 7.05 (d, J = 8.1 Hz, 1H), 6.65 (dd, J = 8.1, 2.3 Hz, 1H), 5.20 (dt, J = 10.2, 1.6 
Hz, 1H), 3.75 (s, 3H), 3.61 (dd, J = 15.8, 10.7 Hz, 1H), 3.22 (d, J = 15.9 Hz, 1H), 0.98 (s, 
9H), 0.24–0.21 (m, 6H); 13C NMR (101 MHz, CDCl3) δ/ppm 171.1, 156.0, 154.6 (q, J = 
37.9 Hz), 142.7, 124.8, 121.3, 117.9, 116.0 (q, J = 288.2 Hz), 110.8, 61.40 (q, J = 3.2 Hz), 
53.2,  33.8,  25.8,  18.4,  −4.28,  −4.33;;  19F NMR (376 MHz, CDCl3) δ/ppm  −71.4;;  HRMS ESI 
m/z calc. for C18H25F3NO4 [M+H]+: 404.1500, found: 404.1494. 
 
Methyl (R)-6-acetoxy-1-(pyridin-2-ylsulfonyl)indoline-2-carboxylate (3.102) 
PhI(OAc)2 (1.06 g, 3.30 mmol, 2.0 eq.) and Pd(OAc)2 (37.0 mg, 
0.170 mmol, 0.10 eq.) were added to a solution of sulfonamide 3.100 
(625 mg, 1.65 mmol, 1.0 eq.) in toluene (20 mL). The reaction mixture 
was heated for 11 h at 130 °C in a microwave reactor. The solvent was 
removed under reduced pressure and the obtained residue purified by flash column 
chromatography (SiO2, pentane/EtOAc 2:3) to give indoline 3.102 (495 mg, 1.32 mmol, 80%) 
as a slightly brown solid. 
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Rf = 0.62 (SiO2, pentane/EtOAc 1:2); Mp = 45.6–46.7 °C; Optical rotation [𝛼]஽ଶହ = –106.8 
(c = 0.34, CHCl3); FTIR ṽ/cm−1 2959, 1751, 1490, 1428, 1356, 1274, 1202, 1175, 1142, 
1119, 1085, 1042, 1013, 990, 926, 894, 775, 736, 621, 601; 1H NMR (400 MHz, CDCl3) 
δ/ppm 8.60 (ddd, J = 4.7, 1.8, 0.9 Hz, 1H), 7.96 (dt, J = 7.9, 1.0 Hz, 1H), 7.84 (td, J = 7.8, 
1.7 Hz, 1H), 7.43 (ddd, J = 7.7, 4.7, 1.2 Hz, 1H), 7.03 (d, J = 8.1 Hz, 1H), 6.68 (dd, J = 8.1, 
2.1 Hz, 1H), 5.54 (dd, J = 11.0, 4.1 Hz, 1H), 3.79 (s, 3H), 3.52 (ddd, J = 16.2, 11.0, 1.2 Hz, 
1H), 3.19 (dd, J = 16.2, 4.1 Hz, 1H), 2.26 (s, 3H); 13C NMR (101 MHz, CDCl3) δ/ppm 171.7, 
169.4, 156.4, 150.6, 150.3, 141.9, 138.0, 127.4, 125.2, 123.4, 117.6, 109.6, 64.3, 53.0, 32.8, 
21.2; HRMS ESI m/z calc. for C17H17N2O6S [M+H]+: 377.0802, found: 377.0799. 
 
Methyl (R)-6-hydroxyindoline-2-carboxylate (3.106) 
Magnesium powder (352 mg, 14.5 mmol, 10 eq.) was added to a 
solution of indoline 3.102 (545 mg, 1.45 mmol, 1.0 eq.) in MeOH 
(34 mL) at 0 °C and the mixture was stirred for 3.5 h at 0 °C. Sat. aq. 
NH4Cl solution (50 mL) and Et2O (50 mL) were added and the mixture was stirred for 1 h at 
room temperature until the remaining magnesium powder was quenched. The layers were 
separated and the aqueous layer was extracted with Et2O (2 x 50 mL). The combined organic 
layers were dried over MgSO4 and the solvent was removed under reduced pressure. To 
remove residual H2O from the product, the residue was diluted with CH2Cl2 (10 mL) and H2O 
was added (5 mL). The layers were separated and the aqueous layer was extracted with 
CH2Cl2 (10 mL). The combined organic layers were dried over MgSO4 and the solvent was 
removed to give indoline 3.106 (280 mg, 1.45 mmol, quant.) as a viscous brown syrup. The 
crude product was of sufficient purity to be used without further purification. For analytical 
measurements, a small amount of the crude residue was purified by flash column 
chromatography (SiO2, pentane/EtOAc 1:2) to give indoline 3.106 as a colorless oil. 
 
Rf = 0.65 (SiO2, pentane/EtOAc 1:2); Optical rotation [𝛼]஽ଶହ = –28.0 (c = 0.30, CHCl3); 
FTIR ṽ/cm−1 3369, 3029, 2953, 2857, 1729, 1619, 1502, 1469, 1436, 1329, 1294, 1271, 1201, 
1178, 1144, 1096, 1079, 1010, 959, 939, 833, 794, 734, 639, 600, 566, 514; 1H NMR 
(400 MHz, CDCl3) δ/ppm 6.88 (d, J = 8.6 Hz, 1H), 6.23–6.18 (m, 2H), 4.38 (dd, J = 10.2, 
5.2 Hz, 1H), 3.74 (s, 3H), 3.30 (ddd, J = 15.6, 10.2, 1.1 Hz, 1H), 3.19 (ddd, J = 15.6, 5.2, 
1.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ/ppm 175.0, 156.2, 151.3, 125.0, 118.8, 106.6, 
98.5, 60.6, 52.7, 33.1; HRMS ESI m/z calc. for C10H12NO3 [M+H]+: 194.0812, found: 
194.0807. 
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Methyl (R)-6-hydroxy-1-(2,2,2-trifluoroacetyl)indoline-2-carboxylate (3.107) 
Pyridine (0.42 mL, 5.24 mmol, 4.0 eq.) and trifluoroacetic anhydride 
(0.73 mL, 5.24 mmol, 4.0 eq.) were added to a solution of indoline 
3.106 (253 mg, 1.31 mmol, 1.0 eq.) in CH2Cl2 (19 mL) at 0 °C. The 
reaction mixture was stirred for 20 min at 0 °C and further 16 h at room 
temperature. The reaction mixture was diluted with CH2Cl2 (10 mL) and quenched with sat. 
aq. NaHCO3 solution (25 mL). The layers were separated and the aqueous layer was extracted 
with CH2Cl2 (3 x 20 mL). The combined organic layers were washed with H2O (15 mL) and 
brine (15 mL), dried over MgSO4 and the solvent was removed under reduced pressure. 
Toluene (3 x 5 mL) was added and removed under reduced pressure to remove residual 
pyridine, giving indoline 3.107 (380 mg, 1.31 mmol, quant.) as a slightly brown syrup, which 
was used without further purification. For analytical measurements, a small amount of the 
crude residue was purified by flash column chromatography (SiO2, pentane/EtOAc 4:1) to 
give indoline 3.107 as a colorless solid. 
 
Rf = 0.33 (SiO2, pentane/EtOAc 4:1); Mp = 90.8–91.9 °C; Optical rotation [𝛼]஽ଶହ = +113.6 
(c = 0.23, CHCl3);  FTIR ṽ/cm−1 3374, 2960, 2928, 1748, 1671, 1619, 1609, 1506, 1461, 
1439, 1370, 1352, 1324, 1284, 1197, 1147, 1099, 1079, 1008, 972, 945, 859, 821, 749, 733, 
668, 638, 590, 528, 502; 1H NMR (400 MHz, CDCl3) δ/ppm 7.96 (d, J = 2.3 Hz, 1H), 7.09 
(d, J = 8.3 Hz, 1H), 6.73 (dd, J = 8.2, 2.3 Hz, 1H), 6.65 (s, 1H), 5.23 (dt, J = 10.1, 1.6 Hz, 
1H), 3.76 (s, 3H), 3.62 (ddd, J = 15.9, 10.1, 1.3 Hz, 1H), 3.24 (d, J = 16.0 Hz, 1H); 13C NMR 
(101 MHz, CDCl3) δ/ppm 170.9, 156.7, 155.2 (q, J = 37.9 Hz), 142.2, 125.4, 120.3, 116.0 (q, 
J = 287.8 Hz), 113.9, 106.3, 61.7 (q, J = 3.4 Hz), 53.4, 33.7; 19F NMR (376 MHz, CDCl3) 
δ/ppm –71.2; HRMS ESI m/z calc. for C12H10F3NO4Na [M+Na]+: 312.0454, found: 
312.0450. 
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Methyl (R)-6-(methoxymethoxy)-1-(2,2,2-trifluoroacetyl)indoline-2-carboxylate (3.108) 
DIPEA (0.43 mL, 2.62 mmol, 2.0 eq.) and MOMBr (0.23 mL, 
2.62 mmol, 2.0 eq.) were added to a solution of crude indoline 3.107 
(380 mg, 1.31 mmol, 1.0 eq.) in CH2Cl2 (20 mL) at 0 °C. The reaction 
mixture was stirred for 20 min at 0 °C and further 16 h at room 
temperature. The reaction mixture was quenched with sat. aq. NH4Cl solution (25 mL), the 
layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 20 mL). The 
combined organic layers were washed with brine (15 mL), dried over MgSO4 and the solvent 
was removed under reduced pressure. The crude product was purified by flash column 
chromatography (SiO2, pentane/EtOAc 4:1) to give indoline 3.108 (270 mg, 0.81 mmol, 62% 
over three steps from indoline 3.102) as a colorless solid. 
 
Rf = 0.54 (SiO2, pentane/EtOAc 4:1); Mp = 93.6–94.7 °C; Optical rotation [𝛼]஽ଶହ = +69.4 
(c = 0.32, CHCl3); FTIR ṽ/cm−1 2958, 2069, 1753, 1700, 1614, 1600, 1496, 1439, 1352, 
1299, 1278, 1262, 1206, 1185, 1151, 1105, 1088, 1069, 1007, 924, 873, 816, 774, 750, 730, 
673, 581, 527; 1H NMR (400 MHz, CDCl3) δ/ppm 7.97 (d, J = 2.3 Hz, 1H), 7.14–7.10 (m, 
1H), 6.86 (dd, J = 8.3, 2.3 Hz, 1H), 5.23–5.19 (m, 1H), 5.18 (s, 2H), 3.75 (s, 3H), 3.62 (dd, 
J = 16.2, 9.4 Hz, 1H), 3.49 (s, 3H), 3.24 (d, J = 16.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) 
δ/ppm 171.0, 157.6, 154.6 (q, J = 37.5 Hz), 142.7, 125.0, 122.1, 116.0 (q, J = 287.9 Hz), 
114.2, 107.5, 94.9, 61.4 (q, J = 3.6 Hz), 56.3, 53.3, 33.8; 19F NMR (376 MHz, CDCl3) δ/ppm 
−71.4;;  HRMS ESI m/z calc. for C14H15F3NO5 [M+H]+: 334.0897, found: 334.0892. 
 
Methyl (2R,3aR,6R,7aR)-6-(methoxymethoxy)-1-(2,2,2-trifluoroacetyl)octahydro-1H-
indole-2-carboxylate (3.109) 
Rh/C (5% w/w, 54.3 mg, 26.0 µmol, 0.10 eq.) was added to a solution 
of indoline 3.108 (88.0 mg, 0.260 mmol, 1.0 eq.) in MeOH (2.5 mL). 
The reaction mixture was stirred for 4.5 h at room temperature in an 
autoclave under H2 pressure (15 bar). The catalyst was filtered off 
over a short pad of Celite®, the Celite® was washed with MeOH (2 x 10 mL) and the solvent 
was removed under reduced pressure. The crude product was purified by flash column 
chromatography (SiO2, pentane/EtOAc 4:1) to give octahydroindole 3.109 (50.0 mg, 
0.150 mmol, 56%) as a colorless solid and recovered starting material 3.108 (8.00 mg, 
24.0 µmol, 9%). 
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Rf = 0.36 (SiO2, pentane/EtOAc 3:1); Optical rotation [𝛼]஽ଶହ = +72.8 (c = 0.13, CHCl3); 
FTIR ṽ/cm−1 2955, 1751, 1684, 1447, 1360, 1312, 1274, 1256, 1238, 1204, 1166, 1142, 1105, 
1058, 1038, 951, 939, 917, 868, 836, 804, 763, 726, 668, 623, 571, 529, 458; 1H NMR 
(500 MHz, CDCl3) δ/ppm 4.67 (s, 2H), 4.55 (dd, J = 10.0, 8.5 Hz, 1H), 4.16 (dt, J = 12.0, 
6.0 Hz, 1H), 3.77 (s, 3H), 3.48 (tt, J = 11.5, 3.9 Hz, 1H), 3.37 (s, 2H), 2.43–2.34 (m, 1H), 
2.33–2.20 (m, 2H), 2.09–2.00 (m, 1H), 1.92–1.83 (m, 2H), 1.77–1.63 (m, 2H), 1.47–1.36 (m, 
1H); 13C NMR (126 MHz, CDCl3) δ/ppm 170.1, 154.5 (q, J = 38.0 Hz), 115.1 (q, J = 
287.0 Hz), 93.6, 71.9, 59.0, 57.5 (q, J = 2.5 Hz), 54.3, 51.6, 36.3, 33.2, 28.2, 25.4, 21.5; 
19F NMR (376 MHz, CDCl3) δ/ppm   −71.1;;   HRMS ESI m/z calc. for C14H20F3NO5Na 
[M+Na]+: 362.1186, found: 362.1187. 
 
Methyl (2R,3aR,6R,7aR)-6-(methoxymethoxy)octahydro-1H-indole-2-carboxylate (3.110) 
NaBH4 (24.1 mg, 0.640 mmol, 5.8 eq.) was added to a solution of 
octahydroindole 3.109 (36.0 mg, 0.110 mmol, 1.0 eq.) in MeOH 
(2.5 mL) at 0 °C. The reaction mixture was stirred for 1 h at 0 °C and 
subsequently diluted with MeOH (2.5 mL). One spatula of silica gel was added and the 
solvent was removed under reduced pressure. The impregnated silica gel containing the crude 
product was purified by flash column chromatography (SiO2, CH2Cl2/MeOH 20:1 changing to 
2:1) to give octahydroindole 3.110 (21.0 mg, 86.0 µmol, 81%) as a colorless solid. 
 
Rf = 0.32 (SiO2, CH2Cl2/MeOH 10:1); Optical rotation [𝛼]஽ଶହ = +2.4 (c = 0.22, CHCl3); 
FTIR ṽ/cm−1 3418, 2930, 1739, 1632, 1442, 1374, 1332, 1305, 1256, 1211, 1148, 1103, 1035, 
919, 825, 713, 642, 498; 1H NMR (400 MHz, CDCl3) δ/ppm 4.71–4.60 (m, 2H), 3.82 (dd, 
J = 10.1, 6.3 Hz, 1H), 3.74 (s, 4H), 3.38 (s, 3H), 3.11 (q, J = 5.4 Hz, 1H), 2.99 (br s, 1H), 
2.19 (ddd, J = 12.9, 10.1, 7.0 Hz, 1H), 2.11–2.00 (m, 1H), 1.94–1.79 (m, 3H), 1.74–1.64 (m, 
2H), 1.62–1.49 (m, 2H), 1.47–1.37 (m, 1H); 13C NMR (101 MHz, CDCl3) δ/ppm 176.0, 94.8, 
71.9, 59.0, 58.0, 55.5, 52.3, 38.0, 35.9, 32.9, 28.2, 22.3; HRMS ESI m/z calc. for C12H22NO4 
[M+H]+: 244.1543, found: 244.1543. 
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2.2.7.  Synthesis of Hpla-Phe-OH Dipeptide 
D-Phenylalanine methyl ester hydrochloride (3.111) 
D-Phenylalanine (0.500 g, 3.03 mmol, 1.0 eq.) was dissolved in MeOH 
(6 mL) and cooled to 0 °C. SOCl2 (0.33 mL, 4.54 mmol, 1.5 eq.) was 
slowly added at 0 °C and the reaction mixture was heated at reflux for 
12 h. The solvent was removed under reduced pressure to give D-phenylalanine methyl ester 
hydrochloride (3.111) (0.540 g, 3.01 mmol, 99%) as a colorless solid, which was used without 
further purification.  
 
Optical rotation [𝛼]஽ଶହ= 16.6 (c = 0.92, MeOH); 1H NMR (400 MHz, MeOD) δ/ppm 7.41–
7.29 (m, 3H), 7.29–7.25 (m, 2H), 4.33 (t, J = 6.7 Hz, 1H), 3.80 (s, 3H), 3.27 (dd, J = 14.4, 
6.1 Hz, 1H), 3.19 (dd, J = 14.3, 7.2 Hz, 1H); 13C NMR (101 MHz, MeOD) δ/ppm 170.4, 
135.3, 130.4, 130.2, 129.0, 55.2, 53.6, 37.4. 
Analytical data are in accordance with those reported in the literature.[20] 
 
Methyl ((S)-2-acetoxy-3-(4-(benzyloxy)phenyl)propanoyl)-D-phenylalaninate (3.112) 
D-Phenylalanine methyl ester hydrochloride (3.111)  (161 mg, 0.750 mmol, 
1.0 eq.) and phenyllactic acid derivative 3.67 (306 mg, 0.970 mmol, 1.3 eq.) 
were dissolved in CH2Cl2 (9 mL). The solution was cooled to 0 °C and 
2,6-lutidine (0.44 mL, 3.75 mmol, 5.0 eq.) and PyBOP (507 mg, 
0.970 mmol, 1.3 eq.) were added. The mixture was stirred for 20 min at 
0 °C and further 20 h at room temperature. The reaction mixture was diluted 
with CH2Cl2 (10 mL), washed with aq. HCl solution (1 M, 10 mL), sat. aq. Na2CO3 solution 
(10 mL) and brine (10 mL). The organic layer was dried over Na2SO4 and the solvent was 
removed under reduced pressure. The crude product was purified by flash column 
chromatography (SiO2, pentane/EtOAc 3:2) to give dipeptide 3.112 (265 mg, 0.550 mmol, 
77%) as a colorless solid. 
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Rf = 0.66 (SiO2, pentane/EtOAc 3:2); Mp = 105.4–107.0 °C; Optical rotation [𝛼]஽ଶହ = 57.5 
(c = 0.40, CHCl3); FTIR ṽ/cm−1 3324, 3063, 3032, 2952, 1742, 1679, 1611, 1584, 1512, 
1455, 1436, 1371, 1297, 1220, 1177, 1114, 1026, 921, 818, 741, 699, 639, 608, 530; 1H NMR 
(400 MHz, CDCl3) δ/ppm 7.44–7.29 (m, 6H), 7.26–7.22 (m, 2H), 7.13–7.05 (m, 2H), 7.01–
6.95 (m, 2H), 6.92–6.84 (m, 2H), 6.32 (d, J = 7.9, 1H), 5.33 (dd, J = 8.0, 4.6 Hz, 1H), 5.02 (s, 
2H), 4.86 (dt, J = 7.9, 5.5 Hz, 1H), 3.72 (s, 3H), 3.15 (dd, J = 14.4, 4.6 Hz, 1H), 3.09 (dd, J = 
5.5, 4.1 Hz, 2H), 2.97 (dd, J = 14.3, 8.1 Hz, 1H), 1.97 (s, 3H); 13C NMR (101 MHz, CDCl3) 
δ/ppm 171.5, 169.5, 168.9, 158.0, 137.1, 135.5, 130.6, 129.4, 128.7, 128.3, 128.1, 127.6, 
127.4, 114.9, 74.5, 70.1, 52.7, 52.5, 37.8, 37.1, 20.9; HRMS ESI m/z calc. for C28H30NO6 
[M+H]+: 476.2068, found: 476.2070. 
 
Methyl ((S)-3-(4-(benzyloxy)phenyl)-2-hydroxypropanoyl)-D-phenylalaninate (3.113) 
Hpla-Phe-OMe dipeptide 3.112 (130 mg, 0.270 mmol, 1.0 eq.) was 
dissolved in MeOH (4 mL). K2CO3 (113 mg, 0.820 mmol, 3.0 eq.) was 
added and the mixture stirred for 2 h at room temperature. Sat. aq. NH4Cl 
solution (5 mL) was added and the mixture was extracted with CH2Cl2 
(3 x 10 mL). The combined organic layers were dried over MgSO4 and the 
solvent was removed under reduced pressure. The crude residue was 
purified by flash column chromatography (SiO2, pentane/EtOAc 3:2) to give dipeptide 3.113 
(100 mg, 0.226 mmol, 84%) as a colorless solid. 
 
Rf = 0.53 (SiO2, pentane/EtOAc 1:1); Mp = 117.5–118.6 °C; Optical rotation [𝛼]஽ଶହ = 75.0 
(c = 0.27, CHCl3); FTIR ṽ/cm−1 3394, 3063, 3030, 2952, 2925, 2096, 1743, 1655, 1611, 
1584, 1511, 1455, 1437, 1362, 1240, 1177, 1112, 1080, 1025, 917, 819, 740, 698, 609, 572, 
527; 1H NMR (400 MHz, CDCl3) δ/ppm 7.45–7.35 (m, 4H), 7.35–7.23 (m, 4H), 7.16–7.07 
(m, 4H), 6.95–6.90 (m, 2H), 6.88 (d, J = 8.3 Hz, 1H), 5.04 (s, 2H), 4.88 (dt, J = 8.2, 6.1 Hz, 
1H), 4.23 (dt, J = 8.7, 4.3 Hz, 1H), 3.70 (s, 3H), 3.19–3.05 (m, 3H), 2.79 (dd, J = 14.1, 
8.7 Hz, 1H), 2.27 (d, J = 4.6 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ/ppm 172.4, 171.8, 
158.1, 137.1, 135.9, 130.7, 129.3, 128.8, 128.7, 128.1, 127.6, 127.3, 115.4, 73.0, 70.2, 53.0, 
52.5, 40.0, 38.2; HRMS ESI m/z calc. for C26H23NO5 [M+H]+: 434.1962, found: 434.1958. 
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Methyl ((S)-3-(4-(benzyloxy)phenyl)-2-((tert-butyldimethylsilyl)oxy)propanoyl)-D-
phenylalaninate (3.114) 
TBSCl (21.1 mg, 0.140 mmol, 1.5 eq.), imidazole (18.9 mg, 0.280 mmol, 
3.0 eq.) and DMAP (0.560 mg, 5.00 µmol, 0.050 eq.) were added to a 
solution of dipeptide 3.113 (40.0 mg, 92.0 µmol, 1.0 eq.) in DMF (1 mL) 
and stirred for 18 h at room temperature. The reaction mixture was 
partitioned between H2O (10 mL) and CH2Cl2 (10 mL), the layers were 
separated and the aqueous layer was extracted with CH2Cl2 (2 x 10 mL). 
The combined organic layers were washed with brine (10 mL), dried over MgSO4 and the 
solvent was removed under reduced pressure. The crude product was purified by flash column 
chromatography (SiO2, pentane/EtOAc 2:1) to give dipeptide 3.114 (18.0 mg, 33.0 µmol, 
36%) as a colorless solid. Further, starting material 3.113 could be recovered (23.0 mg, 
53.0 µmol, 58%). 
 
Rf = 0.78 (SiO2, pentane/EtOAc 2:1); Optical rotation [𝛼]஽ଶହ = 72.7 (c = 0.055, CHCl3); 
FTIR ṽ/cm−1 3416, 2927, 2856, 1747, 1679, 1612, 1511, 1456, 1362, 1251, 1176, 1093, 1027, 
940, 832, 781, 737, 697, 509; 1H NMR (400 MHz, CDCl3) δ/ppm 7.43–7.34 (m, 4H), 7.33–
7.19 (m, 4H), 7.14–7.07 (m, 4H), 6.95 (d, J = 7.6 Hz, 1H), 6.88–6.83 (m, 2H), 5.04 (s, 2H), 
4.79 (dt, J = 7.6, 6.4 Hz, 1H), 4.21 (dd, J = 7.7, 3.4 Hz, 1H), 3.67 (s, 3H), 3.18 (dd, J = 14.1, 
6.1 Hz, 1H), 3.07 (dd, J = 14.1, 6.7 Hz, 1H), 3.03 (dd, J = 13.9, 3.4 Hz, 1H), 2.79 (dd, J = 
13.8,  7.7  Hz,  1H),  0.78  (s,  9H),  −0.23  (s,  3H),  −0.35  (s,  3H);;   13C NMR (101 MHz, CDCl3) 
δ/ppm 173.2, 171.8, 157.7, 137.3, 136.0, 131.2, 129.8, 129.2, 128.71, 128.66, 128.0, 127.5, 
127.2,  114.7,  74.9,  70.1,  53.1,  52.4,  41.0,  38.3,  25.8,  18.0,  −5.3,  −5.4;;  HRMS ESI m/z calc. 
for C32H42NO5Si [M+H]+: 548.2827, found: 548.2830. 
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((S)-3-(4-(Benzyloxy)phenyl)-2-((tert-butyldimethylsilyl)oxy)propanoyl)-D-phenyl-
alanine (3.115) 
LiOH monohydrate (3.68 mg, 88.0 µmol, 3.0 eq.) was added to a solution of 
dipeptide 3.114 (16.0 mg, 29.0 µmol, 1.0 eq.) in THF/H2O (5:3, 0.5 mL) 
and stirred for 1 h at room temperature. The reaction mixture was acidified 
with aq. citric acid solution (5% w/w, 5 mL) to a pH of around 3. The THF 
was removed under reduced pressure and the residue was extracted with 
CH2Cl2 (3 x 10 mL). The combined organic layers were washed with H2O 
(10 mL), dried over MgSO4 and the solvent was removed under reduced pressure to obtain 
Hpla-Phe-OH dipeptide 3.115 (15.0 mg, 28.0 µmol, 96%) as a colorless solid which was used 
without further purification. 
 
Rf = 0.16 (SiO2, pentane/EtOAc 2:1); Mp = 157.7–158.3 °C; Optical rotation [𝛼]஽ଶହ = 50.6 
(c = 0.16, CHCl3); FTIR ṽ/cm−1 3404, 3032, 2952, 2929, 2858, 1733, 1629, 1585, 1512, 
1455, 1382, 1348, 1298, 1242, 1177, 1095, 1026, 939, 921, 831, 811, 782, 734, 697, 613, 548, 
520, 488; 1H NMR (400 MHz, CDCl3) δ/ppm 7.43–7.34 (m, 4H), 7.33–7.22 (m, 4H), 7.17–
7.14 (m, 2H), 7.10–7.05 (m, 2H), 6.89–6.83 (m, 2H), 5.03 (s, 2H), 4.83–4.73 (m, 2H), 4.23 
(dd, J = 7.4, 3.6 Hz, 1H), 3.28 (dd, J = 14.5, 5.7 Hz, 1H), 3.12–2.97 (m, 2H), 2.80 (dd, J 
= 13.9, 7.5 Hz,   1H),   0.75   (s,   9H),   −0.28   (s,   3H),   −0.34   (d,   J = 1.3 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ/ppm 174.5, 173.4, 157.8, 137.3, 135.7, 131.2, 129.4, 129.2, 128.9, 
128.7,  128.0,  127.6,  127.3,  114.8,  74.7,  70.1,  53.2,  41.0,  37.3,  25.9,  18.0,  −5.3,  −5.5;;  HRMS 
ESI m/z calc. for C31H40NO5Si [M+H]+: 534.2670, found: 534.2674. 
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2.2.8.  Assembly of the Different Building Blocks 
Methyl (2R,3aR,6R,7aR)-1-(((S)-3-(4-(benzyloxy)phenyl)-2-((tert-butyldimethylsilyl)-
oxy)propanoyl)-D-phenylalanyl)-6-(methoxymethoxy)octahydro-1H-indole-2-
carboxylate (3.116) 
DMTMM (7.77 mg, 28.0 µmol, 1.2 eq.) and NMM (5.15 µL, 
47.0 µmol, 2.0 eq.) were added to a solution of D-diepi-derivative 
3.110 (5.59 mg, 23.0 µmol, 1.0 eq.) and Hpla-Phe-OH dipeptide 
3.115 (15.0 mg, 28.0 µmol, 1.2 eq.) in CH2Cl2 (0.5 mL) at 0 °C. 
The reaction mixture was stirred for 20 min at 0 °C and further 2 h 
at room temperature. The solvent was removed under reduced 
pressure and the crude product was purified by flash column 
chromatography (SiO2, pentane/EtOAc 1:1) to give a 4:1 rotameric mixture of tripeptide 
3.116 (12.6 mg, 17.0 µmol, 71%) as a colorless amorphous solid. 
 
Rf = 0.70 (SiO2, pentane/EtOAc 3:2); FTIR ṽ/cm−1 3415, 2928, 2857, 1751, 1648, 1512, 
1436, 1362, 1250, 1196, 1176, 1144, 1103, 1041, 921, 833, 781, 739, 699, 509; 1H NMR 
(400 MHz, CDCl3, major rotamer) δ/ppm 7.45–7.40 (m, 2H), 7.39–7.34 (m, 2H), 7.34–7.28 
(m, 1H), 7.28–7.24 (m, 2H), 7.23–7.20 (m, 3H), 7.08–7.04 (m, 2H), 6.95 (d, J = 8.8 Hz, 1H), 
6.86–6.81 (m, 2H), 4.90–4.79 (m, 1H), 4.61–4.48 (m, 2H), 4.38 (dd, J = 10.4, 8.0 Hz, 1H), 
4.22 (dt, J = 12.3, 6.4 Hz, 1H), 4.17 (dd, J = 7.7, 3.3 Hz, 1H), 3.73 (s, 3H), 3.40 (tt, J = 11.9, 
4.0 Hz, 1H), 3.31 (s, 3H), 3.23 (dd, J = 13.9, 7.3 Hz, 1H), 2.95 (dd, J = 13.8, 3.3 Hz, 1H), 
2.83 (dd, J = 14.0, 7.2 Hz, 1H), 2.75 (dd, J = 13.9, 7.7 Hz, 1H), 2.34–2.25 (m, 1H), 2.08 (dt, J 
= 12.4, 7.3 Hz, 1H), 1.91 (td, J = 12.9, 10.4 Hz, 1H), 1.82–1.73 (m, 2H), 1.71–1.52 (m, 3H), 
1.37–1.21  (m,  3H),  0.82  (s,  9H),  −0.22  (s,  3H),  −0.32  (s,  3H);;  13C NMR (101 MHz, CDCl3, 
major rotamer) δ/ppm 172.9, 172.3, 169.9, 157.7, 137.3, 136.3, 131.12, 131.09, 129.7, 129.6, 
129.5, 128.69, 128.66, 128.0, 127.6, 127.1, 114.6, 94.4, 74.8, 72.9, 70.1, 59.3, 57.8, 55.3, 
52.3,   51.1,   40.9,   39.4,   36.8,   34.9,   30.5,   26.8,   25.9,   23.0,   18.1,   −5.3,   −5.5;;  HRMS ESI m/z 
calc. for C43H58N2O8SiNa [M+Na]+: 781.3855, found: 781.3853. 
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(2R,3aR,6R,7aR)-1-(((S)-3-(4-(Benzyloxy)phenyl)-2-((tert-butyldimethylsilyl)oxy)-
propanoyl)-D-phenylalanyl)-6-(methoxymethoxy)octahydro-1H-indole-2-carboxylic acid 
(3.117) 
Tripeptide 3.116 (12.5 mg, 16.5 µmol, 1.0 eq.) was dissolved in 
THF/H2O (5:3, 0.3 mL) and LiOH monohydrate (2.08 mg, 
49.5 µmol, 3.0 eq.) was added. The reaction was stirred for 7 h at 
room temperature before aq. citric acid solution (5% w/w, 3 mL) 
was added. The aqueous layer was extracted with CH2Cl2 
(3 x 5 mL), the combined organic layers were dried over Na2SO4 
and the solvent was removed under reduced pressure. The crude 
residue was purified by flash column chromatography (SiO2, CH2Cl2/MeOH 10:1) to obtain a 
4:1 rotameric mixture of tripeptidic acid 3.117 (9.50 mg, 13.0 µmol, 77%) as a colorless solid. 
 
Rf = 0.59 (SiO2, CH2Cl2/MeOH 10:1); Optical rotation [𝛼]஽ଶହ = –14.2 (c = 0.20, CHCl3); 
FTIR ṽ/cm−1 3408, 3059, 3033, 2927, 2856, 1739, 1645, 1612, 1512, 1455, 1362, 1302, 1247, 
1177, 1144, 1104, 1042, 939, 918, 833, 781, 738, 698, 542, 509; 1H NMR (400 MHz, CDCl3, 
major rotamer) δ/ppm 7.44–7.38 (m, 2H), 7.38–7.34 (m, 1H), 7.34–7.30 (m, 1H), 7.30–7.23 
(m, 3H), 7.22–7.17 (m, 2H), 7.09–7.05 (m, 2H), 6.99 (d, J = 8.6 Hz, 1H), 6.86–6.82 (m, 3H), 
5.04 (d, J = 1.8 Hz, 2H), 4.79 (td, J = 8.6, 6.3 Hz, 1H), 4.55–4.47 (m, 2H), 4.22 (dd, J = 7.4, 
3.4 Hz, 1H), 3.43–3.34 (m, 1H), 3.31 (s, 3H), 3.21 (dd, J = 13.4, 8.5 Hz, 1H), 2.96 (dd, J = 
13.9, 3.4 Hz, 1H), 2.86 (dd, J = 13.4, 6.1 Hz, 1H), 2.78 (dd, J = 13.8, 7.4 Hz, 1H), 2.29–2.21 
(m, 2H), 2.07–2.00 (m, 1H), 1.82–1.73 (m, 2H), 1.72–1.57 (m, 1H), 1.38–1.16 (m, 5H), 0.86 
(s,   9H),  −0.14   (s,   3H),  −0.25   (s,   3H);;   13C NMR (101 MHz, CDCl3, major rotamer) δ/ppm 
173.0, 172.6, 171.7, 157.7, 137.2, 135.7, 131.1, 129.5, 128.9, 128.71, 128.67, 128.6, 128.1, 
127.6, 127.4, 114.6, 94.2, 74.7, 72.5, 70.2, 59.5, 58.7, 55.4, 51.7, 40.8, 39.5, 36.1, 34.1, 29.9, 
25.9,  22.8,  18.2,  −5.2,  −5.4;;  HRMS ESI m/z calc. for C42H56N2O8SiNa [M+Na]+: 767.3698, 
found: 767.3698. 
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tert-Butyl ((E)-N-(4-((2R,3aR,6R,7aR)-1-(((S)-3-(4-(benzyloxy)phenyl)-2-((tert-butyldi-
methylsilyl)oxy)propanoyl)-D-phenylalanyl)-6-(methoxymethoxy)octahydro-1H-indole-
2-carboxamido)butyl)-N'-(tert-butoxycarbonyl)carbamimidoyl)-O2-azanecarboxylate 
(3.118) 
2-6-lutidine (4.2 µL, 36.3 µmol, 3.0 eq.) was added to 
a solution of tripeptidic acid 3.117 (9.01 mg, 
12.1 µmol, 1.0 eq.), agmantin side chain 3.64 
(8.00 mg, 24.2 µmol, 2.0 eq.) and PyBOP (12.6 mg, 
24.2 µmol, 2.0 eq.) in CH2Cl2 (0.4 mL) at 0 °C. The 
reaction mixture was stirred for 30 min at 0 °C and 
further 5 h at room temperature. CH2Cl2 (3 mL) was 
added and the solution was washed with sat. aq. NaHCO3 solution (1 mL) and brine (1 mL). 
The organic layer was dried over Na2SO4 and the solvent was removed under reduced 
pressure. The crude product was purified by flash column chromatography (SiO2, 
pentane/EtOAc 2:3) to give a 7:1 rotameric mixture tetrapeptide 3.118 (7.00 mg, 6.70 µmol, 
55%) as a white amorphous solid. 
 
Rf = 0.72 (SiO2, pentane/EtOAc 2:3); Optical rotation[𝛼]஽ଶହ = –3.4 (c = 0.17, CHCl3); FTIR 
ṽ/cm−1 3422, 3336, 2929, 2858, 1720, 1679, 1639, 1584, 1511, 1472, 1446, 1417, 1368, 1332, 
1253, 1228, 1158, 1134, 1043, 940, 919, 833, 810, 780, 751, 698, 666, 537, 508, 462; 
1H NMR (400 MHz, CDCl3, major rotamer) δ/ppm 11.49 (s, 1H), 8.32 (t, J = 5.3 Hz, 1H), 
7.45–7.34 (m, 4H), 7.33–7.28 (m, 1H), 7.25–7.21 (m, 2H), 7.18–7.15 (m, 2H), 7.10–7.05 (m, 
2H), 6.98 (d, J = 8.3 Hz, 1H), 6.87–6.83 (m, 2H), 6.59 (t, J = 5.9 Hz, 1H), 5.04 (s, 2H), 4.83 
(td, J = 8.6, 6.1 Hz, 1H), 4.60–4.50 (m, 2H), 4.41 (t, J = 8.9 Hz, 1H), 4.26–4.18 (m, 2H), 
3.46–3.35 (m, 2H), 3.32 (s, 3H), 3.19–3.11 (m, 2H), 2.98 (dd, J = 13.8, 3.4 Hz, 1H), 2.87 (dd, 
J = 13.4, 6.0 Hz, 1H), 2.74 (dd, J = 13.9, 7.9 Hz, 1H), 2.55 (s, 1H), 2.36 (td, J = 12.9, 9.2 Hz, 
1H), 2.15 (dt, J = 13.2, 6.2 Hz, 1H), 1.91 (dt, J = 12.7, 8.0 Hz, 1H), 1.76 (d, J = 12.0 Hz, 2H), 
1.69–1.54 (m, 4H), 1.50 (s, 9H), 1.48 (s, 9H), 1.44–1.29 (m, 1H), 1.14 (q, J = 12.2 Hz, 1H), 
0.85   (s,   9H),   −0.16   (s,   3H), −0.29   (s,   3H);;   13C NMR (101 MHz, CDCl3, major rotamer) 
δ/ppm 172.9, 170.8, 170.5, 163.8, 157.7, 156.3, 153.4, 137.2, 136.1, 131.1, 129.7, 129.4, 
128.8, 128.7, 128.1, 127.5, 127.4, 114.7, 94.3, 83.2, 79.4, 75.0, 73.0, 70.2, 59.8, 58.8, 55.3, 
51.6, 41.0, 40.7,   39.6,   39.4,   36.4,   34.2,   28.5,   28.2,   27.1,   26.8,   25.9,   23.0,   18.2,   −5.3,   −5.4;;  
HRMS ESI m/z calc. for C57H85N6O11Si [M+H]+: 1057.6040, found: 1057.6060. 
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tert-Butyl ((E)-N'-(tert-butoxycarbonyl)-N-(4-((2R,3aR,6R,7aR)-1-(((S)-2-((tert-butyldi-
methylsilyl)oxy)-3-(4-hydroxyphenyl)propanoyl)-D-phenylalanyl)-6-(methoxymethoxy)-
octahydro-1H-indole-2-carboxamido)butyl)carbamimidoyl)-λ2-azanecarboxylate (3.119) 
Tetrapeptide 3.118 (4.00 mg, 3.78 µmol, 1.0 eq.) was 
dissolved in EtOAc/MeOH (1:1, 0.4 mL). Pd/C 
(10% w/w, 4.00 mg, 1.0 eq.) was added, the reaction 
mixture was stirred for 16 h at room temperature 
under an atmosphere of H2 and was monitored by 
UPLC. Additional Pd/C (10% w/w, 1.30 mg, 
12.6 µmol, 0.33 eq.) was added and the mixture was 
stirred for 4 h at room temperature under an atmosphere of H2. The catalyst was filtered off 
over Celite® and the Celite® was washed with EtOAc/MeOH (1:2, 2 x 5 mL). The solvent was 
removed under reduced pressure to give a 3:1 rotameric mixture of tetrapeptide 3.119 
(3.50 mg, 3.67 µmol, 97%) as a colorless amorphous solid which was used without further 
purification. 
 
Rf = 0.30 (SiO2, pentane/EtOAc 1:2); 1H NMR (500 MHz, CDCl3, major rotamer) δ/ppm 
11.52 (d, J = 13.0 Hz, 1H), 8.41 (s, 1H), 7.33–7.17 (m, 5H), 7.15–7.10 (m, 1H), 7.03–6.94 (m, 
2H), 6.84 (d, J = 9.0 Hz, 1H), 6.72–6.65 (m, 2H), 4.78–4.71 (m, 1H), 4.57–4.48 (m, 2H), 
4.33–4.26 (m, 2H), 4.26–4.20 (m, 1H), 3.48–3.42 (m, 1H), 3.39–3.32 (m, 1H), 3.31 (s, 3H), 
3.10 (dd, J = 13.3, 8.7 Hz, 1H), 2.92–2.83 (m, 1H), 2.79 (dd, J = 13.4, 6.3 Hz, 1H), 2.26 (dd, 
J = 12.7, 9.4 Hz, 1H), 2.20–2.11 (m, 1H), 1.95 (dt, J = 11.9, 7.3 Hz, 1H), 1.81–1.55 (m, 12H), 
1.50 (s, 9H), 1.43 (s, 9H), 1.39–1.24   (m,   2H),   0.90   (s,   9H),   −0.04   (s,   3H),   −0.07   (s,   3H);;  
13C NMR (126 MHz, CDCl3, major rotamer) δ/ppm 172.5, 171.0, 170.2, 156.4, 155.3, 153.4, 
136.2, 131.1, 130.9, 129.5, 129.4, 129.1, 128.8, 127.3, 115.4, 94.2, 83.5, 74.4, 73.0, 60.3, 
58.5, 55.3, 51.2, 41.0, 40.5, 39.3, 36.3, 34.4, 29.2, 28.3, 28.2, 27.1, 26.8, 26.7, 26.0, 23.1, 
18.3,   −4.9,   −5.3;;   HRMS ESI m/z calc. for C50H79N6O11Si [M+H]+: 967.5571, found: 
967.5581. 
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Aeruginosin KT608A (3.1) 
Tetrapeptide 3.119 (3.5 mg, 3.62 µmol, 1.0 eq.) was 
dissolved in CH2Cl2 (2 mL). To this solution TFA 
(0.2 mL) was added and the reaction mixture stirred for 3 
h at room temperature and further for 3.5 h at 40 °C. 
Toluene (2 mL) was added and the TFA and CH2Cl2 
removed under reduced pressure. The obtained residue 
was dissolved in MeCN/aq. HF (48% w/w) (9:1, 0.5 mL) 
and the reaction stirred for 1 h at room temperature. The reaction was quenched by the 
addition of sat. aq. Na2CO3 solution (2 mL) and the layers were separated. The aqueous layer 
was extracted with MeCN (2 mL) and the combined organic layers dried over MgSO4. The 
solvent was removed under reduced pressure and the obtained crude product dissolved in 
H2O. The aqueous solution was subjected to solid phase extraction using a C18 cartridge. The 
C18 cartridge was eluted with MeOH/H2O (9:1, 10 mL) to give a 2:1 rotameric mixture of 
aeruginosin KT608A (3.1) (2.20 mg, 3.61 µmol, quant.) as an amorphous white solid. 
1H NMR (600 MHz, DMSO-d6, major rotamer) δ/ppm 9.08 (s, 1H), 7.88 (d, J = 8.4 Hz, 1H), 
7.83 (t, J = 5.7 Hz, 1H), 7.42 (t, J = 5.4 Hz, 1H), 7.29–7.19 (m, 6H), 6.88 (d, J = 8.5 Hz, 2H), 
6.59 (d, J = 8.4 Hz, 2H), 5.27 (d, J = 6.5 Hz, 1H), 4.73–4.64 (m, 2H), 4.30–4.19 (m, 2H), 
3.96–3.92 (m, 1H), 3.42–3.24 (m, 1H), 3.16–3.04 (m, 3H), 2.92 (dd, J = 14.1, 4.6 Hz, 1H), 
2.81 (dd, J = 14.2, 9.5 Hz, 1H), 2.65 (dd, J = 13.9, 3.9 Hz, 1H), 2.42 (dd, J = 13.9, 8.3 Hz, 
1H), 2.20–2.12 (m, 1H), 2.00–1.94 (m, 1H), 1.93–1.87 (m, 1H), 1.85–1.75 (m, 1H), 1.71–1.64 
(m, 1H), 1.62–1.53 (m, 2H), 1.51–1.40 (m, 2H), 1.32–1.17 (m, 1H); 13C NMR (151 MHz, 
DMSO-d6, major rotamer) δ/ppm 173.0, 171.1, 169.3, 156.6, 155.5, 137.4, 130.2, 129.3, 
129.2, 128.3, 128.1, 126.4, 114.6, 71.9, 66.8, 59.8, 57.3, 50.9, 40.4, 39.4, 37.9, 37.8, 37.8, 
36.0, 30.5, 29.2, 26.3, 25.8, 22.6; HRMS ESI m/z calc. for C32H45N6O6 [M+H]+: 609.3395, 
found: 609.3398. 
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3. Toxicity Assays 
The   assay   “Thamnotokit   FTM”   was purchased from MicrobioTest Inc., Kleimoer 15, 9030 
Mariakerke (Gent), Belgium. The assay was conducted as described in the operating 
procedure. The standard freshwater (SFW) was prepared as described and oxygenated prior 
use by bubbling air for 20 minutes through it. Diluted standard freshwater (DFW) was 
prepared by mixing SFW (2.5 ml) with deionized water (17.5 ml). The T. platyurus cysts were 
hydrated in DFW (1.0 ml) for 30 minutes before they were added to DFW (9 ml) and 
incubated in a Petri dish for 24 hours at 25 °C under continuous light (Philips TL-D 36W/840 
lamp).  Aqueous  solutions  in  SFW  with  concentrations  of  150,  100,  33.3,  11.1,  3.7,  1.3  μM  of  
the different test compounds (A828A, A126A, A748A, A794A and A616A) were prepared. 
For the blank SFW was used. In a 24 well plate, four repetitions of each concentration were 
prepared. About 40 larvae were added to the first vial of each dilution by a pipette. From 
there, 10 larvae were transported to each of the remaining three vials of each concentration. 
Only these three vials were counted for compounds A126A, A748A, A794A and A616A; for 
A828A all four repetitions were counted. The plate was covered with parafilm and incubated 
for 24 hours at 25 °C in the dark. The mortality was determined by counting the dead larvae. 
Dead was defined as no movement within 10 seconds. 
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1. Chiral HPLC
Racemic Ethyl-1-acetyl-6-methoxyindoline-2-carboxylate (3.56) 
Chiralpak AS-H column, heptane/iPrOH (90:10), 0.8 mL/min, 30 °C, 208 nm 
Ethyl (R)-1-acetyl-6-methoxyindoline-2-carboxylate (3.56)
Chiralpak AS-H column, heptane/iPrOH (90:10), 0.8 mL/min, 30 °C, 208 nm 
APPENDIX 
 
 
 
269 
2. NMR Spectra 
1H, 13C and 19F NMR spectra of previously unreported compounds can be found on the 
accompanying CD to this PhD thesis. 
 
